



61ST ANNUAL MEETING

**EUROPEAN ASSOCIATION
FOR THE STUDY OF DIABETES**

**15 - 19 September 2025
Vienna - Austria**

61ST EASD ANNUAL MEETING

Content	Page
General Information	2
About EASD and EFSD	2
Information for Onsite Attendance in Vienna	3
Floorplan Vienna	4
Information for Online Attendance via Virtual Meeting platform	7
Certificates	8
EASD App	8
Programme.	10
Programme Committee	10
Abstract Review Committee	11
Programme Overview	12
Tuesday, 16 September 2025	20
Claude Bernard Lecture	21
Short Oral Discussions Event A.	28
Short Oral Discussions Event B.	30
Camillo Golgi Lecture	38
Wednesday, 17 September 2025	42
Albert Renold Lecture	43
Short Oral Discussions Event C.	51
Short Oral Discussions Event D.	53
Minkowski Lecture	62
Thursday, 18 September 2025.	66
Rising Star Symposium	67
Short Oral Discussions Event E.	78
Short Oral Discussions Event F.	81
EASD-NNF Diabetes Prize for Excellence Lecture	89
Friday, 19 September 2025.	92
Diabetes Global Impact Prize Lecture.	93
Short Oral Discussions	109
Presenter Index	242
Orals and Short Oral Discussions	242
Invited Speaker	257
Satellite Symposia	260
Industry Sessions and Exhibition	281
Programme	282
Exhibition.	342
Thanks	346
EASD Acknowledgements.	346
EFSD Acknowledgements	347

GENERAL INFORMATION

About EASD and EFSD

The **European Association for the Study of Diabetes e.V. (EASD)** is a membership-based academic non-profit organization. It was founded in 1965 and is based in Duesseldorf, Germany.

GENERAL INFO

The aims of the Association are to encourage and support research in the field of diabetes, the rapid diffusion of acquired knowledge and to facilitate its application.

PROGRAMME

For more information about EASD, please visit: www.easd.org.

TUESDAY

The **European Foundation for the Study of Diabetes (EFSD)** was founded in 2000 to stimulate diabetes research in Europe. It offers support in all areas of diabetes research through a wide range of joint and stand-alone initiatives.

WEDNESDAY

THURSDAY

For more information about EFSD and funding programmes, please visit: www.europeandiabetesfoundation.org.

FRIDAY

EASD and EFSD Board:

Chantal Mathieu, Belgium (President)
Francesco Giorgino, Italy
Andreas Fidelak, Germany
Jean-François Gautier, France
Kamlesh Khunti, UK
Ruth Loos, Denmark
Julia Mader, Austria
Hindrik Mulder, Sweden
Patrick Schrauwen, Netherlands
Tina Vilsbøll, Denmark
Robert Wagner Germany

EASD and EFSD Headquarters:

Rheindorfer Weg 3
40591 Düsseldorf
Germany
Phone: +49 211 758 469 0
Email: info@easd.org
foundation@easd.org

SHORT ORAL DISCUSSIONS

PRESENTER INDEX

SATELLITE SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Format of the EASD Annual Meeting

The 61st EASD Annual Meeting will take place as a hybrid event from 15 to 19 September 2025, providing the option to attend in person in Vienna, Austria or online via the Virtual Meeting platform.

All sessions in the scientific programme will take place onsite at the meeting venue in Vienna, Austria at the times indicated in the programme (All times shown are CEST - Central European Summer Time) and will be live-streamed for delegates attending the meeting virtually.

Recordings of all sessions will be available, access to recordings will be limited to registered delegates until 17 October 2025.

Information for onsite attendance in Vienna


Venue:

VIECON - Vienna Congress & Convention Center (Messe Vienna)

Messeplatz 1, 1020 Vienna, Austria



Messeplatz 1
1020 Wien



GENERAL INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL DISCUSSIONS

PRESENTER INDEX

SATELLITE SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Registration Counters - Opening Hours:

Sunday	14 September 2025	12:00 - 18:00
Monday	15 September 2025	08:00 - 18:00
Tuesday	16 September 2025	07:30 - 18:30
Wednesday	17 September 2025	07:00 - 18:00
Thursday	18 September 2025	06:30 - 18:30
Friday	19 September 2025	06:30 - 14:00


Badges:

The delegates' name badges serve as an admission pass to all scientific sessions and the exhibition. Delegates are asked to keep their name badges displayed at all times during the meeting. Badges can be replaced and will be charged for.

FLOORPLAN




- GENERAL INFO
- PROGRAMME
 - TUESDAY
 - WEDNESDAY
 - THURSDAY
 - FRIDAY
- SHORT ORAL DISCUSSIONS
- PRESENTER INDEX
- SATELLITE SYMPOSIA
- INDUSTRY PROGRAMME
 - EXHIBITION
- THANKS



HALL A

VIENNA



GENERAL INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL DISCUSSIONS

PRESENTER INDEX

SATELLITE SYMPOSIA

INDUSTRY PROGRAMME EXHIBITION

THANKS

First Aid:

First Aid is located in the Congress Centre after the Registration Area. Follow the signs with the white cross on a green background. In case of an emergency contact staff member.

Restaurants:

Restaurants can be found on the main walkway between halls and on the 1st floor of the Congress Centre. A Food Court can be found in Hall B.

Cloakroom/Lost and Found Counter:

The cloakroom is located in the basement of the Registration Hall (Foyer A). The lost and found is also located in the cloakroom.

Suitcases, including cabin trolleys are not allowed in the halls and must be left in the cloakroom.

EASD Member Lounge and Booth - Opening Hours:

Tuesday	16 September 2025	08:00 - 18:30
Wednesday	17 September 2025	08:00 - 18:30*
Thursday	18 September 2025	08:00 - 18:30
Friday	19 September 2025	08:00 - 14:00

*Member Lounge will close at 18:00 on Wednesday, 17 September 2025

Industry Exhibition - Opening Hours:

Tuesday	16 September 2025	09:00 - 16:30
Wednesday	17 September 2025	09:30 - 16:30
Thursday	18 September 2025	09:30 - 16:30

Speaker Centre - Opening Hours:

Sunday	14 September 2025	10:00 - 18:00
Monday	15 September 2025	08:00 - 18:00
Tuesday	16 September 2025	07:30 - 18:30
Wednesday	17 September 2025	07:00 - 19:00
Thursday	18 September 2025	08:00 - 19:00
Friday	19 September 2025	07:30 - 14:00

Transportation:

Registered delegates will receive a free Public Transportation Ticket (valid from Monday, 15 to Friday, 19 September 2025).

The transportation ticket allows you to make unlimited journeys on the subway, commuter train, tram, and bus. Please be aware that special express lines (e.g., the airport bus/train) are excluded and require a separate

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

ticket. The travel ticket is valid only for the dates as shown on your badge and for travel within the Core Zone (previously known as Zone 100).

By metro, the venue can be reached using metro line U2. Get off a station 'Messe-Prater'.

Security:

Any suspicious or unidentified items onsite at the meeting venue are to be reported immediately to the nearest staff member. Security staff are on duty to ensure that all persons entering the venue are wearing a badge. For your safety, it is strongly advised to leave all your valuables in a safe at your hotel.

Insurance:

The registration fees do not include the insurance of participants against accidents, sickness, cancellation, theft, property loss or damage. Participants are advised to take out adequate insurance especially with regards to travel.

Information for online attendance via Virtual Meeting platform

Registered delegates can access the [Virtual Meeting platform](#) by using the MyEASD account connected to the registration (respective email is provided on the registration confirmation).

The [Virtual Meeting platform](#) can be accessed directly or via the EASD website www.easd.org.

Technical requirements:

Delegates must ensure at their own expense that they meet the technical requirements necessary for following the EASD Annual Meeting virtually.

In addition to the necessary hardware, the following requirements will be needed:

- A stable internet connection with a minimum of 5 MBITs (data speed) to follow the online programme,
- A browser in an up-to-date version e.g. Chrome®, Firefox® or Safari®.

EASD recommends the participation via PC/Mac Computers and a resolution of Full HD 1920x1080 pixels or higher. Cookie and Pop-Up blocking measures may lead to problems. On smart phone/tablet devices only basic viewing features are being supported. It is recommended to use the Safari® browser for Apple® devices.

Please note: When using the Safari® browser on Apple® devices, you will need to enable pop-ups. Pop-ups are disabled by default in the Safari® browser. Please go to the settings of your Safari® browser and enable pop-ups.

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

For further instructions how to enable pop-ups, please see [here](#).

EASD is not responsible if delegates are unable to successfully access the virtual meeting platform if they do not fulfil the technical requirements.

Certificates

Certificates will be available online via the attendee's [MyEASD](#) account after the EASD Annual Meeting 2025.

The **Certificate of Attendance** will be available online from 22 September 2025, 10:00 hrs CEST.

The **EACCME Certificate** will be available online from 20 October 2025, 10:00 hrs CEST.

Only sessions within the scope of the EASD Scientific Programme (colour code dark blue as shown in the online programme) watched in person / live stream and on demand between 16 September 2025, 09:00 hrs CEST and 17 October 2025, 23:59 hrs CEST are considered for EACCME Accreditation.

Maximum credits available: 26

Please note that you will not automatically receive maximum accreditation. Credits will be based on your monitored watch time / attendance (in person / live stream and on demand).

EASD App

The EASD App provides access to the programme, speakers, floorplans, live sessions, on-demand content and other opportunities.



The app is now available for download from the [Apple App Store for IOS](#) and [Google Play for Android](#).

Disclaimer

All efforts will be made to adhere to the programme as provided. However, EASD and its agents reserve the right to alter or cancel, without prior notice, any of the arrangements, timetables, plans or other items relating directly or indirectly to the Meeting, for any case beyond their reasonable control. EASD and the local conference organisers are not liable for any other loss or inconvenience caused as a result of such changes.

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

WHO WE ARE

We are one of the largest diabetes expert communities worldwide with the mission to promote excellence in diabetes care through research, networking and education

WHAT IS IN IT FOR YOU

- *Exchange and connect* with a broad network of international colleagues
- *Grow your research and career* through various grant, fellow- and mentorship programmes
- *Gain knowledge* by having access to publications and educational resources
- *Shape the future* of diabetes through a large number of leadership opportunities
- *Benefit from exclusive rates* for the EASD Annual Meeting – one of the largest diabetes conferences in the world

WHAT TO DO NEXT

Check easd.org/membership.html or scan the code below to learn more and become a member of EASD – benefit from a wide array of opportunities, connect with peers from all over the world and enhance your career in diabetes research or care



PROGRAMME COMMITTEE



Tina Vilsbøll
Denmark, Chair



Diego Balboa
Finland



Caroline Bonner
France



Alice Cheng
Canada



Leszek Czupryniak
Poland



Salvatore De Cosmo
Italy



Eelco De Koning
Netherlands



Simon Dreher
Germany



Niels Jessen
Denmark



Tomasz Klupa
Poland



Timo D. Müller
Germany



Anna Novials
Spain



Kashyap Patel
United Kingdom



Naveed Sattar
United Kingdom



Patrick Schrauwen
Germany/Netherlands



Jelizaveta Sokolovska
Latvia



Adam G. Tabák
Hungary



Tsvetalina Tankova
Bulgaria

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

ABSTRACTS

2,170 abstract submissions were received by EASD and 1,354 abstracts were accepted for inclusion. All abstracts were reviewed anonymously and scored by the Abstract Review Committee members.

Publication of Abstracts

Accepted abstracts are available online and will be published in the Abstract Volume by Diabetologia.

Embargo Policies

Information contained in abstracts may not be released until 1 July 2025 when the abstracts are published online. Oral Presentations are under embargo until the commencement of the speaker's presentation. Short Oral Discussion Presentations are under embargo until the start of the session in which the Short Oral is going to be presented. For ePosters, the embargo is lifted at 12:00 CEST on Tuesday, 16 September 2025.

Abstract Review Committee

In addition to the members of the Programme Committee, the Abstract Review Committee comprises the following members:

Harpreet S. Bajaj (Canada)	Luigi Laviola (Italy)
Kåre I. Birkeland (Norway)	Angela Martinez Valverde (Spain)
Malin Fex (Sweden)	Claire Meek (United Kingdom)
Rosa Gasa (Spain)	Rick Meijer (Netherlands)
Tomás P. Griffin (Ireland)	Nicolae Mircea Panduru (Romania)
Sofie Hædersdal (Denmark)	Cristine Rode Schwarz (Denmark)
Martin Haluzik (Czechia)	Femke Rutters (Netherlands)
Erifili Hatzigelaki (Greece)	Karin Stenkula (Sweden)
Alicia Jenkins (Australia)	Thomas Stulnig (Austria)
Alexandra Kautzky-Willer (Austria)	Tiinamaija Tuomi (Finland)
Daniel Konrad (Switzerland)	Dorota Zozulinska-Ziolkiewicz (Poland)

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

TUESDAY, 16 SEPTEMBER 2025

	TIME	VIENNA HALL	PARIS HALL	LONDON HALL	MUMBAI HALL
GENERAL INFO	08:30 - 09:00	Presidential Address			
	09:00 - 09:45	57th Claude Bernard Lecture			
PROGRAMME	10:00 - 11:30	OP 1	OP 2	OP 3	OP 4
TUESDAY					
WEDNESDAY	12:00 - 13:00	Short Oral Discussion Sessions Event A			
THURSDAY					
FRIDAY	13:15 - 14:15	Short Oral Discussion Sessions Event B			
SHORT ORAL DISCUSSIONS					
PRESENTER INDEX	14:45 - 16:15	OP 7	OP 8	OP 9	OP 10
SATELLITE SYMPOSIA					
INDUSTRY	16:45 - 17:45	40th Camillo Golgi Lecture	The emerging consensus for population level screening to detect early stage type 1 diabetes	How close are we to fully closed loop systems?	Diabetologia Symposium: Global opportunities and challenges – prevention, care and therapy
PROGRAMME					
EXHIBITION					
THANKS					

TUESDAY, 16 SEPTEMBER 2025

SOFIA HALL	MILAN HALL	WARSAW HALL	SPOTLIGHT STAGE	ARENA
OP 5	OP 6	LBA OP 1		
Short Oral Discussion Sessions Event A		EASD e-Learning expert session: Early stage type 1 diabetes	Type 1 diabetes and inflammation	Lab Talk with Dan Drucker
Short Oral Discussion Sessions Event B			Are incretin therapies a game changer for type 1 diabetes?	Lab Talk with Juleen Zierath
OP 11	OP 12	LBA OP 2	Artificial Intelligence in diabetes care today and tomorrow	
Losing weight: Can the balance be preserved?	EASD-ADA Joint Symposium: Incorporating pharmacogenomics and genomic medicine in type 2 diabetes clinical care	Unique issues in people with diabetes and Black heritage		

GENERAL INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL DISCUSSIONS

PRESENTER INDEX

SATELLITE SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

WEDNESDAY, 17 SEPTEMBER 2025

	TIME	VIENNA HALL	PARIS HALL	LONDON HALL	MUMBAI HALL
GENERAL INFO	08:30 - 09:30	SOUL Trial: Effects of oral semaglutide on cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk	Diabetologia-Diabetes-Diabetes Care Expert Forum: Insulin resistance in the 21st century: new takes on an old problem	EASD-EASO Joint Symposium: Obesity +/- diabetes "peri"-pregnancy – what to focus on:	19th Albert Renold Lecture
PROGRAMME					
TUESDAY					
WEDNESDAY	09:45 - 11:15	OP 13	OP 14	OP 15	OP 16
THURSDAY					
FRIDAY					
SHORT ORAL DISCUSSIONS	11:45 - 12:45	Short Oral Discussion Sessions Event C			
PRESENTER INDEX	13:00 - 14:00	Short Oral Discussion Sessions Event D			
SATELLITE SYMPOSIA					
INDUSTRY PROGRAMME	14:30 - 16:00	OP 19	OP 20	LBA OP 3	OP 21
EXHIBITION					
THANKS	16:30 - 17:30	<i>Induction of Honorary Members</i> 60th Minkowski Lecture	Assessment and management of diabetes distress: the EASD's first clinical practice guideline	ATTAIN-1, the first phase 3 clinical trial investigating orforglipton for obesity management	DKD treatment in type 2 diabetes: Where do we stand?

WEDNESDAY, 17 SEPTEMBER 2025

SOFIA HALL	MILAN HALL	WARSAW HALL	SPOTLIGHT STAGE	ARENA
Dementia in diabetes: reasons for hope or concern	Mitochondrial function: a key regulator of pancreatic beta cell maturation, function, and inflammatory vulnerability	WHO Europe-EASD-EUDF session: Enabling high quality diabetes care by setting targets, monitoring data and initiating action		
OP 17	OP 18	EASD General Assembly	Introducing a competency framework for diabetes technologies	
Short Oral Discussion Sessions Event C		EASD e-Learning expert session: Technology	Incretin associated sarcopenia: Does it matter which drug we use?	Lab Talk with Antonio Zorzano
Short Oral Discussion Sessions Event D		EASD e-Learning expert session: Obesity	Minimum expectations for market authorization of CGM devices in Europe	Lab Talk with Mikael Rydén
OP 22	OP 23	OP 24	In-hospital diabetes management: characteristics and challenges	
Clinical application of precision medicine in diabetes	Extracellular vesicles: new players in metabolic diseases	Open science - predatory journals - peer review: benefits, challenges, and ethics of the scientific publishing process		

GENERAL INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL DISCUSSIONS

PRESENTER INDEX

SATELLITE SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

THURSDAY, 18 SEPTEMBER 2025

	TIME	VIENNA HALL	PARIS HALL	LONDON HALL	MUMBAI HALL
	07:15 - 08:15	SURPASS-CVOT			
GENERAL INFO					
PROGRAMME	08:30 - 09:15	Fostering the next generation: What is the role of GLP-1 based therapies?	Do we need "new" insulins?	Rising Star Symposium (08:30 - 10:10)	Diet and exercise: when how and what matters!
TUESDAY					
WEDNESDAY					
THURSDAY	09:30 - 10:15	Pregnant and digital	Getting the most of the CGM data		Tailored nutrition and low-calorie diet remission updates
FRIDAY					
SHORT ORAL DISCUSSIONS	10:45 - 12:15	OP 25	LBA OP 4	OP 26	OP 27
PRESENTER INDEX	12:45 - 13:45	Short Oral Discussion Sessions Event E			
SATELLITE SYMPOSIA					
INDUSTRY PROGRAMME	14:00 - 15:00	Short Oral Discussion Sessions Event F			
EXHIBITION					
	15:30 - 17:00	OP 31	LBA OP 5	OP 32	OP 33
THANKS	17:30 - 18:30	11th EASD-NNF Diabetes Prize for Excellence Lecture	Management of type 1 diabetes in adults. An update of the EASD-ADA consensus report	Results from SURPASS-PEDS phase 3 Trial	9th EASD-AASD Joint Symposium: Ageing with diabetes in East and West: sarcopenia, frailty and cognitive decline

THURSDAY, 18 SEPTEMBER 2025

SOFIA HALL	MILAN HALL	WARSAW HALL	SPOTLIGHT STAGE	ARENA
Implications of novel islet endocrine cell biology for type 1 and type 2 diabetes	Glucagon: No longer the bad guy in diabetes?	EASD-CEDA Joint Symposium: Diabetic neuropathies in the era of precision medicine		
Engineering of stem cell-derived islets	Clinical psychologist in a diabetic treatment team: Do we really know how to use each other's skills?	EASD-EASL Joint Symposium: Metabolic interplay between liver and diabetes: emerging mechanisms and therapeutic insights		
OP 28	OP 29	OP 30		
Short Oral Discussion Sessions Event E	EFSD-NNF Future Leaders Symposium (12:45 - 14:15)	EASD e-Learning expert session: Management of hyperglycaemia crises	EUDF Symposium	Lab Talk with Miriam Cnop
Short Oral Discussion Sessions Event F		EASD e-Learning expert session: Diabetic foot	Diabetes cured? A provocative rethink in the era of GLP-1 analogues	Lab Talk with Roberto Mallone
OP 34	OP 35	OP 36		
Obesity and its impact on diabetes outcomes	Recurrent severe hypoglycaemic events: What to do?	The other side of the balance: adipose tissues role in energy expenditure and storage		

GENERAL INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL DISCUSSIONS

PRESENTER INDEX

SATELLITE SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

FRIDAY, 19 SEPTEMBER 2025

TIME	VIENNA HALL	PARIS HALL	LONDON HALL	MUMBAI HALL
07:15 - 08:15	Towards arresting type 1 diabetes: Breaking results of the MELD-ATG trial and Ver-A-T1D trial using the INNODIA masterprotocol			
08:30 - 09:30	New paths for old friends: potential new roles for GLP1RAs and SGLT2is	EASD Diabetes Global Impact Prize	EASD-ESC Joint Symposium: Hot topics in cardiovascular medicine	From drug-/ toxicity screening to precision medicine: What's to gain from human tissue engineering for diabetes research?
10:00 - 11:00	OP 37	OP 38	OP 39	OP 40
11:30 - 12:30	OP 43	OP 44	OP 45	OP 46
13:00 - 14:00	New ES/ESE guideline on pregnancy related treatment and care for women with pre-existing diabetes	Trends in diabetes complications and multimorbidity	How might anti-obesity medication look like in the future?	Scientific communication on social media: authoritative voices vs. self-proclaimed experts - Shall we enter the arena?

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

FRIDAY, 19 SEPTEMBER 2025

SOFIA HALL	MILAN HALL	WARSAW HALL	SPOTLIGHT STAGE	ARENA
From De Do Do Do, De Da Da Da through Every breath you take to Synchronicity or how to police big data in diabetes	Eye health in diabetes today	The right timing to prevent type 2 diabetes		
OP 41	OP 42	LBA OP 06	Continuous ketone monitoring: a glimpse into the near future	Lab Talk with Guido Sebastiani
OP 47	OP 48	LBA OP 07	Revisiting Latent Autoimmune Diabetes in Adults (LADA): What is the evidence?	Lab Talk with Reiner Jumpertz-von Schwartzberg
Correctly classifying diabetes in adults in routine clinical practice	Personalised diabetes diagnosis: beyond the one-size-fits-all HbA1c cutoff	Is type 1 diabetes a slow virus disease?		

GENERAL INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL DISCUSSIONS

PRESENTER INDEX

SATELLITE SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

08:30 - 09:00

Vienna Hall

Presidential Address

Speaker: Chantal Mathieu, Belgium
President EASD/EFSD

09:00 - 09:45

Vienna Hall

57th Claude Bernard Lecture

The Claude Bernard Prize recognises an individual's innovative leadership and lifetime achievements in diabetes research.

Chair: Chantal Mathieu, Belgium

Speaker: Andrew T. Hattersley, UK:
Precision diabetes: learning from the rare and applying to the common

Andrew Hattersley is a Professor of Molecular Medicine at the University of Exeter, UK and a practicing consultant diabetologist. He trained in Medicine at Cambridge and Oxford. His postgraduate education was in London, Oxford and Birmingham.



He started in Exeter in 1995 and, working with Professor Sian Ellard, set up a genetics laboratory from scratch. Exeter is now the top international laboratory for monogenic diabetes, testing over 30,000 samples from 109 countries and discovering 29 different genetic subtypes. Gene discovery has been just the beginning; as the Exeter team also optimised diagnosis, treatment and clinical care for monogenic diabetes. Crucially they proved there was highly effective precision treatment for the commonest genetic subtypes.

Andrew has applied lessons learned from rare monogenic diabetes to improving the diagnosis and treatment of Type 1 and Type 2 diabetes. His recent work has allowed successful tailoring of glucose lowering treatment for individual patients with Type 2 diabetes using readily available clinical features.

He has published over 600 papers with more than 150,000 citations and given 300 national and international invited lectures. He has received major national and international research awards for his research. The legacy he is most proud of are the 27 outstanding young researchers he supervised and mentored who now are independent research leaders

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

OP 01 Influencing cardiovascular outcomes: medications and behaviours

Chairs: Janaka Karalliedde, UK; Naveed Sattar, UK

1 WITHDRAWN

2 Oral semaglutide and cardiovascular outcomes by baseline A_{1c} and BMI in people with type 2 diabetes in the SOUL trial

S. E. Inzucchi, J. E. Deanfield, M. D. Engelmann, G. Hovingh, O. Kleist Jeppesen, K. Mandavya, J. F. Mann, N. Marx, D. K. McGuire, S. L. Mulvagh, R. Pop-Busui, N. R. Poulter, M. S. Ripa, J. B. Buse, on behalf of the SOUL study group, USA, UK, Denmark, India, Germany, Canada

3 Comparative cardiovascular effectiveness of GLP-1 RAs vs insulin in early-onset type 2 diabetes

Y. Wei, T. Nyström, T. Andersson, S. Misra, T. Tuomi, S. Carlsson, Sweden, UK, Finland

4 Efficacy of icosapent ethyl across the spectrum of baseline triglyceride glucose indices

R. Aggarwal, D. L. Bhatt, C. M. Ballantyne, M. Miller, E. A. Brinton, T. A. Jacobson, S. Ketchum, A. Lira Pineda, R. T. Doyle, J.-C. Tardif, P. Steg, USA, Canada, France

5 Impact of background insulin treatment on cardiorenal outcomes in patients with type 2 diabetes: a patient-level analysis of merged CANVAS and CREDENCE trials

M. Chiriacò, D. Trico, L. Nesti, L. Sacchetta, N. Cimbalo, L. Santoni, S. Gallo, B. Simona, M. K. Hansen, E. Ferrannini, Italy, USA

6 Association between self-reported physical activity and cardiovascular events and all-cause mortality in individuals recently diagnosed with type 2 diabetes

L. B. Eriksen, J. V. Stidsen, T. B. Olesen, J. S. Nielsen, M. H. Olsen, K. Højlund, S. L. Domazet, Denmark

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

10:00 - 11:30

Paris Hall

OP 02 Novel risk factors for type 2 diabetes

Chairs: Adam Hulman, Denmark; Kamlesh Khunti, UK

7 Identifying household diabetes risk for family-based diabetes prevention using electronic health records

T. Thomas, H. Finertie, M. Yassin, L. Rodriguez, O. Duru, J. Schmittdiel, USA

8 Large-scale proteome mapping reveals heterogeneity in biological aging and its prediction of health outcomes across glycaemic status

Y. Lu, J. Li, J. Li, X. Xu, Y. Yu, W. Shen, Y. Sun, Y. Fu, X. Tan, N. Wang, B. Wang, China

9 Bone marrow fat content, glycaemic status and obesity: an MR-based analysis in the German national cohort

T. Haueise, A. L. Birkenfeld, J. Machann, Germany

10 Association between miRNAs differentially expressed regarding PM10 particle matter exposure levels and the risk of type 2 diabetes in the Spanish population: Di@bet.es study

W. Oualla Bachiri, A. M. Lago-Sampedro, C. Maldonado-Araque, V. Doulatram-Gamgaram, S. Garcia-Serrano, E. Garcia-Escobar, M. García-Vivanco, F. Martín-Llorente, J. L. Galán-García, G. Aguilera-Venegas, S. Valdés, G. Rojo-Martínez, Spain

11 Genetic, prenatal, and inferred postnatal disease aetiologies are associated with a differential type 2 diabetes clinical presentation and disease course

A. Hansen, C. Brons, M. Andersen, T. Hansen, K. Højlund, P. Vestergaard, J. Nielsen, M. Olsen, R. Thomsen, A. Vaag, Denmark, Sweden

12 Ethnic-specific associations of predefined dietary patterns with type 2 diabetes: a systematic review and meta-analysis of 826 000 adults with 71 000 incident cases from 29 cohorts in 15 countries

J. Y. Lee, N. Sarwar, F. Imamura, N. G. Forouhi, UK

10:00 - 11:30

London Hall

OP 03 CGM matrix: no life outside?

Chairs: Ramzi Ajjan, UK; Leszek Czupryniak, Poland

13 Novel diabetes classification based on glucose variability patterns from CGM data

S. Singla, S. Patil, A. Saxena, A. Maheshwari, J. Kumar, A. Shaikh, A. Raghunandan, India

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

14 Distinct glycaemic signatures predict medication response and complication risk in diabetes: a multicentre CGM analysis

S. Patil, S. Singla, A. Maheshwari, A. Saxena, A. Raghunandan, A. Shaikh, J. Kumar, D. Bagri, P. Sanghavi, D. Patil, D. Ansari, D. Gangurde, D. Gajare, D. Rathi, N. Kumawat, India

15 Continuous glucose monitoring in early pregnancy can predict the development of gestational diabetes

S. Nazir, M. Kennelly, M. Turner, A. O'Higgins, Ireland

16 Glycaemic variability fingerprints: early predictors of diabetes complications and treatment failure

S. Singla, S. Patil, A. Shaikh, A. Saxena, A. Maheshwari, A. Raghunandan, J. Kumar, India

17 Real-time continuous glucose monitoring vs hourly point-of-care testing in diabetic ketoacidosis: impact on clinical outcomes

M. M. Bogun, C. Wang, P. A. Kurlansky, N. Bedeir, G. E. Umpierrez, USA

18 Continuous glucose monitoring metrics in adolescents with type 1 diabetes depending on physical activity

A. J. Eckert, M.-A. Burckhardt, K. Wertgen, L. S. Dock, C. Kamrath, S. Lanzinger, Germany, Switzerland, Austria

10:00 - 11:30

Mumbai Hall

OP 04 Behind the screens: adventures in type 1 diabetes clinical trials

Chairs: Irene Caruso, Italy; Anette-Gabriele Ziegler, Germany

19 Immunomodulation without sustained lymphodepletion: SAB-142, a fully human anti-thymocyte globulin

S. Stoyanov, K. Eglund, T. Luke, A. Kropotova, D. Vermeer, B. Prins, USA

20 Acceptability and feasibility of general population screening for pre-symptomatic paediatric type 1 diabetes in the UK: lessons from the Early Surveillance for Autoimmune diabetes (ELSA) study

P. Narendran, J. Garstang, D. Shukla, S. Faustini, F. Zakia, C. Burt, O. Boiko, I. Litchfield, F. Boardman, S. M. Greenfield, A. Richter, T. Barrett, R. P. Dias, L. M. Quinn, ELSA team, UK

21 Screening for islet autoantibodies in childhood: insights from the Fr1da study on single islet autoantibody prevalence and progression

S. S. Schill, N. Friedl, C. Winkler, F. Haupt, M. Scholz, J. Stock, E. Bonifacio, A.-G. Ziegler, P. Achenbach, Fr1da Study Group, Germany

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

22 Higher HbA_{1c} thresholds are needed to predict type 1 diabetes progression in islet autoantibody-positive adults compared to children

E. Templeman, N. Thomas, D. Wherrett, M. J. Redondo, C. Evans-Molina, J. Sosenko, R. Oram, E. K. Sims, L. Ferrat, UK, Canada, USA, Switzerland

23 Mechanistic testing identifies chromogranin A as a biomarker of verapamil treatment response in children with type 1 diabetes

E. Sims, L. Kanapka, G. Scavacini de Freitas Monaco, I. Almalaraj, C. Evans-Molina, C. Bauza, A. Moran, CLVR Study Group, USA

24 Achievement of target CGM metrics in people with type 1 diabetes treated with zimislecel (VX-880) in the FORWARD study

L. Philipson, M. Nijhoff, B. A. Perkins, T. W. Reichman, P. Witkowski, L. S. Kean, C. Mathieu, A. L. Peters, Y. Zhang, K. Vanijcharoenkarn, F. Pagliuca, J. S. Sherwood, B. G. Bruinsma, C. Ricordi, M. Rickels, USA, Netherlands, Canada, Belgium

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

10:00 - 11:30

Sofia Hall

OP 05 Did we underestimate the role of gut microbiota in the pathogenesis of diabetes?

Chairs: Anna Krentowska, Poland; Joan Vendrell, Spain

25 Antipsychotic drugs, gut microbiota and Langerhans islet damage: an emerging new paradigm to explain pathogenesis of antipsychotic-induced diabetes

F. Folli, F. Cappa Mittestainer, A. Pereira Camacho, I. Pes, G. Finzi, S. La Rosa, A. Santos, U. Mortola, D. Guadagnini, H. Balan Assalin, A. Gabarra de Oliveira, M. J. Saad, Italy, Brazil

26 Adipose tissue bacterial load is increased in hyperglycaemic individuals with obesity and correlates with intestinal permeability in type 2 diabetes

D. Rosendo-Silva, P. Matafome, Portugal

27 Donor-derived microbial engraftment and gut microbiota shifts associated with weight loss following fecal microbiota transplantation

Y. Ruan, Z. Tongxi, Y. Rui, S. Fugui, A. Chiyong, H. Zhuping, L. Xiaoli, Q. Junjie, C. Hong, C. Rongping, China

28 Data-driven cluster analysis of immune-inflammatory profiles reveals novel type 2 diabetes endotypes and their clinical implications

B. T. Vuong, C. Delepine, M. Diedisheim, J. B. Julla, L. Potier, E. Rinaldi, J. Ratter-Rieck, F. Alzaid, A. Bonnefond, F. Ginhoux, M. Trombetta, R. Bonadonna, C. Herder, J.-F. Gautier, N. Venteclef, France, Italy, Germany

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

29 Depletion of adipocyte perilipin 5 leads to intestinal mitochondrial dysfunction and inflammation via modulating gut microbiota in obese mice

J. Zhang, H. Tian, Y. Ma, H. Qiu, Y. Li, Y. Wang, Z. Guo, X. Zhang, N. Hou, X. Sun, China

30 Phosphatidylinositols and oxidized triglycerides are associated with remission of type 2 diabetes following bariatric surgery

E.-J. Tremblay, A. Forest, P.-L. Plante, M. Nadeau, F. Julien, L. D. Biertho, P. Mauriège, M. Ruiz, A. Tchernof, Canada

10:00 - 11:30

Milan Hall

OP 06 Unseen risks: Understanding liver health risks beyond body weight

Chairs: Maria Paula Macedo, Portugal; Domenico Trico, Italy

31 The severity of metabolic dysfunction-associated steatohepatitis is associated with adipose tissue dysfunction and insulin resistance rather than BMI

S. Sabatini, E. Bugianesi, M. Allison, A. Vidal-Puig, J. M. Schattenberg, V. Ratzu, Q. M. Anstee, A. Gastaldelli, Italy, UK, Germany, France

32 A plasma metabolome-derived model predicts severe liver outcomes of nonalcoholic fatty liver disease

Y. Lu, X. Xu, J. Li, Y. Fu, J. Li, W. Shen, X. Tan, N. Wang, B. Wang, China

33 Fructose-associated gene expression changes are linked to metabolic dysfunction-associated steatotic liver disease: transcriptomic insights from the BARIA study

F. H. Westerbeke, I. Attaye, A. S. Meijnikman, J. Verheij, A. Van de Laar, R. Franken, M. Rios-Morales, M. Nieuwdorp, Netherlands

34 Longitudinal serum proteomics uncovers a protein classifier for non-obese MASLD grading and progression

J. Xu, Y. Chen, H. Li, X. Wu, China

35 Bariatric surgery identifies a protective amino acid in metabolic dysfunction-associated steatotic liver disease

J. V. Asteljoki, L. M. Granö, N. Hongisto, K. Porthan, J. Linden, A. I. Nieminen, H. Sammalkorpi, A. Penttilä, J. Arola, A. Juuti, H. Yki-Järvinen, P. K. Luukkonen, Finland

36 A metabolome-derived classification of metabolic dysfunction-associated fatty liver disease

M.-F. Xia, China

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

LBA OP 01 From aching genes to heartache in type 2 diabetes

Chairs: Jørgen Rungby, Denmark; Stefano Del Prato, Italy

LBA 01 Precision phenotyping of type 2 diabetes in Chinese populations using a variational autoencoder-informed tree model

S. Luo, T. Yue, W. Zhang, Y. Ding, X. Zheng, J. Chan, E. Pearson, J. Weng, China, Hong Kong, UK

GENERAL
INFO**LBA 02 Temporal changes in the impact of genetic susceptibility to type 2 diabetes: the HUNT study 1984-2019**

B. O. Åsvold, V. V. Bjarkø, B. Wolford, E. B. Haug, L. Stene, S. Carlsson, A. Langhammer, K. I. Birkeland, T. J. Berg, E. P. Sørgerjerd, V. Lyssenko, B. Brumpton, G. Å. Vie, Norway, Sweden

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

LBA 03 Depression increases both HbA_{1c} testing frequency and risk of all-cause mortality in type 2 diabetes

D. Handley, R. Bala, K. Young, J. Tyrrell, A. C. Gillett, C. M. Lewis, UK

LBA 04 The impact of early and intensive HbA_{1c} control on the risk of long-term macrovascular and microvascular complications in patients with type 2 diabetes from the Swedish National Diabetes Register

E. Wilkes, J. Mount, K. Boye, J. Lebrech, K. Ranta, A. Toll, E. Joas, I. Sveide, B. Eliasson, J. Redig, USA, Germany, Sweden

SHORT ORAL
DISCUSSIONS**LBA 05 Age-specific associations between blood pressure and cardiovascular disease, renal disease, and death among people with type 2 diabetes: a population-based cohort study**

E. W. Chow, Y. Fan, E. S. Lau, H. Wu, R. C. Ma, A. P. Kong, E. Chow, J. C. Chan, A. O. Luk, Hong Kong

PRESENTER
INDEXSATELLITE
SYMPOSIA**LBA 06 Effectiveness of high-dose vs standard-dose inactivated influenza vaccine in older adults with diabetes: a prespecified analysis of the DANFLU-2 trial**

A. B. Nielsen, N. D. Johansen, D. Modin, M. M. Loiacono, R. C. Harris, M. Dufournet, B. L. Claggett, K. H. Janstrup, S. D. Solomon, M. J. Landray, G. H. Gislason, L. Køber, P. Sivapalan, J. S. Jensen, T. Biering-Sørensen, Denmark, USA, Singapore, France, UK

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

The background features a collage of circular images in shades of blue and yellow. The images include a microscope, a hand holding a smartphone, a stethoscope, a person's face, a molecular structure, and a person's hands. The EASD e-Learning logo is positioned in the top left corner.

 EASD e-Learning

 **CME accredited**

 **free access**

 **80+ modules**

 **regular updates**

easd-elearning.eu

SHORT ORAL DISCUSSIONS EVENT A

	12:00 - 13:00 Short Oral Discussion Area	Page
	SO 001 - Station 01	
	MODY and neonatal diabetes	109
	SO 007 - Station 02	
	Type 1 diabetes epidemiology and metabolic indicators	115
GENERAL INFO	SO 013 - Station 03	
	Metabolic and vascular complications of diabetes	120
PROGRAMME	SO 019 - Station 04	
TUESDAY	It's beta cell replacement time	125
WEDNESDAY	SO 025 - Station 05	
	Islet cell adaptation gone right (and wrong).	131
THURSDAY	SO 031 - Station 06	
	Beta cells breaking under stress	137
FRIDAY	SO 037 - Station 07	
	Move it or lose it: metabolic consequences of exercise and its absence	143
SHORT ORAL DISCUSSIONS	SO 043 - Station 08	
	New frontiers in MASLD risk and diagnosis, from breastfeeding to biomarkers	149
	SO 049 - Station 09	
	Neuroinflammation: Is the brain taking too much heat?	154
PRESENTER INDEX	SO 055 - Station 10	
	Novel insights into regulation of metabolism by GLP-1R agonists	160
	SO 061 - Station 11	
	Peripheral mechanisms of glucose metabolism	166
SATELLITE SYMPOSIA	SO 067 - Station 12	
	Taking control: behavioural changes for optimal management of type 2 diabetes	172
INDUSTRY PROGRAMME	SO 073 - Station 13	
	The GLP-1 portfolio: diverse formulations for expanding clinical applications	178
EXHIBITION	SO 079 - Station 14	
	Mix and inject	184
	SO 085 - Station 15	
	It's getting complicated	190
THANKS	SO 091 - Station 16	
	Basic insights in diabetes-related kidney complications	196
	SO 097 - Station 17	
	Clinical aspects of gestational diabetes	202

12:00 - 13:00 **Short Oral Discussion Area** **Page**

SO 103 - Station 18
 Pathophysiology of diabetes-related neuropathy 208

SO 109 - Station 19
 Diagnosis and treatment of diabetes-related foot 214

SO 115 - Station 20
 Type 1 diabetes and novel CV insights 220

SO 121 - Station 21
 Type 1 diabetes: late and acute complications 226

SO 127 - Station 22
 Cancer, liver and diabetes 231

LBA SO 01 - Station 23
 Beyond GLP-1 horizon: oral drugs, dual agonists. 233

12:00 - 13:00 **Warsaw Hall**

EASD e-Learning expert session: Early stage type 1 diabetes

Chair: Klemen Dovc, Slovenia

Panellists: Chantal Mathieu, Belgium
 Thomas R. Pieber, Austria

12:15 - 13:00 **Spotlight Stage**

Type 1 diabetes and inflammation

Chair: Decio L. Eizirik, Belgium

Speaker: Carmella Evans-Molina, USA:
Is it just the islets?

Discussion

12:15 - 13:00 **Arena**

Lab Talk

Speaker: Daniel Drucker, Canada

GENERAL INFO
PROGRAMME
TUESDAY
WEDNESDAY
THURSDAY
FRIDAY
SHORT ORAL DISCUSSIONS
PRESENTER INDEX
SATELLITE SYMPOSIA
INDUSTRY
PROGRAMME
EXHIBITION
THANKS

SHORT ORAL DISCUSSIONS EVENT B

	Short Oral Discussion Area	Page
	13:15 - 14:15	
	SO 002 - Station 01	
	Genetic and omics in type 1 diabetes	110
	SO 008 - Station 02	
	Prediabetes: prevalence and diagnosis.	116
GENERAL INFO	SO 014 - Station 03	
	Clinical burden of diabetes	121
PROGRAMME	SO 020 - Station 04	
TUESDAY	Crystal balls and beta cells: predicting T1D's next move	126
WEDNESDAY	SO 026 - Station 05	
	Transcribe me if you can: the real regulators of beta cell county . . .	132
THURSDAY	SO 032 - Station 06	
	Feeding signals: how gut hormones shape appetite and metabolism	138
FRIDAY	SO 038 - Station 07	
	Healing the fatty liver: hormones, medications, and metabolic insights	144
SHORT ORAL DISCUSSIONS	SO 044 - Station 08	
	Under pressure: hormonal and neural responses to glycaemic stress	150
PRESENTER INDEX	SO 050 - Station 09	
	Adipocytes in flames	155
	SO 056 - Station 10	
	A refined look at the pancreas in health and disease	161
SATELLITE SYMPOSIA	SO 062 - Station 11	
	CNS regulation of systemic energy and glucose metabolism	167
INDUSTRY	SO 068 - Station 12	
	Dietary diversity in practice: navigating multiple nutritional approaches.	173
PROGRAMME	SO 074 - Station 13	
	In (hospital) bed with diabetes.	179
EXHIBITION	SO 080 - Station 14	
	K like ketones	185
THANKS	SO 086 - Station 15	
	"Don't leave me alone", insulin said.	191
	SO 092 - Station 16	
	Biomarkers in diabetes-related kidney complications	197
	SO 098 - Station 17	
	Gestational diabetes: exciting new data	203

13:15 - 14:15	Short Oral Discussion Area	Page
SO 104 - Station 18	Advancements in diabetes-related autonomic neuropathy	209
SO 110 - Station 19	Epidemiology and treatment of diabetes-related foot	215
SO 116 - Station 20	Known and novel biomarkers in cardiometabolic health.	221
SO 122 - Station 21	Cognitive dysfunction on the target.	227
SO 128 - Station 22	Biochemical face of cognitive impairment and dementia	232
LBA SO 02 - Station 23	Thinking big about treating obesity.	234

13:15 - 14:00 **Spotlight Stage**

Are incretin therapies a game changer for type 1 diabetes?

Chair: Jennifer Snaith, Australia

Speaker: Riitta Veijola, Finland:

Use of GLP-1RA in children with type 1 diabetes

Petter M. Bjornstad, USA:

Use of GLP-1RA in adults with type 1 diabetes

Jerry R. Greenfield, Australia:

Potential benefits of GLP-1 and GIP receptor agonism in T1D

13:15 - 14:00 **Arena**

Lab Talk

Speaker: Juleen R. Zierath, Sweden

GENERAL INFO
PROGRAMME
TUESDAY
WEDNESDAY
THURSDAY
FRIDAY
SHORT ORAL DISCUSSIONS
PRESENTER INDEX
SATELLITE SYMPOSIA
INDUSTRY
PROGRAMME
EXHIBITION
THANKS

14:45 - 16:15

Vienna Hall

OP 07 Adiposity related interventions/measures and CV outcomes

Chairs: Vanita Aroda, USA; Romyana Dimova, Bulgaria

37 Long-term incidence and case-fatality rates of myocardial infarction in people with newly diagnosed diabetes and impaired glucose tolerance: the Da Qing Diabetes 34-year follow-up

J. Xu, Y. Chen, S. He, G. Li, S. Zhou, X. Feng, M. Chen, China

GENERAL
INFO

38 The acute molecular effects of five dietary pattern revealed by a prospective proteomics study

T. Zhang, USA

PROGRAMME

TUESDAY

39 Long-term impact of bariatric surgery on cardiovascular events and atherosclerotic complications in patients with and without type 2 diabetes

D. Moriconi, E. Guidotti, A. Troilo, L. Bonvicini, M. Bianchi, R. Bellini, M. Nannipieri, Italy

WEDNESDAY

THURSDAY

FRIDAY

40 The normalisation of insulin resistance before stroke improves functional outcome in type 2 diabetes

V. Darsalia, E. Vercauteren, D. Karampatsi, M. Neicu, M. O. Romanitan, T. Nyström, T. Klein, C. Patrone, Sweden, Germany

SHORT ORAL
DISCUSSIONS

41 Cardiometabolic and kidney outcomes validate the prognostic value of adiposity-based obesity classification system: a longitudinal analysis of the UK Biobank

S. Gunnarsson, C. Karlsson, D. Loesch, R. Prasad B, S. Hansson, Sweden, UK

PRESENTER
INDEX

42 Predictive value of TyG-ACW for cardiovascular disease and mortality risk in diabetic patients

G. Zhao, B. Qi, X. Yu, A. Yang, Y. Jin, X. Wang, F. Bao, B. Gao, China

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

14:45 - 16:15

Paris Hall

OP 08 Type 1 diabetes onset, metabolic indicators and complications

Chairs: Miriam Longo, Italy; Arleta Rewers, USA

43 Geographical hotspots of type 1 diabetes in Sweden: Are rural environments early-life risk factors?

S. Sebraoui, O. Englund, F. Nyberg, A. Carlsson, O. Korsgren, G. Forsander, K. Eeg-Olofsson, B. Eliasson, H. Carlsen, K. Åkesson, S. Gudbjörnsdottir, Sweden

EXHIBITION

THANKS

44 Metabolic control in adults living with type 1 diabetes across northwestern Europe: a comparative study

A. Lavens, S. Wild, S. Metso, K. Åkesson, K. Eeg-Olofsson, G. Åstrøm Ueland, J. Cooper, Belgium, UK, Finland, Sweden, Norway

45 Intermittently scanned continuous glucose monitoring adoption decreases diabetic ketoacidosis hospitalisations and healthcare costs in adults with type 1 diabetes

P. Rodríguez de Vera Gómez, B. Rodríguez Jiménez, E. Mayoral Sánchez, F. Jódar Sánchez, R. Ravé García, G. Umpierrez, M. Martínez Brocca, Spain, USA

46 Fracture incidence rates among persons with type 1 diabetes, type 2 diabetes, or without diabetes in Denmark 1997-2021

A. V. Kvist, V. P. Visker, J. H. Driessen, P. Vestergaard, Denmark, Netherlands

47 Sex differences in risk for cardiovascular disease and all-cause mortality: a direct comparison of type 1 with type 2 diabetes patients in a nationwide register-based study

V. Patsoukaki, L. Lind, K. Eeg-Olofsson, B. Eliasson, J. W. Eriksson, Sweden

48 Trends in mortality among individuals with type 1 diabetes from 15 to 25 years post-diagnosis in different eras: a cross-sectional, real-world observational study

A. Lavens, C. De Block, P. Oriot, J.-C. Philips, M. Vandenbroucke, L. Crenier, F. Nobels, C. Mathieu, Belgium

14:45 - 16:15

London Hall

OP 09 Living with pumping and looping

Chairs: Sergio Di Molfetta, Italy; Tsvetalina Tankova, Bulgaria

49 Sustainable effect of an aid system in 2-6-year-olds: results from the LENNY trial extension phase

K. Dovc, S. Kuusela, A. Shetty, A. Tuomaala, A. Zanfardino, B. Jullian, F. Di Piazza, T. Van den Heuvel, O. Cohen, on behalf of the LENNY study group, Slovenia, Finland, UK, Italy, Switzerland

50 Achieved and sustained glycaemic outcomes with reduction in burden: three-year real-world follow-up of the MiniMed 780G system

J. McVean, M. Juachon, B. Voelker, J. Castaneda, J. Shin, T. Van den Heuvel, G. Petrovski, R. Vigersky, O. Cohen, Switzerland

51 Lived experience of using fully closed-loop insulin delivery in adolescents with type 1 diabetes and HbA_{1c} above target

N. Kadiyala, J. Allen, J. Ware, R. Lakshman, C. Boughton, M. E. Wilinska, A. Thankamony, S. Hartnell, H. Thabit, R. Williemsens, P. Shah, R. Hovorka, UK

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

52 Efficacy and safety of the Omnipod 5 system compared with MDI in adults with type 1 diabetes in the RADIANT study

B. Guerci, H. Hanaire, P. Gillard, M. Joubert, P. Choudhary, L. Leelarathna, S. Lablanche, T. S. Crabtree, T. T. Ly, E. G. Wilmot, the RADIANT Study Group, France, Belgium, UK, USA

53 Real-world outcomes of the DBLG1 hybrid closed-loop system in adults living with type 1 diabetes in Belgium

M. Lytrivi, V. Thielen, C. Vercammen, I. Matthys, C. De Block, P. Gillard, R. Radermecker, I. Ramon, L. Van Huffel, D. Scarnière, I. Colin, V. Preumont, L. Crenier, Belgium

GENERAL
INFO

54 Long-term glycaemic management and person-reported outcomes two years after Control-IQ initiation in adults with type 1 diabetes

J. De Meulemeester, B. Keymeulen, C. De Block, L. Van Huffel, Y. Taes, D. Ballaux, K. Spincemaille, J. Marlier, G. Vanhaverbeke, I. Lowyck, C. Vercammen, I. Colin, V. Preumont, C. Mathieu, P. Gillard, Belgium

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

14:45 - 16:15

Mumbai Hall

OP 10 Updates in autonomic neuropathy and diabetes-related foot complications

Chairs: Joanna Gastol, Poland; Luigi Laviola, Italy

55 Association of CGM metrics and HbA_{1c} with ECG-derived CAN in type 1 diabetes

B. Braffett, I. Bebu, L. El ghormli, C. Martin, K. Farrell, V. Trapani, M. Johnson, R. Bergenstal, E. Z. Soliman, R. Gubitosi-Klug, R. Pop-Busui, USA

56 Association of inflammatory and cardiovascular proteomics biomarkers with indices of heart rate variability in the general population: KORA S4/FF4 Study

K. Oluwagbemigun, D. Ziegler, A. Strom, M. Heier, G. Bönhof, M. Roden, W. Rathmann, C. Meisinger, A. Peters, S. M. Hauck, A. Petrera, M. F. Sinner, S. Käb, B. Thorand, C. Herder, Germany

57 Impact of cardiovascular autonomic neuropathy on cardiopulmonary, sympathoadrenal, and metabolic responses to physical exercise in adults with type 1 diabetes

O. M. McCarthy, R. Brødsgaard, S. Tawfik, S. Lundemose, E. Lindkvist, S. H. Naaman, C. Hansen, R. Bracken, K. Noergaard, Denmark, UK

58 Association of different types of diabetic autonomic neuropathy with left ventricular diastolic dysfunction in patients with type 2 diabetes: a cross-sectional study

R. Feng, D. Yan, X. Ran, Y. Gao, China

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

59 The polymicrobial metaproteomic signature impact on host defences of diabetic foot ulcers

M. Petkovic, J. A. Raguz, M. M. Nielsen, A. Rasmussen, M. B. Blond, K. Kirketerp-Møller, R. R. Jersie-Christensen, J. Gilman, Z. Li, T. Kümler, P. Rossing, A. Veves, L. T. Dalgaard, T. S. Ahluwalia, Denmark, USA

60 Diabetic foot ulcers and their impact on foot care habits and quality of life

J. Røikjer, M. Borbjerg, M. B. Poulsen, P. W. Holm, N. Ejskjaer, C. Brock, P. Vestergaard, Denmark

14:45 - 16:15

Sofia Hall

OP 11 Promising therapies in type 2 diabetes and obesity

Chairs: Aaron Novikoff, Germany; Athena Philis-Tsimikas, USA

61 Mifepristone, a glucocorticoid receptor antagonist, reduced HbA_{1c} and body weight in difficult-to-control type 2 diabetes with hypercortisolism: the CATALYST prevalence and treatment trial

R. A. DeFronzo, V. Fonseca, V. R. Aroda, R. J. Auchus, T. Bailey, J. B. Buse, E. A. Christofides, J. W. Findling, Y. Handelsman, S. E. Kahn, R. Pratley, J. Rosenstock, G. Umperiez, I. C. Tudor, D. Einhorn, USA

62 Symphony 2: a randomised, placebo-controlled phase 3 study of berberine ursodeoxycholate in patients with type 2 diabetes inadequately controlled with metformin

L. Ji, Z. Cheng, J. Ma, D. Liu, X. Zhang, X. Dong, Y. Lin, M. Yang, S. Gan, H. Cai, X. Wang, Y. Liu, X. Shi, L. Liu, China

63 Amycretin, a novel, unimolecular glucagon-like peptide-1 and amylin receptor agonist: results of a phase 1b/2a clinical trial

K. Dahl, K. Adelborg, S. Dey, R. Duque do Vale, C. Key, S. Toubro, A. M. Jastreboff, Denmark, India, USA

64 Efficacy and safety of HRS9531, a novel dual GLP-1/GIP receptor agonist in Chinese overweight or obese adults without diabetes

Q. Wen, J. Zhou, H. Ling, T. Wu, K. He, F. Zheng, M. Zeng, T. Yu, L. Wang, Y. Wang, China

65 Characterisation of Myo4 in the murine diet-induced obesity model: a first-in-class anti-obesogenic muscle-preserving small molecule metabolic modulator.

X. Jacq, J. Holder, R. Torregrossa, L. Humbert, R. Cousins, N. Law, J. Rees, M. Whiteman, UK

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

66 Icovamenib and semaglutide combination therapy enhances body weight loss and glycaemic control while preserving lean mass in a type 2 diabetes animal model

P. Somanath, T. Zhang, T. Butler, J. Frias, M. Balakrishnan, USA

14:45 - 16:15

Milan Hall

OP 12 Monogenic diabetes diagnosis, treatment and aetiology

Chairs: Kashyap Patel, UK; Tiinamaija Tuomi, Finland

67 Exploring MODY in the population: understanding the prevalence, variable penetrance and mortality in 454,275 people

L. N. Sharp, K. Colclough, J. Murray Leech, S. J. Cannon, T. W. Laver, A. T. Hattersley, M. N. Weedon, K. A. Patel, UK

68 Polygenic background modifies glycaemic variability and clinical outcomes in GCK-MODY

J. Murray Leech, A. M. Arni, L. N. Sharp, K. Colclough, K. Chundru, A. T. Hattersley, M. N. Weedon, K. A. Patel, UK

69 A type 1 diabetes genetic risk score helps uncover hidden type 1 diabetes cases in a MODY cohort

A. Sriram, K. Colclough, A. Hattersley, J. Houghton, T. W. Laver, K. Patel, UK

70 Empagliflozin in HNF1A-MODY (MODY3): a randomised, double-blind, placebo-controlled, crossover trial

H. Maagensen, S. O. Høyerup, J. S. Jensen, A. C. Thuesen, J. L. Forman, H. H. Thomsen, H. Vestergaard, F. K. Knop, T. Hansen, S. Hædersdal, J. Stø, T. Vilsbøll, Denmark

71 TMEM167A mutations, causing a novel form of neonatal diabetes, impair pancreatic beta cell function and survival

E. Virgilio, T. Sawatani, C. Vinci, A. Liboz, F. Fantuzzi, M. Lytrivi, F. Natividade Da Silva, T. Papadopoulou, A. Piron, R. Scharfmann, A. T. Hattersley, E. De Franco, M. Cnop, Belgium, France, UK

72 Defects in the minor spliceosome cause infancy onset diabetes through immune dysregulation

M. B. Johnson, J. Russ-Silsby, P. A. Blair, G. Bonfield, M. Govier, M. N. Wakeling, S. E. Flanagan, T. Tree, R. A. Oram, K. A. Patel, A. T. Hattersley, E. De Franco, UK

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

LBA OP 02 Before and after pregnancy with diabetes

Chairs: Signe Foghsgaard, Denmark; Christian Göbl, Austria

LBA 07 Treatment of gestational diabetes in women with discordant OGTT results using the 2013 and 1999 WHO criteria: the TANGO-DM randomised controlled trial

R. C. Painter, A. W. Van der Wel, D. Rademaker, R. G. Duijnhoven, P. M. Bossuyt, B. W. Mol, A. Franx, J. DeVries, B. B. Van Rijn, TANGO-DM Study Group, Netherlands, Australia

LBA 08 Glycaemic control and pregnancy outcomes with real-time continuous glucose monitoring in gestational diabetes (GRACE): an open-label, international, randomised controlled trial

T. Linder, I. Dressler-Steinbach, S. Wegener, K. Schellong, S. Schmidt, D. Eppel, C. Monod, K. Redling, B. Winzeler, B. Mosimann, F. Weschenfelder, T. Groten, J. Jendle, L. Bozkurt, C. Göbl, Austria, Germany, Switzerland, Sweden

LBA 09 Analysis of mitochondrial respiration of peripheral blood mononuclear cells and serum growth differentiation factor 15 in women with gestational diabetes

N. Krako Jakovljevic, K. Pavlovic, T. Milicic, L. Lukic, M. Macesic, J. Stanarcic Gajovic, M. Stojilkovic, M. Milovancevic, D. Rafailovic Cvetkovic, M. Gojnic Dugalic, K. Lalic, N. Lalic, A. Jotic, Serbia

LBA 10 Mid-pregnancy lipidomic signatures identify metabolic subtypes associated with divergent pregnancy outcomes

D. Yu, T. Yue, J. Wang, S. Luo, X. Zheng, China

LBA 11 Adherence to diabetes screening in high-risk women after gestational diabetes in Denmark

S. Haedersdal, K. K. Jacobsen, S. Foghsgaard, P. Rossing, T. Vilsbøll, Denmark

LBA 13 Blood biomarkers as predictors of infant weight independent of maternal factors

N. Kabbani, H. Stepan, T. Ebert, M. Blüher, W. Kiess, M. Lia, R. Baber, M. Vogel, A. Tönjes, S. Schrey-Petersen, Germany

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONSPRESENTER
INDEXSATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

15:00 - 16:00

Spotlight Stage

Artificial Intelligence in diabetes care today and tomorrow

Chair: Torben Biester, Germany

Speaker: Amit K. Dey, India:
Artificial Intelligence in diabetes care: pumps, decision support, and DSME chatbots

Rutul Gokalani, India:
Potential role of Artificial Intelligence and machine learning in hyperglycaemia in pregnancy

GENERAL
INFO

PROGRAMME

TUESDAY

16:45 - 17:45

Vienna Hall

40th Camillo Golgi Lecture

The Camillo Golgi Prize recognises outstanding contributions in the field of histopathology, pathogenesis, prevention and treatment of the complications and comorbidities of diabetes mellitus.

Chair: Francesco Giorgino, Italy

Speaker: Mikael Rydén, Sweden:
Everything you want to know about adipose tissue: from cellular mechanisms to clinical complications

Mikael Rydén is a leading authority in human adipose tissue biology and metabolic research. He is Chair of Clinical and Experimental Adipose Tissue Research at Karolinska Institutet in Stockholm, Sweden, where he also serves as Director of both the Center for Clinical Metabolic Research in Diabetes (CCMRD) and the Center for Reproduction, Metabolism and Molecular Medicine (CeRM). In addition, he is a senior consultant in Endocrinology and Diabetology at Karolinska University Hospital, and since 2024, he has also been affiliated with the Steno Diabetes Center Copenhagen, Denmark.



Professor Rydén's research focuses on elucidating the functional role of adipose tissue in human physiology and disease. A major emphasis of his research lies in uncovering the mechanisms by which adipose tissue dysfunction contributes to metabolic, reproductive, and cardiovascular disorders - including type 2 diabetes, obesity, polycystic ovary syndrome (PCOS), hypertension, and atherosclerosis.

Professor Rydén has contributed to the development of clinical guidelines for diabetes care and served as Honorary Secretary of the European Association for the Study of Diabetes (EASD) from 2018 to 2022. He currently serves on the EASD Committee for Clinical Affairs and also on numerous scientific advisory boards across Europe. Professor Rydén is an elected member of the Nobel Assembly at the Karolinska Institutet

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

16:45 - 17:45

Paris Hall

The emerging consensus for population level screening to detect early stage type 1 diabetes

Chair: Anastasia Albanese-O'Neill, USA

Speaker: Marian Rewers, USA:

What are the benefits, harms, and available methods for type 1 diabetes screening?

Anette-Gabriele Ziegler, Germany:

Who should we screen, at what age, and how often?

Chantal Mathieu, Belgium:

Where should screening take place and how do we effectively communicate the results?

16:45 - 17:45

London Hall

How close are we to fully closed loop systems?

Chair: Roman Hovorka, UK

Speaker: Moshe Phillip, Israel:

Automated insulin delivery technologies in clinical practice

Katrien Benhalima, Belgium:

Hybrid closed-loop systems currently available: benefits and challenges

Charlotte Boughton, UK:

Fully automated closed-loop delivery systems in type 1 and type 2 diabetes

16:45 - 17:45

Mumbai Hall

Diabetologia Symposium: Global opportunities and challenges – prevention, care and therapy

Chairs: Christian Herder, Germany; Cheryl Pritlove, Canada

Speaker: Nish Chaturvedi, UK:

Race, ethnicity and ancestry: What do they mean for diabetologists?

Richard Oram, UK:

Type 1 diabetes: a global perspective

Dianna Magliano, Australia:

Global variation in type 2 diabetes prevalence

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

16:45 - 17:45

Sofia Hall

Losing weight: Can the balance be preserved?

Chair: Niels Jessen, Denmark

Speaker: Marco Sandri, Italy:
Mechanisms preserving muscle mass

Signe S. Torekov, Denmark:
Health weight-loss with exercise and GLP-1 receptor agonist

Jan Eriksson, Sweden:
Whole body imaging after obesity surgery or diet induced weight loss

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

16:45 - 17:45

Milan Hall

EASD-ADA Joint Symposium: Incorporating pharmacogenomics and genomic medicine in type 2 diabetes clinical care

Chairs: Alice Y. Cheng, Canada; Cassandra N. Spracklen, USA

Speaker: Jose C. Florez, USA:
Practical utility of genomic medicine in the clinic for type 2 diabetes

Andreas L. Birkenfeld, Germany:
Using genetics to identify novel treatments for type 2 diabetes and obesity

Scott C. Ritchie, UK:
Leveraging genetics to improve prediction, detection and prevention of type 2 diabetes

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Unique issues in people with diabetes and Black heritage

Chair: Jonathan Rosen, USA

Speaker: Daniel Newman, UK:
Living with type 1 diabetes as a person of black heritage: my personal journey TBA

Janaka Karalliedde, UK:
Emerging data and evidence on the burden of diabetes complications in adults with type 1 diabetes of black heritage

Sarah Finer, UK
Diagnostic and clinical challenges in people of Black heritage with type 2 diabetes

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

08:30 - 09:30

Vienna Hall

SOUL Trial: Effects of oral semaglutide on cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk

Chair: Johannes F.E. Mann, Germany

Speaker: Nikolaus Marx, Germany:
SOUL: Design, primary findings and analysis of CV outcomes by SGLT2i use

Rodica Pop-Busui, USA:
SOUL: Heart failure (HF)

Matthew A. Cavender, USA:
SOUL: Major adverse limb events (MALE) subgroups and meta-analysis

Ildiko Lingvay, USA:
Commentary

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

08:30 - 09:30

Paris Hall

Diabetologia-Diabetes-Diabetes Care Expert Forum: Insulin resistance in the 21st century: new takes on an old problem

Chair: TBA

Speaker: TBA
Supported by the Novo Nordisk Foundation

08:30 - 09:30

London Hall

EASD-EASO Joint Symposium: Obesity +/- diabetes “peri”-pregnancy – what to focus on:

Chairs: Tina Vilsbøll, Denmark; Volkan D. Yumuk, Türkiye

Speaker: Sara Suliman, UAE:
...before pregnancy

Signe Foghsgaard, Denmark:
...during pregnancy

Claire Meek, UK:
...after pregnancy

08:30 - 09:30

Mumbai Hall

19th Albert Renold Lecture

The Albert Renold Prize recognizes outstanding achievements in the field of pathophysiology and treatment of diabetes mellitus.

Chair: Francesco Giorgino, Italy

Speaker: Raphael Scharfmann, France:

Pancreas development: a key to discover unexpected treatments of diabetes

Raphael Scharfmann went to Medical School in Lille during 5 years, switched to a PhD obtained in 1989 at University Paris VII, France. He next did a post doc at the Salk institute, La Jolla, CA (1989-1991) and obtained a permanent position at INSERM at the end of 1991.



He obtained the prestigious Minkowski Award from EASD (for distinguished research in the field of Diabetes in Europe) (1999), the Bettencourt Award (2012) and the Assan Award from the French speaking society of diabetology (SFD).

He is currently Research Director at INSERM within the Cochin Institute, University Paris-Cité, France. He is one of the co-founders of EndoCells/Human Cell Design, a French biotech company. The major objective of his group is to develop innovative ways to define signals regulating functional pancreatic endocrine cell mass in rodent and human.

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

08:30 - 09:30

Sofia Hall

Dementia in diabetes: reasons for hope or concern

Chair: Alice Y. Cheng, Canada

Speaker: Gill Livingston, UK:

What causes dementia? Lessons from the dementia commission

Thomas T. van Sloten, Netherlands:

Connecting the dots: Why are dementia rates in diabetes rising?

Alireza Atri, USA:

Can diabetes therapies treat dementia?

08:30 - 09:30

Milan Hall

Mitochondrial function: a key regulator of pancreatic beta cell maturation, function, and inflammatory vulnerability

Chair: Niels Jessen, Denmark

Speaker: Sarah Zangen, Israel:

Disruption of mitochondrial oxidative phosphorylation through cytochrome c oxidase dysfunction compromises beta cell function

Maike Sander, Germany:

Nutrient sensing and functional adaptation in beta cell

Scott A. Soleimanpour, USA:

Retrograde mitochondrial signaling governs the identity and maturity of metabolic tissues

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

08:30 - 09:30

Warsaw Hall

WHO Europe-EASD-EUFD session: Enabling high quality diabetes care by setting targets, monitoring data and initiating action

Chair: Chantal Mathieu, Belgium

Speaker: Stefano Del Prato, Italy:

It takes more than just a registry to improve care: use data to raise awareness and initiate action to improve outcomes

Jill Farrington, WHO:

Achieving the global diabetes targets in the WHO European Region: case studies and key learnings

Astrid Lavens, Belgium:

The use of data to implement and evaluate diabetes policy: perspective from the Belgian public health research institute

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

OP 13 GLP-1 trending: the latest developments

Chairs: Alice Cheng, Canada; Andreas Andersen, Denmark

73 REDEFINE 2: a randomised trial of combined semaglutide 2.4 mg and cagrilintide 2.4 mg for the treatment of adults with BMI $\geq 27\text{kg/m}^2$ and type 2 diabetes

M. J. Davies, H. S. Bajaj, C. Broholm, A. Eliassen, W. T. Garvey, C. W. Le Roux, I. Lingvay, C. Lyndgaard, J. Rosenstock, L. Von Huth Smith, S. D. Pedersen, UK, Canada, Denmark, USA, Ireland

75 Tirzepatide reduces weight and insulin dose and improves body composition in type 1 diabetes: a 12-week, randomised, double-blind, placebo-controlled trial (TIRTLE1)

J. R. Snaith, R. Frampton, D. Samocha-Bonet, J. R. Greenfield, Australia

76 Safety of semaglutide among people treated with dialysis: a pooled analysis of SUSTAIN-6, SELECT, FLOW, and SOUL

K. R. Klein, A. Menacher, K. Tuttle, A. T. Storås, M. Andersen, M. M. Mayrdorfer, I. Lingvay, USA, Denmark

77 Six-week continuous s.c. infusion of GIP alone or added to semaglutide treatment had no effect on mean glucose levels or body weight in individuals with type 2 diabetes

M. M. Helsted, C. Fonnesbech-Wulff, N. L. Schaltz, I. W. Lund, J. Forman, C. K. Nielsen, A. Englund, B. Hartmann, T. Vilsbøll, J. J. Holst, A. B. Lund, M. B. Christensen, F. K. Knop, L. S. Gasbjerg, Denmark

78 A novel antibody-peptide conjugate targeting PCSK9, GLP-1R, GCGR, GIPR improves cardiovascular risk markers in preclinical study

Y. Li, H. Shen, X. Deng, L. Cao, X. Pan, Y. Gao, J. Chen, C. Zhu, W. Wu, D. Ren, China

OP 14 Lifestyle and pharmacological risk factors for type 2 diabetes

Chairs: Nevena Chakarova, Bulgaria; Adam Tabák, Hungary

79 Rising burden of diabetes, stroke, and ischaemic heart disease attributable to sugar-sweetened beverages among young adults: a global analysis and 30-year projection (1990-2051)

C. Liu, China

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONSPRESENTER
INDEXSATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

80 Timing of moderate-to-vigorous physical activity and the risk of developing type 2 diabetes: evidence from UK Biobank and NHANES

Q. Feng, G. Albalak, L. Ao, Q. Xiao, H. Wang, J. Van der Velde, J. C. De Jong, M. K. Rutter, J. R. Freeman, K. Willems van Dijk, D. Van Heemst, R. Noordam, Netherlands, USA, UK

81 The association between statin therapy and the incidence of diabetes, microvascular complications, and cardiovascular events in patients without pre-existing cardiovascular disease

J. Kim, J. Choi, K. Kim, Y.-E. Kim, S. Shin, K. Kim, S. Kim, Republic of Korea

82 Glucocorticoid use and risk of incident diabetes: a nationwide Danish case-control study

N. Rasmussen, A. Kvist, P. Vestergaard, Denmark

83 Characterisation of patients with difficult-to-control type 2 diabetes and a post-dexamethasone suppression test cortisol of 1.2-1.8 µg/dL: findings from a large prospective study

R. S. Busch, R. J. Auchus, T. Bailey, L. Blonde, J. B. Buse, E. A. Christofides, R. A. DeFronzo, B. Eilerman, V. Fonseca, Y. Handelsman, M. H. Shanik, L. Sloan, G. Umpierrez, I. C. Tudor, D. Einhorn, USA

84 Intellectual disability and overall and type-specific cardiovascular disease risk in individuals with type 2 diabetes

J.-H. Baek, Y.-M. M. Park, O.-K. Hong, S.-H. Ko, S.-S. Lee, K. Han, Republic of Korea, USA

09:45 - 11:15

London Hall

OP 15 Pregnancy and diabetes: new insights

Chairs: Annunziata Lapolla, Italy; Ute Schäfer-Graf, Germany

85 Higher parity is associated with lower likelihood of diabetic complications and mortality in women with type 1 diabetes

K. Rimpeläinen, F. Jansson Sigfrids, P.-H. Groop, V. Harjutsalo, L. M. Thorn, Finland

86 Glycaemic control and daily insulin requirement in mothers of LGA and eutrophic newborns in patients with type 1 diabetes treated with sensor-augmented insulin pumps: a retrospective cohort study

R. Sibiak, M. Sochacki, U. Mantaj, P. Gutaj, E. Wender-Ozegowska, Poland

87 International Diabetes Federation 2024 criteria: impact on the postpartum glucose tolerance assessment of women with gestational diabetes

R. Corcoy, L. C. Mendoza, A. C. Serrano, M. Bonet, A. Martínez, M. Romero, E. Safont, I. Pujol, A. Lopez, Spain

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

88 Metabolomic profiles at birth and age 7: contrasting association with maternal glycaemia and potential influence pathway on childhood metabolic outcomes in the HAPO cohort

Y. Deng, C. H. Tam, C. Wang, W. L. Lowe Jr, W. Tam, R. C. Ma, Hong Kong, USA

89 The effects of pre-meal and post-meal exercise on postprandial glucose excursions in pregnant women with type 1 diabetes

P. Acosta-Manzano, J. Wenninger, A. Gjergji, J. Lex, M. Flor-Aleman, P. Birnbaumer, A. Dieberger, G. Tschakert, P. Hofmann, M. Van Poppel, Austria, Spain

90 Appendicular lean mass, grip strength and risk of gestational diabetes

F. Lai, N. Chen, C. Xu, S. Liang, Y. Li, H. Xiao, X. Cao, China

09:45 - 11:15

Mumbai Hall

OP 16 Monitoring the fall of the type 1 diabetes islet empire

Chairs: Eelco De Koning, Netherlands; Raphael Scharfmann, France

91 The glucagonotropic effect of glucose-dependent insulinotropic polypeptide is negated during insulin-induced hypoglycaemia in persons with type 1 diabetes

N. E. Sørnum, J. V. Nielsen, J. J. Holst, B. Hartmann, L. S. Gasbjerg, J. Størling, T. F. Dejgaard, M. B. Christensen, J. E. Campbell, F. K. Knop, A. B. Lund, Denmark, USA

92 Fasting proinsulin: C-peptide ratio as minimally invasive alternative to predict development of stage 3 type 1 diabetes: a longitudinal analysis

A. K. Desouter, H. Kahya, B. Keymeulen, U. Van de Velde, A. Van Dalem, S. Demeester, B. Lapauw, E. V. Balti, P. De Pauw, F. K. Gorus, Belgian Diabetes Registry, Belgium

93 Risk of future diabetes in single glutamate decarboxylase autoantibody positive adults

S. L. Grace, Alistair Williams Antibody Facility, The BOX Study Group, A. E. Long, K. M. Gillespie, UK

94 Immunomic profiling revealed distinct molecular patterns specific to type 1 diabetes compared to other autoimmune diseases

E. Zügner, F. Monedeiro, B. Prietl, M. Oberhuber, J. Woelk, N. Hermann-Kleiter, M. H. Stradner, M. Khalil, C. Magnes, T. R. Pieber, Austria

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

95 Preclinical analysis of 4hD29, a single-domain antibody against the islet-specific marker DPP6, for in vivo beta cell mass imaging

A. Roca-Rivada, A. Khalil, I. Veliky, S. Vasylovska, J. Lau, O. Eriksson, D. L. Eizirik, Belgium, Sweden

96 The CGM results do not always match with the classical glucose metabolism criteria in HLA-susceptible individuals monitored in the Finnish DIPP study

R. Squintani, E. Lahti, H. Kontola, J. Koskenniemi, J. Kero, T. Honkanen, T. Pokka, J. Toppari, R. Veijola, Finland

GENERAL
INFO

09:45 - 11:15

Sofia Hall

OP 17 New evidence in diabetes-related neuropathy: from biomarkers to imaging

Chairs: Zoltan Kender, Germany; Vincenza Spallone, Italy

97 Serum lipidomics profiling unveiling biomarkers for diabetes neuropathy in type 1 diabetes patients

T. Muk, T. Okdahl, M. Kokla, T. Suvitaival, G. Kaur, C. Hansen, P. Karlsson, T. Jensen, P. Rossing, F. Pociot, B. Brock, C. Legido-Quigley, C. Brock, J. Størling, K. Sulek, Denmark, UK

98 Peripheral diabetic neuropathy is associated with an increased risk of stroke, independently from other diabetic complications, in individuals with type 1 diabetes

S. Itkonen, E. Dahlström, M. Eriksson, J. Puutala, P.-H. Groop, V. Harjutsalo, L. Thorn, Finland

99 Neuroimaging biomarkers for neuropathic pain: a machine learning approach to predicting treatment response

D. Selvarajah, J. Zhang, L. R. Rizky, K. Teh, S. Tesfaye, J. Wild, A. Segerdahl, D. Steele, D. Bennett, L. Colvin, H. Lu, UK

100 Pilavapadin, an oral, non-opioid, AAK1 inhibitor for diabetic peripheral neuropathic pain (DPNP): results from a Phase 2b, dose-ranging, randomised, placebo-controlled, multicenter study

R. Pop-Busui, S. Gopinathan, C. Granowitz, M. Hardin, P. Banks, P. Pierce, M. Girard, G. Umpierrez, USA

101 Gut microbiota and its metabolites promote painful diabetic peripheral neuropathy complicated with cognitive dysfunction in mice

J. Yang, H. Yuan, China

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

102 Genome-wide association study meta-analysis identifies new locus associated with increased risk of diabetic neuropathy in European ancestry individuals with diabetes

C. Armirola-Ricaurte, A. Veluchamy, S. Lemmellä, O. Fedotkina, P. Nilsson, S. S. Singh, C. S. Hansen, P. Rossing, T. S. Ahluwalia, V. Lyssenko, E. Sijbrands, C. N. Palmer, FinnGen, A. Jordanova, I. Barroso, UK, Belgium, Finland, Norway, Sweden, Netherlands, Denmark

09:45 - 11:15

Milan Hall

GENERAL
INFO

OP 18 Timing, type, and targets: mechanisms of exercise adaptation

Chairs: Kirstin MacGregor, Sweden; Othmar Moser, Germany

103 Personalised phosphoproteomics establish mTORC1 as regulator of human muscle insulin sensitivity following exercise

M. R. Leandersson, J. D. Onslev, N. S. Henriksen, H. Huckstep, J. M. Kristensen, M. N. Zankel, R. Elmquist, J. T. Madsen, J. B. Birk, R. Kjøbsted, D. E. James, S. J. Humphrey, J. F. Wojtaszewski, Denmark, Australia

104 Timing of high intensity interval training differentially affects peripheral insulin sensitivity and skeletal muscle mitochondrial adaptations in overweight and obese adults

R. Mancilla Fuentes, M. Bergman, P. Veeraiyah, V. De Wit-Verheggen, Y. Op den Kamp-Bruls, J. Hoeks, P. Schrauwen, V. Schrauwen-Hinderling, M. Hesselink, Netherlands, Chile, Germany

105 Type 2 diabetes is associated with lower oxygen uptake and metabolic inflexibility during exercise in heart failure with preserved ejection fraction

L. Nesti, L. Santoni, S. Gallo, N. Pugliese, S. Frascerra, M. Chiriaco, L. Sacchetta, D. Tricò, A. Natali, Italy

106 Immediate and extended effects of aerobic and anaerobic exercise on glycaemia in type 1 and type 2 diabetes

J. Zivkovic, M. Mitter, D. Theodorou, T. Glatzer, Austria, Switzerland, Germany

107 Sex-specific exercise adaptations in hippocampal energy metabolism: a multi-proteomic analysis in mice

K. J. Sevits, A. K. Asokan, R. G. Leija, T. Dutta, K. S. Nair, USA

108 Impaired lipid oxidation during exercise in type 2 diabetes and its role in exercise intolerance: a case-control study

L. Santoni, L. Nesti, S. Gallo, S. Frascerra, S. Baldi, N. R. Pugliese, M. Chiriaco, L. Sacchetta, D. Trico, A. Natali, Italy

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

09:45 - 11:00

Spotlight Stage

**Introducing a competency framework for diabetes technologies:
supporting development from novice to expert**

Chair: Laura Willcocks UK

Panellists: Erica Richardson, UK
Pratik Choudhary, UK

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

SHORT ORAL DISCUSSIONS EVENT C

11:45 - 12:45	Short Oral Discussion Area	Page
SO 003 - Station 01	Genetics of type 2 diabetes	111
SO 009 - Station 02	Mortality in type 2 diabetes	117
SO 015 - Station 03	Glycaemia in diabetes	122
SO 021 - Station 04	Islets in the T1D storm	127
SO 027 - Station 05	No more secrets just secretion	133
SO 033 - Station 06	Metabolic flexibility and insulin sensitivity: drivers, disruptors, and interventions.	139
SO 039 - Station 07	Cardiometabolic complications and mortality risk in MASLD	145
SO 045 - Station 08	Fit and functional: reversing metabolic risk through muscle-centric interventions.	150
SO 051 - Station 9	[Br]eaking [Ba]t	156
SO 057 - Station 10	Adipose tissue function after training, bariatric surgery and during senescence.	162
SO 063 - Station 11	News on adipocyte biology	168
SO 069 - Station 12	SGLT2 inhibitors: glycaemic indicators and beyond in clinical practice.	174
SO 075 - Station 13	It's all personal	180
SO 081 - Station 14	Hi Hybrid :) how are you today?	186
SO 087 - Station 15	CGM: replacing low glucose with low cost	192
SO 093 - Station 16	Animal and cell culture models of diabetes-related kidney complications.	198
SO 099 - Station 17	Biomarkers and mechanisms in diabetes and pregnancy	204

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

11:45 - 12:45

Short Oral Discussion Area

Page

SO 105 - Station 18

Treatment of diabetes-related retinopathy 210

SO 111 - Station 19

Lipid and non-lipid drugs impacts on lipids, vascular tissues and outcomes 216

SO 117 - Station 20

Heart failure and other CV insights in people with diabetes 222

SO 123 - Station 21

Neurological, emotional, cognitive status of people with diabetes. . . 228

LBA SO 03 - Station 22

Incredible incretins 235

LBA SO 07 - Station 23

The Diabetes-Brain Axis: from pathophysiology to protection 239

GENERAL INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL DISCUSSIONS

PRESENTER INDEX

SATELLITE SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

11:45 - 12:45

Warsaw Hall

EASD e-Learning expert session: Technology

Chair: Julia Mader, Austria

Panellists: Amit Gupta, India
Sabine E. Hofer, Austria

12:00 - 12:45

Spotlight Stage

Incretin associated sarcopenia: Does it matter which drug we use?

Chair: Tomasz Klupa, Poland

Speaker: Gabriele Riccardi, Italy:
No, sarcopenia depends on the degree of weight loss and not on the treatment used

Martin Haluzik, Czechia:
Yes, it matters which GLP-1RA or GLP-1/GIP RA we use

12:00 - 12:45

Arena

Lab Talk

Speaker: Antonio Zorzano, Spain

SHORT ORAL DISCUSSIONS EVENT D

13:00 - 14:00	Short Oral Discussion Area	Page
SO 004 - Station 01	Epigenetics of type 2 diabetes	<u>112</u>
SO 010 - Station 02	Post GDM consequence in mother and child	<u>118</u>
SO 016 - Station 03	Drugs epidemiology in diabetes	<u>123</u>
SO 022 - Station 04	Stem cell top models on the molecular mystery runway	<u>128</u>
SO 028 - Station 05	Chemical romance: compounds that woo islets	<u>134</u>
SO 034 - Station 06	Molecular keys to unlocking insulin sensitivity	<u>140</u>
SO 040 - Station 07	Mapping the molecular maze of MASLD and MASH	<u>146</u>
SO 046 - Station 08	Hot, heavy, and hidden, unpacking the unusual drivers of glycaemic health	<u>151</u>
SO 052 - Station 09	Lipid metabolism and metabolic health	<u>157</u>
SO 058 - Station 10	Beyond BMI: predictors of glucometabolic health	<u>163</u>
SO 064 - Station 11	Beyond BMI 02	<u>169</u>
SO 070 - Station 12	Real-world evidence for non-insulin therapies: clinical practice insights	<u>175</u>
SO 076 - Station 13	How to have a happy life in a love/hate triangle of diabetes + pregnancy + CGM	<u>181</u>
SO 082 - Station 14	Now let's count to seven, ready?	<u>187</u>
SO 088 - Station 15	Diabetes in cyberspace	<u>193</u>
SO 094 - Station 16	New in the treatment of diabetes-related kidney complications . . .	<u>199</u>
SO 100 - Station 17	Treatment and monitoring of gestational diabetes	<u>205</u>
SO 106 - Station 18	Pathophysiology of diabetes-related retinopathy	<u>211</u>

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

13:00 - 14:00

Short Oral Discussion Area

Page

SO 112 - Station 19

Novel lipid and lipoprotein insights 217

SO 118 - Station 20

Prediction and management of complications and adverse therapy outcomes 223

SO 124 - Station 21

Neurodegeneration and depression in people with diabetes 228

LBA SO 04 - Station 22

Putting obesity under microscope. 236

LBA SO 08 - Station 23

If type 1 diabetes has any secrets, they can be found here 239

GENERAL INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

13:00 - 14:00

Warsaw Hall

EASD e-Learning expert session: Obesity

Chair: Johanna Brix, Austria

Panellists: Caterina Conte, Italy
Carel le Roux, Ireland

SHORT ORAL DISCUSSIONS

13:00 - 13:45

Spotlight Stage

Minimum expectations for market authorization of continuous glucose monitoring (CGM) devices in Europe

Chair: Tadej Battelino, Slovenia

Speaker: Concetta Irace, Italy:
Current status of CGM authorisation in Europe

Peter Adolffsson, Sweden:
Need for change: why?

Stefano Del Prato, Italy:
Minimum expectations for market authorization of CGM in Europe

PRESENTER INDEX

SATELLITE SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

13:00 - 13:45

Arena

Lab Talk

Speaker: Mikael Rydén, Sweden

14:30 - 16:00

Vienna Hall

OP 19 Revealing the inner life of islets

Chairs: Sofie Haedersdal, Denmark; Timo Otonkoski, Finland

109 Impact of glucagon-like peptide-1 receptor agonism on beta cell Ca²⁺ dynamics within the pancreatic islet in vivo

L. Delgadillo Silva, G. Rutter, S. Salazar, S. Larouche, A. Prat, L. López, A. Provencher-Girard, Canada, UK

110 Deciphering the role of non-beta cells in nutrient homeostasis with an in vitro / in silico approach

D. Chapeau, A. Pirog, J. Gaitan, M. Lallouet, L. Olçomendy, S. Renaud, J. Lang, M. Raoux, France

111 Sodium/potassium ATPase-mediated alpha-cell hyperpolarisation sustains metabolic control of glucagon secretion

M. Dickerson, P. Dadi, J. Dobson, S. Behera, S. Peachee, S. Gibson, D. Jacobson, USA

112 Disrupted alpha cell function in human and murine islets devoid of other endocrine cells

E. Bru-Tari, M. Perez-Frances, C. Renaud, F. Thorel, P. L. Herrera, Switzerland

113 In-depth transcriptome comparisons between human alpha and beta cells identify MEG3 depletion as a new approach to protect beta cells against cytokine-induced apoptosis

E. Martin-Vazquez, X. Yi, S. Jawurek, P. L. Zimath, E. Ilegems, J. D. Wesley, A. Title, B. Yesildag, D. L. Eizirik, Belgium, Switzerland, Denmark, USA

114 Endocrine-vascular coupling in the pancreatic islet and its impact on blood flow

L. Mateus Goncalves, R. Diaz Cruz, E. Pereira, J. Almaca, USA

14:30 - 16:00

Paris Hall

OP 20 "We want to live our lives": quality of life and psychological well-being matters

Chairs: Katarzyna Cyranka, Poland; Frank Snoek, Netherlands

115 Thresholds for the 20-item problem areas in diabetes scale: a population-based study of adults with type 1 diabetes

I. Hernar, R. M. Nilsen, A. Haugstvedt, R. B. Strandberg, M. M. Iversen, H. K. Riise, G. Å. Ueland, T. C. Skinner, Norway, Australia

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

116 Feelings of guilt as a central trigger of diabetes distress in the daily lives of people with type 1 and type 2 diabetes: analysis of a dynamic, temporal network

D. Ehrmann, N. Hermanns, A. Schmitt, L. Klinker, B. Kulzer, Germany

117 Type 1 diabetes stigma: thematic analysis of the experiences of UK adults

H. Housby, N. Oliver, A. Kaur, T. Wylie, K. Scior, V. McKechnie, UK

GENERAL
INFO

118 Loneliness, worrying, and burnout are the most influential psychosocial burden in type 1 diabetes: a cross-sectional network analysis from the SFDT1 study

G. A. Aguayo, V. P. Martin, D. Canha, E. Cosson, G. Arnault, B. Delenne, B. Guerci, A. Berot, S. Barraud, J.-P. Riveline, G. Fagherazzi, Luxembourg, France

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

119 Physical activity and health-related quality of life: a bidirectional association in individuals recently diagnosed with type 2 diabetes

S. F. Kristoffersen, S. Domazet, F. Pouwer, J. Nielsen, T. Olesen, J. Stidsen, M. H. Olsen, K. Højlund, Denmark

120 Factors associated with higher type 1 diabetes stigma scores in the UK

H. Housby, N. Oliver, A. Kaur, T. Wylie, K. Scior, V. McKechnie, UK

SHORT ORAL
DISCUSSIONS

14:30 - 16:00

London Hall

PRESENTER
INDEX

LBA OP 03 Is there a life after GLP-1?

Chairs: Tina Vilsbøll, Denmark; Roman Vangoitsenhoven, Belgium

SATELLITE
SYMPOSIA

LBA 13 CagriSema improves glycaemic outcomes across weight loss categories in adults with BMI ≥ 27 kg/m² and type 2 diabetes in the blinded continuous glucose monitoring subgroup in REDEFINE 2

R. Pratley, H. S. Bajaj, C. Broholm, M. M. Byrne, M. H. Christensen, A. Eliassen, J. N. Kraft, I. Lingvay, S. Wharton, M. J. Davies, USA, Canada, Denmark, Ireland, UK

INDUSTRY

PROGRAMME

EXHIBITION

LBA 14 Pharmacokinetics, weight loss, and tolerability of the ultra-long acting amylin analogue MET-233

G. Gaich, L. Burnett, R. Stoekenbroek, S. Kolluri, M. Dilleen, N. Sahr, M. Stroh, J. Minnion, B. Hubbard, S. P. Marso, USA

THANKS

LBA 15 Pharmacokinetics, safety and tolerability of amycretin in people with renal impairment

S. P. Haugaard, T. Karlsson, V. Kegel-Hübner, L. I. Oldenburg, M. Parwez, C. Wiingard, A. Flint, Denmark, Germany, India

LBA 16 Weekly PG-102 plus bimagrumab enhances net muscle gain compared to daily semaglutide-based regimens

S.-A. Lee, S.-I. Yang, S. Kim, J.-G. Kim, Y. Sung, Korea, Republic of

LBA 17 Anti-Myostatin (trevogrumab) with and without anti-Activin a (garetosmab) preserves lean mass and increases loss of fat mass in people with obesity treated with semaglutide

O. Mosenzon, R. A. Calle, J. Rosenstock, J. G. Raya, J. Grimsby, N. Sarkar, G. D. Yancopoulos, B. Hirshberg, USA

LBA 18 PG-102, a bispecific GLP-1/GLP-2 Fc fusion protein, outperforms dual-function peptide and combination therapy in preclinical models and induces dose-dependent weight loss in obese subjects

S.-I. Yang, S. Kim, K.-H. Son, S.-A. Lee, J.-G. Kim, Y. Sung, Korea, Republic of

14:30 - 16:00

Mumbai Hall

OP 21 Diabetes-related nephropathy: from bench to bedside

Chairs: Samy Hadjadj, France; Giuseppina Russo, Italy

121 Angiotensin-like protein 8 mediates inflammation and fibrosis of tubular cells in diabetic nephropathy progression by interacting with Akt2

X. Yu, L. Pan, Y. He, Y. Xiang, B. Mao, X. Meng, Y. Guo, R. Kan, S. Wang, D. Li, China

122 Predictors of significant kidney function decline in more than 5500 people with type 1 diabetes: a comparison of London and Finland cohorts to explore the role of heritage and other risk factors

M. Ozdede, R. Lithovius, E. Valo, S. Mutter, L. Thorn, S. Ayis, P.-H. Groop, N. Sandholm, J. Karalliedde, UK, Finland

123 Epidemiology and management of CKD with type 2 diabetes: insights from German claims data

T. Ebert, R. Schürfeld, M. Schultze, M. Müller, C.-D. Köhler, J. Birnbaum, Germany

124 Red cell distribution width and microalbuminuria in type 2 diabetes: insights from the UK Biobank

S. Saluja, S. Anderson, E. Jude, UK, Barbados

125 Precision medicine in type 2 diabetes: targeting GLP1 receptor agonist and SGLT2-inhibitor combination treatment for kidney protection

T. Jansz, K. Young, B. Shields, A. Jones, A. Hattersley, E. Pearson, R. Oram, J. Dennis, UK

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

126 TLE4 modulates diabetic nephropathy-associated inflammation via the cGAS-STING pathway

X. Xu, P. Chen, L. Lin, X. Liu, China

14:30 - 16:00

Sofia Hall

OP 22 Breaking boundaries: novel therapeutics and precision medicine in diabetes

Chairs: Harpreet S. Bajaj, Canada; Charlotte Moffett, UK

127 Effects of oral semaglutide on hospitalisation rates in people with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease: SOUL trial results

J. B. Buse, N. Marx, S. L. Mulvagh, J. E. Deanfield, S. E. Inzucchi, R. Pop-Busui, J. F. Mann, S. S. Emerson, N. R. Poulter, M. D. Engelmann, G. K. Hovingh, D. K. McGuire, on behalf of the SOUL Study Group, USA, Germany, Canada, UK, Denmark

128 First report on the small-molecule, oral GLP-1 receptor agonist RGT-075 in obesity: a randomised, placebo-controlled phase 2a proof-of-concept 12-week study

D. Lender, K. Crawford, D. Guzman, F. Raiser, J. Lin, Q. Cai, F. Sun, F. Liu, M. Grimm, J. Rosenstock, USA

129 Eloralintide, a selective, long-acting amylin receptor agonist for obesity: phase 1 proof of concept

E. Pratt, S. Bhattachar, A. Haupt, K. Mather, L. San Tham, B. Tidemann-Miller, USA

130 Integrating clinical data and genetic risk scores to identify predictors of drug response in type 2 diabetes cohorts

S. Garg, E. Pearson, R. Kitchen, R. Gupta, UK

131 Enhancement of a five-drug class model for type 2 diabetes treatment selection to include oral and injectable semaglutide

P. Cardoso, K. Young, L. Gudemann, A. G. McGovern, A. Jones, T. J. McKinley, E. Pearson, B. Shields, A. Hattersley, J. Dennis, UK

132 Efficacy and durability of early quadruple with lorglitazone and empagliflozin to uncontrolled type 2 diabetes under metformin and DPP4 inhibitors: 112-week interim results of a 224-week RCT

S. Kim, Y.-H. Lee, J. Hong, J. Yu, B.-W. Lee, Republic of Korea

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

14:30 - 16:00

Milan Hall

OP 23 New avenues for the GLP-1R agonists

Chairs: Francesco Giorgino, Italy; Asger Lund, Denmark

133 Metabolic effects of semaglutide combined with a calorie-restricted diet in patients with obesity and type 2 diabetes

X. Tang, China

134 Phase 2 clinical trials of NA-931 to study subjects who are obese with at least one weight-related comorbid condition

L. L. Tran, F. D. Vu, Z. V. Tran, USA

135 VRB-101 is a potent oral GLP-1 tablet with once-weekly dosing potential

M. Fenaux, K. Junaidi, C. Jones, W. Guo, J. Deng, W. Zhong, S. Trieu, R. Ho, M. Eid, UK, China

136 Association between Alzheimer's disease and obesity: clinical trials of NA-831 for AD and clinical trials of NA-931 for obesity

L. L. Tran, F. D. Vu, Z. V. Tran, USA

137 GLP-1 receptor agonists (GLP-1RAs) protect against hepatocyte senescence

F. Zatterale, A. Podraza-Farhanieh, L. Zinna, S. Gogg, A. Nerstedt, F. Beguinot, R. Spinelli, U. Smith, Sweden, Italy

138 Weight loss maintenance with exercise but not with GLP-1 receptor agonist treatment decreases atherosclerosis development

R. M. Sandsdal, J. Holt, H. G. Alkhefagie, J. R. Jørgensen, C. R. Juhl, L. Gliemann, B. M. Stallknecht, J. J. Holst, K. N. Bojsen-Møller, S. Madsbad, J. Størling, E. M. Bladbjerg, C. Antoniades, S. B. Jensen, S. S. Torekov, Denmark, UK

14:30 - 16:00

Warsaw Hall

OP 24 Risk stratification and treatment of diabetes-related retinopathy

Chairs: Alicia Jenkins, Australia; Niina Sandholm, Finland

139 The effect of fenofibrate on progression of diabetic retinopathy according to background statin use and retinopathy grading

V. Silva, M. Zayed, E. Sammons, D. Preiss, LENS Collaborative Group, UK

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

140 Intensive glucose control with newer automated insulin devices: ramifications for early worsening of diabetic retinopathy and implications for eye screening intervals

M. S. Varughese, A. U. Nayak, L. Payne, L. Varadhan, UK

141 Lipidomic profiles and their relationship to incident diabetic retinopathy in type 2 diabetes: the Fremantle Diabetes Study Phase II

T. M. Davis, J. J. Drinkwater, A. Grant-St James, E. Holmes, W. A. Davis, N. Gray, Australia

142 Systemic inflammatory biomarkers and diabetic retinopathy progression in type 2 diabetes: a prospective cohort study

T. Olesen, M. Johansen, A. Lühr Hansen, J. Stidsen, J. Grauslund, F. Pedersen, J. Nielsen, M. Olsen, K. Højlund, Denmark

143 Genome-wide association and survival analysis of genetic variants associated with severe diabetic retinopathy in type 1 diabetes

N. Vuori, L. M. Thorn, E. Dahlström, M. Eriksson, V. Harjutsalo, P.-H. Groop, N. Sandholm, FinnDiane Study Group, Finland

144 GLP-1 receptor agonists enhance antioxidant defense and cell viability in retinal cells under diabetic conditions

I. A. Anastasiou, A. Tentolouris, E. Rempelou, P. Sarantis, I. Eleftheriadou, N. Tentolouris, Greece, Italy

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

In-hospital diabetes management: characteristics and challenges

Chair: Ketan Dhatariya UK

Speaker: Mikkel T. Olsen, Denmark:
CGM for every hospitalised patient with diabetes in order to prevent typical deterioration of glycaemic control?

Elias K. Spanakis, USA:
Current challenges and future perspectives in inpatient diabetes management: an overview

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

16:30 - 16:45

Vienna Hall

Induction of EASD Honorary Members

16:45 - 17:30

Vienna Hall

60th Minkowski Lecture

The Minkowski Prize recognises research which contributes to the advancement of knowledge concerning diabetes mellitus.

Chair: Chantal Mathieu, Belgium

Speaker: Teresa Mezza, Italy:

Back to the future: re-centring the role of the pancreas in type 2 diabetes

Teresa Mezza earned her medical degree and specialized in endocrinology at the Catholic University of Rome, where she also completed a PhD in Metabolic and Nutritional Sciences. As part of her academic training, she pursued a postdoctoral fellowship at the Joslin Diabetes Center, Harvard Medical School, in Boston.



She is currently an Assistant Professor at the Catholic University of Rome and a clinical researcher at the A. Gemelli University Hospital, where she combines outpatient care with translational research in diabetes.

Dr. Mezza's research focuses on the mechanisms of beta-cell dysfunction and plasticity in type 2 diabetes, combining in vivo metabolic profiling with ex vivo analysis of human pancreatic islets. Her innovative model using tissue from partial pancreatectomy has provided key insights into the pathogenesis of diabetes and islet adaptation. She is Principal Investigator or Co-PI on several national and international grants, including projects funded by the NRRP, the Italian Ministry of Health, and the Ministry of University and Research.

She has received several prestigious awards, including the Rising Star Award, Young Investigator Research Award, Future leaders for Clinical Diabetologist Award from EFSD, the Alcmeone Prize from the Italian Diabetes Society, and the L'Oréal-UNESCO For Women in Science Fellowship.

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

16:30 - 17:30

Paris Hall

Assessment and management of diabetes distress: the EASD’s first clinical practice guideline

Chairs: Jane Speight, Australia; Richard I.G. Holt, UK

Speaker: Jane Speight, Australia:

Introduction

Michelle Law, UK:

What this guideline means for people with diabetes

Thomas Karagiannis, Greece:

Development of the EASD’s first evidence-based guideline

Jacqueline Sturt, UK:

Recommendations for the assessment of diabetes distress

Karin Kanc, Slovenia:

Recommendations for the clinical management of diabetes distress

Richard I.G. Holt, UK:

Conclusions

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

16:30 - 17:30

London Hall

ATTAIN-1, the first phase 3 clinical trial investigating orforglipron for obesity management

Chair: Ania M. Jastreboff, USA

Speaker: Louis J. Aronne, USA:

The evolution of incretin-based therapies for obesity

Sean Wharton, Canada:

ATTAIN-1: study design, baseline characteristics, and efficacy results

Nasreen Alfaris, Saudi Arabia:

ATTAIN-1 safety results and conclusions

Vanita R. Aroda, USA:

Commentary

16:30 - 17:30

Mumbai Hall

DKD treatment in type 2 diabetes: Where do we stand?

Chair: Jelizaveta Sokolovska, Latvia

Speaker: Paola Fioretto, Italy:
SGLT2i and GLP1-RA: for prevention and treatment of DKD

Rajiv Agarwal, USA:
nsMRA: new evidence

Hiddo J. Lambers Heerspink, Netherlands:
Combination therapy: Is today the more appropriate approach to DKD?

GENERAL
INFO

PROGRAMME

TUESDAY

16:30 - 17:30

Sofia Hall

Clinical application of precision medicine in diabetes

Chair: Jordi Merino, Denmark

Speaker: Ewan R. Pearson, UK:
What is needed to deliver precision medicine for type 2 diabetes in the clinic?

Amelie Bonnefond, France:
Oligogenic diabetes: the spectrum of genetic risk in diabetes and how it could be leveraged for precision medicine, clinically

Chirag J. Patel, USA:
Harnessing real-world data to deliver targeted type 2 diabetes prevention and care strategies

Supported by the Novo Nordisk Foundation

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

16:30 - 17:30

Milan Hall

Extracellular vesicles: new players in metabolic diseases

Chair: Joan-Marc Servitja, Spain

Speaker: C. Ronald Kahn, USA:

Extracellular vesicles as mediators of metabolic diseases

Romano Regazzi, Switzerland:

Role of extracellular vesicles in lymphocyte-beta cell crosstalk in type 1 diabetes

Carolina Balbi, Switzerland:

Extracellular vesicles: from biomarkers to therapeutic tools

16:30 - 17:30

Warsaw Hall

Open science - predatory journals - peer review: benefits, challenges, and ethics of the scientific publishing process

Chair: Ilke Sen, Sweden

Speaker: Hindrik Mulder, Sweden:

Traditional peer reviewed journals, a dying breed in times of emerging new formats, preprints and predatory journals: perspective of an EIC

Annette Schürmann, Germany:

The relevance of peer review in times of preprints and predatory journals: perspective of an experienced reviewer

Pierre Larraufie, France:

Non traditional journal models and benefits and experiences of disseminating your work outside of publishing in a traditional journal

Maria Hodges, UK:

Ethical publishing in the age of open access and predatory journals: perspective of a publisher

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

07:15 - 08:15

Vienna Hall

Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT

Chair: Tina Vilsbøll, Denmark

Speaker: Stephen Nicholls, Australia:

The cardiovascular outcomes in participants on tirzepatide versus dulaglutide of the SURPASS-CVOT

David D'Alessio, USA:

The glycaemic control and metabolic changes in participants on tirzepatide versus dulaglutide of the SURPASS-CVOT

Sophia Zoungas, Australia:

The evolution of renal status in participants on tirzepatide versus dulaglutide of the SURPASS-CVOT

Hertzel C. Gerstein, Canada:

Commentary

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

08:30 - 09:15

Vienna Hall

Fostering the next generation: What is the role of GLP-1 based therapies?

Chair: Melanie J. Davies, UK

Speaker: Charlotte Moffett, UK:

Could GLP-1 hold the key to unlocking fertility?

Helen R. Murphy, UK:

GLP-1 RA in pregnancy: knowns and unknowns

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

08:30 - 09:15

Paris Hall

Do we need "new" insulins?

Chair: Harald Sourij, Austria

Speaker: Andrej Janez, Slovenia:

Yes, we need new injectable insulin

Nicholas J. Hunt, Australia:

Yes, we need oral insulin

Matthew J. Webber, USA:

Yes, we need smart insulin

THANKS

Rising Star Symposium

The EASD Rising Star Symposium and EFSD Rising Star Fellowship Programme aims to identify promising and innovative young researchers who are developing their research activities in Europe.

Chair: Tina Vilsbøll, Denmark

Speaker: Cristina Cadenas Sanchez, Spain:
Fit for life? Longitudinal associations between physical fitness in preschoolers and cardiovascular health in adolescence



Sindre Lee-Ødegård, Norway:
Optimising exercise interventions to improve insulin sensitivity in South Asians: targeting unique metabolic pathways



Jens Lund, Denmark:
Circulating metabolites regulating energy homeostasis



Martin Schön, Germany:
Exploring diabetes heterogeneity: toward mechanistic insight, improved classification, and clinical translation



GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

08:30 - 09:15

Mumbai Hall

Diet and exercise: when how and what matters!

Chair: Andreas F. Pfeiffer, Germany

Speaker: Frédéric B. Gachon, Denmark:

Physiology of circadian rhythms

Olga Pivovarova-Ramich, Germany:

Meal timing and its role in obesity and associated diseases

Jeroen van der Velde, Netherlands:

Timing of exercise and diet quality in diabetes prevention

GENERAL
INFO

PROGRAMME

TUESDAY

08:30 - 09:15

Sofia Hall

Implications of novel islet endocrine cell biology for type 1 and type 2 diabetes

Chair: Miriam Cnop, Belgium

Speaker: Ulf Ahlgren, Sweden:

Illuminating the complete beta cell mass of the human pancreas

Patrick E. MacDonald, Canada:

Alpha cell heterogeneity in type 1 and type 2 diabetes

Huixia Ren, China:

Pancreatic islet oscillation rhythmicity arises from delta and alpha cell interactions

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

08:30 - 09:15

Milan Hall

Glucagon: No longer the bad guy in diabetes?

Chair: Åke Sjöholm, Sweden

Speaker: Jens J. Holst, Denmark:

Is there a future of glucagon for treatment of metabolic diseases? Glucagon: an overview

Jonathan E. Campbell, Denmark:

The role of glucagon in the paracrine regulation of beta cell function

Timo D. Müller, Germany:

Glucagon regulation of energy metabolism

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

08:30 - 09:15

Warsaw Hall

EASD-CEDA Joint Symposium: Diabetic neuropathies in the era of precision medicine

Chairs: Leszek Czupryniak, Poland; Anca Pantea-Stoian, Romania

Speaker: Julia Szendroedi, Germany:
Acknowledging prediabetic polyneuropathy

Péter Kempler, Hungary:
Update on cardiovascular autonomic neuropathy

Christian Herder, Germany:
Inflammation, diabetes heterogeneity and polyneuropathy

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

09:30 - 10:15

Vienna Hall

Pregnant and digital

Chair: Adam Tabák, Hungary

Speaker: Latife Bozkurt, Austria:
Continuous glucose monitoring and hybrid closed-loop systems in pregnancy with type 1 diabetes

Christian Göbl, Austria:
Continuous glucose monitoring reduces adverse outcomes in gestational diabetes: the GRACE study

Katrien Benhalima, Belgium:
Diabetes technology for pregnancy: international consensus statement

09:30 - 10:15

Paris Hall

Getting the most of the CGM data

Chair: Jelizaveta Sokolovska, Latvia

Speaker: Tracey L. McLaughlin, USA:
Use of CGM to identify metabolic subphenotypes and help on type 2 diabetes prevention

Christophe De Block, Belgium:
Signatures of insulin resistance in CGM reports in subjects with type 1 diabetes

09:30 - 10:15

Mumbai Hall

Tailored nutrition and low-calorie diet remission updates

Chair: Mariëtte R. Boon, Netherlands

Speaker: Nita G. Forouhi, UK:

From forks to forecasts: unravelling the dietary crystal ball of type 2 diabetes

Michael E. Lean, UK:

Accumulated data from diabetes remission trials: Where are the gaps?

GENERAL
INFO

PROGRAMME

TUESDAY

09:30 - 10:15

Sofia Hall

Engineering of stem cell-derived islets

Chair: Diego Balboa, Finland

Speaker: Matthias Hebrok, Germany:

Immune modulating engineered stem cell islets

Raniero Chimienti, Italy:

Immune evasive and hypoimmune stem cell islets

Maria C. Nostro, Canada:

Tissue engineering of stem cell islets

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

09:30 - 10:15

Milan Hall

Clinical psychologist in a diabetic treatment team: Do we really know how to use each other's skills?

Chair: Frank J. Snoek, Netherlands

Speaker: Norbert Hermanns, Germany:

Roles and competencies of the clinical psychologist in adult diabetes care

Dominic Ehrmann, Germany:

Person-reported outcomes in diabetes care: unobvious necessity?

Maciej T. Malecki, Poland:

How a diabetologist sees/should see the role of a clinical psychologist in the era of patient-centered diabetes care?

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

EASD-EASL Joint Symposium: Metabolic interplay between liver and diabetes: emerging mechanisms and therapeutic insights

Chairs: Cyrielle Caussy, France; Niels Jessen, Denmark

Speaker: Laurent Castera, France:

SLD and type 2 diabetes: a syndemic challenge for clinicians

Ele Ferrannini, Italy:

Ketone metabolism and liver function: implications for diabetes

Philip N. Newsome, UK:

Glucagon liver metabolism and therapeutic target in MASH

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

OP 25 Is semaglutide taking a step up?

Chairs: Mette Rosenkilde, Denmark; Sini Heinonen, Finland

145 Effect of semaglutide 7.2 mg on anthropometric measures of obesity: the STEP UP trial

S. Wharton, J. Hjelvesæth, I. Lingvay, H. Angelene K M, M. De Los Angeles Quiroga Pelaez, N. Kahr Rasmussen, J. Rosenstock, W. T. Garvey, Canada, Norway, USA, India, Denmark

GENERAL
INFO

146 Control of eating with semaglutide 7.2 mg in adults with obesity: the STEP UP trial

S. Wharton, S. Bhat, M. Dalton, J. Hjelvesæth, I. Lingvay, M. De Los Angeles Quiroga Pelaez, N. Kahr Rasmussen, J. Rosenstock, J. S. Tronieri, W. T. Garvey, Canada, India, UK, Norway, USA, Denmark

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

147 Effect of semaglutide on body composition and proximal muscle strength: the STEP UP trial

J. Hjelvesæth, S. Bhat, W. T. Garvey, K. Jensen Kolnes, I. Lingvay, N. Kahr Rasmussen, J. Rosenstock, S. Wharton, Norway, India, USA, Denmark, Canada

SHORT ORAL
DISCUSSIONS

148 Impact of once-weekly semaglutide on cardiovascular events in adults with overweight or obesity in a real-world Danish population

J. Fernandes, T. Arnaut, N. Clausen, L. M. Hagelund, M. Kany, M. Mæng, Denmark

PRESENTER
INDEX

149 Bimagrumb prevents semaglutide-induced muscle mass loss in diet-induced obese mice

M. Tozzi, N. Sonne, N. Eskesen, A. K. Sárvári, S. Bossi, J. Nersting, H. B. Hansen, Denmark

SATELLITE
SYMPOSIA

INDUSTRY

150 The GLP1-receptor agonist semaglutide as an adjunct to a lifestyle intervention in the treatment of type 2 diabetes: effects on glucose metabolism

H. Haltia, M. Muniandy, P.-H. Groop, J. Karppinen, S. Heinonen, B. Van der Kolk, K. H. Pietiläinen, Finland

PROGRAMME

EXHIBITION

THANKS

LBA OP 04 The best abstracts with 'semaglutide' in the title

Chairs: Christine Rode Schwarz, Denmark; Melanie J. Davies, UK

LBA 19 Comparative effectiveness of once-weekly semaglutide vs dulaglutide on cardiovascular outcomes in US Medicare beneficiaries with type 2 diabetes and atherosclerotic cardiovascular disease

X. Tan, J. Harton, Y. Liang, L. Xie, C. Gutierrez, C. Muhammad, C. Swift, USA

LBA 20 WITHDRAWN

LBA 21 Semaglutide and risk reduction of major adverse limb events in diabetes: a pooled analysis of 13,975 participants from the SOUL, FLOW and STRIDE randomised trials

S. Verma, M. P. Bonaca, J. Nordanstig, J. B. Buse, M. A. Cavender, K. W. Mahaffey, R. Pratley, P. Rossing, A. Videmark, A.-M. Catarig, S. Rasmussen, F. M. Baeres, M. D. Engelmann, D. K. McGuire, Canada, USA, Sweden, Denmark

LBA 22 Incidence of non-arteritic ischaemic optic neuropathy across completed phase 2, 3 and 4 trials evaluating the glucagon-like peptide-1 receptor agonists liraglutide and semaglutide

T. Vilsbøll, D. A. L. Aiello, C. Rönnbäck, M. Stellfeld, M. Larsen, Denmark, India, USA

LBA 23 Safety and efficacy of semaglutide, 2.4mg, once weekly vs placebo in patients with weight regain following metabolic/bariatric surgery: the BARI-STEP randomised clinical trial

R. Mallik, C. Stanley, N. Hamid, F. Jassil, V. Reuven, T. Ruwona, D. Boniface, S. Qamar, B. Norton, M. Adamo, R. Batterham, K. Devalia, J. Loy, J. Mok, J. Makaronidis, UK

LBA 24 Efficacy and safety of once-weekly semaglutide 2.0 mg as an add-on to dose-reduced insulin glargine vs titrated insulin glargine in people with type 2 diabetes and overweight: SUSTAIN OPTIMIZE

H. W. Rodbard, C. Irace, J. Lobo, K. Makrilakis, P. Priyadarshini, S. Sivalingam, S. T. Povedano, USA, Italy, India, Greece, Denmark, Spain

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

10:45 - 12:15

London Hall

OP 26 **Diagnosis, markers and burden of prediabetes**

Chairs: Femke Rutters, Netherlands, Matthias B. Schulze, Germany

151 Global patterns of prediabetes from 1990-2023: a systematic analysis of the Global Burden of Disease study

Y. Y. Xu, J. Lee, H. Lenox, L. Ong, USA

GENERAL
INFO

152 Long-term remission of impaired glucose tolerance in the Finnish Diabetes Prevention Study

J. Tuomilehto, M. Valtanen, J. Lindström, M. Uusitupa, Finland

153 Prediabetes remission and cardiovascular outcomes

A. L. Birkenfeld, E. Vazquez-Arreola, Q. Gong, R. L. Hanson, J. Wang, A. Sandforth, S. He, L. Sandforth, X. Qian, A. Fritsche, N. Stefan, E. W. Gregg, R. Jumperetz-von Schwartzberg, N. Marx, G. Li, Germany, USA, China, UK

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

154 HbA_{1c} and OGTT: Equally useful in diagnosing prediabetes?

K. H. Popp, R. Sehgal, M. Ennis, G. Ufer, A. Peter, G. E. Delgado, A. P. Moissl, M. Kleber, R. Wagner, M. Wagner, R. Sabia, W. März, M. Heni, Germany

155 Body mass index and pre-diabetes phenotypes: results from NHANES 2011-2016

J. Rong, M. Ho, S. Garnett, P. H. Chau, Hong Kong, Australia

156 Protein biomarkers for the future development of dysglycaemia, insulin resistance, and beta cell dysfunction

J. Otten, A. Mendham, S. Söderberg, R. Landberg, J. Goedecke, T. Olsson, Sweden, Australia, South Africa

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

10:45 - 12:15

Mumbai Hall

OP 27 **When, what and how of nutritional therapy**

Chairs: Jonas Salling Quist, Denmark; Jan Gojda, Czechia

157 Effects of 5:2 intermittent fasting meal replacement on body composition and abdominal fat distribution in adults with early type 2 diabetes

D. Yu, M. Zou, B. Cheng, P. Yang, D. Huang, Q. Pan, L. Guo, China

158 Time-restricted eating vs individualised dietetic guidance on glycaemia in adults at risk of type 2 diabetes: a non-inferiority randomised trial

E. B. Parr, R. Charrouf, A. T. Hutchison, S. A. Flint, X. Teong, A. D. Vincent, A. Bravo-Garcia, Z. Siviour, G. Wittert, L. Brennan, B. L. Devlin, J. A. Hawley, L. K. Heilbronn, Australia

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

159 Dietary carbohydrate restriction affects hepatic glucose production and intestinal glucose absorption independently of body weight loss

N. Cimbalo, D. Trico, M. Chiriaco, M. Masoni, L. Sacchetta, M. Scozzaro, S. Frascerra, S. Gallo, G. Nesti, A. Mengozzi, L. Nesti, B. Simona, A. Mari, A. Natali, Italy

160 Interindividual variation in gastric emptying is dependent on the magnitude of the GLP-1 response to intestinal nutrients in healthy humans

Y. Sun, C. Xie, W. Huang, M. Bound, J. Grivell, K. Jones, M. Horowitz, T. Wu, C. Rayner, Australia

161 Impact of breathe well-being's structured lifestyle intervention on GLP-1 receptor agonist side effects: a 48-week observational study

A. Kaicker, P. K. Goyal, R. Verma, R. Bhargava, P. C. Indu, India

162 A randomised control trial assessing the effect of the Mediterranean diet vs Australian Guide for Healthy Eating on body composition and glucose metabolism

R. Kabthlymer, J. Danaher, B. DeCourten, Australia

10:45 - 12:15

Sofia Hall

OP 28 Guardians of the islet galaxy: protect and replace

Chairs: Nikki Farnsworth, USA; James Shaw, UK

163 Mechanism of action of a fully human anti-thymocyte globulin, SAB-142, for the treatment of type 1 diabetes

P. L. Colbert, C. Bausch, A. Kropotova, E. S. Sandhurst, D. M. Maher, A. Parizek, USA

164 Engineered Tregs specific for post-translationally modified beta cell epitopes exhibit robust bystander immune suppression upon activation by stressed iPSC-islets

A. Callebaut, S. Yang, R. Tewari, E. Mortenson, K. Herko, E. McClain, D. J. Rawlings, E. A. James, J. H. Buckner, USA

165 ADO12, a non-fibrotic encapsulation system enables stem cell-derived islets in vivo maturation for type 1 diabetes treatment

O. Jouannot, A. Martin, M. Frelon, J. Brun, C. Gautier, C. Cocita, J. Saarimäki-Vire, T. Otonkoski, D. Balboa, N. Laurent, A.-L. Gaffuri, M. Gaudier, R. Eloy, O. Soula, France, Finland

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

166 Durable glycaemic control and elimination of exogenous insulin use with VX-880 in patients with type 1 diabetes: VX-880-101 (FORWARD)

E. J. De Koning, M. R. Rickels, P. Witkowski, T. W. Reichman, J. F. Markmann, J. S. Odorico, M. Wijkstrom, L. S. Kean, C. Mathieu, A. L. Peters, Y. Tan, K. Vanijcharoenkarn, B. G. Bruinsma, G. Marigowda, C. Ricordi, Netherlands, USA, Canada, Belgium

167 First-in-human case: allogeneic transplantation of human induced pluripotent stem cell-derived islet cells in a patient with type 1 diabetes

T. Nakamura, J. Fujikura, Y. Keidai, K. Motohashi, R. Ito, K. Yamane, T. Anazawa, T. Toyoda, H. Ueno, R. Ito, D. Yabe, Japan

168 Bioprinting using novel hydrogels enables functional islet transplants into diabetic animals without immunosuppression

H. Stover, Canada

10:45 - 12:15

Milan Hall

OP 29 Multimorbidity in diabetes - are we aware of its magnitude?

Chairs: Maciej Malecki, Poland; Anne Peters, USA

169 The role of type 2 diabetes in shaping multimorbidity progression: evidence from the UK Biobank cohort

J. Zhang, L. Bjerg, S. B. Graversen, H. Støvring, C. C. Dahm, L. Johnston, B. Carstensen, D. Witte, Denmark

170 Up-regulation of inflammatory cytokines in human monocytes by intermittent hypoxia through down-regulation of microRNA-146a

S. Takasawa, M. Makino, R. Shobatake, A. Yamauchi, S. Sakuramoto-Tsuchida, T. Uchiyama, M. Takeda, Y. Takeda, K. Mizuta, K. Asai, H. Ota, Japan

171 The relationship of mitochondrial DNA copy number with cardiovascular and microvascular complications in adults with type 2 diabetes: a FIELD trial sub-study

A. Mangani, A. S. Januszewski, K. Ong, H. Francis, R. L. O'Connell, L. Li, D. R. Sullivan, R. S. Scott, P. G. Colman, A. J. Jenkins, A. C. Keech, on behalf of the FIELD Study Investigators, Australia, New Zealand

172 Early brain impact of type 1 diabetes: fNIRS evidence of subclinical neurovascular alterations and glycaemic correlates

M. Parenti, E. Malloggi, A. Dardano, M. Aragona, F. Campi, S. Cappelli, E. Rebelos, M. C. Morrone, P. Binda, S. Del Prato, G. Daniele, Italy

173 Association between lung function and risk of peripheral vascular diseases among patients with type 2 diabetes: a prospective cohort study

N. Wang, Y. Sun, L. Cai, B. Yu, Y. Yu, K. Zhang, Y. Lu, China

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

174 The association between sarcopenia and mortality in relatively young adults: National Health and Nutrition Examination Survey (NHANES) 1999-2006 and linked mortality data

S. Kim, E. Park, S. Kwon, J.-H. Lee, Republic of Korea

10:45 - 12:15

Warsaw Hall

OP 30 Signals of dysfunction: decoding the molecular language of MASLD

Chairs: Angela Martinez Valverde, Spain; David Rizo Roca, Sweden

175 Induction of liver injury in metabolic dysfunction associated steatotic liver disease by microbial metabolite 3-4-Hydroxyphenyllactate through hepatic cellular senescence

M. Koning, M. F. Fondevila, I. A. Van Thiel, A. Oravilahti, V. Männistö, A. Van de Laar, S. Bruin, V. Gerdes, W. De Jonge, J. Verheij, N. Hanssen, H. Herrema, B. Schnabl, M. Nieuwdorp, A. Meijnikman, Netherlands, USA, Finland

176 Reprogramming obesity: preclinical development and phase 1 study design of RES-010, a novel miRNA-targeting therapy

A. Nitsche, A. Altieri, S. Tomasini, R. Temel, S. Kauppinen, R. Panella, Italy, Denmark, USA

177 Intestinal glucose absorption is enhanced in metabolic dysfunction-associated steatotic liver disease

D. Trico, N. Cimbalo, M. Chiriaco, L. Sacchetta, G. Nesti, M. T. Scozzaro, S. Frascerra, S. Gallo, L. Nesti, G. Petralli, S. Baldi, T. V. Fiorentino, M. R. Brunetto, A. Mari, A. Natali, Italy

178 GPRC5B-Gα12 signalling activates SREBP1c transcription to promote hepatic lipid accumulation in MASLD

S. Wu, M. Yang, China

179 Hepatic STK4 plays a role in systemic lipid homeostasis and hepatic ferroptosis

D. Li, L. Li, China

180 Relationship of GDF15 with hepatic mitochondrial respiration is depending on the presence of fibrosis in obese and insulin-resistant individuals

A. Giannakogeorgou, S. Kahl, C. Granata, G. Heilmann, L. Mastrototaro, B. Dewidar, I. Esposito, S. Trenkamp, M. Schlensak, F. A. Granderath, C. S. Mantzoros, M. Roden, P. Schrauwen, Germany, USA

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

SHORT ORAL DISCUSSIONS EVENT E

	12:45 - 13:45	Short Oral Discussion Area	Page
	SO 005 - Station 01	Classification of diabetes subtype	<u>113</u>
	SO 011 - Station 02	Risk and outcome of diabetes in pregnancy.	<u>118</u>
GENERAL INFO	SO 017 - Station 03	More on risk factors for type 2 diabetes onset.	<u>123</u>
PROGRAMME	SO 023 - Station 04	Who let the T cells in: saving beta cells in type 1 diabetes	<u>129</u>
TUESDAY	SO 029 - Station 05	Beta cells lost in signal transduction	<u>135</u>
WEDNESDAY	SO 035 - Station 06	The secret life of beta cells: forecasting, firing, and failing	<u>141</u>
THURSDAY	SO 041 - Station 07	From nutrition to medications: influencing MASLD through the metabolic axis.	<u>147</u>
FRIDAY	SO 047 - Station 08	Clinical studies on unconventional drivers of diabetes	<u>152</u>
SHORT ORAL DISCUSSIONS	SO 053 - Station 09	Novel mechanisms regulating energy metabolism.	<u>158</u>
PRESENTER INDEX	SO 059 - Station 10	Novel mechanisms of glucose management	<u>164</u>
SATELLITE SYMPOSIA	SO 065 - Station 11	Pathways and paradoxes: unraveling the complexities of metabolic health	<u>170</u>
INDUSTRY	SO 071 - Station 12	Bench to bedside: incretin research across species	<u>176</u>
PROGRAMME	SO 077 - Station 13	Hi Hypo :) I would like to know you better	<u>182</u>
EXHIBITION	SO 083 - Station 14	More A1D needed	<u>188</u>
THANKS	SO 089 - Station 15	Doesn't CGM mean "Can Get Motivated"?	<u>194</u>
	SO 095 - Station 16	Epidemiology of diabetes-related kidney complications	<u>200</u>
	SO 101 - Station 17	Diagnosis of diabetes-related neuropathy.	<u>206</u>
	SO 107 - Station 18	Arterial hypertension: more than a risk factor in diabetes	<u>212</u>
	SO 113 - Station 19	Endothelial interaction in diabetes	<u>218</u>

12:45 - 13:45

Short Oral Discussion Area

Page

SO 119 - Station 20

Type 2 diabetes: muscles, fat, bones 224

SO 125 - Station 21

Type 2 diabetes: financial, social considerations,
prevention of complications 229

LBA SO 05 - Station 22

Beta cell reserve and resilience: new insights 237

LBA SO 09 - Station 23

From mastering the scoring to fine-tuning the treatment 240

12:45 - 14:15

Milan Hall

EFSD-NNF Future Leaders Symposium

Chairs: Fatima Bosch, Spain; Marie-Louise Hartoft-Nielsen, Denmark

Speaker: Alexander Jais, Germany:

Unbased identification of sucrose-responsive neuronal circuits in control of glucose metabolism

Zhichao Zhou, Sweden:

Functional role of erythrocyte-derived non-coding RNAs in diabetes-associated vascular complications

Atul S. Deshmukh, Denmark:

Disentangling insulin resistance by mass spectrometry-based proteomics

Supported by the Novo Nordisk Foundation

12:45 - 13:45

Warsaw Hall

EASD e-Learning expert session: Management of hyperglycaemia crises

Chair: Jan Gojda, Czechia

Panellists: Rodolfo J. Galindo, USA

Shivani Misra, UK

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

13:00 - 13:45

Spotlight Stage

EUDF Symposium: Digitally enabled diabetes care through optimal use of AI and technology

Chair: Stefano Del Prato, Italy

Speaker: Stefano Del Prato, Italy

The European Diabetes Forum (EUDF): a forum for turning the tide on diabetes in Europe

Panellists: Eric Renard, France; Sabine Hofer, Austria:

How can we optimally and safely use AI and technology to improve outcomes for people with diabetes?

GENERAL
INFO

PROGRAMME

TUESDAY

13:00 - 13:45

Arena

Lab Talk

Speaker: Miriam Cnop, Belgium

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

SHORT ORAL DISCUSSIONS EVENT F

14:00 - 15:00	Short Oral Discussion Area	Page
SO 006 - Station 01	Predicting type 2 diabetes using standard statistical and machine learning algorithms	114
SO 012 - Station 02	Risk factors for type 2 diabetes onset	119
SO 018 - Station 03	Clinical tales from the T1D trenches.	124
SO 024 - Station 04	Beyond glucose: multidimensional phenotyping of type1 diabetes .	130
SO 030 - Station 05	The islet games: caught in the immune attack fire	136
SO 036 - Station 06	Exercise as a metabolic modulator in people with type 1 diabetes: carbs, circuits, and control	142
SO 042 - Station 07	Emerging predictors of steatosis and fibrosis in the context of metabolic risk	148
SO 048 - Station 08	Mechanisms, modifiers, markers, the complex roots of insulin resistance.	153
SO 054 - Station 09	W[H]AT's up! Novel mechanisms of white adipose tissue function . .	159
SO 060 - Station 10	Towards a better understanding of white fat cell metabolism	165
SO 066 - Station 11	Novel therapeutics: preclinical evidence for next-generation treatments.	171
SO 072 - Station 12	Next-generation therapeutics: novel approaches to diabetes and obesity	177
SO 078 - Station 13	Everyone needs AID.	183
SO 084 - Station 14	Predicting a smart, bright and intelligent future for diabetes care . .	189
SO 090 - Station 15	Prediction and treatment of diabetes-related kidney complications.	195
SO 096 - Station 16	Clinical aspects of diabetes during pregnancy	201

GENERAL INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL DISCUSSIONS

PRESENTER INDEX

SATELLITE SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

14:00 - 15:00 **Short Oral Discussion Area** **Page**

SO 102 - Station 17
Potential treatments of diabetes-related neuropathy 207

SO 108 - Station 18
Pathogenetic mechanisms in diabetes-related foot 213

SO 114 - Station 19
All things immune. 219

SO 120 - Station 20
Non-obvious (?) complications of type 2 diabetes 225

SO 126 - Station 21
Type 1 diabetes: it is not just about insulin management 231

LBA SO 06 - Station 22
Diabetes-related nephropathy: contemporary approaches
to prevention and treatment 237

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

14:00 - 15:00 **Warsaw Hall**

EASD e-Learning expert session: Diabetic foot

Chair: Janaka Karalliedde, UK

Panellists: Frank Nobels, Belgium; Prashanth R. J. Vas, UK

14:00 - 14:45 **Spotlight Stage**

Diabetes cured? A provocative rethink in the era of GLP-1 analogues

Chair: Vinayak Hiremath, India

Steven E. Kahn, USA:

GLP-1, weight loss and islet recovery: mechanistic basis for a cure? A look at how GLP-1 therapies may preserve beta cell function, restore insulin sensitivity, and offer true metabolic reset

Speaker: Roy Taylor, UK:

Remission vs reversal vs cure: Do we need new language to match clinical realities in 2025?

14:00 - 14:45 **Arena**

Lab Talk

Speaker: Roberto Mallone, France

OP 31 Once weekly on weekend or weekday?

Chairs: Giulia Hofer, Switzerland; Dario Rahelic, Croatia

181 Efficacy and hypoglycaemia outcomes with once-weekly insulin icodec vs once-daily basal insulin in type 2 diabetes by baseline HbA_{1c}: ONWARDS 1-5

A. Y. Cheng, L. Canani, J. K. Lindeløv, S. B. Søjgaard, S. Vinther, C. Mathieu, Canada, Brazil, Denmark, Belgium

182 Weekly insulin efsitora alfa in adults with type 2 diabetes treated with basal insulin (QWINT-3)

A. Philis-Tsimikas, R. Bergenstal, J. Thrasher, T. S. Bailey, H. Jinnouchi, L. Ilag, K. Syring, J. Mitra, R. J. Threlkeld, USA, Japan

183 Characteristics and glycaemic outcomes of insulin naive adults with type 2 diabetes treated with an innovative fixed-dose regimen of weekly insulin efsitora in QWINT-1

L. Connery, J. Rosenstock, N. Rasouli, A. Y. Cheng, A. Liebl, C. J. Child, Q. Wang, V. Pires, A. Knights, M. B. Davidson, USA, Canada, Germany

184 Innovative fixed-dose titration of weekly insulin efsitora alfa using a single-dose pen vs daily glargine to facilitate insulin therapy in type 2 diabetes: the QWINT-1 phase 3 trial

J. Rosenstock, T. Bailey, L. Connery, E. Miller, C. Desouza, Q. Wang, J. Leohr, A. Knights, M. C. Carr, C. J. Child, USA

185 Superior glycaemic control achieved with once-weekly insulin GZR4 compared to once-daily insulin degludec in insulin-treated Chinese participants with type 2 diabetes

H. Wu, L. Chen, X. Dong, H. Wang, H. Shu, Z. Cheng, X. Deng, G. Wang, J. Zhao, C. Hao, T. Xie, A. He, Y. Li, S. Carter, W. Chen, USA, China

186 Comparable glycaemic control of once-weekly insulin GZR4 relative to once-daily insulin degludec in insulin-naive Chinese participants with type 2 diabetes

W. Chen, L. Chen, X. Dong, H. Wang, H. Shu, Z. Cheng, X. Deng, G. Wang, J. Zhao, C. Hao, T. Xie, A. He, Y. Li, S. Carter, H. Wu, China, USA

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

15:30 - 17:00

Paris Hall

LBA OP 05 Living with type 1 and without complications

Chairs: Viswanathan Mohan, India; Thomas F. Dejgaard, Denmark

LBA 25 Global type 1 diabetes prevalence, incidence, and mortality in 2025 and projections to 2040: Estimates from the T1D Index Version 3.0 and IDF Atlas 11th Edition

F. Wang, R. Scibilia, S. Pearson, USA

LBA 26 Multi-omics profiling reveals microbiota, metabolite and immunological heterogeneity of age-related endotypes in type 1 diabetes

L. Pan, H. Tan, T. Yue, X. Zheng, J. Weng, China

LBA 27 Prevalence and characteristics of diabetic ketoacidosis in type 1 diabetes: real-world data from the French SFDT1 cohort

J.-P. Riveline, L. Potier, T. Ihaddadene Salzgeber, F. Levrat Guillen, A. Bagel, M. Joubert, E. Cosson, France, UK

LBA 28 Hyperkalaemia in acutely hospitalised persons with type 2 and type 1 diabetes does not increase 30 days mortality compared to hospitalised persons without diabetes

F. Egeberg, H. Nygaard, R. G. Mottlau, S. B. Haugaard, Denmark

LBA 29 The effect of fenofibrate on the progression of diabetic retinopathy in participants with type 1 diabetes: results from the LENS trial

R. Humphrey, M. Zayed, E. Sammons, D. Preiss, UK

LBA 30 Cumulative glycaemic exposure is associated with heart failure in type 1 diabetes

R. Bergdal, V. Harjutsalo, P.-H. Groop, S. Mutter, the FinnDiane Study Group, Finland, Australia

15:30 - 17:00

London Hall

OP 32 It takes two to tango: news on the dual-agonists

Chairs: Peter Flatt, UK; Frank Reimann, UK

187 Survodutide, a novel dual GLP-1 receptor/glucagon receptor agonist, improves kidney health in a mouse model of advanced diabetic kidney disease

T. Klein, M. Ougaard, M. Hahn, U. Roostalu, H. H. Hansen, R. Augustin, B. Bajrami, M. Christensen, Germany, Denmark

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

188 The effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats

R. E. Kuhre, B. Ballarin-Gonzalez, C. L. Brand, T. Glendorf, K. G. Madsen, K. R. Hjöllund, W. F. Hogendorf, D. H. Ipsen, S. Lundh, T. Kruse, S. B. Petersen, A. Secher, A. Vegge, K. Raun, Denmark

189 Safety, tolerability and clinical effects of dapigliptide, a once-weekly GLP-1R/GLP-2R agonist

S. Just Maarbjerg, R. Zachariae, U. Hövelmann, N. Johansen, J. Lundahl, L. Frost Larsen, N. Skall Sørensen, E. Frary, T. Heise, Denmark, Germany

190 REDEFINE1: a randomised study of combined semaglutide 2.4 mg and cagrilintide 2.4 mg for the treatment of overweight or obesity in adults

W. T. Garvey, M. Blüher, C. Karenina Osorto Contreras, M. J. Davies, E. Winning Lehmann, K. H. Pietiläinen, D. Rubino, P. Sbraccia, L. Von Huth Smith, T. Wadden, N. Zeuthen, J. Wilding, USA, Germany, Denmark, UK, Finland, Italy

191 Proteomics of hepatocytes revealed that the GLP-1 / GCG receptor dual agonist IB1362 improved lipid and energy metabolism in palmitic acid/oleic acid-induced MAFLD model

J. Zhou, X. Xiao, J. Liu, China

192 GIP/GLP-1 receptor agonist tirzepatide improved hepatic steatosis in obese/diabetic mouse by reducing inflammation and improving insulin signalling pathway

L. Demizieux, A. Lainé, P. Degrace, T. Jourdan, J. Leemput, P. Passilly-Degrace, O. Pointeau, R. Barbosa, L. Ludwig, T. Coskun, B. Verges, France, USA

15:30 - 17:00

Mumbai Hall

OP 33 SGLT2 inhibitors: the multi-benefit breakthrough

Chairs: Andrea Natali, Italy; John Petrie, UK

193 Mortality, kidney, and safety outcomes with SGLT2 inhibitors vs DPP4 inhibitors in patients with type 2 diabetes treated with systemic glucocorticoids

M. Schechter, O. Mosenzon, Y. Cohen, A. Fishkin, G. Leibowitz, G. Aharon-Hananel, Israel, USA

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

194 Impact of increased SGLT2 inhibitor initiation on HbA_{1c}, weight, and diabetes complications across age and frailty subgroups in the UK, 2019-2024

M. M. Dinsdale, P. Cardoso, A. P. McGovern, A. T. Hattersley, A. G. Jones, T. J. McKinley, B. M. Shields, K. G. Young, J. M. Dennis, UK

195 SGLT-2 inhibitor-induced erythrocytosis and risk of incident cardiovascular disease in type 2 diabetes: a nationwide cohort study

A. Gosmanov, D. Gemoets, USA

196 Impact of SGLT2i use on risk of phimosis and penile cancer: a Danish cohort study emulating a target trial

C. Ljungberg, M. Nørgaard, C. Vandenbroucke-Grauls, J. K. Jakobsen, M. H. Charles, A. Pottegård, M. Dalager-Pedersen, H. T. Sørensen, R. W. Thomsen, Denmark, Netherlands

197 Mortality and persistence in therapy in elderly patients treated with gliflozines vs incretins

A. Del Zoppo, E. Rebelos, D. Moriconi, D. Trico, A. Solini, Italy

198 A short term treatment with an SGLT-2i is associated with a reduction in insulin-stimulated renal glucose uptake

S. Gugliandolo, C. Morciano, L. Leccisotti, U. Capece, A. Guarneri, T. Mezza, G. Di Giuseppe, G. Ciccarelli, L. Soldovieri, M. Brunetti, A. Avolio, A. Splendore, M. Calcagni, A. Giaccari, F. Cinti, Italy

15:30 - 17:00

Sofia Hall

OP 34 Predictors of cardiovascular risk in people with diabetes

Chairs: Cristina Cadenas Sanchez, Spain; Paul Welsh, UK

199 Evaluating SCORE2-diabetes for cardiovascular risk prediction in type 1 diabetes: insights from the Swedish National Diabetes Register

S. Karayiannides, N. Rajamand-Ekberg, S.-B. Catrina, Sweden

200 Validation of the PREVENT and SCORE2-DM equations for cardiovascular risk prediction in a territory-wide cohort of patients with type 2 diabetes in Hong Kong

L. Li, C. H. Fong, D. T. Lui, W.-S. Chow, B. H. Lang, C. K. Wong, C.-H. Lee, Hong Kong

201 Cardiovascular risk stratification in an ethnically mixed type 1 diabetes population: comparison of the Steno Type 1 Risk Engine and Scottish-Swedish model

I. C. Paliaras, P. M. Dualib, P. M. Aroucha, L. S. Torres, J. R. De Sa, S. A. Dib, Brazil

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

202 Estimated glucose disposal rate and risk of first myocardial infarction in people with diabetes

L. Glynn, R. Hofmann, T. Andersson, M. Persson, T. Nyström, Sweden

203 Age-related difference in the impact of diabetes on all-cause mortality after acute myocardial infarction

P.-S. Song, Republic of Korea

204 Impact of COVID-19 diagnosis on the association between age at diagnosis of diabetes and incidence of cardiovascular diseases in England

G. Cezard, W. Shi, C. Chilala, E. Walker, T. Bolton, F. Chalmers, L. Pennells, E. Raffetti, R. Denholm, E. Di Angelantonio, A. Wood, S. Kaptoge, UK

15:30 - 17:00

Milan Hall

OP 35 Glow, never go low!

Chairs: Martin Prazny, Czechia; Emma Wilmot, UK

205 Hypoglycaemia frequency and glycaemic control during exercise in type 1 diabetes: results from the RAPPID prospective multicentre study on closed-loop systems

B. Guerci, M. Joubert, L. Meyer, S. Bekka, France

206 Time below range alone is insufficient to identify severe hypoglycaemia risk in type 1 diabetes: the critical role of hypoglycaemia awareness: results from the SFDT1 study

D. Canha, P. Choudhary, E. Cosson, I. Banu, B. Delemer, R. Valero, S. Tatulashvili, B. Delenne, L. Dufaitre, T. Vidal Trecan, P. Schaepelynck, C. Sanz, G. A. Aguayo, G. Fagherazzi, J.-P. Riveline, Luxembourg, UK, France

207 Relationship between time below range and weekly rates of hypoglycaemia in people with type 1 diabetes: results from the Hypo-METRICS study

G. Martine-Edith, J. Thomas, P. Calhoun, V. Koutroukas, B. Pieri, P. Choudhary, UK, USA

208 Real-world level 3 hypoglycaemia incidence and risk factors in older adults with diabetes: iNPHORM, USA

A. Ratzki-Leewing, J. E. Black, S. Chun, J. Bhatti, G. Zou, B. L. Ryan, R. McCoy, S. B. Harris, USA, Canada

209 Differences in sensor glucose progression from level 1 to level 2 hypoglycaemia based on waking/sleeping and awareness status in type 2 diabetes: Hypo-METRICS study

A. Tziannou, V. Koutroukas, J. Thomas, G. Martine-Edith, P. Choudhary, Hypo-RESOLVE, UK

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

210 Acute effects of different exercise types on CGM-derived metrics in type 1 diabetes: an analysis of 22,254 exercise sessions from the SYNTACTIQ Cockpit dataset

J. Schierbauer, S. Sanfilippo, L. Schuster, H. Sourij, O. Moser, Germany, Austria

15:30 - 17:00

Warsaw Hall

GENERAL
INFO

OP 36 Metabolic motion: exercise, muscle, and mechanisms in people with type 2 diabetes

Chairs: Simon Dreher, Germany; Anna Novials, Spain

211 Physical function outcomes in people with type 2 diabetes: What is the impact of type 2 diabetes duration above and beyond chronological age?

M. Hamza, D. Papamargaritis, A. P. Hall, T. Yates, M. J. Davies, J. Henson, UK

212 Age-related changes in skeletal muscle metabolic economy and mitochondrial function during acute ketosis: a randomised, double-blind, crossover study

O. E. Andersen, R. G. Larsen, N. Møller, A. Stouge, K. Overgaard, N. Jessen, Denmark

213 Dysregulated inflammatory response to exercise in type 2 diabetes: a role of CXCL12 in hypoxia-induced signalling

J. Ortiz de Zevallos, M. Jollet, A. A. Marica, L. Lehtonen, B. Jude, J. T. Lanner, A. Krook, J. R. Zierath, N. Pillon, Sweden

214 Exeriken: a novel exercise-dependent gene regulating glucose homeostasis in skeletal muscle

D. Steffan, M. Esposito, C. Barison, J.-P. Leduc Guadet, S. Hussain, D. Hammers, M. Sandri, A. Armani, Italy, Switzerland, Canada, USA

215 Deciphering molecular pathways of exercise in type 2 diabetes through multi-omic approaches

B. Stocks, S. Ashcroft, J. Kjærgaard, S. S. Hansen, M. Savikj, D. Rizo Roca, J. Otten, T. Olsson, S. Rasmussen, K. Caidahl, H. Wallberg-Henriksson, A. Krook, A. Deshmukh, J. Zierath, Denmark, Sweden

216 The impact of acute AM vs PM exercise on nocturnal energy and substrate metabolism in individuals at risk of developing type 2 diabetes

M. Kotte, S. De Kam, I. Habets, M. Timmermans, T. Van de Weijer, D. Blondin, A. Carpentier, P. Schrauwen, J. Hoeks, Netherlands, Canada, Germany

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

11th EASD-NNF Diabetes Prize for Excellence Lecture

The EASD-NNF Diabetes Prize for Excellence recognises outstanding achievements in research which has led to significant advances in the understanding, prevention or treatment of diabetes or its complications.

Chair: Chantal Mathieu, Belgium

Speaker: Gerald I. Shulman, USA:

Targeting mitochondria to treat type 2 diabetes and cardiometabolic disease

Dr. Gerald I. Shulman is the George R. Cowgill Professor of Internal Medicine and Cellular & Molecular Physiology at Yale University and an Investigator Emeritus of the Howard Hughes Medical Institute. He is also Co-Director of the Yale Diabetes Research Center.



Dr. Shulman has pioneered the use of nuclear magnetic resonance spectroscopy combined with stable isotopes and mass spectrometry to non-invasively examine intracellular glucose and fat metabolism in humans that have led to several paradigm shifts in our understanding of type 2 diabetes, including the molecular mechanisms by which ectopic lipids promote liver and muscle insulin resistance. The results of these studies have led to the development of novel drugs for the treatment of type 2 diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH).

Dr. Shulman is the recipient of the Stanley J. Korsmeyer Award from the American Society for Clinical Investigation, the Outstanding Clinical Investigator Award from the Endocrine Society, the Solomon Berson Award from the American Physiological Society, the Arthur Riggs Award, the Outstanding Scientific Achievement Award and the Banting Medal for Lifetime Scientific Achievement from the American Diabetes Association, the EASD-Lilly Centennial Anniversary Prize for Landmark Discoveries in Diabetes, and the Manpei-Suzuki International Prize for Diabetes Research.

Dr. Shulman is a Fellow of the American Association for the Advancement of Science, Inaugural Fellow of the American Physiological Society, Mastership in the American College of Physicians, Mastership in the American College of Endocrinology, Fellowship in the Royal College of Physicians (Lond.) and he has been elected to the American Society for Clinical Investigation, the Association of American Physicians, the National Academy of Medicine, the American Academy of Arts and Sciences and the National Academy of Sciences.

Supported by the Novo Nordisk Foundation

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

17:30 - 18:30

Paris Hall

Management of type 1 diabetes in adults. An update of the EASD-ADA consensus report

Chairs: Richard I.G. Holt, UK; Anne Peters, USA

Speaker: Richard I. G. Holt, UK:
Rationale for the update

Anne Peters, USA:
Key changes in the update

Audience discussion and feedback

GENERAL
INFO

PROGRAMME

TUESDAY

17:30 - 18:30

London Hall

SURPASS therapeutic challenges of paediatric type 2 diabetes with tirzepatide: Results from SURPASS-PEDS phase 3 Trial

Chair: Melanie J. Davies, UK

Speaker: Tamara S. Hannon, USA:
Results from SURPASS - PEDS Trial

Martin Wabitsch, Germany:
Putting SURPASS-PEDS results in context: Where do we stand now?

Agnieszka Szadkowska, Poland:
Commentary

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

17:30 - 18:30

Mumbai Hall

9th EASD-AASD Joint Symposium: Ageing with diabetes in East and West: sarcopenia, frailty and cognitive decline

Chairs: Caterina Conte, Italy; Hidenori Arai, Japan

Speaker: Leocadio Rodriguez Manas, Spain:
Epidemiology and pathophysiological mechanisms of muscle decline in ageing and some metabolic conditions

Hidenori Arai, Japan:
Strengthening the ageing body: Preventive management of sarcopenia and frailty in older adults with diabetes

Alan J. Sinclair, UK:
Clinical challenges in the management of diabetes and frailty in older people

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

17:30 - 18:30

Sofia Hall

Obesity and its impact on diabetes outcomes

Chair: Naveed Sattar, UK

Speaker: Peter Rossing, Denmark:
Does obesity accelerate CKD independently of hyperglycaemia: implications for care

Laura M. G. Meems, Netherlands:
Obesity and incident heart failure: a new dawn in case

Helen Colhoun, UK:
Obesity and type 1 diabetes: concerns and research gaps

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

17:30 - 18:30

Milan Hall

Recurrent severe hypoglycaemic events: What to do?

Chair: Eelco De Koning, Netherlands

Speaker: J H. DeVries, Netherlands:
Technology

James A. M. Shaw, UK:
Transplantation

Jane Speight, Australia:
Psychology

17:30 - 18:30

Warsaw Hall

The other side of the balance: adipose tissues role in energy expenditure and storage

Chair: Stephan Herzig, Germany

Speaker: Christian Wolfrum, Switzerland:
Futile cycles and metabolic health

André C. Carpentier, Canada:
The adipose tissue-liver metabolic unit in energy storage and expenditure

Philipp E. Scherer, USA:
Role of GIPR in adipose tissue

07:15 - 08:15

Vienna Hall

Towards arresting type 1 diabetes: Breaking results of the MELD-ATG trial and Ver-A-T1D trial using the INNODIA masterprotocol

Chairs: Jay S. Skyler, USA; Sanjoy Dutta, USA

Speaker: Chantal Mathieu, Belgium:

MELD-ATG: finding the minimal effective dose of ATG for arresting beta cell destruction in young people with new onset stage 3 type 1 diabetes

Thomas Pieber, Austria:

The effect of verapamil SR in adults with new onset stage 3 type 1 diabetes: a multi-center, randomized, placebo-controlled trial

Francesco Dotta, Italy:

Commentary

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

08:30 - 09:30

Vienna Hall

New paths for old friends: potential new roles for GLP1RAs and SGLT2is

Chair: Caroline Bonner, France

Speaker: Martin Heni, Germany:

Mind over metabolism: central actions of SGLT2 inhibitors

Paul Edison, UK:

GLP-1 RAs as novel therapeutic strategy in Alzheimer's and other neurodegenerative diseases

Mehdi Farokhnia, USA:

No longer stuck on you: GLP-1 RA in addiction

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Diabetes Global Impact Prize Lecture

The EASD Diabetes Global Impact Prize recognises individuals with outstanding contributions in clinical/translational research on diabetes that have had a 'global impact'.

Chair: Francesco Giorgino, Italy

Speaker: Viswanathan Mohan, India:
Impacting lives of people with diabetes in resource constrained settings

Dr. V. Mohan is Chairman, Dr. Mohan's Diabetes Specialities Centre at Chennai in South India which is an IDF Centre of Excellence in Diabetes Care. Dr. Mohan oversees a chain of 50 diabetes centres across 8 states of India and has over 6,65,000 registered diabetes patients in his electronic records. He is also Chairman, Madras Diabetes Research Foundation which is an ICMR- Collaborating Centre of Excellence (ICMR-CCoE). His main research interests are Epidemiology of diabetes and its complications, Genomics of diabetes including Monogenic Diabetes, Precision Diabetes and Nutrition in Diabetes.



Deeply interested in research from his undergraduate medical student days, ie., from the age of 18 years, Dr. Mohan has published 1780 of papers in peer reviewed journals which includes 1159 original articles which is a world record by a practicing doctor. His research has attracted over 232,000 citations and has a 'h index' of 167 with i-10 index of 1135. He has published 40 books and has over 1.5 million followers on local media.

Dr. Mohan has trained a large number of Physicians & Diabetologists in addition to Dieticians, Educators and Nurses from India and several other countries. He has received over 230 awards including the Dr. Harold Rifkin Award and Dr. Kelly West Award by the American Diabetes Association and FRS from the Royal Society of Edinburgh.

Dr. Mohan provides lifelong free treatment to thousands of poor patients through the free diabetic clinics established by him and has conducted over 3000 free diabetes camps

In 2012, Dr. Mohan was awarded Padma Shri, the fourth highest civilian award given by the Govt. of India.

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

08:30 - 09:30

London Hall

EASD-ESC Joint Symposium: Hot topics in cardiovascular medicine

Chairs: Francesco Cosentino, Sweden; Naveed Sattar, UK

Speaker: Kieran Docherty, UK:

How and when to screen for heart failure in diabetes?

Hertzel C. Gerstein, Canada:

Combining SGLT2i and GLP-1RAs: evidence for cardiovascular and kidney benefits?

Paul Welsh, UK:

Cardiovascular risk in pre-diabetes: how high and what to do?

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

08:30 - 09:30

Mumbai Hall

From drug-/toxicity screening to precision medicine: What's to gain from human tissue engineering for diabetes research?

Chair: Simon Dreher, Germany

Speaker: Peter Loskill, Germany:

White adipose tissue on chip: interconnecting organ models for diabetes research, drug- and toxicity screening

Nenad Bursac, USA:

Engineered skeletal muscle to study metabolic dysfunction

Volker M. Lauschke, Germany, Sweden:

3D human liver models for translational pharmacology and toxicology

08:30 - 09:30

Sofia Hall

From De Do Do Do, De Da Da Da through Every breath you take to Synchronicity or how to police big data in diabetes

Chair: Ele Ferrannini, Italy

Speaker: Joao-Filipe Raposo, Portugal:

It is easy and important: say "hi" to AI!

Harald Sourij, Austria:

It is impossible and redundant as it is all about good old clinical medicine

08:30 - 09:30

Milan Hall

Eye health in diabetes today

Chair: Rafael Simo, Spain

Speaker: Maria V. Cicinelli, Italy:
AI-assisted screening for diabetic retinopathy: Is it changing the next future?

Alicia Jenkins, Australia:
Lipids, lipid drugs and diabetic retinopathy

Inês Pereira Marques, Portugal:
Novel diabetes therapies in diabetic retinopathy and macular oedema

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

08:30 - 09:30

Warsaw Hall

The right timing to prevent type 2 diabetes

Chair: Patrick Schrauwen, Netherlands/Germany

Speaker: Denis P. Blondin, Canada:
Unlocking human postprandial organ-specific metabolism through high intensity interval training in prediabetes: insights from the TIMED consortium

Femke Rutters, Netherlands:
The effect of altering timing of energy intake, physical activity and sleep on glycaemia: meta-analyses and pragmatic trial

David J.T. Campbell, Canada:
Patient perspectives on TIMED health behaviours: results from quantitative and qualitative studies

10:00 - 11:00

Vienna Hall

OP 37 From insulin advances to novel therapies: latest clinical evidence

Chairs: Christophe Kosinski, Switzerland, Roopa Mehta, Mexico

217 Fixed-dose titration of insulin efsitora alfa demonstrates greater patient preference vs daily glargine in insulin naive adults with type 2 diabetes in QWINT-1

F. Perez Manghi, E. Miller, J. Rosenstock, L. Sauque-Reyna, C. Child, Q. Wang, M. B. Davidson, A. Knights, F. Gelsey, Argentina, USA, Mexico

218 Insulin efsitora alfa (efsitora) demonstrates better overall health state vs daily degludec in basal switch adults with type 2 diabetes in QWINT-3

H. Rodbard, R. Bergenstal, A. Philis-Tsimikas, S. Gangi, R. Threlkeld, J. Mitra, L. Ilag, M. Davidson, K. Syring, F. Gelsey, USA

219 Insulin efsitora alfa (efsitora) demonstrates better overall health state vs daily degludec in insulin naive adults with type 2 diabetes in QWINT-2

T. Vilsbøll, H. Bajaj, C. Wysham, I. Lingvay, L. Goncalves, C. Zhou, M. Davidson, A. Knights, F. Gelsey, Denmark, Canada, USA

220 Baricitinib in new-onset type 1 diabetes: BANDIT 2-year outcomes

M. Waibel, M. So, J. Wentworth, J. Couper, F. Cameron, R. MacIsaac, G. Atlas, J. Harbison, B. Krishnamurthy, A. Gorelik, S. Vogrin, L. Sanz Villanueva, P. Trivedi, H. Thomas, T. Kay, Australia

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

10:00 - 11:00

Paris Hall

OP 38 New medications on the horizon?

Chairs: Matthias Blüher, Germany; Zach Gerhart-Hines, Denmark

221 INV-347, a next generation cannabinoid receptor 1 inverse agonist, promotes body weight loss in obese mice

A. Vivoli, F. Paré, S. Rial, F. Abou Azar, B. Mani, C. Castorena, G. Gaucher, J. Duan, G. E. Lim, Canada, USA

222 A multiple dose study to evaluate the safety and tolerability of nimacimab, a peripherally restricted, inhibitory CB1 antibody in subjects with metabolic associated fatty liver disease

P. S. Arora, T. Diep, C. Twitty, P. Grayson, USA

223 Efficacy of a novel oral amylin analogue and the development of an oral GLP-1/amylin co-formulated tablet to produce high in vivo plasma exposures

J. Francis, M. Fenaux, H. Zou, X. Wu, W. Guo, J. Deng, C. Jones, S. Trieu, R. Ho, M. Eid, J. Hughes, W. Zhong, UK, China

224 MET-233 is a differentiated efficacious amylin analogue in preclinical studies, combinable with MET-097, an ultra-long acting GLP-1 receptor agonist

J. Minnion, B. Toungue, C. Hinds, C. Pernstich, R. Hansford, USA

10:00 - 11:00

London Hall

OP 39 From muscle to health: growth, atrophy, and adaptation in people with diabetes

Chairs: Pedro Pablo Acosta Manzano, Austria; Patrick Schrauwen, Germany/Netherlands

225 HDAC3 inhibitor prevents diabetic skeletal muscle atrophy by reducing myostatin

K.-W. Lee, S. An, T. Kim, Y. Son, Y. Kim, S. Choi, Y. Heo, S. Lee, S.-E. Choi, J. Jeon, S. Han, H. Kim, N. Lee, Republic of Korea

226 Proteomic analysis of skeletal muscle supporting muscle growth and metabolic improvement effects by HM17321 in diet induced obesity mouse model

H. Chon, B. Kim, H. Lee, S. Jung, Y.-Y. Kim, H. Kwon, S. Lee, S. Lee, S. Bae, I. Choi, Republic of Korea

227 Semaglutide treatment decreases lean mass and impairs exercise capacity in C57BL/6J mice

B. J. Baranowski, P. Basirian, M. Akcan, A. Bellucci, S. Trang, K. Eisner, A. Moore, S. Jeromson, D. C. Wright, Canada

228 Incomplete skeletal muscle adaptations to exercise training in Inuit homozygous TBC1D4 p.Arg684Ter variant carriers

C. With, N. Josefsen, R. E. Jørgensen, J. B. Birk, R. Kjøbsted, T. Hansen, M. E. Jørgensen, J. F. Wojtaszewski, Denmark, Greenland

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

10:00 - 11:00

Mumbai Hall

OP 40 Back to the future: building islet cells from scratch

Chairs: Diego Balboa, Finland; Françoise Carlotti, Netherlands

229 Improving stem cell derived beta cell differentiation and function with regenerative macrophages

B. Freitas, S. A. Fox, J. Velghe, P. C. Orban, M. Mojibian, D. Dai, G. Soukhatcheva, F. C. Lynn, M. K. Levings, C. Verchere, Canada

230 Deciphering the function of gastrin and cholecystokinin during human endocrinogenesis

L. Saber, K. Kozowa, M. Akgün, C. Karampelias, J. Jaki, I. Burtscher, H. Lickert, M. Bakhti, Germany

231 RFX3 is essential for the development and maturation of human pancreatic islets derived from pluripotent stem cells

E. Abdelalim, B. Memon, N. Aldous, A. Abdelaal, S. Ijaz, S. Hayat, Qatar, Germany

232 Spatial transcriptomic analysis of the early developing human pancreas

G. D. Jackson, M. Gierlinski, J. Cantley, UK

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

10:00 - 11:00

Sofia Hall

OP 41 For those who love to sleep (and exercise)

Chairs: Martin Haluzík, Czechia; Martin Schön, Germany

233 The relationship between sleep duration and quality and glycaemic variability in adults with type 1 diabetes

A. Duda-Sobczak, M. Kulecki, S. Pilacinski, D. Naskret, D. Zozulinska-Ziolkiewicz, Poland

234 Sleep and glycaemic patterns in hyperglycaemic pregnancies: evidence from continuous glucose monitoring

S. Rawal, A. Win, A. Khan, E. Mucahit, V. Martinez, T. Sangmo, USA

235 Performance of three simultaneously used rtCGM systems around a physically active weekend camp in adults with type 1 diabetes: a prospective lab and real-world study

S. Sanfilippo, U. Thurm, M. Renfordt, J. Schierbauer, C. Schramm, T. Plachta, H. Sourij, D. Schultes, A. Holtay-Mayer, P. Zimmermann, T. Voit, O. Moser, Germany, Austria

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

236 Glucoselo: causal modelling approach using matched-pair analysis to evaluate physical activity as a real-world glucose-lowering strategy in type 1 diabetes

C. Russon, R. Pulsford, E. Cockcroft, M. Allen, A.-M. Frohock, R. C. Andrews, J. Pemberton, UK

10:00 - 11:00

Milan Hall

OP 42 Old risk factors for cardio-renal complications

Chairs: Djordje Popovic, Serbia; Francesco Zaccardi, UK

237 Triglyceride-glucose index, renal function and 5-year all-cause mortality in patients with diabetes and comorbid hypertension: evidence from two prospective cohort studies

Y. Liu, H. You, J. Yuan, S. Wu, W. Yang, China

238 Heritability and genome-wide association study of arterial stiffness in type 1 diabetes

A. Tynjälä, A. Antikainen, A. Syreeni, S. Theilade, E. Dahlström, V. Harjutsalo, P. Rossing, T. S. Ahluwalia, P.-H. Groop, D. Gordin, N. Sandholm, Finland, Denmark

239 Visit to visit blood pressure variability is an independent risk-factor for kidney disease progression and renal function loss in people with type 1 diabetes

V. Krasniqi, M. Ozdede, P. Pavlou, S. Ayis, J. Karalliedde, UK

240 Progression of albumin/creatinine ratio and estimated glomerular filtration rate over 24 years in people with type 2 diabetes: drivers and potential protectors

A. Matheou, O. Zavlis, S. White, T. McDonnell, A. Warner-Levy, J. Warner-levy, L. Wilkins, A. Lay, L. Shalamanova, B. Mankovsky, M. Whyte, M. Gibson, P. Kalra, A. Heald, UK, Ukraine

10:00 - 11:00

Warsaw Hall

LBA OP 06 Combating complications with combining compounds

Chair: Jochen Seufert, Germany

LBA 31 Fixed-dose vs loose-dose combination antidiabetic therapy and cardiorenal risk in type 2 diabetes: a nationwide comparative effectiveness study

Q. Liu, P. Welsh, C. Celis-Morales, J. Lees, P. Mark, L. Pazzagli, UK, Sweden

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

LBA 32 The effect of empagliflozin on extracellular fluid volume and epicardial adipose tissue in patients at risk of heart failure: main results of a randomised controlled trial

C. F. Andersen, J. H. Larsen, M. Omar, N. Nouhravesh, C. Kistorp, C. Tuxen, F. K. Knop, P. L. Madsen, J. L. Forman, F. Davidovski, L. Køber, M. Schou, J. E. Møller, J. Jensen, Denmark

GENERAL
INFO

LBA 33 Simultaneous initiation of finerenone and empagliflozin by baseline glucagon-like peptide-1 receptor agonist use: a prespecified analysis of CONFIDENCE

R. Agarwal, J. B. Green, H. J. Heerspink, J. F. Mann, J. B. McGill, A. Mottl, M. Nangaku, J. Rosenstock, M. Vaduganathan, M. Brinker, C. Scott, L. Li, N. Li, K. Rohwedder, P. Rossing, USA, Netherlands, Germany, Japan, China, Denmark

PROGRAMME

TUESDAY

LBA 34 GLP-1 receptor agonists and risk of myeloma progression and cardiovascular events in patients with MGUS: a real-world propensity-matched study

A. Tentolouris, I. Ntanasis - Stathopoulos, C. Filippatos, M.-A. Dimopoulos, M. Gavriatopoulou, A. Briasoulis, Greece

WEDNESDAY

THURSDAY

FRIDAY

10:15 - 10:45

Spotlight Stage

Continuous ketone monitoring: a glimpse into the near future

Chair: Ketan Dhatariya, UK

Speaker: Jennifer L. Sherr, USA:

What are the potential benefits of continuous ketone monitoring?

Richard M. Bergenstal, USA:

What are the potential challenges of continuous ketone monitoring?

10:15 - 10:45

Arena

Lab Talk

Speaker: Guido Sebastiani, Italy

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

OP 43 The many faces of insulin resistance

Chairs: Antonio Amor, Spain; H el ene Hanaire, France

241 White adipose tissue adapts first: increased mitochondrial respiration and insulin resistance after short-term high-fat diet in healthy adults

G. Xourafa, C. Granata, S. Trenkamp, B. Korzekwa, V. Schrauwen-Hinderling, K. Petersen, G. Shulman, S. Kahl, M. Roden, Germany, USA

242 Harnessing a pathogenic mitochondrial DNA mutation to uncover mitochondrial mechanisms driving insulin resistance in humans

T. L. Nielsen, M. Andersen, M. Dun , M. Murgia, S. Larsen, S. S. Torekov, J. Vissing, M. Fiorenza, Denmark, Germany, Italy

243 Euglycaemic hyperinsulinaemic clamps reveal lower insulin sensitivity in type 1 diabetes adults with vs without nephropathy

A. S. Januszewski, R. Simonsen, A. Grzelka-Wozniak, J. R. Snaith, N. Sachithanandan, G. M. Ward, D. N. O'Neal, L. M. Thorn, A. J. Jenkins, J. R. Greenfield, A. Uruska, D. A. Zozulinska-Ziolkiewicz, P.-H. Groop, Australia, Finland, Poland

244 Differences in body fat distribution and risk of type 2 diabetes between subtypes of insulin resistance

J. H. Van der Velde, S. Wopereis, J. E. Oosterman, T. Van der Broek, F. R. Rosendaal, H. J. Lamb, F. Rutters, R. De Mutsert, Netherlands

OP 44 Dementia and cognitive dysfunction: Do we realise their magnitude and importance for people with diabetes?

Chairs: Tali Cukierman-Yaffe, Israel; Thomas van Sloten, Netherlands

245 Exome-wide analysis identifies risk alleles associated with dementia in type 2 diabetes

T. Wu, C. Yu, Z. Zhang, Y. Bi, China

246 Sex-specific patterns of obesity and overweight on brain aging and brain atrophy: a multi-cohort study

F. Anagnostakis, M. Kokkorakis, K. A. Walker, I. Skampardoni, J. Wen, G. Erus, Y. Cui, S. T. Govindarajan, D. Srinivasan, R. Melhem, E. Mamourian, H. Shou, I. M. Nasrallah, C. S. Manztoros, C. Davatzikos, USA, Netherlands

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONSPRESENTER
INDEXSATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

247 Age-specific trends in mortality from dementia among people with and without diabetes: a multi-country population-based analysis

K. Mehta, J. Morton, L. Chen, B. Carstensen, E. Gregg, M. Pavkov, M. Arffman, G. L. Booth, L. Chu, K. Fleetwood, S. Fosse-Edorth, T. Laurberg, S. Wild, J. Shaw, D. Magliano, Australia, Denmark, Ireland, USA, Finland, Canada, UK, France

248 Type 1 diabetes and dementia: findings from a national registry-based matched cohort study

M. Jancev, B. Eliasson, H. Gerstein, K. Eeg-Olofsson, T. Cukierman-Yaffe, G. Biessels, J. DeVries, F. L. Visseren, N. Sattar, T. Van Sloten, Netherlands, Sweden, Canada, Israel, UK

GENERAL
INFO

PROGRAMME

TUESDAY

11:30 - 12:30

London Hall

WEDNESDAY

OP 45 Fueling longevity: metabolic pathways in muscle and adipose tissue

Chairs: Simone Huber, Austria; Jonas T. Treebak, Denmark

THURSDAY

FRIDAY

249 Age-depedent Fgfr3 DNA methylation contributes to failure of adipose progenitor cells differentiating into beige adipocytes

G. Zhichao, China

SHORT ORAL
DISCUSSIONS

250 Deletion of miR-494 improves metabolic health and extends lifespan in mice through enhanced skeletal muscle mitochondrial biogenesis

L. Sugawara, K. Morino, H. Iwasaki, M. Lemecha, H. Yamamoto, N. Ohashi, S. Ida, D. Yanagisawa, H. Maegawa, S. Kume, Japan, USA

PRESENTER
INDEX

SATELLITE
SYMPOSIA

251 Analysis of age-related dysfunctions in thermogenic brown adipocytes

S. Gohlke, J. A. Heida, T. J. Schulz, Germany

INDUSTRY

252 TUDCA enhances insulin sensitivity and restores skeletal muscle mass in aged mice

M. S. Carvalho, L. Zangerolamo, H. C. Barbosa, Brazil

PROGRAMME

EXHIBITION

11:30 - 12:30

Mumbai Hall

OP 46 Targeting islets in type 2 diabetes: What is the bull's eye?

Chairs: Miriam Cnop, Belgium; Piero Marchetti, Italy

THANKS

253 Identifying new therapeutic targets for functional recovery of pancreatic beta cells in type 2 diabetes

T. Sawatani, M. Suleiman, X. Yi, T. Papadopoulou, M. Tesi, C. De Luca, J. Kerr-Conte, F. Pattou, M. Nacher, E. Montanya, N. I. Mourad, D. L. Eizirik, P. Marchetti, L. Marselli, M. Cnop, Belgium, Italy, France, Spain

254 Glucosamine-mTORC1 signalling contributes to beta cell dysfunction during glucotoxicity

Y. Riahi, A. Kogot-Levin, E. Zemelman, I. Abramovich, L. Hinden, E. Cerasi, R. Piran, Y. Tam, E. Bernal Mizrahi, G. Leibowitz, Israel, USA

255 Pyruvate dehydrogenase kinase 4 inhibition or deletion in alpha cells enhances glucagon secretion at low glucose in mouse and human islets and improves glucose tolerance in diet-induced obese male mice

F. Butaye, P. Gilon, Belgium

256 Early-onset type 2 diabetes: association and mechanisms of gut microbiota dysbiosis and metabolic disorders

L. Zhao, H. Yuan, H. Heng, China

11:30 - 12:30

Sofia Hall

OP 47 AID parade

Chairs: Elisabeth Mathiesen, Denmark; Agnieszka Szadkowska, Poland

257 Automated insulin delivery with automated algorithm updates and cloud integration: Does it outperform manual algorithm adjustments and uploading?

J. Pemberton, S. Uday, R. P. Dias, V. Saraff, L. Drummond, L. Collins, Z. Mohamed, R. Krone, UK

258 Glucose control of type 1 diabetes for 24 months under automated insulin delivery in usual practice: a nation-wide survey

C. Amouyal, J.-B. Julla, M. Joubert, S. Lablanche, C. Ben Signor, E. Bistmuth, Y. Chartier, N. Garrec, I. Banu, E. Pinto Da Rocha, C. Vazier, M. Marques, J. Gautier, E. Renard, J. Riveline, France

259 A-HCL response to unannounced meals: a comparison between PID and MPC algorithm in a cohort of paediatric patients with type 1 diabetes

S. Scirè Calabrisotto, D. Lo Presti, L. Tomaselli, G. Pezzino, F. Galeano, V. Oteri, A. Tumminia, Italy

260 A real-world multicentre study comparing automated insulin delivery systems during pregnancy in type 1 diabetes

C. Quiros, A. M. Wägner, S. Azriel, B. Soldevilla Madorell, P. Beato Vibora, M. Herrera Arranz, L. Nattero Chávez, M. Picón Cesar, E. Climent, J. Amigó, V. Perea, Spain

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

11:30 - 12:30

Milan Hall

OP 48 Genetic factors relating to type 1 and type 2 diabetes

Chairs: Anna Nowak-Szwed, Poland; Adám G. Tabák, Hungary

261 Interpreting type 1 diabetes risk across populations in the HLA region with genetics and single-cell transcriptomics

J. Zheng, Y. Shi, Y. Sun, L. Pan, H. Tan, T. Yue, S. Chang, X. Zheng, C. Guo, J. Weng, China

262 EDENT1FI: uncovering presymptomatic early-stage type 1 diabetes in children and adolescents across Europe

J.-F. Raposo, D. Agardh, B. Berka, O. Cinek, M. Kohls, V. Lampasona, A. Loff, F. Pociot, P. Narendran, R. Ribeiro, A. Szypowska, J. Vercauteren, C. Mathieu, A.-G. Ziegler, EDENT1FI consortium, Portugal, Sweden, Czechia, Germany, Italy, Denmark, UK, Poland, Belgium

263 Genetic risk scores discriminate between type 1 and type 2 diabetes in Chinese individuals

G. Yu, R. Wan, A. Jones, B. Fan, J. Hu, C. H. Tam, C. K. Lim, Y. Xiao, A. Luk, M. Weedon, W. A. Hagopian, Z. Zhou, J. Chan, R. C. Ma, R. Oram, Hong Kong, UK, China, USA

264 A latent genetic factor for glycaemic and atherosclerotic traits predicts cardiovascular disease comorbidity among individuals with type 2 diabetes

T. Le, M. Fernandes, X. Zhou, J. Merino, Denmark, USA

11:30 - 12:30

Warsaw Hall

LBA OP 07 Food and exercise - the best marriage of convenience

Chairs: Banshi Saboo, India; Dominik Pesta, Germany

LBA 35 Effects of the first European Food Prescription Programme for people with type 2 diabetes and low socioeconomic status: a randomised controlled pilot trial

K. A. Berk, C. A. Dietvorst, N. Perdeck, Z. Zielinska, Netherlands

LBA 36 Ingesting ketone monoesters decreases postprandial glycaemia across consecutive meals in people with type 2 diabetes: preliminary data

G. F. Pavis, G. Whelehan, A. Mari, B. T. Wall, R. C. Andrews, J. P. Little, F. B. Stephens, UK, Italy, Canada

LBA 37 Response to a complex lifestyle intervention in adults with obesity is modulated by metabolic adaptation to exercise

J. Ukropec, R. Klepochová, A. Amiri, P. Forišek Paulová, O. Mytiai, N. Alchus Laiferová, P. Dubajová, P. Konrády, V. Litváková, L. Slobodová, P. Minárik, M. Krššák, B. Ukropcová, Slovakia, Austria

LBA 38 Voluntary wheel running exercise orchestrates hepatic Lac-Phe and facilitates energy metabolism by activating oxidative phosphorylation

J. Zheng, W. Zou, L. Zhang, Y. Gao, China

11:45 - 12:15

Spotlight Stage

Revisiting Latent Autoimmune Diabetes in Adults (LADA): What is the evidence?

Chair: Raffaella Buzzetti, Italy

Speaker: Tiinamaija Tuomi, Finland:
LADA: Time for a new definition?

Ernesto Maddaloni, Italy:

Complications of LADA: more type 2 diabetes- or type 1 diabetes-like?

11:45 - 12:15

Arena

Lab Talk

Speaker: Reiner Jumpertz-von Schwartzberg, Germany

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

13:00 - 14:00

Vienna Hall

New ES/ESE guideline on pregnancy related treatment and care for women with pre-existing diabetes

Chairs: Annunziata Lapolla, Italy; Adam Tabák, Hungary

Speaker: Jennifer A. Wyckoff, USA:
Use of novel technologies

Linda A. Barbour, USA:
Non-insulin treatments

Rosa Corcoy Pla, Spain:
Contraception and pre-conception care

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

13:00 - 14:00

Paris Hall

Trends in diabetes complications and multimorbidity

Chair: Sarah Wild, UK

Speaker: Jonathan Valabhji, UK:
Diabetes complications (in type 1 and type 2 diabetes) over two decades in the UK: The good and the bad

Aidin Rawshani, Sweden:
Swedish patterns of macrovascular health since 2000

Edward W. Gregg, Ireland:
What do we know about multimorbidity trends in type 2 diabetes in high income countries?

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

13:00 - 14:00

London Hall

How might anti-obesity medication look like in the future?

Chair: Peter Flatt, UK

Speaker: Zach Gerhart-Hines, Denmark:
Leveraging novel GPCR pathways for the treatment of cardiometabolic diseases

Juan P. Frias, USA:
Update on the clinical trials using CagriSema

Daniela Liskiewicz, Germany:
Novel incretin-based quintuple agonist for the treatment of obesity and diabetes

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

13:00 - 14:00

Mumbai Hall

Scientific communication on social media: authoritative voices vs. self-proclaimed experts - Shall we enter the arena?

Chair: Caterina Conte, Italy

Speaker: Partha Kar, UK:

Communicating diabetes research on social media: new media

Hanna Boëthius, Switzerland:

Living and communicating diabetes: a personal and professional journey

James D. Johnson, Canada:

Ups and downs of entering the arena to foster diabetes awareness and care

13:00 - 14:00

Sofia Hall

Correctly classifying diabetes in adults in routine clinical practice

Chair: Ronald Ma, Hong Kong

Speaker: Angus Jones, UK:

Type 1 or type 2? Overcoming diagnostic challenges in routine practice

Mark Strachan, UK:

Changing practice: how routine biomarker assessment is improving diabetes classification in Scotland

13:00 - 14:00

Milan Hall

Personalised diabetes diagnosis: beyond the one-size-fits-all HbA_{1c} cutoff

Chair: Kashyap Patel, UK

Speaker: Inês Barroso, UK:

Genetic influences on HbA_{1c}: implications for diagnosis

Astrid Petersmann, Germany:

Age-related variations in HbA_{1c}: refining diagnostic criteria

Guido Freckmann, Germany:

Integrating continuous glucose monitoring with HbA_{1c} for improved diagnosis

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Is type 1 diabetes a slow virus disease?

Chair: Teresa Rodriguez-Calvo, Germany

Speaker: Knut Dahl-Jorgensen, Norway:

The orchestrated death of the beta cell: the role of virus

Heikki A. Hyoty, Finland:

Enterovirus in beta cells: the role of vaccination

Decio L. Eizirik, Belgium:

Islet viral infections in type 1 diabetes: Why beta but not alpha cells suffer the consequences?

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

SO 001 MODY and neonatal diabetes*Chair:* Kashyap Patel, UK**265 Recessive TMEM167A variants are a novel cause of neonatal diabetes, epilepsy and microcephaly syndrome**

E. De Franco, G. Bonfield, M. Govier, E. Virgilio, M. N. Wakeling, M. B. Johnson, S. E. Flanagan, M. Cnop, A. Hattersley, UK, Belgium

266 Characterisation of HNF1A-MODY in Asia: mutation profiles and clinical manifestations

J. Tang, A. B. Murusuri, China

267 Low prevalence of monogenic diabetes in patients with adult-onset diabetes from the Middle East living in Sweden

N. Shaat, N. F. Dhaher, L. Bennet, Sweden

268 Prevalence and screening for glucokinase monogenic diabetes amongst women diagnosed with gestational diabetes in a large ethnically diverse hospital population

M. Hamza, U. Ashraf, C. L. Meek, J. Dales, UHL Diabetes and Pregnancy Team, UK

269 Clinical characterisation of individuals with MODY

J. S. Jensen, H. Maagensen, S. O. Høyerup, H. Vestergaard, T. Hansen, J. Krogh, A. C. Thuesen, T. Vilsbøll, Denmark

270 Biallelic pathogenic variants in IL2RA cause neonatal onset monogenic autoimmune diabetes

G. Bonfield, J. Russ-Silby, M. Wakeling, S. Ramchand, A. Hattersley, S. E. Flanagan, E. De Franco, M. B. Johnson, UK

271 Complete loss of PAX4 causes transient neonatal diabetes in humans

J. Russ-Silby, Y. Lee, V. Rajesh, M. Amoli, N. Mirhosseini, T. Godbole, M. B. Johnson, D. E. Ibarra, H. Sun, N. A. Krentz, M. N. Wakeling, S. E. Flanagan, A. T. Hattersley, A. L. Gloyn, E. De Franco, UK, USA, Iran, Islamic Republic of, India

272 Initiation of incretin-based treatments is associated with lowered HbA_{1c}, weight and less hypoglycaemia in individuals with HNF1A-MODY

H. Maagensen, S. O. Høyerup, J. S. Jensen, H. Vestergaard, T. Hansen, A. C. Thuesen, T. Vilsbøll, Denmark

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONSPRESENTER
INDEXSATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

SO 002 Genetic and omics in type 1 diabetes

Chair: Helena Elding Larsson, Sweden

273 Killer cell immunoglobulin-like receptor genetic variation and type 1 diabetes in TEDDY

R. K. Johnson, S. D. Slack, S. Sadeeq, L. A. Leaton, K. M. Kichula, J. M. Norris, M. Rewers, P. J. Norman, USA

274 Genome-wide analysis identifies variants linked to protein glycation products in type 1 diabetes: insights from the FinnDiane Study

K. Adeshara, E. Valo, M. Lehto, P.-H. Groop, N. Sandholm, on behalf of the FinnDiane Study Group, Finland

275 Discovery of novel autoantibodies associated with protection from vascular complications using large scale proteomics in long-standing type 1 diabetes

X. Trinh, J. H. Biel, S. Kaur, M. Begum, P. Nilsson, F. Pociot, P. Rossing, V. Lyssenko, Denmark, Norway, Sweden

276 Clinical implementation of polygenic risk scores for cardio-renal-metabolic disease: uptake and impact in a large community health system

L. K. Billings, M. Raviv, S. R. Mwanda, A. Ashworth, A. Epshteyn, A. Grewal, A. Joseph, A. Kondilis, A. Qamar, Z. Shi, A. Shon, O. M. Siddiqui, J. Wilson, J. Xu, USA

277 Differences in the expression of insulin pathway genes according to the basal insulin analogue treatment used in the INEOX study

A. Lago Sampedro, V. Morillas, E. Garcia Escobar, M. Ruiz de Adana, Spain

278 Genetics and lipidomics insights into early-stage type 1 diabetes: a longitudinal study

J. Hernansanz, T. Suvitaival, T. Fløyel, J. Johannesen, P. Meikle, A. J. Overgaard, F. Pociot, S. Kaur, Denmark, Australia

279 A dynamic risk score for type 1 diabetes stratification, misdiagnosis and treatment efficacy testing

A. Hardikar, M. Joglekar, W. Wong, P. S. Kunte, H. P. Hardikar, R. A. Kulkarni, S. Kaur, I. Ahmed, A. Akil, M. K. Piya, J. Chan, S. Gitelman, R. Ma, F. Pociot, PREDICT T1D Study Group, Australia, Denmark, Qatar, Hong Kong

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONSPRESENTER
INDEXSATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

SO 003 Genetics of type 2 diabetes

Chair: Inês Barroso, UK

280 The role of body mass index and genetic risk for adiposity measures in early onset type 2 diabetes across ancestries

B. Orazumbekova, J. Zöllner, S. Hodgson, M. Bigossi, Genes & Health Research Team, S. Finer, R. Mathur, M. K. Siddiqui, UK

281 The relationship between amino acids, type 2 diabetes and brain health: a Mendelian randomisation study in the UK Biobank

A. C. Mason, C. E. Dale, N. Chaturvedi, V. Garfield, UK

282 Rare variants associated with diabetes and its complications: the All of Us research programme

S.-H. Hong, Q. Mei, R. Zukowski, J. Zhang, S. Choi, Republic of Korea, USA

283 Mechanistic heterogeneity in type 2 diabetes and hypertension comorbidity revealed with partitioned polygenic scores

I. Prokopenko, V. Pascat, L. Zudina, L. Maurin, A. Ulrich, A. Demirkan, Z. Balkhiyarova, A. Bonnefond, Y. Sharhorodska, F. Pattou, B. Staels, M. Kaakinen, A. Abdelgader-Khamis, P. Munroe, P. Froguel, UK, France, Ukraine

284 A pilot study on genetic variants associated with GLP-1 receptor agonist treatment response

Y. Kim, Republic of Korea

285 Multi-phenotype GWAS uncovers shared genetic loci between type 2 diabetes, colorectal, breast, and prostate cancers, leading to reclassification of risk loci

A. Demirkan, V. Lagou, I. Pupko, Z. Balkhiyarova, A. Ulrich, J. Maina, M. Kaakinen, I. Prokopenko, UK

286 PCSK9 coding DNA variants affect glucose levels and could predict hyperglycaemic events in inhibitor treatments: a UK Biobank study

Z. Balkhiyarova, Y. Qi, V. Pascat, Y. Sharhorodska, A. David, B. Jones, C. N. Izzing-Engbeaya, I. Prokopenko, UK, France, Ukraine

287 Improving type 2 diabetes machine learning-based prediction accuracy with SNPs and younger age

P. Zalloua, C. Al Hageh, A. Henschel, J. Zubelli, S. Chacar, N. Iakovidou, H. Hatzikirou, A. Abchee, S. O'Sullivan, United Arab Emirates

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

SO 004 Epigenetics of type 2 diabetes*Chair:* Zhichao Zhou, Sweden**288 Identification of a circulating MiRNA signature for sodium-glucose cotransporter 2 inhibitors (SGLT2i) treatment response**

H. C. Tam, C. K. Lim, E. S. Lau, A. Yang, C. H. Tam, B. Fan, A. O. Luk, J. C. Chan, J. C. Choi, E. Y. Chow, R. C. Ma, Hong Kong

GENERAL
INFO**289 Differential response of extracellular vesicle miRNA to acute exercise in men with type 2 diabetes**

P. Pinto-Hernandez, I. Sen, N. Pillon, J. R. Zierath, A. Krook, Sweden, France

PROGRAMME

TUESDAY

290 Development and replication of methylation risk scores for novel diabetes subtypes

H. Lin, C. H. Tam, M. Shi, C. K. Lim, C.-K. O, B. Fan, H. Wu, A. O. Luk, W.-Y. So, J. Chan, R. C. Ma, TRANSCEND Consortium, Hong Kong

WEDNESDAY

THURSDAY

291 Development of a predictive algorithm based on serum biomarkers to identify patients with morbid obesity who achieve type 2 diabetes remission one year after bariatric surgery

S. Garcia Serrano, E. Garcia-Escobar, M. Fontalba-Romero, A. Lago_Sampedro, S. Valdés, M. Gonzalo-Marín, M. Francisco Javier, A. Rodríguez Cañete, J. Domínguez-Bendala, E. Garcia-Fuentes, Spain, USA

FRIDAY

SHORT ORAL
DISCUSSIONS**292 Placenta-derived serum biomarkers for early detection of gestational diabetes: a systematic review**

N. V. Pujeri, R. Bilgaiyan, D. B. Pandya, S. Ponnada, P. Maddur, L. B. Pithalla, R. Chitturi, S. Parasuram, N. Kolanu, India, USA

PRESENTER
INDEXSATELLITE
SYMPOSIA**293 Associations between exercised-induced DNA methylation changes and metabolomic profiles in skeletal muscle from women with type 2 diabetes and normal glucose tolerance**

K. A. MacGregor, J. Zierath, A. Krook, Sweden

INDUSTRY

PROGRAMME

EXHIBITION

294 Distinct epigenetic landscapes of age and diabetes in human islets reveal non-genetic drivers of beta cell adaptation or dysfunction in type 2 diabetes pathophysiology

A. Khamis, L. Maurin, L. Marselli, M. Suleiman, F. Burdet, C. De Luca, A. Piron, M. Tesi, M. Cnop, M. Ibberson, A. Bonnefond, P. Marchetti, P. Froguel, France, Italy, Switzerland, Belgium

THANKS

SO 005 Classification of diabetes subtype

Chair: Christophe De Block, Belgium

295 Identification of metabolic characteristics and differential diagnostic biomarkers for type 3c diabetes based on untargeted metabolomics

X. Wang, L. Li, China

296 Urinary C-peptide as a non-invasive biomarker for subtyping adult-onset diabetes

C. Binsch, T. R. Londhe, I. Yurchenko, K. Prystupa, S. Trenkamp, G. Heilmann, T. Mori, M. Heni, K. B. Bodis, R. Wagner, Germany

297 Identification of pyroptosis-related molecular markers in diabetes of the exocrine pancreas

G. Li, X. Mao, China

298 C-peptide as an adjunctive diagnostic tool for early identification of young-onset type 2 diabetes

S. H. Song, B. M. Frier, S. Tesfaye, A. Iqbal, UK

299 Diabetes subgroups identified by cluster analysis: a systematic review and meta-analysis of replication and validation studies

J. Wang, Y. Deng, X. Li, L. Jiu, Netherlands

300 Acanthosis nigricans as a visual biomarker for overt insulin resistance: implications for early diabetes risk stratification

K. Mutailipu, Y. Zhao, Y. Wang, J. Cheng, J. Wen, C. Tong, Y. Li, S. Qu, L. Bu, China

301 HbA_{1c} trajectories among children and young people with type 2 diabetes in multi-ethnic Singapore

J. H. Yung, R. Sultana, Y. Book, P. Lim, Y. Hui, N. Lek, Singapore

302 Plasma small RNA profiling reveals a predictive three-miRNA signature for early beta cell dysfunction across glucose tolerance stages

E. Aiello, S. Auddino, R. Bizzotto, A. Mari, M. Brunetti, L. Soldovieri, G. Di Giuseppe, G. Ciccarelli, A. Giaccari, G. Daniele, A. Dardano, M. Parenti, G. Sebastiani, F. Dotta, T. Mezza, Italy

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

SO 006 Predicting type 2 diabetes using standard statistical and machine learning algorithms*Chair:* Adam Tabák, Hungary**303 Dose-response relationship between postload-fasting glucose gap and risk of developing diabetes**

X. Xu, D. Wang, S. Jaffar, U. Alam, S. Qiu, Z. Sun, A. Garrib, UK, China

304 The visceral adiposity index predicts the development of type 2 diabetes in patients with established coronary artery disease

T. Plattner, A. Vonbank, B. Larcher, A. Mader, L. Schnetzer, M. Neyer, J. Vogel, P. Elsner, A. Leiherer, A. Muendlein, A. Festa, H. Drexel, C. H. Saely, Austria, Liechtenstein

305 Clustering of continuous glucose monitoring data reveals distinct phenotypes of insulin resistance in individuals with overweight and grade 1 obesity

A. Fedulovs, E. Vilunas, S. Ivanova, Z. Smite, S. Skrebinska, G. Bilande, M. Arisova, L. Pahirko, J. Sokolovska, Latvia

306 Skinfold thickness, not BMI or waist circumference, increases the risk of developing type 2 diabetes in non-obese Japanese men

T. Hayashi, H. Miyagawa, M. Shibata, C. Hamada, Y. Taniguchi, K. Okada, K. K. Sato, Japan

307 Predicting diabetes among adults living with HIV and hypertension using a machine learning algorithm

O. J. Molefe-Baikai, M. Mawi, K. Molebatsi, K. Kebotsamang, T. Moshomo, G. E. Mogaetsho, M. Kelepile, T. Gaolathe, S. Jaffar, L. R. Hirschhorn, D. Wang, M. Mosepele, Botswana, UK, USA

308 Lipid accumulation product as a predictor of type 2 diabetes: insights from Qatar Biobank

A. Kerkadi, L. Alkaabi, I. Ramzan, M. Barigou, Qatar

309 A machine learning microRNA predictor for long-term remission following short-term intensive insulin therapy in newly diagnosed type 2 diabetes

S. Tang, L. Liu, China

310 A review of evidence level and causal support in prediction models of complications in health economic models of type 2 diabetes

W. Wang, J. Wang, Australia, Netherlands

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONSPRESENTER
INDEXSATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

SO 007 Type 1 diabetes epidemiology and metabolic indicators

Chair: Djordje Popovic, Serbia

311 Obesity and overweight prevalence in patients with type 1 diabetes: data from Czech registry DiaPanther

J. Urbanova, L. Brunerova, A. Adamikova, R. Bem, J. Broz, J. Homolova, D. Janickova-Zdarska, D. Karasek, M. Klementova, E. Papezova, M. Policar, J. Vejrychova, M. Haluzik, Czechia

312 Aging with type 1 diabetes: a perspective on “octogenarians” living with type 1 diabetes in Italy

A. Da Porto, R. Candido, V. Manicardi, A. Rocca, S. De Cosmo, G. Di Cianni, G. Russo, Italy

313 Overweight, obesity, and glycemic control: insights from the T1D Exchange Registry

J. Lucove, R. Lal, H. Nguyen, M. Peter, W. Wolf, USA

314 High prevalence of autoimmune comorbidities in Norwegian adults with type 1 diabetes: similar HbA_{1c} and vascular complication rates compared to type 1 diabetes only

K. Hatlen, T. Berg, K. Stavem, K. Løvaas, E. Husebye, A. Sharma, I. Neramoen, Norway

315 Pancreatic exocrine insufficiency is associated with lower time in range, longer diabetes duration and altered food intake in a cohort of 418 individuals with type 1 diabetes

D. F. De Wit, C. M. Fuhri Snethlage, J. H. Levels, E. Rampanelli, A. S. Meijnikman, M. Nieuwdorp, N. M. Hanssen, Netherlands

316 Type 1 diabetes incidence is lower in children of South Asian and Black ethnicity compared to those of White ethnicity: a UK population-based study

K. Young, R. Hopkins, N. Thomas, A. McGovern, A. Jones, K. Patel, B. Shields, J. Dennis, UK

318 Bridging the gaps in diabetic ketoacidosis management: real-world experience of protocol adherence and outcomes in a major UK centre

H. Tan, S. Haughton, J. Maliakkal, J. Tan, E. McNally, L. Hunt, S. Song, P. Kempegowda, A. Iqbal, UK

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

SO 008 Prediabetes: prevalence and diagnosis

Chair: Ronald Ma, Hong Kong

319 Prediabetes remission is linked with reduced type 2 diabetes and nephropathy risk independent of initial glucose regulation

A. Sandforth, L. Sandforth, R. Wagner, J. Szendroedi, M. Blüher, M. Hrabce de Angelis, A. Schuermann, S. Kabisch, S. Bornstein, M. Roden, N. Stefan, A. Fritsche, A. Birkenfeld, R. Jumpertz von Schwartzberg, and the PLIS Group, Germany

GENERAL
INFO

PROGRAMME

TUESDAY

320 Younger males with prediabetes exhibit a significantly elevated risk of progressing to diabetes: evidence from the Tongren Health Care study

X. Cao, D. N. Chen, Y. Li, China

WEDNESDAY

321 Longitudinal study reveals plasma glycans associations with prediabetes / type 2 diabetes in KORA F4/FF4

J. Niu, A. Peters, G. Lauc, C. Gieger, H. Grallert, Germany, Croatia

THURSDAY

FRIDAY

322 Novel subgroups of prediabetes and their association with outcomes: a 4-year follow-up study

Y. Liu, Z. Sun, China

SHORT ORAL
DISCUSSIONS**323 Prevalence of undiagnosed type 2 diabetes and prediabetes in central Europe: analyses of a multicentre registry study and health insurance data in Austria**

C. Sourij, T. Bergmair, F. Aziz, H. Kojzar, L. Knoll, M. Clodi, P. Fasching, A. Krauter, M. Schaffnerath, S. Kaser, H. Sourij, Austria

PRESENTER
INDEXSATELLITE
SYMPOSIA**324 Prevalence of prediabetes and undiagnosed diabetes in patients with obstructive sleep apnoea syndrome**

M. Ammi, F. Meçabih, A. Tebaibia, Algeria

INDUSTRY

325 Sex specific mechanisms of weight loss-induced prediabetes remission

Y. Wang, V. Englert, Y. Cheng, A. Sandforth, L. Sandforth, J. Machann, M. Solimena, M. Hrabce de Angelis, S. Kabisch, M. Roden, N. Stefan, A. Fritsche, H. Preissl, R. Jumpertz von Schwartzberg, A. Birkenfeld, Germany

PROGRAMME

EXHIBITION

THANKS

326 Optimal threshold of 1-h post-load plasma glucose for detecting prediabetes

R. Bouzid, Algeria

SO 009 Mortality in type 2 diabetes

Chair: Claire Meek, UK

327 The association between body mass index and mortality: a cohort study

S. Gribsholt, A. Andersen, J. Starup-Linde, K. Hygum, T. Harsløf, J. Bruun, Denmark

328 Trends in cardiovascular disease mortality and DALYs associated with metabolic risk factors in Central Asia: 1990-2021

A. Kabibulatova, R. Akhmedullin, A. Sarria-Santamera, K. Atageldiyeva, Kazakhstan

329 Association between diabetes and increased mortality in the Japanese oldest-old: a cohort study of individuals aged 85 and older

Y. Kabeya, S. Yamashita, N. Aoyama, Japan

330 Carbohydrate quality, metabolomic signatures and risk of mortality, diabetes and cardiovascular disease

A. Lahiri, F. Imamura, N. G. Forouhi, UK

331 Impact of undiagnosed diabetes on mortality and major cardiovascular events after acute coronary syndrome: insights from the STRONG-MI Cohort in Austria

F. Aziz, C. Strohhofer, F. Von Lewinski, M. Meister, A. Kainz, D. Von Lewinski, H. Sourij, Austria

332 Unequal progress in mortality outcomes for type 2 diabetes: insights from a 20-year comparative cohort study of 429,284 people with diabetes

M. Anson, D. Riley, A. E. Henney, G. H. Ibarburu, S. Azmi, G. Y. Lip, L. Fauchier, S. S. Zhao, D. J. Cuthbertson, U. Alam, UK, USA, France

333 Osmolarity and mortality in patients with extreme hyperglycaemia: a nationwide cohort study

E. V. Rosager, J. Petersen, F. E. Nielsen, S. B. Haugeard, R. Gregersen, Denmark

334 Heterogeneity in fatal cardiovascular risk across data-driven diabetes subgroups in 25,000 adults in Mexico City

J. Perezalonso-Espinosa, J. P. Díaz-Sánchez, C. A. Fermín-Martínez, M. R. Basile-Álvarez, N. E. Antonio-Villa, J. A. Seiglie, O. Y. Bello-Chavolla, Mexico, USA

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

SO 010 Post GDM consequence in mother and child*Chair:* Rosa Corcoy Pla, Spain

335 Dietary intake and body composition in 3-year-old offspring of mothers with gestational diabetes: insights from the PONCH cohort
S. Åberg, U. Andersson Hall, E. Kristiansson, A. Holmäng, Sweden

GENERAL
INFO

336 Glucose tolerance and metabolic health in relation to stress and sleep patterns four years after gestational diabetes: the PREPP study
U. Andersson Hall, E. Kristiansson, S. Åberg, K. Wallenius, A. Holmäng, Sweden

PROGRAMME

TUESDAY

337 Uncovering cardiometabolic risks in postpartum women with prior gestational diabetes: baseline insights from the I-HIPS randomised trial in Singapore

P. Quah, S. Chai, M. Tan, W. Han, E. Lim, A. Abu Bakar, F. Binti Mohamad, K. Tan, Singapore

WEDNESDAY

THURSDAY

FRIDAY

338 In utero exposure to maternal gestational diabetes and depression in association with childhood obesity risk

A. Ferrara, A. K. Peterson, Y. Zhu, A. Ngo, C. Quesenberry, L. Avalos, USA

SHORT ORAL
DISCUSSIONS

339 Exploring intersectional cultural experiences of diabetes prevention after gestational diabetes among Chinese and South Asian women in Australia

Y. Dou, J. Boyle, S. Lim, Australia

PRESENTER
INDEX

340 Systematic review of the health beliefs and perspectives on gestational diabetes in women after pregnancy: a comparative study across different cultures

Y. Dou, J. Boyle, S. Lim, Australia

SATELLITE
SYMPOSIA

INDUSTRY

341 Unravelling the 6P lifestyle tool: predicting cardiometabolic risk in a postpartum diabetes prevention trial

S. M. Chai, P. Quah, M. H. Tan, W. M. Han, E. J. Lim, F. Fadzully, M. A. Bakar, K. H. Tan, Singapore

PROGRAMME

EXHIBITION

Short Oral Event E

Thursday, 12:45 - 13:45

SO 011 Risk and outcome of diabetes in pregnancy*Chair:* Pedro Pablo Acosta Manzano, Austria

342 The impact of built and social environments on gestational diabetes risk: Are all women equally affected?

W. W. Takele, L. L. Dalli, R. Beare, K. Adhinugraha, D. Taniar, S. Lim, J. A. Boyle, Australia

THANKS

343 Trends of maternal and neonatal outcomes in women with pre-gestational and gestational diabetes compared to women without diabetes in Germany from 2004 to 2019

H. Claessen, M. Narres, T. Kvitkina, A. Icks, L. Reitzle, A. Beyerlein, M. Kalthéuner, H. Adamczewski, Germany

344 Risk factors associated with adverse perinatal outcomes in early gestational diabetes: a perspective from the DREAMBee study in Japan

T. Sugiyama, N. Iwama, K. Miyakoshi, M. Kawasaki, N. Arata, DREAMBee Study Gestational Diabetes Mellitus Group, Japan

345 Significant differences in incretin and glucagon hormone responses between South Asian and Nordic women after gestational diabetes

A. Sharma, E. Qvigstad, I. Nerموen, S. Sollid, B. Hartmann, J. Holst, S. Lee-Ødegård, K. Birkeland, Norway, Denmark

346 Tissue specific differences in insulin resistance in South Asian and Nordic women with or without previous gestational diabetes

A. A. Kvist, A. Sharma, E. Qvigstad, N. Sattar, J. M. Jill, C. D. Bjørnval, T.-L. Kalleklev, P. Shakya, F. A. Norheim, G. Van Hall, S. Lee-Ødegård, K. I. Birkeland, Norway, UK, Denmark

347 Parental socioeconomic status and risk of poor pregnancy outcomes in pregnancies with maternal type 1 diabetes

T. W. Gundersen, T. D. Clausen, L. Ringholm, D. M. Jensen, P. Damm, K. Kragelund Nielsen, H. Backman, J. Lauenborg, E. R. Mathiesen, N. Skipper, A. Kofoed-Enevoldsen, S. Knorr, Denmark, Sweden

Short Oral Event F

Thursday, 14:00 - 15:00

SO 012 Risk factors for type 2 diabetes onset

Chair: Naveed Sattar, UK

348 Longitudinal study on sweetened beverage consumption and risk of type 2 diabetes in Australia

R. Kabthlymer, T. Wu, S. Beigrezaei, O. H. Franco, A. M. Hodge, B. De Courten, Australia, Netherlands

349 Smoking, genetic susceptibility, and the risk of type 2 diabetes subtypes

E. Keysendal, E. Ahlqvist, B. O. Åsvold, J. Edstorp, T. Tuomi, V. Vik Bjarkø, S. Carlsson, Sweden, Norway, Finland

350 Potential protective effect of hepatitis B immunity against diabetes: a retrospective propensity-score-matched cohort study

N.-Q. Phan, S.-J. Lin, J.-H. Chen, M.-H. Hsu, V.-T. Nguyen, P.-M. Thang, Y.-L. Huang, C. Chen, Taiwan, Viet Nam

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

351 The antiepileptic drug use increased new-onset diabetes in middle-aged individuals aged 50 years and older based on the National Health Insurance Service-National Health Screening cohort

D.-H. Lee, J.-W. Lee, H. Jeon, Republic of Korea

352 Calculated small dense LDL cholesterol levels are associated with the onset of diabetes irrespective of LDL cholesterol levels: a 10-year period population-based study

W. Kawaharata, M. Tanaka, T. Sato, H. Aida, R. Matsumori, I. Hosaka, Y. Akiyama, H. Kouzu, N. Hanawa, M. Furuhashi, Japan

GENERAL
INFO

353 The role of atmospheric pollutants in type 2 diabetes prevalence across Italy

F. Carrieri, E. Aruffo, A. Mascitelli, P. Chiacchiaretta, M. P. Baldassarre, G. Formoso, A. Consoli, P. Di Carlo, Italy

PROGRAMME

TUESDAY

WEDNESDAY

354 Cannabis use and the risk of developing diabetes: a real-world evidence study

I. Kamel, S. Esteghamati, A. Esteghamati, USA, Iran, Islamic Republic of

THURSDAY

355 Associations between physical fitness components and the risk of type 2 diabetes in middle-aged Japanese men: a prospective cohort study

M. Shibata, K. Sato, H. Miyagawa, Y. Taniguchi, C. Hamada, K. Okada, T. Hayashi, Japan

FRIDAY

SHORT ORAL
DISCUSSIONS

Short Oral Event A

Tuesday, 12:00 - 13:00

PRESENTER
INDEX

SO 013 Metabolic and vascular complications of diabetes

Chair: Jens Lund, Denmark

SATELLITE
SYMPOSIA

356 Average area under the HbA_{1c} curve and the legacy effect of diabetes: evidence from a real-world multiethnic cohort

J. K. Tan, G. Lim, H. Tan, G. G. Sng, J. Thumboo, Y. Bee, Singapore

INDUSTRY

357 Phenotype-based clustering identifies a novel diabetes subtype among Chinese individuals with type 2 diabetes predicting cardiovascular-kidney complications

H. Lin, C. Tam, M. Shi, E. Lau, C. Lim, B. Fan, C.-K. O, A. Yang, H. Wu, A. P. Kong, E. Y. Chow, R. Ozaki, A. O. Luk, J. C. Chan, R. C. Ma, Hong Kong

PROGRAMME

EXHIBITION

THANKS

358 Ten-year incidence of liver disease in people with newly diagnosed type 2 diabetes: a nationwide cohort study

J. Løhde, S. Nicolaisen, K. Højlund, M. Olsen, J. Nielsen, P. Vestergaard, T. Hansen, M. Andersen, H. Grønbæk, H. Sørensen, C. Brøns, A. Vaag, P. Jepsen, R. Thomsen, N. Jessen, Denmark

359 Type 2 diabetes associates with higher occurrence of cardiorenal comorbidities in people living with overweight or obesity: the CALOR study

H. Waki, E. Lesén, C. M. Gray, M. Bjursell, D. B. Horn, Japan, Sweden, UK, USA

360 Prevalence and social disparities of metabolic syndrome and its components among 50,694 middle-aged Danes

R. W. Thomsen, M. Madsen, F. P. Kristensen, H. T. Sørensen, Denmark

361 Prevalence of foot complications in 10,112 adults with newly diagnosed type-2 diabetes and associated characteristics: a cross-sectional study of the Danish DD2 cohort

C. A. Hansen, A. Kousholt, U. R. Madsen, S. F. Lehn, S. Moeini, R. W. Thomsen, Denmark

362 Sex differences in risk factors for micro- and macro-vascular complications in early and usual onset type 2 diabetes

B. Orazumbekova, E. Remfry, R. Henkin, M. Barnes, R. Mathur, UK

363 Global, regional and national burden of core components in cardiovascular-kidney-metabolic syndrome, 1990-2021: a systematic analysis from the Global Burden of Disease Study 2021

D. Lin, China

Short Oral Event B

Tuesday, 13:15 - 14:15

SO 014 Clinical burden of diabetes

Chair: Stavros Th. Liatis, Greece

364 Longitudinal study of diabetes and depressive symptoms in middle-aged and older adults in China: the mediating impact of functional limitations and social interaction

Y. Tao, C. MacGilchrist, E. Kirwan, M. Caroline, Ireland

365 Clinical burden associated with type 2 diabetes in France: an update from the national insurance claim database

J.-P. Riveline, C. Blanc-Bisson, E. Vicaut, G. De Pouvourville, B. Detournay, C. EMERY, I. Bureau, T. Ihaddadene Salzgeber, F. Levrat-Guillen, B. Guerci, France, UK

366 Long-term survival associated with continuous positive airway pressure in type 2 diabetes and obstructive sleep apnoea: results from Swedish national data

J. Agholme, M. Koosje Jaarsma, O. Sysoev, B. Eliasson, J. Theorell-Haglöw, M. Ulander, M. Wijkman, K. Eeg-Olofsson, L. Grote, F. Iredahl, Sweden

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

367 High burden of cardiometabolic comorbidities in obese children presenting to a tertiary hospital in South Africa from 2002 to 2022

N. Peer, J. Sewlall, Y. Balakrishna, S. Tayob, A.-P. Kengne, Y. Ganie, South Africa

368 Management of cystic fibrosis related diabetes in Denmark: a nationwide population-based, cross-sectional study

T. Almdal, I. Grimsgaard, M. Jeppesen, B. U. Nielsen, E. H. Henriksen, D. Faurholt-Jepsen, E. Søndergaard, Denmark

GENERAL
INFO

Short Oral Event C

Wednesday, 11:45 - 12:45

SO 015 Glycaemia in diabetes

Chair: Tiinamaija Tuomi, Finland

369 Related factors of the dawn phenomenon in patients with type 2 diabetes

Y. Xia, China

370 CLEC11A regulates glycolipid metabolism: new evidence for potential therapeutic targets in type 2 diabetes

Q. Wang, Z. Cai, H. Wang, Z. Sun, China

371 Diagnosing type 2 diabetes and pre-diabetes in emergency room attendees in an acute hospital in England

E. Jude, S. Saluja, A. Heald, S. Anderson, UK, Barbados

372 Repurposing colorectal cancer screening faecal tests for type 2 diabetes screening

T. Laurberg, A. L. Madsen, O. Frøbert, H. Støvring, S. Wild, D. R. Witte, S. B. Graversen, Denmark, Sweden, UK

373 1,5-anhydroglucitol: a valuable bioactive marker for exploring microbiome and nutrition interplay in diabetes

J. M. Lopez-Pedrosa, M. T. García-Corcoles, M. Manzano, R. Rueda, Spain

374 The air we breathe: associations of long-term exposure to air pollution with HbA_{1c}, whole-body insulin sensitivity and beta cell function in people with type 1 and type 2 diabetes

N. Singh, C. Wigmann, O.-P. Zaharia, S. Trenkamp, B. Sun, S. Schlesinger, R. Wagner, T. Schikowski, M. Roden, C. Herder, Germany

375 Perioperative glycaemic control and outcomes in Aboriginal and Torres Strait Islander people with diabetes undergoing surgery in south Australia

K. Flabouris, O. Pearson, K. Morey, S. Edwards, D. Jesudason, C. S. Marathe, Australia

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Short Oral Event D

Wednesday, 13:00 - 14:00

SO 016 Drugs epidemiology in diabetes

Chair: Angus Jones, United Kingdom

376 Efficacy and safety of mesoporous silica particles for blood glucose control: randomised, double-blind, placebo-controlled multicentre trial: SHINE

J. Baek, G. Robert-Nicoud, M. L. Borg, A. Ioannidou, K. Pietiläinen, T. Bengtsson, Sweden, Finland

377 Determinants of non-initiation with SGLT2i and GLP-1 receptor agonists: a Danish nationwide study of risk factors and sex differences in patients with type 2 diabetes and cardiovascular disease

E. Calderon, L. Bjerg, A. A. Isaksen, A. Sandbaek, K. L. Funck, E. L. Grove, Denmark

378 Insulin prescription trends by sex and income level: population-based analyses from BDCAP (2017-2023)

J. Ares, I. Masid, C. Lambert-Goitia, Spain

379 Efficacy and safety of imeglimin in metformin-intolerant patients with type 2 diabetes: a retrospective real-world study

A. Pande, M. Agarwal, V. Nagesh, M. Bhartia, A. Tewari, India

380 Significant increase in use of weight-loss medications in Norway: analysis of trends 2004-2024 and implications

H. L. Gulseth, K. Furu, P. L. Ruiz, Ø. Karlstad, Norway

381 Combination lipid lowering therapy and the risks of various types of cancers in patients with type 2 diabetes

S. Kim, Y. Cho, H.-S. Park, D. Seo, S. Hong, Republic of Korea

Short Oral Event E

Thursday, 12:45 - 13:45

SO 017 More on risk factors for type 2 diabetes onset

Chair: Fariba Ahmadizar, Netherlands

382 Diabetes and depressive symptoms: examining the potential roles of country-level and individual-level factors across European countries

J. Gottfried, K. Gajewska, A. Hever, B. Hernández, C. Lloyd, A. Nouwen, S. O'Donnell, R. Rodrigues, N. Schmitz, S. Deschênes, Ireland, UK, Portugal, Germany

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

383 Differences between Southeast Asians and Caucasians in intraorgan fat deposition patterns in type 2 diabetes

A. H. Al-Mrabeh, U. Dhar, C. Gray, C. V. Cabanilla, J. Guilaran, R. Fragante, I. Angeles-Agdeppa, B. Ahmad, A. Zaini, J. C. Mathers, C. Jimeno, G. Lietz, UK, Philippines, Malaysia

384 Lifestyle intervention is more effective in reducing incident type 2 diabetes in high 1-hour post-load plasma glucose than impaired glucose regulation

A. Sandforth, R. Jumpertz von Schwartzberg, L. Sandforth, S. Katzenstein, J. Machann, F. Schick, K. Kantartzis, H. Preissl, A. Fritsche, N. Stefan, M. Bergman, A. Birkenfeld, Germany, USA

GENERAL
INFO

PROGRAMME

TUESDAY

385 The incidence of recent-onset diabetes in pancreatic cancer: a systematic review and meta-analysis

Y. Jin, X. Wang, M. Zhang, China

WEDNESDAY

386 Dynamics of blood glucose and anthropometric measures in Northern Sweden: cross-sectional analysis of the Västerbotten Intervention Programme

O. Rolandsson, E. Ekback, D. J. Magliano, P. Wennberg, I. Danquah, Sweden, Australia, Germany

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

387 Exposome-wide association study of incident type 2 diabetes

K.-H. Song, K. Kim, Y.-B. Ahn, J.-S. Yun, Republic of Korea

388 Age at diagnosis of type 2 diabetes and accelerometer-assessed physical activity

J. Goldney, A. V. Rowlands, C. Edwardson, E. Daynes, A. Hall, F. Zaccardi, K. Khunti, T. Yates, M. J. Davies, J. Henson, UK, Australia

PRESENTER
INDEX

SATELLITE
SYMPOSIA

389 Association between local corticosteroid injections and incident diabetes: a propensity score-matched nested case-control study using the Korean National Health Screening cohort

H. Kim, S.-W. Kim, E.-H. Cho, W.-J. Lee, Republic of Korea

INDUSTRY

PROGRAMME

EXHIBITION

Short Oral Event F

Thursday, 14:00 - 15:00

SO 018 Clinical tales from the T1D trenches

Chair: Thomas Pieber, Austria

THANKS

390 Central biomarkers within a network of 76 biomarkers of inflammation and depressive symptom clusters in people with type 1 and type 2 diabetes: a network analysis

D. Ehrmann, S. Brandt, C. Herder, A. Schmitt, M. Roden, B. Kulzer, N. Hermanns, Germany

391 Novel pharmacokinetic assay for measuring SAB-142, a fully human anti-thymocyte globulin

H. Wu, E. Gardner, S. Springman, T. Luke, C. Bausch, E. S. Sandhurst, USA

392 Specimen quality for multicenter clinical trials: comparing novel blood preservation methods to cryopreserved PBMC

E. S. Sandhurst, D. M. Maher, K. A. Egland, T. Beadnell, S. Jasti, USA

393 Higher fecal butyrate is associated with lower time in range in a cohort of 398 individuals with type 1 diabetes

L. C. Blok, D. F. De Wit, C. M. Fuhri Snethlage, J. H. Levels, E. H. Serné, E. Rampanelli, S. A. Meijnikman, M. Nieuwdorp, N. M. Hanssen, Netherlands

394 Diabetic ketoacidosis after immune checkpoint inhibitor Avelumab therapy

E. Giagourta, E. Kostouros, A. Galanopoulou, A. Markou, Greece

395 Association between insulin sensitivity and islet autoantibody profile in relatives of individuals with type 1 diabetes

A. Petrelli, D. Cuthbertson, H. Ismail, A. Galderisi, I. Libman, A. Moran, P. Fiorina, J. Sosenko, Italy, USA

396 A time resolved transcriptomic view of the natural progression of type 1 diabetes in alpha and delta cells

D. Ben-Zvi, H. Benhayon, R. Ben-Haroush Schyr, M. M. Danziger, M. Rozen-Zvi, Israel

397 Accelerated T cell memory decline to SARS-CoV-2 vaccination in diabetes

M. Dominguez-Villar, E. M. Jones, C. Sourij, M. Stradner, P. Schlenke, N. Sereban, O. Moser, R. Quinlan, C.-E. Short, B. H. Harris, M. Fertleman, G. P. Taylor, N. Oliver, H. Sourij, UK, Austria, Germany

Short Oral Event A

Tuesday, 12:00 - 13:00

SO 019 It's beta cell replacement time

Chair: Shareen Forbes, UK

398 Unveiling the critical role of neutrophil extracellular traps in islet transplantation

M. Albiero, F. I. Amendolagine, S. Gabriela, M. Ludovica, R. Cappellari, M. Massimo, V. Ravarotto, E. Nuzzolese, L. Rizzato, C. Di Bella, L. Furian, Italy

399 Actual 20-year follow-up of pancreas transplant alone in subjects with type 1 diabetes

M. R. Iacobelli, M. Scopelliti, E. F. Kauffmann, C. Lombardo, A. Coppelli, F. R. Femia, G. Amorese, F. Vistoli, G. Penno, U. Boggi, P. Marchetti, Italy

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

400 ADO12, a non-fibrotic encapsulation system for human islet transplantation without immunosuppression

O. Jouannot, A.-L. Gaffuri, M. Frelon, G. Blache, J. Brun, G. Lefebvre, C. Gautier, R. Besnard, A. Martin, C. Mégret, N. Laurent, G. Martin, R. Eloy, F. Pattou, O. Soula, France

401 Role of type 1 and type 2 diabetes genetics in diabetes outcomes after islet autotransplantation

T. M. Triolo, A. Eaton, S. Onengut-Gumuscu, A. K. Steck, M. Bellin, USA

402 Continuous glucose monitoring and assessment of islet function in autologous islet transplantation after total pancreatectomy for pancreatic neoplasia: preliminary data from the Verona cohort

A. Csermely, G. Lionetto, M. Fontana, M. Pilati, A. Turazzini, S. S. Sheiban, M. Colombini, R. Melzi, R. Nano, A. Mantovani, R. C. Bonadonna, M. Trombetta, L. Piemonti, M. Tuveri, R. Salvia, Italy

403 Adipose stromal cell secretome for a sustainable microenvironment within a subcutaneous polymeric scaffold for insulin-producing cell transplantation

A. M. Smink, E. Pinheiro Machado, T. Kuiper, R. H. Huurman, L. H. Corrêa, A. H. Petersen, B. J. De Haan, M. C. Harmsen, Netherlands, Germany

404 Vascularised hierarchical structured hydrogel for minimally invasive islet transplantation

Z. Huan, J. Li, J. Sun, L. Li, China

405 Breaking immune evasion: NK cell surveillance of hypoinmunogenic pancreatic islets under viral challenge

G. Siracusano, R. Chimienti, C. Tacconi, F. Deambrogio, V. Sordi, M. De Giovanni, L. Piemonti, Italy

Short Oral Event B

Tuesday, 13:15 - 14:15

SO 020 Crystal balls and beta cells: predicting T1D's next move

Chair: Nordin Hanssen, Netherlands

406 Progression from stage 2 to stage 3 type 1 diabetes in children identified by general population screening

M. Rewers, K. Bautista, F. Dong, D. Felipe-Morales, P. Gesualdo, K. M. Simmons, A. Steck, B. Frohnert, USA

407 Factors associated with slower progression to stage 3 type 1 diabetes in children with multiple islet autoantibodies

H. Elding Larsson, F. Thunblad, I. Jönsson, M. Maziarz, Sweden

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

408 The type 1 diabetes risk in adults study

K. M. Gillespie, I. Kelland, S. Toms, C. Megson, A. Williams Antibody Facility, V. Lampasona, A. E. Long, R. Aitken, UK, Italy

409 Psychosocial implications, acceptability and ethics of screening for paediatric type 1 diabetes: a systematic review and mixed methods evidence synthesis

P. Narendran, O. Boiko, D. Stanley, F. Milano, M. Randell, F. Gatti, J. Dunne, E. Bosi, K. Barnard-Kelly, K. Lange, R. Dias, S. Greenfield, F. Boardman, L. Quinn, EDENT1FI, UK, Italy, France, Germany

410 Correlation of home monitoring and in clinic C-peptide values in patients with new onset type 1 diabetes

T. Triolo, F. A. Tensun, B. Palencia Li, H. Broncucia, M. Sooy, T. Skeens, A. K. Steck, H. W. Davidson, USA

411 D1Ce screen: a pilot feasibility project of the Italian paediatric national screening programme for type 1 diabetes and coeliac disease

F. Pricci, C. Porfilio, A. Sedile, F. Iacoponi, M. Villa, V. Cherubini, C. Catassi, A. D'Avino, E. Bosi, O. Vincentini, Italy

412 C-peptide as a predictor for diabetes onset in patients with possible insulin autoimmune syndrome

S. Ljubic, A. Jazbec, I. Antal, T. Bulum, M. Tomic, D. Rahelic, Croatia

413 Zinc transporter 8 contributes to pancreatic islet cell cytoplasmic antibody complexes in type 1 diabetes

C. L. Williams, J. Belgrade, A. Kaur, D. Pittman, T. Wylie, C. H. Wasserfall, W. E. Winter, D. G. Johnston, K. M. Gillespie, A. E. Long, UK, USA

Short Oral Event C

Wednesday, 11:45 - 12:45

SO 021 Islets in the T1D storm

Chair: Matthias Von Herrath, USA

414 Role of Viperin (RSAD2) in pancreatic beta cell inflammation during the pathogenesis of type 1 diabetes

C. Patibandla, P. Hill, N. N. Tebeka, M. Gierlinski, J. Abbott, J. Cantley, UK

415 Fecal microbiota from type 1 diabetes patients induces accelerated onset of pancreatic immune injury in NOD/ShiLtJGpt mice

H. Yuan, Y. Fang, Y. Wang, China

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

416 Modelling alpha cell dysfunction in type 1 diabetes with reaggregated primary human islet and proinsulin-specific cytotoxic T lymphocyte co-cultures

B. Yesildag, A. Title, K. Henriksen, S. Jawurek, C. Rufer, L. Scherpe, J. Storling, Switzerland, Denmark

417 Inhibition of the viral sensor IFIH1 protects from pancreatic YAP hyperexpression in a model of type 1 diabetes

F. Atawneh, A. Aishwarya, Y. Oğuz, Z. Morse, I. Shanina, K. Cook, A. Mahr, H. Tse, M. Horwitz, K. Maedler, Germany, Canada, USA

GENERAL
INFO

418 Early elevations of plasma proinsulin predict the development of diabetes in NOD mice

V. Bhagat, J. Gill, M. Lopes, C. B. Verchere, Canada, France

PROGRAMME

TUESDAY

419 Beta cell stress triggers formation of hybrid insulin peptide through granular pH modulation

T. Delong, USA

WEDNESDAY

THURSDAY

FRIDAY

420 MiR-155 is upregulated in the pancreas in type 1 diabetes

K. Maedler, F. Hellmold, H. Pahwa, H. Liu, B. Dasgupta, A. Grasso, J. Mistry, S. Geravandi, Germany

SHORT ORAL
DISCUSSIONS

421 Pancreatic YAP expression induces classical beta cell dedifferentiation pathways

A. Kruf, H. Pahwa, S. Geravandi, K. Maedler, Germany

PRESENTER
INDEX

Short Oral Event D

Wednesday, 13:00 - 14:00

SO 022 Stem cell top models on the molecular mystery runway

Chair: Essam Abdelalim, Qatar

SATELLITE
SYMPOSIA

422 Impact of the recessive HNF1A p.A251T variant on insulin secretion in patient-derived and genome-edited stem cell-derived beta cells

I. Cherkaoui, Q. Du, C. Dion, M. Gasser, H. Leitch, D. Egli, S. Misra, G. A. Rutter, Canada, USA, UK

INDUSTRY

PROGRAMME

EXHIBITION

423 Targeting ARX to turn human alpha cells into insulin producers

C. Renaud, E. Bru-Tari, F. Thorel, P. L. Herrera, Switzerland

THANKS

424 Modelling clinically relevant PCBD1 variants associated with monogenic diabetes to uncover their role in human endocrine pancreas development

A. Bartolomé, M. G. De la Fuente, M. Hernanz, D. Matas-Aguado, Spain

425 Re-evaluating KLF11 in human endocrine pancreas development: implications for monogenic diabetes pathogenesis

M. Hernanz, D. Matas-Aguado, M. G. de la Fuente, A. Bartolomé, Spain

426 Examining the influence of the glucokinase mutation on the development of monogenic diabetes through the use of human induced pluripotent stem cell models

Y. Abu Aqel, I. Ahmed, N. Fadulemula, A. Al Nesf, A. Elsayed, E. Abdelalim, Z. Islam, P. Kolatkar, K. Hussain, R. Chouaib, G. Ali, Qatar

427 EPDR1, an obesity-induced protein, support autophagy and functional maturation of beta cells

F. Munoz, S. Gobius, M. Fex, H. Mulder, L. R. Cataldo, Sweden

428 Roles of zinc depletion in the protective effects of SLC30A8 variants in human beta-like cells

M. Gasser, I. Cherkaoui, Q. Du, D. Egli, G. Rutter, Canada, USA, UK

429 Islets-on-chips for dynamic functional analysis of genetic variants in human iPSC beta cells

R. Lartigue, E. Virgilio, T. Sawatani, D. Chapeau, J. Lang, M. Cnop, M. Raoux, France, Belgium

430 Transitioning from 2D to 3D culture enhances differentiation and functionality of iPSC-derived hepatocytes: a better model for liver disease

S. S. Ghanem, T. Al-Barazengi, R. Badi, E. Abdelalim, Qatar

Short Oral Event E

Thursday, 12:45 - 13:45

SO 023 Who let the T cells in: saving beta cells in type 1 diabetes

Chair: Siracusano Gabriel, Italy

431 Targeting IL-8/CXCR1-CXCR2 to unleash regulatory B cells in type 1 diabetes

V. Usuelli, M. Ben Nasr, S. Khalefa, P. Yerra, E. Assi, A. Petrazzuolo, M. Zocchi, F. D'Addio, C. Loretelli, I. Pastore, A. Rossi, M. Lunati, G. Zuccotti, M. Allegretti, P. Fiorina, Italy

432 An mRNA immunotherapy for the prevention and reversal of type 1 diabetes

L. P. Pallo, V. Ng, S. Chen, J. Zaifman, Y. Y. Tam, H. C. Denroche, C. B. Verchere, Canada

433 Exploring an islet-protective role for native human pancreatic mesenchymal stromal cells in health and in type 1 diabetes

R. E. Dewhurst-Trigg, J. Atkins, N. G. Morgan, M. Eichmann, S. J. Richardson, C. L. Rackham, UK

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

434 A novel monoclonal antibody blocks TMEM219 signal and prevents type 1 diabetes

E. Assi, M. Nardini, V. Marin, S. Porzio, S. Lodovichi, G. Amabile, A. Maestroni, V. Usuelli, C. Loretelli, M. Ben Nasr, F. Canducci, F. D'addio, L. Olson, P. Fiorina, Italy

435 Targeting of the AGE-RAGE axis during prediabetes can restore glucose homeostasis and induce changes to immune phenotype that reduce type 1 diabetes incidence in preclinical models

C. Du, J. Loaiza Naranjo, F. Y. Yap, R. O. Whiddett, S. Zambre, M. T. Coughlan, A. K. Fotheringham, I. Buckle, J. M. Forbes, Australia

GENERAL
INFO

PROGRAMME

TUESDAY

436 Hide and seek: protecting human beta cells in type 1 diabetes by modulating their PDL1 and HLA class I expression

S. Jawurek, C. Rufer, A. C. Title, P. L. Zimath, X. Yi, E. Martin-Vazquez, J. G. Oliveira, D. L. Eizirik, B. Yesildag, Switzerland, Belgium

WEDNESDAY

437 Strategic reduction of hybrid insulin peptide formation significantly delays diabetes onset in NOD mice

J. Groegler, K. Mangold, K. Nicholson, M. Dang, J. M. Wenzlau, S. Beard, A. Hohenstein, R. Powell, R. L. Baker, K. Haskins, J. Matsuda, T. Delong, USA

THURSDAY

FRIDAY

438 Oral RAGE antagonists induce Tregs and anergy on effector T cells to protect against preclinical autoimmune diabetes

I. Buckle, C. Du, A. K. Fotheringham, J. D. Loaiza Naranjo, R. O. Whiddett, F. Leitao Henriques, D. McCarthy, S. LeBagge, P. Chandrashekar, M. A. Sullivan, K. Herold, J. M. Forbes, Australia

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Short Oral Event F

Thursday, 14:00 - 15:00

SO 024 Beyond glucose: multidimensional phenotyping of type1 diabetes

Chair: Luca D'Onofrio, Italy

439 Phenotype and clonality of fat-derived CD8 T cells in patients with type 1 diabetes

A. Petrelli, N. Baldoni, F. Aleotti, V. Tomajer, G. Cesana, S. Olmi, M. Falconi, L. Piemonti, P. Fiorina, Italy

440 Type 1 diabetes in adults over 30 years old: a study of 79 cases

Y. Laaloua, L. Yagoubi, A. Ourdi, N. Bouichrat, S. Rouf, H. Latrech, Morocco

441 In-situ pancreatic spatial transcriptomics uncovers novel phenotypic signature of beta cell persistence in long-standing type 1 diabetes donors

G. Sebastiani, E. Pedace, S. Auddino, G. Licata, A. Causarano, A. F. Berteramo, G. E. Grieco, E. Aiello, D. Fignani, L. Nigi, E. Splendiani, L. Marselli, P. Marchetti, E. Ferretti, F. Dotta, Italy

442 Reflections on what might be important in health economic evaluation of type 1 diabetes screening: insights from the EDENT1FI consortium

A. Omar Alsaleh, A. Mahieu, M. I. Buompiensiere, N. Chrastecka, R. P. Dias, J. L. Dunne, C. Hurtado del Pozo, J. Mader, L. Piemonti, H. Basarir, J. Vercauteren, L. Overbergh, A.-G. Ziegler, C. Mathieu, P. Narendran, Italy, France, Switzerland, Czechia, UK, USA, Spain, Austria, Belgium, Germany

443 Autoimmune profile of newly diagnosed adult type 1 diabetes individuals: 6 months' follow-up

G. Sygitowicz, D. Sieńko, K. Wójcik, J. Jarczyńska, L. Czupryniak, Poland

444 Evaluation of clinical, laboratory and immunological characteristics in the early onset (diagnosed age < 30 years old) patients with type 2 diabetes

T. Oh, D.-H. Lee, H. Jeon, Republic of Korea

445 A novel multiplexing approach for comprehensive serological screening of type 1 diabetes

R. Zindrili, A. Wang, M. Simpson, A. Alnabulsi, A. Alnabulsi, T. Wang, R. Long-Britain, N. Mody, M. Delibegovic, UK

446 Insulin inhibitory receptor expression across the stages of diabetes development

G. Ciccarelli, L. Carciero, G. Di Giuseppe, M. Brunetti, L. Soldovieri, G. Quero, S. Alfieri, A. Giaccari, T. Mezza, H. Lickert, Italy, Germany

Short Oral Event A

Tuesday, 12:00 - 13:00

SO 025 Islet cell adaptation gone right (and wrong)

Chair: Isabel Gonzalez Mariscal, Spain

447 Exposure to maternal gestational hyperglycaemia impacts pancreatic islet morphology and beta cell function in mice offspring

J. K. Kruij, K. Hribar, Y. Xiang, R. Munteanu, M. H. Koster, N. L. Mulder, M. Smit, E. M. Van der Beek, Netherlands, Switzerland

448 Does in utero gestational diabetes exposure impair circadian metabolic rhythms in the offspring?

C. A. Doucette, M. Sebastian, K. L. Hunt, Canada

449 Modulation of beta cell endoplasmic reticulum calcium homeostasis by calorie restriction

J. U. Pfabe, C. Dos Santos, M. Cutler, G. Perkins, M. H. Ellisman, M. Slak Rupnik, R. Arrojo e Drigo, Austria, USA

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

450 Elucidation of the role of activating transcription factor 6a in the regulation of pancreatic beta cell mass and proliferation

D. Otani, T. Murakami, M. Fauzi, K. Sakaki, S. Tokumoto, H. Tatsuoka, M. Ogura, N. Inagaki, D. Yabe, Japan

451 The metabolic key enzyme ALDOB is upregulated in cell clusters in pancreatic islets of human living donors with type 2 diabetes

Y. Morgenroth, M. Thielert, J. Aprea Perez, R. Choudhury Nath, A. Seiler, E. D. Quezada Dulcic, E. Schöniger, N. Kipke, D. Friedland, S. Hempel, D. Aust, M. Distler, A. Dahl, M. Mann, M. Solimena, Germany

GENERAL
INFO

452 Serum pancreatic regeneration protein Ia tendency in acute pancreatitis to post pancreatitis diabetes acute: comparative analysis and distinction from type 2 diabetes

Z. Shu, L. Li, China

453 Analysis of publicly available human islet datasets indicates sex differences in resilience to type 2 diabetes

S.-Y. Chen, H. Cen, J. D. Johnson, E. J. Rideout, Canada

454 The reduction of pancreatic noradrenergic innervation, consequent to Roux-en-Y gastric bypass, restores the first-phase of insulin secretion

A. Avolio, C. Morciano, S. Gugliandolo, U. Capece, A. Splendore, T. Mezza, G. Di Giuseppe, G. Ciccarelli, M. Brunetti, L. Soldovieri, A. Giaccari, F. Cinti, Italy

Short Oral Event B

Tuesday, 13:15 - 14:15

SO 026 Transcribe me if you can: the real regulators of beta cell county

Chair: Isabella Artner, Sweden

455 Delineating the role of CHD4 in pancreatic islet development

A. Das Sharma, R. George, A. Taylor, S. Kanojia, R. K. Davidson, J. M. Spaeth, USA

456 Decoding CHD5: unveiling its role in pancreatic beta cell health and function

S. Nag, A. Das Sharma, A. Taylor, J. M. Spaeth, USA

457 Multi-model investigation of pancreatic islet architecture and molecular fingerprint in Hnf1a mice

U. Larsen, L. Unger, T. A. Legøy, F. S. Rahmatabadi, A. Friestad, L. Ghila, S. Chera, Norway

458 Transcriptional coregulator Med15 maintains maturation of adult beta cells

R. J. Spencer, M. Dan, F. C. Lynn, S. Taubert, Canada

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

459 Polyadenylation of insulin mRNA by Tent5a regulates pancreatic beta cell function

P. N. Silva, J. E. Mayrhofer, P. Potalitsyn, G. O. Trüllinger, S. Godbersen, N. Amstutz, M. W. Schmid, M. Stoffel, Switzerland

460 Inflammatory stress induces 3' end trimming of microRNAs, driving isomiR biogenesis in human pancreatic islets and beta cells

S. Auddino, G. E. Grieco, D. Fignani, E. Aiello, E. Pedace, F. Syed, P. Krishnan, C. Guay, C. Evans-Molina, R. Regazzi, G. Sebastiani, F. Dotta, Italy, USA, Switzerland

461 Deletion of beta cell-specific microRNA-33 improves islet function in mice fed with normal chow or high fat diet

R. Ortega, P. Slipchenko, H. Omori, S. J. Persaud, B. Liu, UK

462 A microprotein derived from a pancreatic B cell-enriched lincRNA modulates insulin secretion

F. Oger, B. Toussaint, J. Merrheim, M. Derhourhi, A. R. Van der Slik, J. Delplanque, R. Scharfmann, P. Froguel, A. Zaldumbide, A. Bonnefond, France, Netherlands

463 Lars-2 deficient caenorhabditis elegans as a whole-organism model for the m.3243 A>G mitochondrial mutation

B. Cao, L. Fang, M. Xu, Z. Qin, C. Wang, China

Short Oral Event C

Wednesday, 11:45 - 12:45

SO 027 No more secrets just secretion

Chair: Patrik Rorsman, UK

464 A continuous oxidative phosphorylation is needed to enable depolarisation-induced insulin secretion

C. Tappe, J. Reschke, M. Parambath, I. Rustenbeck, Germany

465 Implication of spermine oxidase in pancreatic beta cell function

L. Nocquet, M. Fex, H. Mulder, S. Gheibi, Sweden

466 Targeting miR-125b in beta cells: Novel approaches to modulate lysosomal dynamics and lysosomal-dependent processes

M. W. Paszek, Z. Wu, R. Sheerin, R. Alen, A. Martinez-Sanchez, UK

467 Functional alpha cell heterogeneity: insights from mice to humans

J. K. Panzer, P. A. Garcia, A. Pugliese, USA

468 Role of Stac2 adaptor protein on membrane excitability and hormone secretion of endocrine cells

L. E. Häfele, Austria

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

469 Insulinotropic nutrient stimuli depolarise single beta cells but not single alpha cells

M. Parambath, D. Brüning, I. Rustenbeck, Germany

470 Pancreatic adipocytes modulate insulin secretion and incretin responsiveness of human beta cells

F. Gerst, G. Rahimi, K. Kansy, D. Neuscheler, D. Hartmann, S. Singer, R. Jumpertz-von Schwartzberg, A. L. Birkenfeld, Germany

GENERAL
INFO

471 Differential impact of pancreatectomy type on postoperative insulin secretion: a retrospective cohort study

M. Kim, J. Yu, E. Lee, J. Yu, Republic of Korea

PROGRAMME

TUESDAY

Short Oral Event D

Wednesday, 13:00 - 14:00

SO 028 Chemical romance: compounds that woo islets

Chair: Guy A. Rutter, Canada

WEDNESDAY

THURSDAY

472 Gabapentin enhances mouse pancreatic beta cell excitability but reduces KCl-induced insulin release without affecting Ca_v calcium influx

R. S. Taguchi, L. E. Häfele, N. Jacobo-Piqueras, S. M. Geisler, P. Tuluc, Austria

FRIDAY

473 FFA4-mediated potentiation of insulin secretion in mouse and human islets involves distinct mechanisms

L. Reininger, A. Bouabcha, M. Rehman, S. Ferragne, C. Tremblay, M. Ethier, J. Ghislain, M. Kimple, M. Huising, V. Poitout, Canada, USA

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

474 Characteristics of berberine effects on insulin exocytosis in pancreatic beta cells

H. Wang, Z.-J. Jiang, Z.-L. Wang, China

SATELLITE
SYMPOSIA

475 A curcumin nanoformulation enhances insulin secretion and improves islet function via microRNA-33 inhibition in mouse islets

R. Ortega, S. H. Chan, H. Omori, S. J. Persaud, S. Somavarapu, M. G. Zariwala, B. Liu, UK

INDUSTRY

PROGRAMME

476 Natural flavonoid Kaempferol alleviates lipotoxicity-induced insulin secretory dysfunction and beta cell death

A. Mukhuty, R. Kundu, India

EXHIBITION

THANKS

477 CD36 inhibition by Salvianolic acid B relieves ER stress and protects beta cell function during hyperlipidaemic condition

N. Das, S. Mandal, O. Mukherjee, R. Kundu, India

478 High-throughput screening for chemicals increasing autophagic flux in pancreatic beta cells identified a novel compound mitigating glucose intolerance

A. Kanai, Y. Nishida, M. Ito, H. Tsuchiya, S. Aoyama, H. Uzawa, H. Watada, Japan

479 Adeno-associated virus capsid variant screen for diabetes research: building a scalable methodology for modification of gene expression in primary human islets

B. Yesildag, S. Jawurek, F. Forschler, C. Rufer, A. Title, T. Lamla, B. Strobel, T. Klein, Switzerland, Germany

Short Oral Event E

Thursday, 12:45 - 13:45

SO 029 Beta cells lost in signal transduction

Chair: Yanni Morgenroth, Germany

480 Effects of mitochondrial protease OMA1 knockout on pancreatic beta cell metabolism and survival

D. Lorenc, B. Bazila, P. Ježek, A. Dlasková, Czechia

481 Investigating protein S-acylation in pancreatic beta cells using mass spectrometry

C. M. Liggett, M. Gierlinski, D. Lamont, P. Hemsley, J. Cantley, UK

482 Direct impairment of insulin biosynthesis by glucocorticoids via the GR/JNK pathway in pancreatic beta cells

Y. Iwamoto, T. Kimura, K. Dan, H. Iwamoto, Y. Fushimi, J. Sanada, Y. Nogami, M. Shimoda, T. Mune, K. Kaku, H. Kaneto, Japan

483 Identification of irisin receptors on pancreatic beta cells

M. Rella, N. Marrano, G. Biondi, V. Galasso, G. Galluzzi, A. Cignarelli, S. Perrini, L. Laviola, F. Giorgino, A. Natalicchio, Italy

484 Does postnatal depletion of 14-3-3zeta enhance functional beta cell mass?

S. Sarkar, Y. Mugabo, F. Paré, S. Djerroud, A. Rathé, T. P. Prakash, N. Wijesekara, E. Pirie, G. E. Lim, Canada, USA

485 Regulation of pancreatic beta cell function by TSC22D4

B. Ekim, S. Anak, S. Lösch, A. Wieder, C. Schwab, J. Szendroedi, S. Herzig, Germany

486 Inflammation increases O-GlcNacylation in pancreas

H. Pahwa, S. Das, A. Kruf, K. Maedler, Germany

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

487 TERT/FOXO1 signalling promotes islet beta cell dysfunction in type 2 diabetes by regulating ATG9A-mediated autophagy

Q. Wu, X. Lei, X. Chen, S. Qiu, S. Geng, G. Yang, China

Short Oral Event F

Thursday, 14:00 - 15:00

SO 030 The islet games: caught in the immune attack fire

Chair: Noel G. Morgan, UK

488 Learning from bats to understand the differences between alpha and beta cell fate in type 1 diabetes

X. Yi, E. Martín-Vázquez, S. Jawurek, M. F. Bonfim, P. Zimath, E. Ilegems, J. Wesley, A. Title, B. Yesildag, D. L. Eizirik, Belgium, Switzerland, Denmark, USA

489 EBI2, a type 1 diabetes candidate gene, regulates virus-induced beta cell apoptosis via the IRF7 pathway

R. Dos Santos, L. Marroqui, I. Santin, D. Eizirik, Spain, Belgium

490 Lipid droplets and lipophagy are induced by proinflammatory cytokines in beta cells: the role of sphingosine-1 phosphate degradation

E. Gurgul-Convey, M. Majewska, Y. Tang, B. Leß, Germany

491 Stressed beta cells degrade the peri-islet extracellular matrix contributing to islet death and dysfunction in type 1 diabetes

N. L. Farnsworth, C. G. Johansen, C. El-Dirani, K. Lam, USA

492 Comparative transcriptomic of immune-induced responses in human pancreatic beta and thyroid cells identifies FGFR1 as a target for beta cell protection against immune attacks

P. L. Zimath, X. Yi, E. Martin-Vazquez, J. G. Oliveira, S. Jawurek, A. C. Title, B. Yesildag, S. Costagliola, M. Romitti, D. L. Eizirik, Belgium, Switzerland

493 Tardigrade Damage Suppressor protein for protecting pancreatic beta cells against immune-mediated cell death

G. E. Grieco, C. Ricci, E. Pedace, G. Sebastiani, F. Dotta, S. Cantara, Italy

494 Beta cell death under chronic cytokine exposure is mediated by excessive sphingosine-1 phosphate degradation linked to defective mitochondrial quality control

M. Majewska, Y. Tang, B. Leß, E. Gurgul-Convey, Germany

495 Pro-inflammatory cytokine treatment of human islets is permissive for gasdermin D-mediated pyroptosis by toll-like receptor 4 and inflammasome activators

F. Mitani, K. Henriksen, C. A. Svane, A. Jørgensen, S. Kaur, C. Frørup, J. Størling, Denmark, Australia

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

SO 031 Beta cells breaking under stress*Chair:* Piero Marchetti, Italy**496 ATPIF1 prevents cell death of pancreatic beta cells under stress conditions**

A. Dlasková, B. Bazila, D. Lorenc, P. Jezek, Czechia

497 Integrative AI-driven modelling of full-length HIF-1 α : unravelling structural insights to address dysregulation in diabetes

C. M. González-Casimiro, Spain

498 Mechanisms of mitochondrial glycerol-3-phosphate dehydrogenase in pancreatic beta cells function: implications for diabetes pathogenesis

J. Qiu, D. Liu, Y. Li, China

499 Structural alterations in human diabetic beta cells: granule clustering and mitochondrial fragmentation revealed by expansion microscopy

V. De Lorenzi, L. A. Pugliese, M. Suleiman, M. Tesi, C. De Luca, G. Ferri, H. V. Vo, A. Lindquist, L. Marselli, Y. Zhao, P. Marchetti, F. Cardarelli, Italy, USA

500 Dietary interventions reverse beta cell dysfunction in type 2 diabetes

N. Sinha, S. Cheng, V. A. Salunkhe, S. Hua, P. Rorsman, A. H. Rosengren, Sweden

501 Single-cell mRNA profiling of human pancreatic islet calcium release channels reveals dysregulation in type 1 and type 2 diabetes

H. Hardikar, W. Wong, A. Papanicolaou, M. Joglekar, M. Islam, A. Hardikar, Australia, Sweden

502 SARS-CoV2 NSP1 inhibits insulin granule biogenesis and secretion but not MHC-class I expression and traffic in MIN6 cells

K.-P. Knoch, K. Senthilkumar, N. Tiwara, C. Wegbrod, A. Sönmez, K. Ganss, M. Solimena, Germany

503 Podoplanin-TGF-beta1 axis drives islet fibrosis via stellate cell activation in diabetes

X. Wang, Q. Wang, Z. Sun, China

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONSPRESENTER
INDEXSATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

SO 032 Feeding signals: how gut hormones shape appetite and metabolism

Chair: Alexander Jais, Germany

504 The gut epithelium-specific mTORC1 activation improves glucose metabolism by increasing GIP secretion selectively in male mice

R. Kawahara, Y. Fujita, T. Yanagimachi, S. Kusui, K. Nishimura, S. Ida, N. Ohashi, K. Murata, K. Morino, S. Kume, Japan

GENERAL
INFO**505 Blunted haemodynamic effects of GLP-2 and altered postprandial appetite sensation in loss-of-function GLP-2 receptor variant carriers**

C. Pless, H. Kizilkaya, M. Michaelsen, H. Reeh, F. Koefoed-Hansen, L. Kårhus, B. Hartmann, A. Linneberg, M. Christensen, T. Hansen, J. Holst, A. Lund, M. M. Rosenkilde, L. Gasbjerg, Denmark

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

506 Exploring associations between GLP-1, PYY and GIP levels with eating behaviour and hypothalamic volume in humans

C. Bannon, S. Brown, L. Moreno Lopez, F. Reimann, F. Gribble, P. Fletcher, UK

507 The effect of GLP-1 receptor antagonists and agonists on islet function in non-diabetic subjects with the GLP1R polymorphism at rs3765467

H. E. Christie, S. Mohan, F. Boscolo, C. Dalla Man, A. M. Egan, A. Vella, USA, Italy

SHORT ORAL
DISCUSSIONS**508 The postprandial vasoactive effect of GIP is maintained in patients with type 2 diabetes**

R. S. Rasmussen, S. W. Nielsen, B. Haddock, L. Alstrup, T. S. Larsson, M. B. Vestergaard, H. H. Johannesen, H. B. Larsson, J. J. Holst, B. Hartmann, M. M. Rosenkilde, A. Asmar, U. B. Andersen, L. S. Gasbjerg, Denmark

PRESENTER
INDEXSATELLITE
SYMPOSIA**509 The GLP-2 receptor antagonist GLP-2(3-33) efficiently blocks the effects of GLP-2 on splanchnic blood flow**

S. W. Nielsen, R. S. Rasmussen, L. Alstrup, A. H. Lange, T. S. Larsson, S. N. Alkaabi, J. K. Hansen, M. B. Vestergaard, H. H. Johannesen, J. J. Holst, B. Hartmann, M. M. Rosenkilde, U. B. Andersen, B. Haddock, L. S. Gasbjerg, Denmark

INDUSTRY

PROGRAMME

EXHIBITION

510 Inactive GLP-1 concentrations are a better measure of gut GLP-1 secretion than total GLP-1 concentrations in the fasting state

F. M. Gribble, C. Bannon, L. Moreno Lopez, P. Fletcher, F. Reimann, UK

THANKS

511 Potential synergistic therapy for metabolic dysfunction targeting GLP-1 and dopamine receptors

D. Sousa, G. Rolo, B. Caramelo, C. C. Magalhães, A. Amaro, D. Rosendo-Silva, P. Matafome, Portugal

SO 033 Metabolic flexibility and insulin sensitivity: drivers, disruptors, and interventions

Chair: Jan Gojda, Czechia

512 Postprandial hypoglycaemia during OGTT: analysis of underlying mechanisms and everyday relevance

G. Ufer, J. Hummel, R. Spies, R. Sabia, M. Märker, A. Paul, S. Wangler, R. Wagner, A. Peter, M. Wagner, M. Heni, Germany

513 A small decrease in body adiposity results in enhanced renal glucose uptake: a 6-month randomised controlled trial to reduce sedentary behaviour

E. Rebelos, P. Dadson, T. Sjoros, S. Laine, J. Norha, T. Garthwaite, E. Löyttyniemi, O. Eskola, M. Koivumäki, H. Vähä-Ypyä, K. Laitinen, N. Houttu, E. Ferrannini, A. Mari, I. Heinonen, Italy, Finland

514 Effects of combined treatment with zibotentan and dapagliflozin compared to dapagliflozin alone on insulin resistance and markers of inflammation

V. Wasehuus, J. D. Smeijer, M. Sayer, P. Ambery, P. J. Greasley, E. Wijkmark, S. Cigarran, J. L. Gorriz, M. J. Soler, P. Rossing, H. J. Heerspink, Denmark, Netherlands, UK, Sweden, Spain

515 Insulin-mediated transcriptional responsiveness and resistance of human adipose tissue involves adipocytes and other cell types

I. Yairi, Y. Haim, O. Lazarescu, M. Ziv-Agam, M. Zamir, N. Bashan, E. Yegeer-Lotem, A. Rudich, Israel

516 Transcriptional response to insulin in muscle of patients with a gain-of-function mutation in LRP5 (T253I)

R. Sabaratnam, K. Brusgaard, M. Burton, J. Havelund, N. Faergeman, M. Kassem, K. Højlund, A. Rauch, M. Frost, Denmark

517 Lactate-ketone ester ingestion improves insulin sensitivity in individuals with obesity: a double-blind, randomised, controlled crossover trial

S. K. Kjær, M. V. Svart, N. Møller, N. Rittig, Denmark

518 Impaired arginine metabolism, due to the accumulation of methylglyoxal and acrolein, leads to hyperglycaemia through reduced insulin signalling

S. Li, H. Li, K. Bennewitz, G. Poschet, M. Buettner, T. Fleming, I. Hausser, J. Szendroedi, P. P. Nawroth, J. Kroll, Germany

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

519 Development of insulin resistance precedes decline in metabolic flexibility: cross sectional comparison

M. Siklova, K. Koudelkova, M. Wilhelm, P. Sedivy, P. Kordac, D. Pajuelo, J. Potockova, J. Pallova, V. Sebo, L. Rossmeislova, J. Gojda, Czechia

Short Oral Event D

Wednesday, 13:00 - 14:00

SO 034 Molecular keys to unlocking insulin sensitivity

Chair: Aida Collado, Sweden

520 The effect of ceramides and specific phospholipids on skeletal muscle insulin resistance in a model of prediabetes: lipidomic approach

H. Malinska, I. Markova, M. Hüttl, J. Šťastný, T. Kačerova, I. Zapletalova, P. Kačer, Czechia

521 Catalytic inactivation of SHIP2 in diabetic mice improves insulin sensitivity, lowers albuminuria, and alleviates anxiety symptoms

C. Schmotz, N. Carcaño, M. Koskinen, S. Imlimthan, S. James, R. Bouslama, E. Lehtonen, S. Schurmans, M. Sarparanta, I. Hovatta, S. Lehtonen, Finland, Belgium

522 AAV-FGF21 reverses type 2 diabetes and improves cardiac insulin resistance in db/db mice

X.-R. Peng, E. Talamonti, D. Karlsson, M. Behrendt, A. Ahnmark, K. Wallenius, Sweden

523 Blunted response to AICAR in cultured myotubes from carriers of p.P50T/AKT2 suggests impaired AMPK signalling

S. Sree, S. Mäkinen, A. Latva-Rasku, P. Nuutila, M. Laakso, H. A. Koistinen, Finland

524 C-peptide suppression as a marker of hyperinsulinemic euglycaemic clamp validity: a retrospective analysis

K. Koudelkova, A. Caturano, M. Šiklová, L. Rossmeislová, J. Gojda, Czechia, France, Italy

525 The haematocrit directly affects blood glucose in mice: Are erythrocytes glucose carriers?

C. Fürnsinn, M. Metz, M. Beghini, O. Koldyka, A. Kautzky-Willer, T. Scherer, Austria

526 FGF21 reduces ER-stress by enhancing the unfolded protein response through sulfide signalling

G. Grandl, A.-C. König, F. Metzger, A. Liskiewicz, T. Hefele, S. Nason, A. Novikoff, K. Habegger, A. Cebrian-Serrano, S. M. Hauck, M. H. Tschöp, T. D. Müller, Germany, USA

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

527 The role of intestinal microbiota in glucose homeostasis in a food-restricted mouse model

S.-P. Chen, Z. Boudra, N. Kassis, O. Viltart, C. Magnan, C. Cruciani-Guglielmacci, France

Short Oral Event E

Thursday, 12:45 - 13:45

SO 035 The secret life of beta cells: forecasting, firing, and failing

Chair: Beatriz Merino Antolin, Spain

528 Differential mirroring between in vivo insulin secretion and ex vivo islet function in humans with and without diabetes

G. Di Giuseppe, G. Gliozzo, G. Ciccarelli, L. Carciere, L. Soldovieri, M. Brunetti, F. Cinti, A. Mari, A. Giaccari, G. Pani, T. Mezza, Italy

529 Impact of overweight and obesity on fasting insulin secretion in men and women without diabetes: effect sizes and mechanisms

M. Chiriaco, D. Trico, J. Petrie, R. Gabriel, A. Gastaldelli, J. Nolan, N. Lalic, G. Mingrone, A. Mari, A. Natali, Italy, UK, Spain, Ireland,

530 Quantitative modelling of beta cell responsivity decline in individuals progressing from stage 2 to stage 3 type 1 diabetes

A. Brunasso, J. Bonet, E. Sundermann, E. Roesch, B. Wagenhuber, C. Dalla Man, M. Schiavon, Italy, Germany

531 Neuro-immune dialogue in pancreatic islets

C. Leveau, E. Sbai, M. Diedisheim, A. Jalon, E. Dalmas, N. Venteclef, France

532 Myeloid immune cell Gq signalling as a modulator of insulin secretion and glucose homeostasis

A. Kumar, S. Singh, S. Paul, A. Gargya, M. Sarkar, S. Duraisamy, I. S. Chauhan, S. Thaleshwari, S. Kuldeep, H. Yadav, S. Bhaumik, K. K. Prajapati, D. Allimuthu, R. Parihar, S. P. Pydi, India

533 Pancreatic islet calcium oscillation rhythm shifts synchronously to maintain blood glucose stability

Y. Deng, Z. Fu, Y. Qiao, X. Wang, S. Yang, L. Hui, H. Ren, China

534 Beta cells as glucose forecasters: the functional relationship between insulin secretion rate, insulin and glucose in normoglycaemic, prediabetic and GLP1-RA treated patients

D. Ben-Zvi, D. Kleiman, R. Ben-Haroush Schyr, I. Samuel, S. Knapp, D. Samocha-Bonet, Israel, Australia

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

535 Association of pancreas steatosis with insulin secretion in subgroups of adult-onset diabetes

A. Laitinen, K. Johansson, A. Käräjämäki, A. Käräjämäki, J. Häggblom, L. Hakaste, K. Lahti, E. Ahlqvist, T. Tuomi, Finland, Sweden

Short Oral Event F

Thursday, 14:00 - 15:00

SO 036 Exercise as a metabolic modulator in people with type 1 diabetes: carbs, circuits, and control

Chair: Richard Bracken, UK

536 Proteomics, aerobic fitness, and muscle strength in relation to glucose metabolism 10 years after gestational diabetes

E. Kristiansson, A. Holmäng, S. Chung, K. Wallenius, U. Andersson Hall, Sweden, USA

537 Machine learning-based differentiation of diabetic and degenerative low back pain using clinical and radiographic biomarkers

Y. Teng, M. Jianjun, China

538 Hyperglycemia during competition in runners with and without type 1 diabetes

R. F. Johansen, N. S. Skriver, S. W. Kudahl-Laursen, K. R. Schmidt, A. Schiellerup, J. F. Mortensen, M. L. Bergmann, J. Fleischer, S. Nielsen, E. T. Vestergaard, E. Søndergaard, Denmark

539 Galactose and lactose: The ideal carbohydrate supplements for exercise in type 1 diabetes?

K. R. Schmidt, R. F. Johansen, S. B. Riis, M. S. Larsen, H. Støvring, G. A. Wallis, D. Rowlands, L. C. Gormsen, E. Søndergaard, Denmark, UK, New Zealand

540 Long-term effects of physical activity and 13,476 exercise sessions on CGM-metrics in a physically active cohort with type 1 diabetes: a retrospective analysis of the Syntactiq COCKPIT database

O. Moser, L. Schuster, J. Schierbauer, H. Sourij, S. Sanfilippo, Germany, Austria

541 Efficacy of the mylife CamAPS FX system during strength training in adults with type 1 diabetes: a preliminary analysis of the randomised controlled crossover REXID study

S. Sanfilippo, K. Schiwiy, L. Reichel, C. Koller, J. Schierbauer, H. Sourij, P. Zimmermann, T. Voit, D. Schultes, A. Holtay-Mayer, O. Moser, Germany, Austria

542 Acute and prolonged effects of endurance training on lactophenylalanine and inflammatory markers in individuals with type 1 diabetes: an analysis of the ULTRAFLEXI-1 study

A. Mueller, U. Glatz, O. Moser, F. Aberer, T. Niedrist, O. Jaruan, C. Sourij, P. Pferschy, N. Tripolt, F. Aziz, H. Sourij, Austria, Germany, Thailand

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

543 Morning exercise protects against hypoglycaemia in individual with type 1 diabetes

R. F. Johansen, S. W. Kudahl-Laursen, N. S. Skriver, J. F. Mortensen, M. L. Bergmann, J. C. Brønd, S. Nielsen, E. T. Vestergaard, E. Søndergaard, Denmark

Short Oral Event A

Tuesday, 12:00 - 13:00

SO 037 Move it or lose it: metabolic consequences of exercise and its absence

Chair: Juleen R. Zierath, Sweden

544 Effects of exercise and exercise timing on acute energy intake and appetite control in individuals with overweight or obesity, with and without type 2 diabetes

N. P. Launbo, L. Jalking, M. M. Jensen, K. Beaulieu, G. Finlayson, M. B. Blond, A. Wiggers, J. Rungby, M. Nilsson, M. K. Gerstenberg, H. E. Pedersen, K. Faerch, L. G. Grunnet, J. S. Quist, Denmark, UK

545 Inflammatory markers and blood glucose are higher after morning versus afternoon exercise in type 2 diabetes

M. J. Keller, Sweden

546 Effect of lifestyle interventions on the prevention of type 2 diabetes: differential responses according to prediabetes phenotype

E. James, J. Henson, M. J. Davies, K. Khunti, T. Yates, UK

547 Exercise cessation rapidly causes hyperinsulinaemia and metabolic dysfunction

L. G. Hall, X. Hu, G. P. Brownrigg, E. Kaye, N. Shahraki, S.-Y. Chen, J. P. Thyfault, J. D. Johnson, Canada, USA

548 Exploring the link between timing of physical activity, body composition, and cardiometabolic health in people with metabolically complicated overweight/obesity

G. Panagiotou, A. Champion, I. Demetriou, M. Metaxaki, M. Maria Chondronikola, UK

549 Comprehensive comparison of self-reported, accelerometer-assessed and genetic predisposition to physical activity and sedentary behaviour in individuals with and without type 2 diabetes

S. L. Domazet, R. Jepsen, J. V. Stidsen, T. B. Olesen, J. S. Nielsen, T. L. Petersen, M. K. Andersen, T. Hansen, J. C. Brønd, M. H. Olsen, K. Højlund, Denmark

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

550 microRNA profiling of circulating extracellular vesicles in response to high-intensity interval training in sedentary individuals: potential biomarkers for exercise adaptation

H. Marí, P. Pérez-Mocholí, M. Ruiz-Holguera, C. Gómez, S. Canivell, A. Portabella-Serra, A. Novials, L. Brugnara, J.-M. Servitja, Spain

551 Identification of contraction-specific phosphorylation pattern of TBC1D1 in murine C2C12 myotubes

L. Peifer-Weiß, S. Lehr, S. Hartwig, M. Turewicz, C. De Wendt, U. Kettel, M. Schiller, A. Chadt, H. Al-Hasani, Germany

GENERAL
INFO

Short Oral Event B

Tuesday, 13:15 - 14:15

SO 038 Healing the fatty liver: hormones, medications, and metabolic insights

Chair: Niels Jessen, Denmark

552 GM-60106, a novel 5-HT_{2a} antagonist improves MASLD and fibrosis with a safe phase 1 profile

W.-I. Choi, S. Song, W. Lee, P. Goughnour, J. Park, J. Ahn, H. Kim, Republic of Korea

553 The role of glucagon in the development of MASLD: focusing on glucagon secretion from alpha cells and its signalling in the human liver

Y.-H. Lee, S. Kim, M. Lee, Y. Hwang, B.-W. Lee, E. Kang, B.-S. Cha, K. Kim, Republic of Korea

554 Redox immunometabolism: NADPH oxidase 4 alleviates Stat6-deficiency-related metabolic dysfunction-associated steatotic liver disease in mice

I. Szanto, Switzerland

555 Impact of semaglutide on liver-related responses in people with metabolic dysfunction-associated steatohepatitis with/without type 2 diabetes: post hoc analysis of the ESSENCE trial

M. Roden, M. T. Arias-Loste, A. M. Cali, L. Castera, N. M. Eklöf, W. Kim, N. Krarup, B. Ludvik, P. N. Newsome, V. Ratziu, M. E. Rinella, A. J. Sanyal, A. Trifan, T. C. Vestergaard, E. Bugianesi, Germany, Spain, Denmark, France, Republic of Korea, Austria, UK, USA, Romania, Italy

556 KS-25, a newly developed synthetic TGF- β inhibitor, mitigates insulin resistance and liver steatosis in mice fed a high-fat diet

K. Pahk, Republic of Korea

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

557 Assessing the effects of naltrexone-bupropion on hepatic steatosis and hepatic fibrosis in type 2 diabetes patients with overweight or obesity: insights from a placebo-controlled trial

A. N. Saidi, L. A. Konings, C. Dietvorst, V. D. De Jong, W. Xu, M. Alings, S. P. Rauh, M. Castro Cabezas, Netherlands

558 Semaglutide-induced weight loss is the main determinant for the improvement of hepatic biochemistry and elastographic repeated measurements with FibroScan® in patients with type 2 diabetes and MASLD

I. Avgousti-Varela, A. Damianakou, M. Chalkias, S. Savvidou, I. Stergiou, Greece

559 Significant weight reduction with improved body composition by HDM1005, a novel long-acting GLP-1R/GIPR dual agonist

R. Zhu, L. Teng, Z. Li, L. Guo, C. Jiang, D. Liu, China

Short Oral Event C

Wednesday, 11:45 - 12:45

SO 039 Cardiometabolic complications and mortality risk in MASLD

Chair: Jan H. Britsemmer, Germany

560 Association study of type 2 diabetes-related metabolic indices with metabolic dysfunction-associated steatotic liver disease

M. Hu, J. Yang, Y. Wu, L. Chen, China

561 Association of liver fibrosis and cardiac diastolic dysfunction in patients with metabolic dysfunction: associated steatotic liver disease

M. Kim, J.-H. Choi, I. Kim, B. Jang, Y. Suh, S. Ryu, G.-H. Jeong, H. Kim, Republic of Korea

562 Association between prediabetes phenotypes and metabolic dysfunction-associated fatty liver disease

M. He, Y. Liu, X. Y. Zhou, S. H. Qiu, Z. L. Sun, China

563 Liver disease monitoring using serial transient elastography assessments in a large real-life cohort of patients with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease

T. Vidal Trecan, J.-B. Julla, Y. Schwartz, H. Fontaine, D. Valla, J.-P. Riveline, L. Castera, J.-F. Gautier, France

564 Liver fibrosis independently predicts long-term mortality in individuals with type 2 diabetes and MASLD: a single center study with 20-year follow-up

I. Barchetta, F. A. Cimini, S. Dule, G. Passarella, A. Oldani, M. Cirelli, M. Alfano, M. N. Hirsch, M. G. Cavallo, Italy

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

565 Association between increment of controlled attenuation parameter and the development of metabolic syndrome: a 6 year longitudinal study

Y. Cao, J. Li, X. Huang, W. Deng, Z. Huang, China

566 Metabolic dysfunction-associated steatotic liver disease in type 1 diabetes: cross-sectional study compared to healthy controls

S. Amuedo, V. Bellido, P. Remón Ruiz, M. Roque-Cuellar, A. Jiménez-Sánchez, N. Gros Herguido, G. López Gallardo, A. Piñar-Gutiérrez, A. Soto-Moreno, Spain

GENERAL
INFO

567 Thigh muscle composition and hepatic steatosis in individuals with impaired glucose metabolism: insights from the SCAPIS/IGT-Microbiota study

A. Osmanovic, A. Gummesson, M. Allison, J. Kullberg, Y. Li, G. Bergström, B. Daka, Sweden, USA

PROGRAMME

TUESDAY

Short Oral Event D

Wednesday, 13:00 - 14:00

WEDNESDAY

SO 040 Mapping the molecular maze of MASLD and MASH

Chair: Sonia Fernandez-Veledo, Spain

THURSDAY

FRIDAY

568 Sex-specific correlation of markers of bone microstructure with MASLD markers

V. Flegka, E. Kliemank, A. Merzweiler, M. Dugas, J. Szendroedi, A. Sulaj, Germany

SHORT ORAL
DISCUSSIONS

569 MARC1 silencing reduces steatosis, but not fibrosis, in biopsy-confirmed GAN diet-induced obese MASH mice and in human 3D multicellular liver spheroids

D. Lindén, A. Lindblom, L. Kovooru, E. Morrison, J. Nøhr-Meldgaard, D. Crysnanto, T. Johannssen, S. Wallin, L. Lidqvist, X. Zhang, N. Guzzi, M. Feigh, A. Bird, S. Romeo, T. Kroon, Sweden, Germany, Denmark

PRESENTER
INDEX

SATELLITE
SYMPOSIA

570 Spatial transcriptomics landscape of livers from patients with metabolic dysfunction-associated steatohepatitis

D. Lee, S. Nam, S. Kim, J. Kim, I. Park, Republic of Korea

INDUSTRY

PROGRAMME

EXHIBITION

571 SDF-1 mediated liver metabolic adaptation through CXCR7: implications for mash pathogenesis

K. Sharabi, R. Barkan-Michaeli, C. Fainshtein, H. Bar-Dagan, N. Hadar, Israel

THANKS

572 Inhibiting 15-PGDH to ameliorate liver fibrosis in MASH: a novel therapeutic approach

X. Li, J. Ma, B. Liu, Q. Chen, F. Wei, Y. Li, China

573 Hepatic selenoprotein S knockout aggravates diet-induced MASLD through modulating LPC-autotaxin-LPA axis

L. Qiao, L. Men, Y. Liu, J. Du, China

574 Proliferation/regeneration and apoptotic cell death in relation to RANKL/NF- κ B-signaling in liver of rats with type 2 diabetes-associated MASLD and after vitamin D₃ treatment

O. Lisakovska, A. Khomenko, D. Labudzynski, O. Mezhenka, M. Veliky, & Shymanskyi, Ukraine

575 Proteomic signature of extracellular vesicles secreted by hepatic stellate cells at different states

L. Balazova, M. Antal, Z. Vince Kazmerova, M. Novotova, M. Balaz, Slovakia

Short Oral Event E

Thursday, 12:45 - 13:45

SO 041 From nutrition to medications: influencing MASLD through the metabolic axis

Chair: Roy Taylor, UK

576 Glucagon-like peptide-1 receptor agonists improve arterial stiffness and liver steatosis in patients with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease

L. Pliouta, A. Kountouri, E. Korakas, J. Thymis, E. Oikonomou, I. Ikonomidis, V. Lambadiari, Greece

577 Adipose tissue insulin resistance as an early indicator for the development of metabolic dysfunction associated steatotic liver disease in severe obesity

L. Henke, L. Seebauer, M. Roshan, V. Flegka, E. Kliemank, E. Von Rauchhaupt, J. Szendroedi, A. Sulaj, Germany

578 Polyunsaturated fatty acids and protein mediate improvements in intrahepatic lipid content directly and through changes in BMI at 36 months: a randomised controlled trial

E. Álvarez Hernández, M. Lazaratos, C. Wernicke, A. Pohrt, L. Pletsch-Borba, N. Meyer, J. Machann, A. F. Pfeiffer, J. Spranger, L. Li, K. Mai, Germany

579 Assessment of the effect of metabolic dysfunction-associated steatotic liver disease on selected metabolic parameters in the group of patients diagnosed with prediabetes

M. Różycka-Kosmalska, I. Szymczak-Pajor, K. Sipowicz, T. Pietras, M. Kosmalski, Poland

580 Sex-specific effects of different diets inducing MAFLD and treatment with the PPAR α agonist elafibranor

I. Raho, R. Bertrand, J. Vicogne, A. Abderrahmani, C. Magnan, C. Cruciani-Guglielmacci, France

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

581 Intravenous infusions of fatty acids and ethanol induce hepatic mitochondrial reductive stress in humans

R. Sane, K. Porthan, S. Jäntti, M. J. Jokinen, T. E. Lehtimäki, A. I. Nieminen, K. Pietiläinen, S. J. O'Connor, M. H. Plawecki, V. A. Ramchandani, P. K. Luukkonen, Finland, USA

582 Cortisol metabolism in metabolic dysfunction-associated steatotic liver disease with type 2 diabetes

F. C. Ng, C. Choi, Hong Kong

GENERAL
INFO

Short Oral Event F

Thursday, 14:00 - 15:00

PROGRAMME

SO 042 Emerging predictors of steatosis and fibrosis in the context of metabolic risk

TUESDAY

Chair: Domenico Trico, Italy

583 Circulating soluble CD14 levels predict liver fibrosis in MASLD independently of obesity and type 2 diabetes

F. A. Cimini, I. Barchetta, F. Sentinelli, S. Dule, G. Passarella, A. Oldani, R. Marchiani, M. G. Baroni, M. G. Cavallo, Italy

WEDNESDAY

THURSDAY

FRIDAY

584 Disruption in bile acids metabolism and increased risk of liver fibrosis in women with high metabolic risk: a metabolomic analysis from Qatar Biobank

M. Barigou, N. Al-mansoori, A. Kerkadi, I. Ramzan, Qatar

SHORT ORAL
DISCUSSIONS

585 Stanniocalcin-1 as a key mediator of Roux-en-Y gastric bypass-induced amelioration of metabolic-associated steatohepatitis

J. Hong, J. Oh, C. Ku, Republic of Korea

PRESENTER
INDEX

586 Negative regulation of lipid deposition by CLEC11A concentration: exploration of novel biomarkers for pathological grading of fatty liver

Q. Wang, H. Wang, Z. Cai, X. Wang, S. Qiu, Z. Sun, China

SATELLITE
SYMPOSIA

587 Real-world utility of non-invasive fibrosis markers of MASLD: a triage model validated against FibroScan

K. Gupta, S. Gupta, India

INDUSTRY

PROGRAMME

EXHIBITION

588 Serum GIP is a potential biomarker for hepatic steatosis/fibrosis in patients with metabolic dysfunction associated fatty liver disease

Z. Cai, Q. Wang, H. Wang, Z. Sun, China

THANKS

589 Association between uric acid/HDL-C ratio and metabolic dysfunction-associated steatotic liver disease: a retrospective study in type 2 diabetes

X. Zhu, L. Li, China

590 Higher plasma dicarbonyl levels are associated with liver fibrosis in obese individuals

O. I. Akinrimisi, M. Koning, J. L. Scheijen, A. S. Meijnikman, D. P. Sindhunata, S. Bruin, A. V. Laar, R. Franken, Y. Acherman, V. E. Gerdes, M. Nieuwdorp, C. G. Schalkwijk, N. M. Hanssen, Netherlands

Short Oral Event A

Tuesday, 12:00 - 13:00

SO 043 New frontiers in MASLD risk and diagnosis, from breastfeeding to biomarkers

Chair: Mijke Buitinga, Netherlands

591 Global investigation of human liver reveals potential fibrosis targets for early MASLD progression in obesity

P. Kaldis, Q. Zhao, W. De Nardo, R. Wang, Y. Zhong, U. Keles, L. Zhao, H. Tay, Y. Kim, S. Lee, R. Lim, G. Teo, V. Lauschke, H. Choi, M. Watt, Sweden, Singapore, Australia, Germany

592 Shorter breastfeeding duration and liver fibrosis risk related to MASLD in postmenopausal females with diabetes or prediabetes

K. Jin Hwa, Y. Lyu, S. Kim, S. Kang, Republic of Korea

593 Bioimpedance analysis and cardiovascular testing as predictors of non-alcoholic fatty liver disease in patients type 2 diabetes

I. Gurieva, N. Soldatenkova, Russian Federation

594 Real-world observational study on GLP-1RA and SGLT2i effect on liver disease in patients with type 2 diabetes and the impact of GLP-1R polymorphisms

V. Velardi, R. Candido, B. Toffoli, M. Sirignano, E. M. Russo, V. Bonato, G. Fusaro, B. Fabris, S. Bernardi, Italy

595 Comparison of noninvasive and invasive diagnostic methods for liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease

P. Werel-Oldziejewska, A. Krentowska, D. Orzechowska, A. Gietka, I. Kowalska, Poland

596 A new horizon in risk assessment: ELF test and cardiovascular health in type 2 diabetes

T. Min, J. Nagaraj, J. W. Stephens, D. Williams, UK

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Short Oral Event B

Tuesday, 13:15 - 14:15

SO 044 Under pressure: hormonal and neural responses to glycaemic stress

Chair: Cyrielle Caussy, France

597 Response of pituitary adrenal axis to hypoglycaemia in different types of diabetes

Y. Hu, B. Ding, China

598 Endogenous glucose production during a 75g oral glucose load is associated with fasting serum serotonin in type 2 diabetes

W. Huang, C. Xie, D. Trico, A. Mari, A. Natali, K. Jones, M. Horowitz, C. Rayner, T. Wu, Australia, Italy

599 Adrenaline at levels observed during hypoglycaemia acutely affects immune cell subsets and monocyte function in people with and without type 1 diabetes

M. S. Hendriksz, I. F. Mustafajev, B. E. De Galan, R. Stienstra, C. J. Tack, R. I. Meijer, Netherlands

600 Differences between men and women in neuroendocrine responses to hypo- and hyperglycaemia; impact for insulin resistance and type 2 diabetes development?

M. H. Lundqvist, M. J. Pereira, S. Hetty, U. Wiklund, J. W. Eriksson, Sweden

601 Impaired postprandial blood glucose homeostasis in humans with cystic fibrosis is associated with hypersomatostatinaemia

N. H. Whitsett, Y. Dai, S. O. Warner, V. Indihar, N. Sheanon, J. J. Winnick, USA

602 Unravelling the gut microbiota regulation of enteroendocrine cell: implications for energy metabolism

D. Polvé, S. Ribes, J. Cadiou, J. Lecardonnel, C. Bevilacqua, C. Henry, F. Castelli, E. Ponweiser, V. Douard, A. Haschemi, N. Lapaque, P. Larraufie, France, Austria

Short Oral Event C

Wednesday, 11:45 - 12:45

SO 045 Fit and functional: reversing metabolic risk through muscle-centric interventions

Chair: Patrick Schrauwen, Germany/Netherlands

603 Effect of combined exercise and hormone replacement therapy on body composition and insulin sensitivity in postmenopausal women

P. Calders, W. Wielfaert, H. Demeyer, M. Vandenende, B. Lapauw, H. Depypere, Belgium

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

604 Skeletal muscle ablation of Pik3c2b improves insulin sensitivity and body weight regulation

S. Han, E. Pannia, R. Simonian, N. Sabha, J. Beaudry, S. Harper, J. J. Dowling, Canada, USA

605 Impact of standing desks on physiological and psychological outcomes in sedentary office workers

A. Buch, O. Kis, O. Lani, O. Saad, L. Kulik, R. Eldor, Israel

606 Protective role of AMP deaminase 3 in skeletal muscle against diabetes-induced sarcopenia in mice

T. Ogawa, H. Kouzu, A. Naito, T. Karaushi, N. Ichise, Y. Tatekoshi, T. Yano, A. Kuno, M. Tanno, T. Yamada, T. Sato, M. Furuhashi, Japan

607 Muscle-to-fat ratio combined with peripheral insulin sensitivity: a novel approach for differentiating diabetes of exocrine pancreas

K. Sun, Y. Jin, Z. Zhou, L. Li, China

608 Effects of bariatric surgery and added exercise training programme on the IGF/IGFBP axis in severe obesity

F. Picard, C. Rauzier, S. Miard, A. Auclair, P. Poirier, Canada

609 Vitamin D supplementation as a protective strategy against aging-related metabolic disorders and sarcopenia

H.-J. Jeong, Y. Lee, D. Yoon, J. Lim, Republic of Korea

610 Effect of long-term testosterone therapy on α -molecular regulators of adipose tissue and skeletal muscle mass in aging men with subnormal testosterone and type 2 diabetes

R. Kruse, R. Sabaratnam, N. Sahebkhari, L. V. Magnussen, M. S. Andersen, K. Højlund, Denmark

Short Oral Event D

Wednesday, 13:00 - 14:00

SO 046 Hot, heavy, and hidden, unpacking the unusual drivers of glycaemic health

Chair: Eduard Montanya, Spain

611 The newly revealed association between normocalcaemic non-renal hyperparathyroidism, hyperinsulinaemia, and diabetes

O. V. Kaminskyi, D. E. Afanasyev, I. G. Chikalova, I. M. Muraviova, O. V. Kopylova, A. O. Kaminska, N. S. Dombrowska, Ukraine

612 Association between estimated glucose disposal rate and life's essential 8 with all-cause and cardiovascular mortality in the U.S. adult population

G. Zhao, X. Yu, A. Yang, Y. Jin, X. Wang, B. Qi, F. Bao, B. Gao, China

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

613 Most individuals with type 2 diabetes on intensified insulin therapy do not require daytime basal insulin: results from a fasting glucose assessment in 531 patients

B. Mertes, S. Gödde, C. Kloos, G. Kramer, N. Kuniß, Germany

614 Longitudinal 4-year relationships between insulin clearance, metabolic parameters and glycaemic deterioration in non-diabetic individuals: an IMI-DIRECT study

C. A. Rossi, L. Marchetti, G. Fantoni, E. R. Pearson, A. Mari, R. Bizzotto, Italy, UK

615 Heat wave ahead: the effects of combined passive and active heat acclimation on thermal resilience and cardiometabolic health in older, overweight adults

S. Pappa, G. Plasqui, W. Van Marken Lichtenbelt, H. Pallubinsky, Netherlands

616 Analysis of glucose biomarkers in phase 1 and phase 2 studies of survodutide in people with type 2 diabetes or living with overweight/obesity

E. Ekinci, J. Arrubla, A. M. Hennige, C. Schoelch, Australia, Germany

617 Depressive symptoms and glucose-lipid metabolic dysregulation in obesity: a cross-sectional analysis

S. Liu, X. Wen, Y. Wan, J. Yin, L. Bu, China

618 The relationship between insulin sensitivity, secretion, clearance and atherosclerosis in a middle-aged population without diabetes: a cross-sectional study

R. Renklint, P. Liv, I. Katsoularis, T. Olsson, J. Otten, Sweden

Short Oral Event E

Thursday, 12:45 - 13:45

SO 047 Clinical studies on unconventional drivers of diabetes

Chair: Laurent Crenier, Belgium

619 Relation between sedentary behavior on micro- and macrovascular complications in advanced type 2 diabetes

N. Oosterom, A. Middelweerd, S. E. Teunissen, G. D. Laverman, Netherlands

620 Post-acute pancreatitis diabetes is characterised by insulin resistance and impaired islet function

Y. Lyu, K. Sun, X. Wang, L. Li, China

621 Moca-study: metabolic impact of different milk vs pea proteins in type 2 diabetes and healthy participants

M. Csanalosi Artigas, B. Schuppelius, S. Kabisch, K. Mittau, J. Schwarze, S. Rohn, A. Pfeiffer, Germany

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

622 The amylin analogue pramlintide suppresses bone resorption without affecting bone formation in individuals with type 1 diabetes and in healthy controls

M. K. Preskou, D. S. Mathiesen, B. Hartmann, A. H. Lange, L. K. Winther, J. Holst, F. Knop, A. Lund, J. Bagger, Denmark

623 Postprandial changes of FGF-19 and FGF-21 in patients with type 2 diabetes

L. A. Konings, B. Burggraaf, E. M. Van der Zwan, T. Noordermeer, P. Rensen, R. P. Peeters, M. Castro Cabezas, Netherlands

624 Individuals with prediabetes and overweight/obesity show blunted ghrelin suppression after a standardised breakfast and greater prospective food intake during the day

A. Velasco-Andonegui, E. Almirón-Roig, M. Duran-Vivar, M. Sánchez-Fernández, M. J. Moreno-Aliaga, P. González-Muniesa, Spain

625 A dual stable-isotope study of the effect of altitude and simulated flight on glucose metabolism in type 1 diabetes: a randomised cross-over study

K. Fan, F. Shojaee-Moradie, F. Jeivad, A. Manoli, A. Haidar, M. Borg Inguanez, F. Sammut, G. Koehler, V. Edwards, V. M. Lee, A. Falinska, Z. Bawlchhim, J. K. Mader, A. Umpleby, D. Russell-Jones, UK, Austria, Canada, Malta

626 Is there vascular insulin resistance in obesity? Insights from a whole-body PET study

A. Latva-Rasku, N. Tuomola, H. Harju, J. Tuisku, L. Nummenmaa, P. Nuutila, Finland, Germany

Short Oral Event F

Thursday, 14:00 - 15:00

SO 048 Mechanisms, modifiers, markers, the complex roots of insulin resistance

Chair: Joris Hoeks, Netherlands

627 The insulin-like growth factor binding protein 5 signalling axis is a new potential therapeutic target in fibrosis

M. Zocchi, C. Loretelli, M. Nardini, E. Assi, S. Lodovichi, A. Petrazzuolo, V. Usuelli, M. Ben Nasr, V. Marin, M. Zangarini, S. Porzio, F. D'addio, G. Amabile, L. M. Olson, P. Fiorina, Italy

628 Sex-specific differences in lipid induced insulin resistance: enhanced adipose tissue adaptation in females

T. Fleming, L. Seebauer, M. Roshan, V. Flegka, E. Kliemank, E. Von Rauchhaupt, M. Campos Campos, Z. Kender, A. Sulaj, J. Szendroedi, Germany

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

629 Characterisation of beta cell dysfunction and insulin resistance in intermediate hyperglycaemia subtypes based on combinations of fasting, 1-hour and 2-hour plasma glucose

C. O, B. Fan, Y. Fan, E. Lau, J. Lui, M. Shi, C. Lim, E. Chow, A. Kong, R. Ma, A. Luk, J. Chan, Hong Kong

630 METS-IR as a superior insulin resistance marker for acanthosis nigricans risk stratification in obese adults

Y. Zhao, K. Mutailipu, Y. Li, X. Jia, S. Qu, L. Bu, China

631 Metabolic memory induced by morning insulin exposure enhances liver responsiveness to a subsequent glucose load later in the day

H. Waterman, M. Smith, K. Yankey, B. Farmer, M. Schleh, K. Coate, T. Howard, D. Edgerton, A. Cherrington, USA

632 Early metabolic and cardiac dysregulation in offspring of obese mothers

L. F. Grilo, M. S. Diniz, P. Valente, J. D. Martins, J. Stevanovic-Silva, J. Beleza, A. Ascensão, J. Magalhães, P. J. Oliveira, S. P. Pereira, Portugal

633 Spatial patterns of hepatocyte glucose flux revealed by stable isotope tracing and multi-scale microscopy

R. Arrojo e Drigo, A. Habashy, C. Acree, K.-Y. Kim, A. Zahraei, M. Dufresne, S. Phan, M. Cutler, E. Patterson, A. G. Mulligan, K. Burkewitz, C. R. Flynn, L. Lantier, O. P. McGuinness, J. M. Spraggins, J. M. Spraggins, USA

634 Serum bile acid response to an oral glucose load is exaggerated in newly diagnosed, treatment-naïve, Chinese with type 2 diabetes and is reduced by insulin-pump therapy

C. Xiang, C. Chen, Y. Sun, Y. Luo, J. Ma, C. Xie, W. Huang, K. Jones, M. Horowitz, C. Rayner, T. Wu, China, Australia

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Short Oral Event A

Tuesday, 12:00 - 13:00

SO 049 Neuroinflammation: Is the brain taking too much heat?

Chair: André Kleinridders, Germany

635 NLRP3 inhibition mitigates obesity-driven neuroinflammation and insulin resistance

D. Basco, R. Moser, J. Molette, T. Jaquier, C. Alliod, G. Bodley, K. Piorowska, C. Bazenet, A. Pfeifer, F. Capotosti, T. Seredenina, Switzerland

636 Pleiotrophin: a bridge between obesity and neurodegenerative disorders: implications for liver disease and neuroinflammation mediated by small extracellular vesicles (sEV)

H. Cañeque-Rufo, A. Zuccaro, I. Garcia-Martinez, M. Limones, J. Pita-Santibáñez, M. G. Sánchez-Alonso, J. Sevillano, E. Gramage, A. Martinez Valverde, G. Herradón, M. D. Ramos-Álvarez, Spain

637 Central FGF19 action attenuates hypothalamic inflammation and improves leptin sensitivity in obese mice

L. Zangerolamo, M. Carvalho, A. Boschero, L. Velloso, H. Barbosa, Brazil

638 Weight loss rapidly normalises dysglycaemia but aggravates hypothalamic inflammation in mid-aged mice

A. Zemer, Y. Haim, H. Muallem, V. Chalifa-Caspi, A. Tsitrina, O. Zilber, A. Monsonogo, A. Rudich, Israel

639 Senolytic therapy in MASH: a potential strategy for reducing fibrosis and inflammation along with prevention of hepatocellular carcinoma

M. Haluzik, J. Dudova, P. Svoboda, D. Machacek, V. Skop, S. Stemberkova Hubackova, Czechia

640 Central leptin resistance induce hepatic fibrosis, pancreatic fat accumulation and inflammation in Wistar rats

C. Pintado Losa, M. Bernabé, L. Mazuecos, O. Gómez Torres, A. Vega Rosa, C. Arribas, A. Andres, N. Gallardo Alpizar, Spain

641 Spatial patterns in the loss of neurometabolic feedback and neurogenic potential in obesity

D. L. Cline, K. I. Dunne, K. E. Sullivan, M. S. Cembrowski, Canada

642 RNA_{seq}-transcriptomics show weight-loss induced upregulation of TP53 (p53) and reorganisation of mitochondrial genes driving immunometabolic improvements in type 2 diabetes patients

A. F. Pfeiffer, M. Nuesch, J. Zang, B. Schuppelius, K. J. Rütter, E. Lalama, M. Csanalosi-Artigas, K. Mai, S. Kabisch, N. Kraenkel, A. Christ, O. Pivovarova-Ramich, E. Latz, Germany

Short Oral Event B

Tuesday, 13:15 - 14:15

SO 050 Adipocytes in flames

Chair: Emma Börgeson, Denmark

643 Adipose tissue inflammation and disproportionate visceral adiposity as potential drivers of insulin resistance in south Asian women with prior gestational diabetes

S. Lee-Ødegård, Norway

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

644 ASC1 and ASC2 mitigate obesity-induced metabolic dysregulation and inflammation in aging mice

H. Lee, J.-Y. Lee, J.-W. Han, J. Jeong, E.-Y. Kwon, S.-K. Shin, Republic of Korea

645 Resolving inflammation in cardiometabolic health and disease

S. Tavajoh, M. Clark, A. Becerril-Campos, B. Suur, P.-A. Jansson, M. Soták, E. Börgeson, Denmark, Sweden

646 Adipose tissue fibrosis and endotrophin: implications for obesity and type 2 diabetes

M. J. Pereira, A. Alhomsy, I. Koiso-Kanttila, M. K. Svensson, M. Sundbom, J. W. Eriksson, Sweden

647 Association of fibrosis in subcutaneous abdominal adipose tissue with higher prevalence of type 2 diabetes: A potential biomarker?

A. Lecube, M. Hernández, A. Ciudin, C. Hernandez, R. Simo, Spain

648 Exploration of glucose metabolism in adipose tissue-specific diacylglycerol kinase delta knock-out mice

M. Jollet, D. Santiago Guimarães, J. Ortiz de Zevallos, D. Rizo-Roca, M. Björnholm, A. Krook, J. R. Zierath, Sweden

649 Cell-autonomous IL-6 signal in adipose tissue reduces fat mass under high-fat diet

K. Brors, A.-R. Minafra, A. Chadt, K. Franke, M. Grandoch, M. Döring, H. Al-Hasani, J. Scheller, Germany

Short Oral Event C

Wednesday, 11:45 - 12:45

SO 051 [Br]eaking [Ba]t

Chair: Christian Wolfrum, Switzerland

650 The development of primary human brown adipose spheroids as a novel tool for metabolic research

F. M. Acosta, J. Örling, A. Wagner, M. Clemente-Postigo, N. Bonet-Morata, T. Saari, M. Monfort-Pires, M. U-Din, M. Klingenspor, K. Virtanen, Finland, Germany, Spain

651 Activating transcription factor 5 regulates thermogenic responses and differentiation in brown adipose tissue during cold exposure

H. Jang, Y. Kwon, H.-S. Yi, Republic of Korea

652 Regulatory function of LATS2 in brown adipose tissue: a modulator of PPARγ activity

A. Jancovicova, R. Urminsky, N. Palesova, L. Petriskova, P. Makovicky, L. Balazova, C. Wolfrum, M. Balaz, Slovakia, Switzerland

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

653 Pioglitazone modulates lipid metabolism in brown adipose tissue and increases energy expenditure in mice

L. F. Valdivia, É. Castro, G. F. Jardim, W. T. Festuccia, P. Reckziegel, Brazil

654 Circulatory NAD⁺ dynamics and brown adipose tissue metabolism following cold acclimation in individuals with obesity

P. Kosijer, T. Saari, M. Monfort-Pires, F. Acosta Manzano, J. Örling, S. Zaidi, R. Ojala, A. I. Nieminen, E. Pirinen, K. A. Virtanen, M. U Din, Finland

655 Body adiposity and long-term cold acclimation influence meal-induced hormonal responses to acute cold exposure

M. Monfort-Pires, T. Saari, M. U Din, F. M. Acosta, J. Örling, S. Zaidi, R. Ojala, K. Pohjanoksa, A. Tornio, K. Virtanen, Finland

656 Multi-omics insights into human brown and white adipose tissue: identifying novel regulators of thermogenesis

L. Petriskova, D. Olesova, A. Ghosh, A. Kvasnicka, N. Palesova, P. Stefanicka, L. Varga, A. Jancovicova, P. Makovicky, D. Dobesova, L. Balazova, H. Neubauer, D. Friedecky, C. Wolfrum, M. Balaz, Slovakia, Switzerland, Czechia, Germany

657 GDF15 regulates development and growth of sympathetic neurons to enhance thermogenesis and weight loss

M.-S. Lee, J. Kim, J. Kim, S. H. Park, Republic of Korea

Short Oral Event D

Wednesday, 13:00 - 14:00

SO 052 Lipid metabolism and metabolic health

Chair: Siegfried Ussar, Germany

658 EGFR-TKI erlotinib safeguards beta cell function in obesity-induced diabetes by targeting lipid metabolism

O. Mukherjee, S. Mandal, N. Das, S. Bag, S. Nag, R. Kundu, India

659 Hyperlipidaemia per se does not induce beta cell hypersecretion or dysfunction in mouse islets and does not impaired beta cell mitochondrial turnover in human islets in vivo

C. Chen, S. Penkov, C. M. Cohrs, A. Palladini, J. Aguilar-Pimentel, B. Rathkolb, M. Fedorova, S. Speier, Germany

660 Dynamic lipidomic features and their clinical correlations after vertical sleeve gastrectomy in obese subjects

D. Lee, S. Kim, J.-H. Park, I. Park, Republic of Korea

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

661 Glycosylated sphingolipids alterations in serum-derived extracellular vesicles in individuals with type 2 diabetes and their role in adipocyte glucose metabolism

D. Paget, A. Checa, K. MacGregor, H. Wallberg-Henriksson, J. Zierath, A. Krook, Sweden

662 From gut to liver: the critical role of specific protein-lipid packed extracellular vesicles in metabolic health deterioration

A. Teshima, E. Torrejón, T. Burrinha, I. Ferreira, A. Carvalho, F. Carli, B. Costa-Silva, A. Gastaldelli, A. Baudot, H. Beck, R. Matthiesen, R. Machado de Oliveira, M. Macedo, Portugal, Italy, France, Denmark

GENERAL
INFO

PROGRAMME

TUESDAY

663 Central mGPDH regulates glycolipid/energy metabolism through the FOXO1-POMC axis

Y. Li, J. Qiu, D. Liu, China

664 LY6D and lipid synthesis: a key player in the pathogenesis of metabolic associated fatty liver disease

S. Wu, M. Yang, China

665 The role of alpha parvin in adipose tissue remodelling and metabolic regulation in obese mice

A. Alqarni, D. Sarnobat, J. Mains, A. Banah, D. H. Wasserman, L. Kang, UK, USA

Short Oral Event E

Thursday, 12:45 - 13:45

SO 053 Novel mechanisms regulating energy metabolism

Chair: Andrea Natali, Italy

666 P19^{ARF} expression in adipocytes lowers obesity and insulin resistance risk via adipocyte differentiation control

I. Mamjoud, N. Boulet, C. Méziat, I. Mucel, J. Jager, J.-F. Tanti, M. Cormont, France

667 WITHDRAWN

668 Activation of glucagon-like peptide-1-, but not glucose-dependent insulinotropic polypeptide-receptor expressing neurons in the parasubthalamic nucleus supresses food intake in mice

F. Reimann, J. E. Lewis, D. Nuzzaci, M. Montaner, P.-P. James-Okoro, F. M. Gribble, UK

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

669 A novel CRFR2 selective UCN2 analogue, HM17321, enhances favourable body recomposition, energy expenditure and metabolic health in DIO mice

S. Lee, E. Kim, E. Park, J. Kim, S. Han, J. Park, S. Hong, S. Bae, S. Lee, I. Choi, Republic of Korea

670 Mechanisms of pericyte detachment as a key regulator of angiogenesis in visceral adipose tissue expansion

Y. Iwasa, T. Wada, C. Iwazaki, Y. Onogi, H. Tsuneki, T. Sasaoka, Japan

671 The protective effect of taurine during the molecular evolution of the visual cortex in animal models of obesity and type 2 diabetes

B. Caramelo, V. M. Mendes, A. Cortez, T. Monteiro-Alfredo, J. Sereno, J. Martins, M. Castelo-Branco, B. Manadas, P. Matafome, Portugal, Brazil

Short Oral Event F

Thursday, 14:00 - 15:00

SO 054 W[H]AT's up! Novel mechanisms of white adipose tissue function

Chair: Matthias Blüher, Germany

672 Adipose tissue signatures characterising bariatric surgery outcomes in type 2 diabetes and weight loss

A. Ghosh, C. Horváth, C. Engl, I. Reinisch, F. Noé, A. Hoffmann, M. Blüher, C. Wolfrum, Switzerland, Germany

673 Circadian transcriptome profiles in human subcutaneous and visceral adipocytes and their relation to diabetes pathogenesis

J. R. Soliz-Rueda, L. Meyer, C. Dibner, O. Pivovarova-Ramich, Germany, Switzerland

674 Metabolic consequences of the reduction of Store-Operated Ca²⁺ Entry

D. E. Al-Ansari, R. Courjaret, F. Yu, L. Zarif, H. Mohamed, N. Nader, K. Machaca, Qatar

675 Alterations in the extracellular matrix proteome of human adipose tissue in obesity and type 2 diabetes

D. Sarnobat, R. Stimson, M. Ashford, L. Kang, UK

676 Greater mitochondrial improvements in subcutaneous adipose tissue following weight loss by bariatric surgery than lifestyle intervention

S. M. Heinonen, B. W. Van der Kolk, J. E. Karppinen, A. Wagner, J. White, Y. Subashi, S. Karaman, M. Fogerholm, K. A. Virtanen, T. Saarinen, E. Pirinen, P. Pajukanta, A. Juuti, N. Docherty, K. H. Pietiläinen, Finland, Ireland, USA

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

677 Whole-exome sequencing identifies novel and rare variants in patients with suspected lipodystrophy and metabolic disorders: a single-centre experience

E. Korakas, A. Kountouri, L. Pliouta, I. Georgiou, N. Tentolouris, S. Liatis, I. Ikonomidis, V. Lambadiari, Greece

678 Unveiling cellular and molecular mechanisms connecting adipose tissue dysfunction to metabolic disease

I. Reinisch, A. Ghosh, C. Wolfrum, M. Blüher, Switzerland

679 Plasticity of obesity-associated epigenetic and transcriptional alterations after bariatric surgery

M. Ulz, M. Ouni, H. Vogel, M. Jähnert, S. Kahl, M. Roden, A. Schürmann, Germany

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Short Oral Event A

Tuesday, 12:00 - 13:00

SO 055 Novel insights into regulation of metabolism by GLP-1R agonists

Chair: Aaron Novikoff, Germany

680 Nonclinical evaluation of SNA-003, a long-acting GLP-1 receptor agonist, demonstrating enhanced pharmacokinetics and metabolic efficacy in rodent models of type 2 diabetes

Y. Park, Republic of Korea

681 Discontinuation of semaglutide therapy for weight loss: population-based study of the first 52,284 users in Denmark

A. Mailhac, L. Pedersen, I. Petersen, A. Pottegård, H. T. Sørensen, R. W. Thomsen, Denmark, UK

682 Effect of semaglutide with metformin for weight loss and fertility in obese polycystic ovary syndrome patients: a pilot prospective study

T. Bolek, P. Turňová, M. Pec, I. Sagová, J. Jurica, M. Boleková Lanyiová, M. Mokaň, M. Samos, Slovakia

683 Development and characterisation of a humanised GLP-1 receptor mouse model for the evaluation of small molecule GLP1R agonists

N. Sonne, M. Roque, L. F. Zachariassen, T. Porsgaard, S. Pors, M. Cavallera, C. Jones, O. Osborn, D. D. Thorbek, M. L. Riis, H. H. Hansen, M. Tozzi, Denmark, USA

684 Cranio-GLP1: efficacy and safety of GLP1 analogue treatments in patients with craniopharyngiomas

F. Lambert, E. Guillon, CranioGLP1_FORCE investigators, H. Soula, C. Poitou, P. Faucher, France

685 Tirzepatide promotes fat and lean mass loss without loss of muscle mass or function in diet-induced obese mice

M. K. Brahma, E. Billingham, M. W. Conway, A. Chand, D. Rial, J. S. Davies, J. F. Unitt, N. R. Mirza, F. McIntosh, W. Pijacka, S. P. Vickers, UK

686 Mechanisms for the preservation of energy expenditure during CagriSema-induced weight loss in obese rats

J. F. Halling, I. Blom, J. M. Jacobsen, A. T. Hoelker, J. F. Havelund, B. D. Eriksfoss, K. K. Lange, R. E. Kuhre, K. Raun, A. Secher, M. Hey-Mogensen, N. J. Færgeman, J. Nielsen, S. Larsen, Denmark

687 Effects of the novel long-acting amylin analogue petrelintide on body weight and waist circumference by sex in a phase 1 trial

D. Hesse, M. Brændholt Olsen, J. Griffin, U. Hövelmann, S. Macura, T. Johansen, B. Fredsted Hagen, H. Frimer-Larsen, T. Heise, Denmark, Germany

Short Oral Event B

Tuesday, 13:15 - 14:15

SO 056 A refined look at the pancreas in health and disease

Chair: Angela Martinez Valverde, Spain

688 Beta cell mass and function in individuals with and without remission of type 2 diabetes after Roux-en-Y gastric bypass

S. Tokgöz, L. Deden, A. Hofboer, R. I. Meijer, E. J. Hazebroek, A. C. Van Bon, B. E. De Galan, C. J. Tack, M. Boss, M. Gotthardt, Netherlands

689 Interaction between pancreatic volume, pancreatic fat infiltration and beta cell mass

S. Tokgöz, H. Yamazaki, K. Prystupa, J. Hummel, L. Deden, M. Gotthardt, R. Wagner, M. Heni, Netherlands, Japan, Germany

690 Identification of novel pancreatic acinar cell sub-populations in type 2 diabetes

B. Ford, D. Duneau, N. Dyson, C. Benezech, J. A. Shaw, A. Al-Mrabeh, UK

691 Linking progressive obesity and islet plasticity in mice: insights from transcriptomics and epigenomics approaches

S. Singh, K. P. Musale, L. Barella, J. Telang, S. Agarwal, A. Shree, A. Goel, S. Thaleshwari, H. Zafar, J. Wess, S. Pydi, India, USA

692 The long-term outcome of mice lacking autophagy in pancreatic beta cell

K. Ikeda, Y. Nishida, H. Uzawa, S. Aoyama, A. Kanai, K. Ueki, H. Iida, H. Watada, Japan

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

693 Beta cell-specific AhR expression is critical to high-fat diet induced hyperinsulinaemia in mice

M. E. Ching, M. P. Hoyeck, R. Tejani, L. Grieco-St-Pierre, J. Bruin, Canada

694 SGLT2 inhibition mitigates glucotoxicity and suppresses m6A RNA methylation defects in pancreatic islets in diabetic mice

T. Kimura, Y. Katakura, Y. Iwamoto, H. Iwamoto, K. Dan, Y. Fushimi, J. Sanada, M. Shimoda, S. Nakanishi, K. Kaku, H. Kaneto, Japan

GENERAL
INFO

695 Adipocyte-derived exosomal ANGPTL2 mediates pancreatic beta cell dysfunction under lipotoxic conditions by activating the EIF2 α /ATF4/CHOP pathway

Y. Ruan, X. Zhong, Q. Wei, Q. Cheng, M. Weng, S. Wang, H. Chen, China

PROGRAMME

TUESDAY

Short Oral Event C

Wednesday, 11:45 - 12:45

WEDNESDAY

SO 057 Adipose tissue function after training, bariatric surgery and during senescence

Chair: Sigrid Bjerge Gribsholt, Denmark

THURSDAY

696 Differential gene expression after bariatric surgery in patients with impaired glucose metabolism may explain weight outcomes

C. Milad, M. Parrizas, R. Olbeyera, A. Ibarzabal, M. Estape, J. Vidal, A. De Hollanda, Spain

FRIDAY

SHORT ORAL
DISCUSSIONS

697 Acute and training effects of high-intensity exercise on lean and adipose tissue fatty acid fluxes in individuals with prediabetes

E. Le Roux, S. Hogan-Lamarre, M. Lepitre, G. Sanchez-Delgado, G. Richard, C. Noll, W. Mampuya, S. Phoenix, M. Fortin, J. Hoeks, P. Schrauwen, B. Guérin, E. E. Turcotte, A. C. Carpentier, D. P. Blondin, Canada, Spain, Netherlands, Germany

PRESENTER
INDEX

SATELLITE
SYMPOSIA

698 PANDAR-driven SAFA regulation promotes senescence programmes in adipocyte precursor cells in obesity and type 2 diabetes

A. Desiderio, M. Pastorino, E. Perrella, M. Cavallo, R. D'Agostino, A. Croce, P. Florese, A. Nicolò, D. Conza, A. Leone, C. Miele, F. Beguinot, G. A. Raciti, Italy

INDUSTRY

PROGRAMME

EXHIBITION

699 Roux-en-y gastric bypass alters metabolomics response to nutrient ingestion and exogenous glucagon infusion

S. Pezzica, A. Alamdari, A. Gastaldelli, M. Salehi, Italy, USA

THANKS

700 Weight cycling deteriorates obesity induced dysglycemia and circadian impairment age dependently

H. Muallem, A. Zemer, Y. Haim, M. Rosengarten-Levin, Y. Noah, A. Rudich, Israel

701 Acute and chronic effects of high-intensity interval training on organ-specific dietary fatty acid partitioning in individuals with prediabetes

S. Hogan-Lamarre, M. Lepitre, E. Le Roux, G. Sanchez-Delgado, F. Frisch, G. Richard, C. Noll, W. Mampuya, S. Phoenix, J. Hoeks, P. Schrauwen, B. Guérin, É. E. Turcotte, A. C. Carpentier, D. P. Blondin, Canada, Spain, Netherlands, Germany

702 Impact of sleeve gastrectomy on hepatic and cardiac postprandial fatty acid metabolism 14 days after surgery

C. Noll, F. Frisch, L. Bouffard, S. Phoenix, S. C. Cunnane, B. Guérin, E. E. Turcotte, F.-C. Malo, A. C. Carpentier, Canada

Short Oral Event D

Wednesday, 13:00 - 14:00

SO 058 Beyond BMI: predictors of glucometabolic health

Chair: Konstantinos Makrilakis, Greece

703 Plasma proteomic insights into the associations of visceral adipose tissue with type 2 diabetes and its subtypes

Z. Li, K. B. Bódis, H. Yamazaki, C. Herder, M. Roden, M. Heni, R. Wagner, Germany, Japan

704 Preoperative clinical and metabolic predictors of dumping syndrome following bariatric surgery: a six-month follow-up study

J. Nowak, L. Henke, W. Neibig, V. Flegka, E. Kliemank, E. Von Rauchhaupt, J. Szendroedi, A. Sulaj, Germany

705 Effectiveness of a body shape index in predicting mortality and major adverse cardiac and cerebrovascular event

B. Seo, S. Moon, J. Yu, C.-M. Oh, D. Kim, J. Park, Republic of Korea

706 Beyond BMI: validating iBMI and dBMI to define novel obesity clusters and stratify metabolic risk

S. N. Shinde, R. S. Shinde, S. Y. Bhangaaley, India

707 The impact of BMI on placebo response in patient-reported symptoms and functional tests in a knee osteoarthritis trial

S. Heimbürger, J. M. Bentin, P. Alexandersen, A. R. Bihlet, Denmark

708 Aging, weight loss and glucose homeostasis: the metabolic influence of CnAβ1

B. M. Rubio, E. Lara-Pezzi, Spain

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

709 Unmasking the thermogenic fingerprint: low-protein meal-challenge predicts weight loss success in severe obesity

W. Diederich, D. Bohlmann, S. Remy, J. Ziegler, L. Homeister, K. Hartmann, L. Kruse, N. Rohmann, C. Geisler, P. Piaggi, A. Bosy-Westphal, D. M. Schulte, M. Laudes, T. Hollstein, Germany, Italy

710 Effect of semaglutide on the initiation of additional glucose-lowering therapy: an analysis of the SELECT trial

S. E. Kahn, O. Jeppesen, A. Lincoff, I. Lingvay, A. De SA Matos, J. Plutzky, A. Rasmussen Rinnov, D. H. Ryan, S. S. Emerson, USA, Denmark

GENERAL
INFO

Short Oral Event E

Thursday, 12:45 - 13:45

SO 059 Novel mechanisms of glucose management

Chair: Cristina Cadenas Sanchez, Spain

711 Cisplatin induces long-term dysglycaemia in high-fat diet-fed male mice, but not females

L. Basu, J. Palaniyandi, M. Ching, E. Van Zyl, M. P. Hoyeck, I. Perera, J. E. Bruin, Canada

712 Estrogen regulates glucose metabolism dependently on the orexin system in the mouse brain

R. Takeda, H. Tsuneki, M. Sugiyama, S. Takata, E. Tokai, C. Koshida, T. Wada, T. Sasaoka, Japan

713 Deletion of ADAR2 improves glucose homeostasis and insulin sensitivity in obese mice by enhancing Glut2 localisation to cytomembrane in pancreatic beta cells

Y.-W. Chen, K.-W. Huang, Taiwan

714 Effects of LEAP2 on total-body PET/CT-assessed glucose fluxes

A. Englund, A. H. Lange, E. Sichelkow, C. A. Hagemann, A. B. Lund, I. Law, T. L. Andersen, P. K. Cramon, F. K. Knop, L. S. Gasbjerg, Denmark

715 Compensating for insulin resistance with extracellular vesicles released by the liver

P. V. Ribeiro, T. Burringha, B. Guerreiro, B. Costa-Silva, M. Paula Macedo, R. Machado de Oliveira, Portugal

716 Beta cell mass in individuals with and without hyperinsulinaemic hypoglycaemia after Roux-en-Y gastric bypass

M. Gotthardt, S. Tokgöz, L. Deden, A. Hofboer, E. J. Hazebroek, H. De Boer, A. C. Van Bon, R. I. Meijer, B. E. De Galan, C. J. Tack, M. Boss, Netherlands

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

717 Obesity, but not a low-energy diet, leads to short-term hormonal adaptations during an oral glucose load

G. Fanni, F. Hukema, S. Hetty, A. Mathioudaki, M. Sundbom, U. Risérus, J. Kullberg, M. Pereira, H. Ahlström, J. Eriksson, Sweden

Short Oral Event F

Thursday, 14:00 - 15:00

SO 060 Towards a better understanding of white fat cell metabolism

Chair: Mikael Rydén, Sweden

718 Generation of two white adipocyte models reflecting distinct mesodermal origins of subcutaneous and visceral white adipocytes from human induced pluripotent stem cells

Y. Keidai, J. Fujikura, T. Nakamura, R. Ito, K. Motohashi, N. Inagaki, D. Yabe, Japan

719 Novel osteogenic secretory factor IGF2 promotes Golgi-endosome trafficking to enhance white adipose tissue browning

X. Lin, W. Gui, G. Wang, China

720 Osteoprotegerin regulates adipose browning and energy metabolism via mTOR-raptor signalling in diet-induced obesity

Q. Zhao, G. Yang, China

721 Women with obesity and prior weight loss and regain exhibit functionally hyper-inflammatory subcutaneous adipose tissue

Y. Haim, A. Shneyour, Y. Noach, M. Rosengarten-Levin, A. Zemer, H. Moallem, A. Rudich, Israel

722 Long-term activation of cAMP/PKA signalling in WAT improves obesity-related lipotoxicity

T. Fujiki, F. Ando, K. Nagaoka, Y. Hara, H. Kikuchi, Y. Mori, S. Mandai, K. Susa, T. Mori, E. Sohara, H. Kagechika, M. Arita, S. Uchida, Japan

723 Adipose tissue CD248 gene expression links obesity and type 2 diabetes to altered adipocyte lipolysis

R. Laterveer, P. Katsogiannos, E. M. Conway, J. W. Eriksson, M. J. Pereira, Sweden, Canada

724 Disease-specific alterations of adipocyte function in lipoedema

S. Gohlke, P. Kruppa, F. Garcia-Carizzo, R. Upmeyer, M. Ghods, T. J. Schulz, Germany

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

725 Progressive differences in adiposity and ectopic fat surrogates across four progressive glycaemia status groups reinforces weight/ectopic fat reduction as the major target for prevention

S. Scilletta, P. Welsh, A. Di Pino, N. Sattar, UK, Italy

Short Oral Event A

Tuesday, 12:00 - 13:00

SO 061 Peripheral mechanisms of glucose metabolism

Chair: Daniel Van Raalte, Netherlands

726 Skeletal myosteatosis and exercise capacity in asymptomatic people with type 2 diabetes: impact of lifestyle interventions

S. A. Suleman, K. S. Parke, N. Brown, L. Algathafi, G. S. Gulsin, J. Henson, D. R. Webb, M. J. Davis, T. Yates, G. P. McCann, E. M. Brady, UK

727 The mechanism of IGF2-IGF2R signalling in regulating testosterone synthesis in testicular Leydig cells

W. Gui, D. Lin, D. Wu, X. Lin, China

728 Oral Reg1B ameliorates glucose metabolism, insulin signalling and liver steatosis in a murine model of obesity and type 2 diabetes

Y. Hao, N. Romp, S. R. Havik, A. Grefhorst, M. Nieuwdorp, E. Rampanelli, Netherlands

729 The impact of estrogen on crosstalk between perivascular adipose tissue and the vasculature

A. C. Keller, M. M. Henckel, L. A. Knaub, G. J. Potter, M. D. Vazquez, J. E.-B. Reusch, USA

730 Circulating proteomics analysis reveals potential beneficial effects of HM17321 on muscle and bone

H. Chon, H. Lee, S. Jung, B. Kim, Y.-Y. Kim, D. Lee, S. Lee, S. Lee, S. Bae, I. Choi, Republic of Korea

731 Low inflammatory phenotypes of monocyte-macrophage system in MODY2 compared to type 2 diabetes

J. Liu, T. Xie, J. Y. Liu, X. H. Xiao, China

732 Acute cold exposure stimulates blood perfusion to perirenal adipose tissue

S. E. Zaidi, T. Saari, M. Monfort-Pires, J. Örling, R. Ojala, F. M. Acosta, K. A. Virtanen, M. U-Din, Finland

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

SO 062 CNS regulation of systemic energy and glucose metabolism

Chair: Jørgen Rungby, Denmark

733 Single nucleus RNA sequencing reveals the impact of LepR deficiency on the transcriptional and communicative profiles of hypothalamic

S. Zhang, M. Yang, China

734 Obesity and schizophrenia: the road back to better physical health with glucagon-like peptide-1 therapy: results at 6 month follow-up

A. Heald, I. Nash, O. Boyle, C. Daly, D. Longson, D. O'Shea, J. Ingram, R. Holt, J. Firth, S. Veluchamy Rathakrishnan, M. Stedman, A. Syed, M. Gibson, M. De Hert, UK, Ireland, Belgium

735 Effect of 8-week intensive lifestyle intervention on prefrontal cortex activity following OGTT in children with obesity

M. Manco, G. Scozia, D. Fintini, V. Russo, M. Rea, N. Gianni, A. Aureli, S. Cianfarani, D. Menghini, Italy

736 The relationship between volumes of limbic system structures and body weight gain in women in the previous year

L. Lapinska, A. Szum-Jakubowska, A. Krentowska, M. Pawlak, Z. Stachurska, M. Dubatowka, K. Kaminski, I. Kowalska, Poland, Netherlands

737 Mir-30a-3p: role as a molecular player and biomarker in the response to ketogenic diet for obesity management

M. Clemente-Postigo, C. Casado, A. Cantarero-Cuenca, A. Gonzalez-Jimenez, A. M. Gentile, R. El Bekay, M. M. Malagon, I. Moreno-Indias, F. J. Tinahones, Spain

738 Eloralintide (LY3841136), a selective amylin analog, lowered body weight with improved quality of weight loss and GI tolerability in rats compared to cagrilintide

D. A. Briere, A. M. Long, D. M. Bullock, L. O'Farrell, B. Bowen, K. Lansu, T. Coskun, J. Moyers, H. Qu, USA

739 Chlorpyrifos modulates hypothalamic orexigenic peptides regulation: the selective role of estrogen receptor beta

M. Pastorino, A. Desiderio, E. Perrella, M. Campitelli, I. Prevezano, T. Peluso, C. Ambrosino, G. A. Raciti, Italy

740 Dopamine regulates NPY and melanocortin systems in the adipose tissue: therapeutic targets for metabolic diseases

E. Lopes, D. Sousa, S. Conde, D. Rosendo-Silva, P. Matafome, Portugal

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

SO 063 News on adipocyte biology

Chair: Jan-Wilhelm Kornfeld, Germany

741 FSTL3: linking thermogenic and immunomodulatory adipocyte formation through potential nuclear function

C. Horvath, S. Søbørg, T. J. Larsen, V. H. Jensen, N. Palani, N. Z. Jespersen, C. Brandt, B. Andersen, A. Sanfridson, J. S. Petersen, Z. Gerhart-Hines, B. K. Pedersen, S. Nielsen, C. Schéele, Switzerland, Denmark

GENERAL
INFO**742 An acute temperature rise increases isoproterenol-induced FFA release from white adipocytes**

F. Foti, R. Schäpper, D. Konrad, S. Wueest, Switzerland

743 High-fat/high-sugar diet leads to divergent effect on transcriptome and translatoe across 5 mice metabolic tissues

B. Toussaint, F. Oger, X. Maréchal, R. Boutry, M. Derhourhi, P. Froguel, A. Bonnefond, France

744 Unravelling the links between obesity, chronic kidney disease and senescence

H. Marlier, M. Decarnoncle, F. Luna Vargas, A. Fizazi, T. Zwakhals, F. Juszczak, F. Debacq-Chainiaux, T. Arnould, A.-E. Declèves, Belgium

745 Abundance of serotonin and its receptor 5HTR1B in the brain and adipose tissue following diet-induced obesity or caloric restriction

F. W. Hukema, S. Hetty, C. Kagios, S. Zellerroth, G. Fanni, M. J. Pereira, M. K. Svensson, M. Sundbom, A. Nilsson, P. E. Andrén, E. Roman, J. W. Eriksson, Sweden

746 Glucose-dependent metabolic alterations in human adipocytes: implications for obesity and diabetes research

E. Herbers, K. Moisis, R. Torregrosa-Muñumer, J. Karppinen, S. Heinonen, B. Van der Kolk, A. Hassinen, E. Pirinen, V. Hietakangas, L. Euro, K. H. Pietiläinen, Finland

747 Metabolic changes drive differentiation of unilocular adipocytes in vitro

C. Hagberg, A. Maestri, M. Cai, R. Schipper, J. Backman, E. Ehrenborg, R. Nilsson, Sweden

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONSPRESENTER
INDEXSATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

748 Subcutaneous adipose tissue and peripheral blood mononuclear cells interferon gamma-related gene expression in obesity and glucose intolerance

M. Stefanowicz, N. Matulewicz, M. Dobrzycka, K. Waczyński, A. Walewska, A. Eljaszewicz, M. Moniuszko, P. Myśliwiec, J. Dadan, I. Kowalska, M. Karczewska-Kupczewska, Poland

Short Oral Event D

Wednesday, 13:00 - 14:00

SO 064 Beyond BMI 02

Chair: Adam Hulman, Denmark

749 Prevalence of obesity and metabolically-defined clinical obesity in a Chinese community-based population: an analysis based on novel diagnostic criteria

Y. Y. Chen, Y. Y. Luo, L. L. Ji, X. X. Zhou, China

750 Multi-omics approach to identify common elements among metabolic syndrome clinical traits

L. Antonetti, R. Menghini, V. Casagrande, M. Cardellini, M. Ballanti, S. Savastano, L. M. Donini, G. Mingrone, M. Federici, Italy

751 The cardiovascular risk depends on the definition of metabolically healthy obesity: a systematic review and meta-analysis

J. E. Nagy, G. Rakoczi, P. Hegyi, I. Amorim, A. Rancz, G. Agocs, B. Szentes, R. Hager, E. Sipter, Hungary

752 Post-fasting respiratory quotient as a marker of metabolic inflexibility in severe obesity

T. Hollstein, L. Homeister, W. Diederich, D. Bohlmann, J. Ziegler, S. Remy, K. Hartmann, L. Kruse, A. Beckmann, P. Wietzke-Braun, N. Rohmann, K. Schlicht, C. Geisler, U. Becker, M. Laudes, Germany

753 Computational modelling enables individual assessment of postprandial glucose and insulin responses after bariatric surgery

S. M. Heinonen, O. Poyraz, T. John, T. Saarinen, A. Juuti, P. Marttinen, K. H. Pietiläinen, Finland

754 Interpretable machine learning-based detection of fatty pancreas in patients with diabetes: models based on multiple machine learning with multilayer perceptrons

Y. Li, J. Su, L. Shen, L. Zhang, F. Li, C. Ding, China

755 Comparative metabolic outcomes after bariatric surgery in diabetic and non-diabetic obese patients: a propensity score-matched cohort study

K. Mutailipu, Y. Zhao, J. Wen, C. Yang, C. Tong, J. Cheng, S. Qu, L. Bu, China

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

756 Differences in the effect of liraglutide on metabolic disorders associated with prediabetes by sex and reproductive age

L. Lebertova, I. Markova, M. Hüttl, K. Cerna, H. Malinska, Czechia

Short Oral Event E

Thursday, 12:45 - 13:45

SO 065 Pathways and paradoxes: unraveling the complexities of metabolic health

Chair: Caterina Conte, Italy

757 The anti-obesogenic and metabolic effects of a novel ceramide synthase inhibitor

L. L. Choong, S. E. Hancock, A. Nguyen, I. Dragutinovic⁴, E. N. Taylor, J. C. Morris, N. Turner, Australia

758 Metabolic profiles and peak expiratory flow: longitudinal association and risk prediction of severe airflow limitation

S. Fu, W. Li, China

759 Insights into circulating cell-free DNA in metabolic disorders

A. Pollastri, S. H. Bernhart, A. Hoffmann, T. Hagemann, K. Krohn, A. Ghosh, F. Noé, C. Wolftrum, R. Chakaroun, I. Schamarek, K. Rohde-Zimmermann, L. Massier, M. Blüher, P. Kovacs, M. Keller, Germany, Switzerland, Sweden

760 Interleukin-17a concentration in patients with diabetes in long COVID, cardiorenal syndrome and obesity

O. Kovzun, V. Pushkarev, L. Sokolova, A. Sokolova, V. Pushkarev, N. Levchuk, M. Tronko, Ukraine

761 Investigation on the current status of negative emotions in patients undergoing metabolic and bariatric surgery and analysis of influencing factors

J. Zhang, Y. Xu, Y. Shen, China

762 Endotrophin response following weight loss treatments in individuals with and without metabolic dysfunction

C. F. Laursen, J. Holt, I. L. Sorribes, F. Genovese, D. Leeming, M. Karsdal, Q. M. Anstee, K. Hallsworth, J. S. Pedersen, F. Bendtsen, S. S. Torekov, Denmark, UK

763 Beta cell regeneration and phenotype stabilisation with canagliflozin in a pediatric model of severe type 2 diabetes

A.-I. Popescu, R. C. Bunn, P. Ray, K. M. Thrailkill, J. L. Fowlkes, USA

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

SO 066 Novel therapeutics: preclinical evidence for next-generation treatments

Chair: Ben Jones, UK

764 The mediating effectors of energy expenditure enhancement within GLP-1/GIP/glucagon triagonism

A. Novikoff, A. Cebrian Serrano, M. Bakhti, B. Finan, K. Habegger, C. Wolfrum, J. Beaudry, J. Douros, T. Mueller, M. Tschoep, Germany, USA, Switzerland, Canada

765 Mechanistic insights into the potent anti-obesity effects of HM15275, a novel long-acting GLP-1/GIP/glucagon triple agonist

Y. Kim, S. Park, S. Lee, D. Lee, E. Park, J. Kim, S. Hong, S. Bae, S. Lee, I. Choi, Republic of Korea

766 An unimolecular GLP-1R/GIPR/Pan-PPAR quintuple agonist eliminates obesity and insulin resistance in mice

D. Liskiewicz, A. Novikoff, A. Khalil, J. Campbell, A. Cebrian Serrano, J. Douros, C. Kusminski, J. Wean, P. Scherer, R. Seeley, R. DiMarchi, M. H. Tschöp, N. Krahmer, P. Knerr, T. D. Müller, Germany, USA

767 The GLP-1/GIP/glucagon triple receptor agonist retatrutide demonstrates multiple metabolic benefits and strong improvement in liver steatosis in a diet-induced obese MASH mouse model

F. Briand, C. Le Cudennec, E. Grasset, C. Bigot, N. Breyner, P. Dillard, T. Sulpice, France

768 Therapeutic NuSH cocktails: co-administration of an ultra-long acting PYY analogue engineered for tolerability and an ultra-long acting GLP-1 analogue induces significant weight loss in DIO mice

C. Hinds, J. Vyse-Waughray, C. Reyes Luna, G. Zoumpoulidou, R. Hansford, R. Gil, J. Minnion, M. Serrano-Wu, W. Adams, USA

769 A novel tetra-agonist peptide targeting GLP-1, GIP, amylin and calcitonin receptors with superior weight loss effects vs tirzepatide while preserving muscle in DIO rats

C. Rondinone, M. Valdecantos, P. Rada, A. Valverde, S. Ghosh, USA, Spain

770 Significant weight reduction with improved body composition and serum TG/TC by HDM1002, a novel oral small molecule GLP-1R agonist

L. Guo, H. Pan, L. Teng, C. Jiang, D. Liu, China

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

771 AZD234, a novel selective amylin receptor agonist (SARA), demonstrates a preferential profile over DACRA or GLP-1R agonist in rat models of aversion and fat-mass loss

D. C. Hornigold, G. Geoghegan, S. Genapathy, C. A. Brighton, S. Hansson, P. Gennemark, L. Hultin, G. Hyberg, S. Omar, S. Will, UK, USA, Sweden

Short Oral Event A,

Tuesday, 12:00 - 13:00

GENERAL
INFO

SO 067 Taking control: behavioural changes for optimal management of type 2 diabetes

Chair: Ruth Loos, Denmark

772 Optimising American Diabetes Association's ABC target (HbA_{1c}, blood pressure, and LDL-C) achievement in type 2 diabetes through lifestyle interventions: an Indian study

D. Tiwari, P. Tripathi, N. Kadam, A. Vyawahare, B. Sharma, T. Kathrikolly, M. Ganla, B. Saboo, India

773 Impact of an integrated lifestyle intervention on body composition and type 2 diabetes remission: the key role of visceral fat reduction

P. Tripathi, A. Vyawahare, N. Kadam, D. Tiwari, B. Sharma, T. Kathrikolly, M. Ganla, B. Saboo, India

774 Efficacy and feasibility of intermittent versus time-restricted or continuous calorie restriction in managing obesity and type 2 diabetes

H. Zhang, Z. Zhu, B. Qiao, W. Li, M. Wu, China

775 The effect of intermittent or continuous calorie-restricted diet on body composition and energy expenditure in type 2 diabetes

C. A. Dietvorst, K. A. Geurts, O. Lodari, K. A. Berk, Netherlands, Italy

776 Nutraceutical improvement of glucose metabolism, NAFLD and insulin resistance by oat-fiber supplementation in type 2 diabetes patients: the randomised-controlled NIMROD study

S. Kabisch, J. Hajir, V. Sukhobaevskaia, J. Machann, M. O. Weickert, A. F. Pfeiffer, Germany, UK

777 Postprandial testosterone levels in type 1 and type 2 diabetes following standardised meals

A. Elksnis, S. Catrina, N. Rajamand Ekberg, Sweden

778 Efficacy and safety of a 6-month protein-enriched diet in older Japanese people with diabetes and low skeletal muscle mass: an exploratory, historically controlled study

S. Moyama, N. Makabe, K. Kunieda, T. Takahashi, K. Murotani, Y. Yamazaki, Y. Hamamoto, H. Kuwata, Y. Seino, Japan

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

779 Effect of a high-intensity physical activity programme on the decline in renal function in high renal risk people with type 2 diabetes: randomised, controlled trial ActiDiaNe

S. Hadjadj, L. Durocher, L. Kessler, I. Tauveron, T. Vidal Treca, P. Saulnier, P. Gourdy, M. Moret, V. Rigalleau, S. Borot, P. Ducluzeau, C. Ciangura, L. Bosquet, B. Cariou, for the ACTIDIANE study group, France

Short Oral Event B

Tuesday, 13:15 - 14:15

SO 068 Dietary diversity in practice: navigating multiple nutritional approaches

Chair: Paul Franks, Sweden

780 Facilitators and barriers for adherence to medical nutrition therapy after one month of dietary intervention among pregnant women with gestational diabetes

M. Duraiswamy, V. Jayaseelan, J. R, S. R, India

781 Impact of dietitian-led medical nutrition therapy on ketonuria and neonatal outcomes in Japanese women with gestational diabetes: a focus on food order and divided meal consumption

S. Imai, S. Kajiyama, Y. Higuchi, T. Miyawaki, S. Kajiyama, Y. Hashimoto, M. Fukui, Japan

782 Interconnections between food intake, continuous glucose monitoring parameters, and inflammatory and insulin-resistance-related markers in individuals with overweight and obesity grade 1

S. Ivanova, A. Fedulovs, Z. Šmite, S. Skrebinska, G. Bīlande, M. Arisova, E. Vilunas, L. Pahirko, J. Sokolovska, Latvia

783 Late-life caloric restriction reduces insulin secretory demand and alters islet immune composition by limiting antigen presentation and t-lymphocyte infiltration

R. Arrojo e Drigo, M. Schleh, A. Cambria, M. Cutler, C. Acree, G. Ferguson, USA

784 Uncovering proteomic and metabolomic pathways linking healthy dietary patterns and cardiometabolic health

R. Li-Gao, J. Han, K. Deng, Z. Hong, Z. Zhang, N. Godneva, R. De Mutsert, A. Van Hylckama Vlieg, F. R. Rosendaal, J.-S. Zheng, Y. Chen, E. Segal, Netherlands, China, Israel

785 The association between ultra-processed food and anthropometric and metabolic parameters, stress and eating behaviour during a combined lifestyle intervention

K. A. Geurts, R. E. Meeusen, K. A. Berk, E. F. Van Rossum, Netherlands

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

786 Sweet Cure? Mannose reverses beta cell dysfunction and improves glucose metabolism in diabetes

S. Ma, L. Song, China

787 Food insecurity and diabetes distress in Bangladesh: exploring a causal relationship by g-computation analysis

M. Kamruzzaman, K. Lange, J. Marathe, K. Jones, M. Horowitz, C. S. Marathe, Australia, Bangladesh

GENERAL
INFO

Short Oral Event C

Wednesday, 11:45 - 12:45

PROGRAMME

SO 069 SGLT2 inhibitors: glycaemic indicators and beyond in clinical practice

TUESDAY

Chair: Sofie Haedersdal, Denmark

WEDNESDAY

788 Sustained impact of dapagliflozin on epicardial fat thickness in type 2 diabetes: insights from the DAPAHEART 4-year experience

THURSDAY

C. Morciano, S. Gugliandolo, A. Avolio, U. Capece, L. Leccisotti, A. Splendore, T. Mezza, G. Di Giuseppe, G. Ciccarelli, M. Brunetti, L. Soldovieri, P. Iozzo, A. Giaccari, F. Cinti, Italy

FRIDAY

789 Efficacy and safety of enavogliflozin as add-on in adults with type 2 diabetes inadequately controlled with insulin or insulin with other antidiabetic drugs

SHORT ORAL
DISCUSSIONS

J. Hong, K. Min, C. Lee, P. Chamnan, T. Sirirak, K. Sony, S. Sattanon, H. Kim, S.-Y. Kim, Y. Kim, J. Heo, J. Cho, J. Nah, M. Park, J. Kim, Republic of Korea, Thailand

PRESENTER
INDEX

790 Discontinuation of SGLT2i after an episode of urogenital infection: a population-based matched cohort study of patients with type 2 diabetes

SATELLITE
SYMPOSIA

C. Ljungberg, C. Vandenbroucke-Grauls, M. Dalager-Pedersen, H. T. Sørensen, M. Nørgaard, R. W. Thomsen, Denmark, Netherlands

INDUSTRY

791 Ketoacidosis associated with type 2 sodium-glucose cotransporter inhibitors in patients aged 65 and over: evidence from the French national pharmacovigilance database

PROGRAMME

N. Bassas Letissier, N. Mirfendereski, J.-L. Faillie, M.-L. Laroche, M. Paccalin, P.-J. Saulnier, M. Allouchery, H. Mosbah, France

EXHIBITION

THANKS

792 SGLT2i use is significantly associated with increased risk of diabetes ketoacidosis in people with type 2 diabetes: a nation-wide population study

M. Retford, H. Wang, E. Pearson, UK

793 Effectiveness of SGLT2is vs GLP-1RAs on diabetic foot disease: an emulated target trial

R. W. Thomsen, F. P. Kristensen, D. H. Christensen, B. C. Callaghan, J. S. Nielsen, H. Andersen, H. T. Sørensen, Denmark, USA

794 Efficacy and tolerance of SGLT2 Inhibitors in patients with Prader-Willi syndrome and type 2 diabetes

C. Amouyal, J. Jacquot Thierry, S. Chalopin, H. Mosbah, E. Montastier, F. Mourre, P. Faucher, B. Gatta-Cherifi, J. Bourry, C. Poitou Bernert, France

795 Partial non-adherence to antidiabetic therapy worsens diabetes management and correlates with treatment complexity: a comprehensive study using direct blood analysis

V. Skop, M. Mraz, I. Lankova, S. Antalova, K. Mala, J. Maly, T. Pelikanova, T. Cajka, M. Haluzik, Czechia

796 SGLT2 inhibitors may reduce advanced glycation end products in patients with type 2 diabetes: a pilot study

N. Altaie, H. Stingl, J. Jabr, R. Umgeher, Austria

Short Oral Event D

Wednesday, 13:00 - 14:00

SO 070 Real-world evidence for non-insulin therapies: clinical practice insights

Chair: Caroline Bonner, France

797 Non-insulin therapies in the inpatient management of type 2 diabetes, safety and effectiveness of a start-stop protocol: the ENDOCARE ALC study

O. Moreno-Perez, E. Santacruz, C. Navarro, B. López, R. Sánchez-Ortiga, P. López-Mondejar, A. Roldán, N. Leiva, A. Tejera-Muñoz, V. Arrarte, M. Sandín, E. Climent, G. Riera, P. Llorens, J. Serrano-Gotarredona, Spain

798 Semaglutide treatment patterns and clinical outcomes in treatment-naive individuals with type 2 diabetes: insights from Swedish and Danish registry data

A. Rawshani, J.-P. David, C. Kruse, C. L. Rasmussen, S. H. Scheuer, T. Vilsbøll, Sweden, Denmark

799 The Diabetes and Ramadan global survey: outcomes among people with type 2 diabetes using sulfonylureas vs non-insulin antidiabetic agents

M. Hassanein, on behalf of DaR investigators, United Arab Emirates

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

800 Real-world adherence and persistence of GLP-1 based treatments in patients with type 2 diabetes

M. S. Girguis, J. P. Almandoz, M. A. Weintraub, E. T. Chang, N. Saleem, P. Muntner, P. J. Druzniowski, USA

801 Acute administration of exogenous glucose-dependent insulinotropic polypeptide affects insulin secretion and sensitivity and cardiovascular function in type 2 diabetes

C. Xie, Y. Sun, W. Huang, M. Bound, J. Grivell, K. Jones, M. Horowitz, C. Rayner, T. Wu, Australia

GENERAL
INFO

802 Phenotypic factors associated with gastrointestinal side effects induced by metformin in newly diagnosed people with type 2 diabetes

K. Kalin, K. Rådholm, B. Daka, S. Jansson, A. Möllsten, V. Tremaroli, F. Bäckhed, O. Rolandsson, Sweden

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

803 Association of changes in taste intensity with satiety, appetite and food cravings in people with overweight and obesity treated with incretin-based therapies: a cross-sectional exploratory study

O. Moser, R. Felsing, T. Waldhör, S. Haider, A. Kapan, Germany, Austria

804 Pharmacodynamic effects of oral small molecule GLP-1 agonist TERN-601 in healthy participants with obesity or overweight

C. Nelson, C. Jones, E. Kwan, E. Castelloe, T. Marmon, E. Kuriakose, USA

SHORT ORAL
DISCUSSIONS

Short Oral Event E

Thursday, 12:45 - 13:45

SO 071 Bench to bedside: incretin research across species

Chair: Daniela Liskiewicz, Germany

805 pH-responsive porous pollen hydrogel for oral tirzepatide delivery to improve glycaemic control and insulin sensitivity

Y. Liu, J. Sun, L. Li, China

806 The response of MiR-151b, MiR-RNA-29c-3p and MiR-4284 on submaximal doses of semaglutide in patients with obesity

M. Samos, J. Jurica, Z. Miertova, D. Brany, D. Dvorska, T. Bolek, M. Sarlinova, M. J. Pec, I. Baranova, E. Halasova, M. Mokaň, Slovakia

807 Direct GIPR-SERCA2 protein-protein interaction regulates lipolysis in stem-cell derived adipocytes from obese patients

A. Tomas, A. E. Pollard, Y. Manchanda, A. Milner, G. Austin, UK

808 Glucolipotoxicity affects the beta cell functional network by reducing leader and hub cell function: effects GLP1 receptor agonism

G. Ostinelli, P. Carapeto, N. Lacete, G. A. Rutter, Canada

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

809 Proinflammatory cytokine-induced alpha cell impairment in human islet microtissues is partially restored by incretin receptor agonism

K. Henriksen, C. Rufer, A. C. Title, S. Jawurek, B. Hartmann, J. J. Holst, F. K. Knop, B. Yesildag, J. Størling, Denmark, Switzerland

810 Critical role of the area postrema for glucose-dependent insulinotropic polypeptide receptor agonists in mice

F. Reimann, J. Lewis, M. Montaner, P.-P. James-Okoro, N. Harada, N. Inagaki, D. Nuzzaci, F. M. Gribble, UK, Japan

811 Beneficial effects of the combinatory therapy with sub-maximal doses of cagrilintide and tirzepatide on body weight loss in obese rats

M. Valdecantos, P. Rada, S. Ghosh, C. Rondinone, A. Martinez Valverde, Spain, USA

812 Dissecting food intake-dependent and independent effects of survodutide on transcriptome, lipidome and systemic insulin sensitivity

V. Efthymiou, C. Engl, A. Ghosh, M. Arnold, M. Klug, M. Giera, H. Neubauer, T. Klein, C. Wolfrum, C. Horvath, Switzerland, Netherlands, Germany

Short Oral Event F

Thursday, 14:00 - 15:00

SO 072 Next-generation therapeutics: novel approaches to diabetes and obesity

Chair: Philippe Froguel, France

813 TN-10 extension study: teplizumab following stage 3 type 1 diabetes diagnosis in participants from the TN-10 trial

L. Knecht, K. C. Herold, J. L. Sherr, M. J. Haller, W. E. Russell, E. Niemoeller, S. Andjelic, O. Gonzalez, P. Picard, P. Gottlieb, USA, Germany, France

814 The antigen-specific immunotherapy rhGAD65 delays progression of stage 3 type 1 diabetes in individual with HLA DR3-DQ2: survival analysis of combined data from three randomised controlled trials

A. Lindqvist, C. Nowak, P. Teixeira, L. Eriksson, U. Hannelius, J. Ludvigsson, Sweden

815 Slowing of intestinal glucose absorption by metformin is not related to the timing of its administration

M. J. Borg, C. Xie, C. Chen, W. Huang, K. Jones, M. Horowitz, C. Rayner, T. Wu, Australia, China

816 Imeglimin improves glycaemic control early after administration via enhanced insulin secretion

T. Tajima, H. Kaga, T. Kogai, H. Naito, N. Ito, S. Takechi, Y. Nishida, Y. Tamura, H. Watada, Japan

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

817 A low-dose, portal dihydrotestosterone implant has a sustained effect to improve glycaemic control and provides cardiovascular and renal protection in a large animal model of type 2 diabetes

C. Malbert, R. Allouche, M. Horowitz, K. Jones, France, Australia

818 Targeting CD36 with Nitro-Oleic Acid to protect pancreatic beta cell function: a hopeful drug candidate for anti-diabetic therapy

S. Mandal, N. Das, O. Mukherjee, K. Maedler, R. Kundu, India, Germany

819 Efficacy of the novel UCN2 analogue HM17321 in weight loss without muscle wasting in obese non-human primates and its applications with incretins in obese mice

J. Kim, H. Kwon, S. Lee, E. Kim, S. Lee, S. Bae, I. Choi, Republic of Korea

820 Milk-derived extracellular vesicles as a potential treatment for glucose control and inflammation in diabetic rats

S. W. Zangen, R. L. LAX, S. Ehrenfeld, S. Reif, R. G. Golan, Israel

Short Oral Event A

Tuesday, 12:00 - 13:00

SO 073 The GLP-1 portfolio: diverse formulations for expanding clinical applications

Chair: Andreas Andersen, Denmark

821 Effect of smoking status on once weekly semaglutide 1 mg treatment in people with peripheral artery disease and type 2 diabetes: a secondary analysis of the STRIDE trial

H. Sourij, E. G. Arslan, A. Catarig, K. Houlind, B. Ludvik, J. Nordanstig, N. Rasouli, S. Thomas, S. Verma, M. Bonaca, Austria, Denmark, Sweden, USA, Canada

822 Effectiveness of semaglutide in oral vs subcutaneous injectable formulation: a UK real-world data from Association of British Clinical Diabetologists national audit

K. Su Khin, T. Crabtree, A. Liarakos, W. Ahmad, A. Maliekal, V. Oguntolu, A. Gough, S. Krishnasamy, H. Reid, K. Adamson, G. R. Mudiyansele, E. Wilmot, I. Idris, R. E. Ryder, UK

823 Dulaglutide for management of type 2 diabetes in a patient with Bardet-Biedle syndrome: a case report

W. N. Laimon, Kuwait

824 Tirzepatide as a potential strategy to overcome leptin resistance in obesity

R. Izumi, A. Hamasaki, A. Narita, Y. Nishikawa, S. Sasaka, R. Tsukaguchi, M. Sakai, K. Shibue, S. Honjo, N. Inagaki, Japan

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

825 Tirzepatide as an adjunctive therapy in type 1 diabetes: real-world experience from a large UK centre

S. A. Berry, E. McNally, I. Goodman, J. Elliott, A. Iqbal, UK

826 A phase 3 evaluation of cAMP-biased GLP-1 analogue ecnoglutide in adults with overweight or obesity

S. Xu, L. Gao, H. Xue, J. Tian, K. Wang, Q. Zheng, M. Yang, J. Ning, M. Guo, Y. Li, L. Ji, the SLIMMER Investigators, USA, China

827 ASC30, an oral GLP-1R biased small molecule agonist demonstrated superior weight loss in participants with obesity: a 28-day multiple ascending dose study

J. J. Wu, V. Wang, Hong Kong

828 Efficacy and safety of bofaglutide (GZR18), a bi-weekly GLP-1 RA, compared to semaglutide in Chinese patients with type 2 diabetes

M. Liu, Z. Cheng, L. Lu, H. Cai, J. Liu, J. Liu, Y. Zheng, J. Zhao, W. Yang, T. Xie, Y. Li, A. He, S. Carter, H. Wu, W. Chen, China, USA

Short Oral Event B

Tuesday, 13:15 - 14:15

SO 074 In (hospital) bed with diabetes

Chair: Didac Mauricio, Spain

829 Continuous glucose monitoring in intensive care unit patients: Is it accurate enough?

M. Zarytovska, O. Krajniak, W. Mroziński, M. Zawadka, P. Andruszkiewicz, L. Czupryniak, Poland

830 Comparison of continuous glucose monitoring vs capillary blood glucose monitoring in glycaemic management of hospitalised diabetic patients

Y. Lu, J. Li, W. Tan, China

831 Adherence to continuous glucose monitoring in an acute geriatric unit: GLYCOGER study

N. Bassas Letissier, X. Piguel, H. Mosbah, P.-J. Saulnier, E. Liuu, M. Paccalin, France

832 Glycaemic control and insulin use daily and during shifts in hospitalised non-critically ill patients with type 2 diabetes

M. T. Olsen, S. H. Jensen, L. M. Rasmussen, C. K. Klarskov, B. Lindegaard, J. A. Andersen, H. Gottlieb, S. Lunding, U. Pedersen-Bjergaard, K. B. Hansen, P. L. Kristensen, Denmark

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

833 Proactive specialist diabetes care for people with type 1 diabetes admitted to hospital improves treatment satisfaction: STOIC-type 1 diabetes randomised controlled trial

M. Kyi, R. D. Barmanray, L. DiSalvo, L. Rowan, C. Hendrieckx, J. Speight, P. G. Colman, S. Furlanos, Australia

834 Transforming inpatient glycaemic management: a system-wide approach to reducing hyperglycaemia and hypoglycaemia

D. K. Plante, B. M. Bagley, C. Reilly, C. Tan, R. Lee, G. Maynard, USA

835 Effect of implementation of inpatient diabetes management service (IDMS) among admitted type 2 diabetes patient in a tertiary care setting 2023-2024

H. Alkady, E. Bukhari, S. Bukhari, M. Alshareef, T. Alharthi, Saudi Arabia

836 Impact of specialised diabetes team on length of stay and hypoglycaemia in hospitalised patients

O. Simó-Servat, P. Gil, Á. Ortiz-Zúñiga, J. Amigó, P. Sancho, M. Sánchez, M. Ozalla, M. Dos Santos, M. Abadias, C. Hernández, R. Simó, Spain

Short Oral Event C

Wednesday, 11:45 - 12:45

SO 075 It's all personal

Chair: Ilias Migdalis, Greece

837 Personalised medicine in diabetes: Immense possibilities, but what is the patient's perspective?

V. Rotbain Curovic, S. Theilade, P. Rossing, Denmark

838 HbA_{1c} and diabetes-specific quality of life changes following structured type 1 diabetes education: exploratory latent profile analysis in the DAFNEplus trial

U. Soeholm, S. Thuraisingam, E. Holmes-Truscott, N. De Zoysa, D. Cooke, S. Heller, J. Speight, for the DAFNEplus Study Group, Australia, UK

839 Stay on Top of Your Diabetes: insights from a one-year follow-up study

A. Nikontovic, J. Nielsen, H. R. Larsen, P. Vestergaard, Denmark

840 Gaps and opportunities for strengthening in-school support for young people with type 1 diabetes: a freedom of information investigation

S. E. Dry, UK

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

841 Achieving glycaemic targets is associated with reduced diabetes distress in adults with type 1 diabetes using hybrid closed loop in the UK

A. L. Liarakos, T. S. Crabtree, T. P. Griffin, S. Hussain, J. Elliott, M. L. Evans, A. Lumb, R. E. Ryder, P. Choudhary, E. G. Wilmot, UK

842 The effect of socioeconomic deprivation on HbA_{1c} reduction in insulin pump users

T. D. Behan, E. Jenkins, S. Penfold, A. Brooks, H. Partridge, UK

843 Adherence to activity trackers in a telemonitoring trial for people with insulin-dependent type 2 diabetes: a post hoc analysis

J. Rosenskjold, S. Ekelund, T. Kronborg, M. Jensen, P. Vestergaard, S. Hangaard, Denmark

844 Predicting no-shows in a Diabetes Center in North Denmark: a machine learning approach

A. Nikontovic, U. Appel, T. A. Heide, P. Vestergaard, Denmark

Short Oral Event D

Wednesday, 13:00 - 14:00

SO 076 How to have a happy life in a love/hate triangle of diabetes + pregnancy + CGM

Chair: Nevena Chakarova, Bulgaria

845 Continuous glucose monitoring metrics and pregnancy outcomes in type 1 diabetes: a secondary analysis of the CRISTAL trial

K. Benhalima, I. Geerts, N. Van Wilder, D. Ballaux, G. Vanhaverbeke, Y. Taes, X.-P. Aers, F. Nobels, J. Marlier, D. Lee, J. Cuypers, V. Preumont, S. Siegelar, P. Gillard, C. Mathieu, Belgium, Netherlands

846 Subtypes of gestational diabetes associated with adverse pregnancy outcomes

G. Liang, S. Yan, N. Li, J. Weng, H. Wu, X. Xu, Y. Wang, China

847 Hyperglycaemia threshold associated with adverse pregnancy outcomes in gestational diabetes

G. Liang, S. Yan, Y. Wang, J. Lu, H. Wu, J. Zhou, Y. Wang, China

848 Early continuous glucose monitoring data and overall glycaemic control in gestational diabetes

K. Zorko, A. Munda, A. Janez, D. Pongrac Barlovic, Slovenia

849 Intermittently scanned continuous glucose monitoring versus self-monitoring of blood glucose in gestational diabetes: a randomised controlled trial

K. Zorko, A. Munda, A. Janez, D. Pongrac Barlovic, Slovenia

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

850 CGM-based metrics vs HbA_{1c} as indicators of glycaemic control in pregnancy following bariatric surgery

M. Xia, S. Ansari, R. Valaiyapathi, K. Alexiadou, N. Oliver, S. Purkayastha, A. Ahmed, R. Agha-Jaffar, B. Jones, C. Yu, L. Sykes, A. Dornhorst, E. Mullins, B. Khoo, T. Tan, UK

851 The choice of continuous glucose monitoring device affects perceived glycaemic control

M. Eichenlaub, G. Freckmann, S. Wehrstedt, S. Pleus, M. Link, N. Jendrike, S. Öter, D. Brandt, C. Haug, D. Waldenmaier, Germany, Switzerland

852 Q-Score (quality-score) can be more sensitive than TIR in detecting responses to changes in therapy

D. Rodbard, P. Augstein, P. Heinke, E. Salzsieder, A. Thomas, J. Reindel, W. Kerner, USA, Germany

Short Oral Event E

Thursday, 12:45 - 13:45

SO 077 Hi Hypo :) I would like to know you better

Chair: Leszek Czupryniak, Poland

853 From metrics to behaviour: regional variations in hypoglycaemia impact among type 1 patients using CGM and AID

J. Lee, P. De Piante, R. Wood, USA

854 Detecting hypoglycaemia with glycaemia risk index in adults with type 1 diabetes using continuous glucose monitoring and multiple daily injection therapy: a multicentric real-world study

A. Csermely, N. D. Borella, M. Colombini, S. S. Sheiban, A. Turazzini, M. Pilati, F. Nocilla, R. Trevisan, R. C. Bonadonna, G. Lepore, M. Trombetta, Italy

855 Personalised risk stratification for nocturnal hypoglycaemia: a novel machine learning approach using CGM glycaemic signatures

A. Saxena, S. Singla, A. Maheshwari, S. Patil, A. Raghunandan, A. Shaikh, A. Shaikh, J. Kumar, India, Saudi Arabia

856 Analysis of the cardiac electrical cycle in type 1 diabetes during hypoglycaemia: a prospective observational study

Á. Kézdi, V. J. Horváth, V. Vass, M. M. Svébis, G. Kocsis, V. Ferencz, T. Jávorfí, B. A. Domján, Á. G. Tabák, Hungary, UK

857 Circulating cardiovascular markers associated with hypoglycaemia in people with type 1 diabetes are linked to inflammation

M. S. Hendriksz, J. I. Van Heck, C. E. Verhulst, R. Stienstra, B. E. De Galan, C. J. Tack, Hypo-RESOLVE consortium, Netherlands

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

858 Canagliflozin or acarbose vs placebo to ameliorate post-bariatric hypoglycaemia: mechanistic insights from the HypoBar I randomised clinical trial

C. B. Lobato, C. T. Winding, K. N. Bojsen-Møller, B. Hartmann, C. Martinussen, S. Veedfald, J. J. Holst, S. Madsbad, N. B. Jørgensen, C. Dirksen, Denmark

859 The effect of acute aerobic exercise on the time spent in hypoglycaemia after bariatric surgery: the BariEX study

I. Podesta, D. Papamargaritis, J. Henson, D. J. Stensel, T. Yates, A. Tziannou, D. Bowrey, I. Idris, O. Anyiam, D. Webb, A. Zalin, S. Katsarova, P. Choudhary, M. Davies, L. Herring, UK

860 Presence, severity and recurrence of hypoglycaemia increases length of stay

W. Chan, P. Lim, S. Chia, S.-Y. Goh, Y. Bee, M. Teh, Singapore

Short Oral Event F

Thursday, 14:00 - 15:00

SO 078 Everyone needs AID

Chair: Rумыana Dimova, Bulgaria

861 Comparing potential benefits between therapy switching and continuous use of automated insulin delivery (AID) systems in children and adolescents with type 1 diabetes

J. Weiskorn, M. Auzanneau, M.-A. Burckhardt, N. Blauensteiner, U. Schierloh, S. Lanzinger, Germany, Switzerland, Austria, Luxembourg

862 Real-world outcomes from four hybrid closed loop systems in adults with type 1 diabetes from a publicly funded service

A. Anandhakrishnan, Guy's and St Thomas' Clinical Diabetes team, J. Karalliedde, S. Hussain, UK

863 A retrospective real-world clinical audit of hybrid closed loop insulin therapy in people with type 1 diabetes and anxiety disorders

J. S. Croos, A. K. Shooshtarian, G. Gallen, B. Stotesbury, A. Shrestha, A. Ahuja, Y. Cheah, K. Lovie, M. Rosenthal, M. Calcia, K. Ismail, R. Tan, M. Stadler, UK

864 Rapid vs ultra-rapid insulin use in the CLOSE IT trial: a fully closed loop study in type 1 diabetes

N. Nanayakkara, T. Wilkinson, D. Burren, A. Jenkins, J. Williman, E. Boyle, Y. Elghattis, A. Bennett, C. Keesing, M. De Bock, N. D. Cohen, Australia, New Zealand

865 Hybrid closed loop in diabetes after total duodeno-pancreatectomy

A. Larroumet, M. Camoin, L. Baillet-Blanco, V. Rigalleau, N. Foussard, K. Mohammadi, France

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

866 Real-world glycaemic outcomes in adults with type 2 diabetes using the Omnipod 5 AID System

A. L. Peters, S. M. Oser, F. J. Pasquel, G. Aleppo, E. Miller, L. M. Huyett, K. M. Miller, L. R. Conroy, J. J. Méndez, T. T. Ly, USA

867 Good glycaemic control is maintained for at least 12 months in MiniMed 780G system users with self-reported type 2 diabetes: a real-world analysis

S. Di Molfetta, F. Giorgino, V. Smaniotto, T. Van den Heuvel, M. Juachon, B. Völker, B. Vigerski, O. Cohen, Italy, Switzerland

868 Cost-effectiveness of AID use in individuals with diabetes across different patient groups in Sweden, Norway, Denmark and Finland; 30-year simulation results

J. Jendle, E. Pimiä, M.-E. Syleouni, A. Khan Miron, K. Nørgaard, Sweden, Finland, Switzerland, Denmark

Short Oral Event A

Tuesday, 12:00 - 13:00

SO 079 Mix and inject

Chair: Krzysztof Strojek, Poland

869 Efficacy and hypoglycaemia outcomes of once-weekly IcoSema in type 2 diabetes according to pre-trial sodium-glucose cotransporter-2 inhibitor use: a post hoc analysis of COMBINE 1-3

L. Ji, J. D. Andersen, S. B. Andersen, L. Pletsch-Borba, V. Mohan, D. Yabe, China, Denmark, India, Japan

870 Continuous glucose monitoring-based outcomes in adults with type 2 diabetes receiving IcoSema vs comparators: post hoc analysis of COMBINE 1 and 3

C. Irace, V. Cejvanovic, J. H. Larsen, T. M. Rocha, Y. Terauchi, C. Mathieu, Italy, Denmark, Japan, Belgium

871 Continuous glucose monitoring-derived model-based postprandial glucose with IcoSema vs other insulin regimens: a post hoc analysis of COMBINE 1 and 3

C. De Block, M. Asong, A. Fu, R. Maltesen, F. Giorgino, Belgium, Denmark, Italy

872 Gastrointestinal adverse events with once-weekly IcoSema: a post hoc analysis of COMBINE 1-3

A. Vianna, J. D. Andersen, L. Chen, P. Fiorina, T. M. Rocha, S. Vinther, L. K. Billings, Brazil, Denmark, China, Italy, USA

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

873 Improved treatment satisfaction with once-weekly IcoSema vs daily basal-bolus therapy in adults with type 2 diabetes inadequately controlled on daily basal insulin: COMBINE 3

P. Fiorina, M. Benamar, B. Harvey, S. G. Kim, S. Vinther, L. Chen, Italy, Denmark, Republic of Korea, China

874 Comparative effectiveness of GLP-1 RA-insulin combination vs insulin-only intensive therapy for hospitalised type 2 diabetes patients

Y. Lu, J. Li, China

875 Cost effectiveness of basal insulin across age groups in France: a post-hoc analysis of an observational longitudinal study

P. Darmon, O. Hanon, P. Gourdy, I. Borget, B. Detournay, P. Evenou, I. Bureau, N. Allali, A. Mahieu, C. Emery, A. Penfornis, France

Short Oral Event B

Tuesday, 13:15 - 14:15

SO 080 K like ketones

Chair: Janusz Gumprecht, Poland

876 A breakthrough in hypoglycaemia management: demonstrating the efficacy and acceptability of FLO23011, a novel ketone glucose combination product in type 1 diabetes

D. Russell-Jones, V. Smout, S. Roy, G. Myers, R. Littlewood, F. Shojaee-Moradie, UK

877 Ketone profiles in free-living people with type 1 diabetes using continuous ketone monitoring

J. Ngan, Y. W. Kong, J. Goad, M. L. Huang, A. J. Jenkins, S. Vogrin, S. Trawley, E. I. Ekinci, S. Furlanos, C. J. Nolan, S. Stranks, D. N. O'Neal, Australia

878 Analysing real world ketone testing behaviours and glucose levels in FreeStyle Libre readers

F. Quadri, S. Rahman, N. Viridi, USA

879 Continuous protein sensor for sarcopenia management during GLP-1 RA therapy

R. Gottlieb, K. Mallires, J. Kavner, B. Wang, J. Tangney, USA

880 Glycaemic status of adult patients with phenylketonuria: preliminary data from a pilot study

M. Kania, L. Pawlinski, M. T. Malecki, Poland

881 Estimated glucose disposal rate and triglyceride profiles across CGM-based glycaemic clusters in type 1 diabetes

A. Luganceva, S. Kistkins, S. Lobanovs, T. Mihailovs, A. Fedulovs, L. Pahirko, V. Pirags, O. Moser, H. Sourij, D. Bliznuks, J. Sokolovska, Latvia, Germany, Austria

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

882 Comparison of the patterns of hyperglycaemia episodes in people with type 1 and type 2 diabetes: a secondary analysis of the Hypo-METRICS study

B. A. Pieri, G. Martine-Edith, J. Thomas, P. Choudhary, UK

883 Understanding the burden of diabetic ketoacidosis in the transitional age (16 to 25 years): a multinational analysis

A. Alieva, A. Kojanazarov, K. Rakhmankulov, A. Manta, S. Hao, P. Vellanki, K. Persad, N. Philip, P. Kempegowda, DEVI collaboration, Uzbekistan, Greece, UK, USA

GENERAL
INFO

Short Oral Event C

Wednesday, 11:45 - 12:45

SO 081 Hi Hybrid :) how are you today?

Chair: Florian Toti, Albania

884 Evaluating the effects of HCL insulin pumps on weight and HbA_{1c} control in type 1 diabetes: a retrospective multi-centre study

E. Carey, C. Kalnoki, I. Allen, D. Slattery, P. Divilly, W. Wan Mahmood, R. Canavan, Ireland

885 Use of hybrid closed loop automated insulin delivery in people with type 1 diabetes and depression in a multidisciplinary setting: a real-world clinical audit

A. K. Shooshtarian, J. Croos, G. Gallen, B. Stotesbury, A. Ahuja, A. Shrestha, Y. Cheah, K. Lovie, M. Rosenthal, M. Calcia, K. Ismail, R. Tan, M. Stadler, UK

886 Real-world outcomes of the Omnipod 5 hybrid closed-loop system in type 1 diabetes: 6 and 12- month data from a major UK centre

E. McNally, I. Goodman, S. Berry, J. Maliekkal, D. Saeed, J. Elliott, A. Iqbal, UK

887 Improved glycaemic outcomes in adults using Omnipod 5 automated insulin delivery and predictors of TIR improvement

F. Gibb, M. Lyall, R. Wright, M. Strachan, A. Dover, UK

888 Impact of the Omnipod 5 hybrid closed-loop system on hypoglycaemia in individuals with type 1 diabetes with impaired awareness

I. Goodman, E. McNally, S. Berry, G. Martine-Edith, J. Thomas, P. Choudhary, J. Elliott, S. Heller, A. Iqbal, UK

889 Comparison of fully closed-loop control using ultra-rapid insulin lispro vs insulin lispro: an open-label, single-centre, randomised, two-period crossover study

H. Thabit, J. Lim, C. Fullwood, M. Wilinska, R. Hovorka, L. Leelarathna, UK

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

890 A study comparing the efficacy of dosing ultra rapid insulin lispro in a Medtronic 780G hybrid closed loop system at mealtime or postmeal

R. Eldor, E. Merzon, M. Margalio, T. Kolitz, A. Buch, Israel

891 Minimed™ 780G system provides equal performance in female users compared to males in all age groups from pre-puberty to menopause

Y. Elhenawy, I. Thijs, S. Siegelaar, J. Castaneda, A. Arrieta, T. Van den Heuvel, O. Cohen, Egypt, Switzerland, Netherlands

Short Oral Event D

Wednesday, 13:00 - 14:00

SO 082 Now let's count to seven, ready?

Chair: Jose Silva Nunes, Portugal

892 Efficacy and safety of a once-daily basal insulin (insulin sudelidec) vs insulin glargine in type 2 diabetes inadequately controlled with oral antidiabetic drugs

H. Chen, L. Ji, L. Gao, J. Zhang, T. Pan, D. Liu, D. Huang, W. Hu, T. Lei, Z. Zeng, L. Xu, X. Dong, W. Dai, M. Zhang, T. Zhong, China

893 Efficacy and safety of a once-daily basal insulin (insulin sudelidec) vs insulin glargine in type 2 diabetes inadequately controlled with basal insulin

X. Li, L. Zhao, D. Liu, S. Zhong, X. Dong, P. Jin, Y. Bi, M. Zhang, G. Wu, S. Li, S. Ye, Y. Fu, L. Li, H. Chen, T. Zhong, China

894 Weekly insulin efsitora alfa vs daily insulin glargine in adults with type 2 diabetes treated with basal and bolus insulin: QWINT-4

D. Dahl, T. Blevins, F. C. Manghi, S. Murthy, R. O. Carrasquillo, A. M. Chang, M. C. Carr, X. Li, M. Katz, Germany, USA, Argentina, India, Puerto Rico

895 Efficacy and hypoglycaemia outcomes with once-weekly insulin icodec vs once-daily basal insulin in type 2 diabetes by diabetes duration: ONWARDS 1-5

A. Y. Cheng, L. Canani, J. K. Lindeløv, S. B. Sogaard, S. Vinther, C. Mathieu, Canada, Brazil, Denmark, Belgium

896 Efficacy and safety of once-weekly basal insulin therapy in people with type 1 diabetes: a systematic review and meta-analysis

L. Di Gioia, S. Di Molfetta, I. Caruso, M. Caporusso, G. Sorice, A. Cignarelli, A. Natalicchio, S. Perrini, L. Laviola, F. Giorgino, Italy

897 A new highly concentrated insulin aspart AT278 (500 IU/ml) demonstrates ultra-rapid pharmacokinetic and pharmacodynamic properties in type 2 diabetes regardless of BMI

E. Svehlikova, C. Gatschelhofer, B. Lackner, M. Ratzer, G. Fluhr, A. Stoisser, D. J. Gerring, J. Jezek, S. J. Howell, L. Zakrzewski, T. R. Pieber, Austria, UK

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

898 Derived time-in-ranges in insulin-naive older adults with type 2 diabetes treated with insulin glargine 300 U/mL vs degludec 100 U/mL: a BRIGHT trial post-hoc analysis

J. Escalada, T. Martens, A. Liebl, Y. Luo, M. Mabunay, F. Lauand, L. Melas-Melt, Spain, USA, Germany, China, Singapore, France

Short Oral Event E

Thursday, 12:45 - 13:45

GENERAL
INFO

SO 083 More AID needed

Chair: Tatjana Milenkovic, North Macedonia, The Republic of

899 Dissemination, barriers and future developments of AID systems from the perspective of health care professionals from Germany, Switzerland, Austria and Spain

B. Kulzer, T. Roos, D. Ehrmann, N. Hermanns, J. Mader, M. Resl, C. Truempi, P. Diem, D. Brandt, F. Ampudia, L. Heinemann, Germany, Austria, Switzerland, Spain

900 Effect of automated insulin delivery systems initiation on reduction of hypoglycaemia in people with type 1 diabetes: retrospective single-centre study

P. Novodvorsky, R. Bem, K. Sochorova, R. Koznarova, D. Vavra, K. Cechova, F. Hruby, P. Girman, M. Dubsy, M. Haluzík, Czechia

901 Impact of fasted morning exercise with and without glucagon on 24 hour post-exercise glycaemic levels in adults with type 1 diabetes using an automated insulin delivery system

C. Solà, S. Lundemose, O. M. McCarthy, K. Nørgaard, Spain, Denmark

902 Glycaemia risk index before and 12 months after hybrid closed loop (HCL) initiation in the CIRDIA, an out-of-hospital French HCL initiation centre

S. Picard, S. Lablanche, S. Borot, CIRDIA Study Group, France

903 The automated correction index, a novel report-derived metric correlated to glucose control and variability in patients with type 1 diabetes on advanced hybrid closed loop therapy

V. Oteri, F. Galeano, G. M. Santoro, R. Baratta, D. Gullo, L. Frittitta, L. Sciacca, R. Le Moli, T. Piticchio, A. Di Pino, G. Pezzino, F. Frasca, L. G. Tomaselli, A. Tumminia, Italy

904 Taming glycaemic excursions: vildagliptin meets closed-loop tech in type 1 diabetes during intermittent fasting of Ramadan

S. Abouelnasr, E. Abdelrahman Ismail, N. Elbarbary, Egypt

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

905 Evaluation of user satisfaction in adolescents and adults after upgrading to a new sensor integrated into an automated insulin delivery system

P. Beato Vibora, E. Gil-Poch, F. Arroyo-Díez, Spain

906 The impact of automated insulin delivery on glucose control in people with diabetes and advanced chronic kidney disease

J. C. Lu, B. Halim, S. Vogrin, J. Apostolopoulos, S. Trawley, N. Cohen, S. Fourlanos, S. Stranks, E. Ekinci, L. Leelarathna, K. Nørgard, D. N. O'Neal, The Automated Insulin Delivery in Diabetes and Advanced Chronic Kidney Disease Study Group*, Australia, UK, Denmark

Short Oral Event F

Thursday, 14:00 - 15:00

SO 084 Predicting a smart, bright and intelligent future for diabetes care

Chair: Hanna Kwiendacz, Poland

907 Improved glycaemic control in adults with type 1 diabetes using insulin pump therapy: results from the Finnish FinDiCon Register study

E. K. Pimiä, H. Vessari, T. Prami, E. J. Peltonen, I. Iso-Mustajärvi, M. Kalaoja, H. Luoto, I. Vauhkonen, T. Saukkonen, Finland

908 Focussing on engagement provides an opportunity for equity of outcomes: no deterioration in glycaemic outcomes in young people aged 15 to 25 years

J. Elliott, Sheffield Diabetes Transition and Young Adult Team, UK

909 Implementation of an informatics based data-led prioritisation strategy to facilitate objective and equitable care for an ethnically diverse urban cohort of people with type 1 diabetes

P. Pavlou, T. Johnston, S. Keane, O. French, R. Hyslop, D. Kariyawasam, A. Brackenridge, L. Yuk Fun, S. Thomas, J. Karalliedde, UK

910 Real world results from the first 1'852 European INPEN™ smartMDI system users: association between user behaviour and outcomes

A. Laurenzi, S. Edd, P. Adolfsson, B. Völker, F. Di Piazza, M. Smith, T. Van den Heuvel, O. Cohen, Italy, Switzerland, Sweden

911 Effect of telemonitoring using connected devices on insulin injection adherence in people living with type 2 diabetes

T. Kronborg, S. Hangaard, N. V. Hartvig, A. Kaas, S. N. Kristensen, R. Kosmina, P. Vestergaard, Denmark

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

912 Greater decline in fasting C-peptide predicts better glycaemic remission after short-term intensive insulin therapy in newly diagnosed type 2 diabetes

Q. Chen, L. Liu, W. Ke, J. Ma, X. Li, F. Wei, Y. Li, China

913 Predictive value of clinical profiles and fasting plasma C-peptide for future insulin therapy in non-insulin-deficient Chinese patients with type 2 diabetes: a register-based cohort study

Y. Fan, B. Fan, E. S. Lau, C. K. Lim, H. Wu, E. W. Chow, R. C. Ma, A. P. Kong, E. Chow, J. C. Chan, A. O. Luk, Hong Kong

GENERAL
INFO

914 Evaluation of AI-based diabetic retinopathy screening in real-world settings

L. Berrada, L. Crenier, M. Lytrivi, A. Burniat, E. Motulsky, M. Cnop, Belgium

PROGRAMME

TUESDAY

Short Oral Event A

Tuesday, 12:00 - 13:00

WEDNESDAY

SO 085 It's getting complicated

Chair: Bogdan Timar, Romania

THURSDAY

FRIDAY

915 What are the modifiable and unmodifiable hypoglycaemia risk factors for type 2 diabetes patients? Implications for clinical practice

M. M. Teh, A. L. Ang, Y. M. Bee, S. Y. Goh, J. C. Choo, Singapore

SHORT ORAL
DISCUSSIONS

916 Individuals with higher HbA_{1c} experience a greater proportion of symptomatic patient reported hypoglycaemia at sensor glucose levels above 4mmol/L: analysis of the Hypo-METRICS study

J. J. Thomas, G. Martine-Edith, V. Koutroukas, P. Choudhary, UK

PRESENTER
INDEX

917 Assessment of autonomic and sensory nervous system function in patients with type 1 diabetes using CGM or AHCL insulin pump

S. Nyiraty, Z. Pecze, B. Bordács, K. Kupai, A. Vágvölgyi, C. Lengyel, P. Kempler, T. Várkonyi, Hungary

SATELLITE
SYMPOSIA

918 Beyond insulin: evaluating sitagliptin for early diabetic nephropathy in type 1 diabetes on advanced closed-loop therapy

N. Elbarbary, E. Abdelrahman Ismail, M. Hamed El-Hamamsy, M. Zaki Ibrahim, A. Abdel Moneim Elkholy, Egypt

INDUSTRY

PROGRAMME

EXHIBITION

919 Quantitative super-resolution ultrasound imaging reveals multidimensional hippocampal microvascular alterations associated with glycaemic fluctuations in type 2 diabetes

S. Wang, Z. Deng, N. Guo, C. Hua, China

THANKS

920 Personalised postprandial glycaemic responses to daily meals and their implications for diabetes prevention: effects of macronutrient composition and gut microbiota in a real-world Korean cohort

S. Ryang, Republic of Korea

921 A tension offloading patch remodels long-standing lipohypertrophy

J. DeVries, S. Famulla, M. Stoffel, H.-V. Coester, J. Guo, H. E. Talbot, L. Hirsch, K. Lipman, J. Jackson, Germany, USA

922 Glucose-responsive nanopolymer for insulin delivery: a potential approach to long-term glycaemic control

A. Roointan, S. Bhangu, F. Cavalieri, F. Caruso, M. Cooper, R. Xu, C. Hagemeyer, Australia

Short Oral Event B

Tuesday, 13:15 - 14:15

SO 086 “Don’t leave me alone”, insulin said

Chair: Joao-Filipe Raposo, Portugal

923 Insulin treatment in type 2 diabetes in Finland: reasons behind poor glycaemic control

H. Vessari, M. Pölkki, L. Nieminen, K. Lahti, S. Fernelius, I. Iso-Mustajarvi, I. Vauhkonen, Finland

924 Reasons for insulin dose deviations in people with type 2 diabetes undergoing telemonitoring

J. T. Nørlev, T. Kronborg, M. Jensen, P. Vestergaard, S. Hangaard, Denmark

925 Data-driven assessment of basal insulin adherence in people with type 2 diabetes

J. Nørlev, T. Kronborg, M. Jensen, P. Vestergaard, S. Hangaard, Denmark

926 The efficacy and safety of iGlarLixi in insulin-naïve adults with type 2 diabetes by baseline A_{1c} and diabetes duration: posthoc analysis of Soli-CGM

A. Ratzki-Leewing, V. Shah, H. Thacker, A. M. Alguwaihes, S. Dagdelen, A. Alvarez, F. Lauand, L. Melas-Melt, A. Cheng, USA, India, Saudi Arabia, Türkiye, Spain, France, Canada

927 Improved glycaemic control with IDegLira in Chinese adults with type 2 diabetes in a real-world setting: a retrospective cohort study

B. Sun, L. Chen, S. Wang, Z. Shen, X. Zhong, D. Zhu, China

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

928 Early glycaemic improvement when switching to iGlarLixi from premixed insulins in adults with type 2 diabetes: a post hoc analysis of Soli-SWITCH

M. Haluzík, F. Lauand, K. Djaballah, L. Melas-Melt, M. Azzouz, M. Almehtel, S. Jib Yoo, J. Kesavadev, R. Sari, Czechia, France, Algeria, Canada, Saudi Arabia, Republic of Korea, India, Türkiye

929 Glycaemic outcomes when switching to iGlarLixi from premixed insulin (PI) in adults with type 2 diabetes by iGlarLixi pen subgroups: post hoc analysis of Soli-SWITCH

F. Lauand, M. Haluzík, S. Servera, L. Melas-Melt, K. Cypryk, M. Al Mehthel, J. Kesavadev, R. Sari, France, Czechia, USA, Poland, Saudi Arabia, Canada, India, Türkiye

930 Impact of time of injection on the efficacy and safety of iGlarLixi vs IDegAsp in Chinese people with type 2 diabetes: exploratory analysis of the Soli-D study

X. Li, J. Wang, T. Liu, A. Alvarez, F. Lauand, L. Melas-Melt, L. Kang, Q. Du, X. Wang, M. Liu, J. Rosenstock, China, Spain, France, USA

Short Oral Event C

Wednesday, 11:45 - 12:45

SO 087 CGM: replacing low glucose with low cost

Chair: Peter Novodvorsky, Slovakia

931 Characterising glycaemic management and severe hypoglycaemia in adults with type 1 diabetes using diabetes technologies in Belgium: a post-hoc analysis of 3 CGM trials

L. Valgaerts, E. Yu, S. Zhang, J. Sherwood, A. DeRemigis, J. De Meulemeester, M. Visser, P. Gillard, Belgium, USA

932 Exploring factors that affect the proportion of sensor hypoglycaemic events <3.9mmol/l that become level 2, in type 1 and insulin-treated type 2 diabetes: Hypo-METRICS study

V. Koutroukas, A. Tziannou, J. J. Thomas, G. Martine-Edith, P. Choudhary, Hypo-RESOLVE Consortium, UK

933 Interstitial vs arterialised-venous glucose under experimental hypoglycaemia in type 2 diabetes

M. Arshad, S. Berry, S. Haughton, E. McNally, H. Casbolt, W. Parker, H. McMellon, I. Rombach, I. Goodman, S. Heller, R. Storey, A. Iqbal, UK

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

934 The impact of a 3-month treatment with oral semaglutide on glycaemic variability assessed by CGM in prediabetic and obese patients: an interventional study

M. Szablowski, A. Paszko, A. Citko-Rojewska, P. Konopka, L. Szczerbinski, A. Kretowski, Poland, USA

935 Continuous glucose monitors for people with type 2 diabetes not on insulin: budget impact analysis from a Medicaid perspective

E. E. Wright, Jr, J. R. Gavin III, J. R. Rowes, A. Lee, Y. Poon, USA

936 Cost-effectiveness of real-time continuous glucose monitoring people with type 2 diabetes on insulin therapy in Japan

H. Alshannaq, J. Matuoka, G. J. Norman, S. Tanaka, USA, Japan

937 Early experiences with Stelo: real-world behavioural and glycaemic outcomes in users with type 2 diabetes, prediabetes, or no diabetes

M. Crawford, A. Monroy, A. Carite, Y. Benitz, H. Singh, USA

Short Oral Event D

Wednesday, 13:00 - 14:00

SO 088 Diabetes in cyberspace

Chair: Emir Muzurovic, Montenegro

938 Machine learning predicts type 2 diabetes incidence using basic clinical and laboratory parameters

A. Leiherer, L. Schnetzer, S. Mink, A. Mader, A. Muendlein, B. Bermeitinger, T. Plattner, A. Vonbank, B. Larcher, C. H. Saely, P. Fraunberger, H. Drexel, Austria, Liechtenstein

939 Machine learning identifies glypican 4 as key predictor of 5-year mortality in heart failure patients with prediabetes or diabetes

A. Leiherer, A. Muendlein, L. Schnetzer, S. Mink, C. Heinzle, E. Brandtner, K. Geiger, S. Gaenger, B. Bermeitinger, T. Plattner, A. Vonbank, A. Mader, C. H. Saely, P. Fraunberger, H. Drexel, Austria, Liechtenstein

940 Effect of telemonitoring on diabetes-specific quality of life in people with insulin-dependent type 2 diabetes

R. Knoph, S. Hangaard, T. Kronborg, P. Vestergaard, M. Jensen, J. Nørlev, Denmark

941 Insulin and glucose events analysis: experts vs artificial intelligence

A. Tolmach, L. Eshel, E. Roitman, N. Minsky, N. Fisch – Shvalb, J. Johnson, D. Duke, E. Dassau, Netherlands, Israel, USA

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

942 Diabetaid: an AI-driven clinical decision support system for personalised diabetes treatment

Ç. Akpınar, S. Topaloğlu, Y. Y. Ozan, O. B. Artaç, B. Kunaç, H. A. Güvenir, O. Topaloğlu, E. Y. Koroğlu, Türkiye

943 Explainable AI for personalised prediction of adherence to drug therapy in people with type 2 diabetes: a nationwide retrospective cohort

M. Kasher Meron, R. Taher, A. Berliner, E. Bachmat, D. Levinson, Israel

944 Forecasting long-range blood glucose in hospitalised type 2 diabetes patients: a comparative study of predictive modelling techniques

L. Alzebdeh, J. Zhang, R. Greiner, A. Lam, Canada

945 Tracking treatment outcomes using the semaglutide patient support solution app

V. Lambadiari, A. Kaas, R. Kosmina, J. H. Martiny, P. Priyadarshini, D. Klonoff, Greece, Denmark, USA

Short Oral Event E

Thursday, 12:45 - 13:45

SO 089 Doesn't CGM mean "Can Get Motivated"?

Chair: Tsvetalina Tankova, Bulgaria

946 Chronotypes of glycaemic vulnerability: time-based risk stratification in diabetes using continuous glucose monitoring

A. Shaikh, S. Singla, S. Patil, A. Saxena, A. Maheshwari, A. Raghunandan, India

948 Efficacy of continuous glucose monitoring using FreeStyle Libre 3 in type 2 diabetes managed with basal insulin plus SGLT2 inhibitor and/or GLP-1 agonist: the FreeDM2 randomised controlled trial

E. G. Wilmot, P. Moore, T. Sathyapalan, P. Choudhary, J. Lim, S. Neupane, A. Iqbal, M. L. Evans, G. Rayman, H. C. Price, R. A. Ajjan, K. Barnard-Kelly, T. Yates, L. Leelarathna, FreeDM2 Study Group, UK

949 Impact of real-time continuous glucose monitoring (rt-CGM) devices among insulin-treated type 2 diabetes patients in France

M. Van Genugten, N. Shigesu, R. Kapnang, N. Quignot, K. Kikuchi, G. Norman, N. Chevalier, Netherlands, UK, France, USA

950 Glucowear: clinical trials and real-life results of a non-invasive wearable blood glucose monitor

D. J. Fowles, M. R. Qureshi, C. Handy, B. Love, I. C. Masso, J. A. Ryan, J. A. Ogborne, M. L. Wilson, M. S. Chaudhry, UK

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

951 Continuous glucose monitoring in insulin-treated commercial pilots within the European diabetes protocol: a prospective multicentred observational study

G. L. Garden, F. Shojaaee-Moradie, G. Koehler, E. J. Hutchison, B. M. Frier, K. M. Shaw, S. R. Heller, G. A. Roberts, J. M. Mader, D. L. Russell-Jones, EASA Diabetes Consortium, UK, Austria, Ireland

952 User reported outcome and alert performance of the iCan CGM system in a pediatric population

J. Zheng, J. Fei, F. Gao, A. Gao, Q. Zhou, F. Flacke, W. Haiying, D. Shuxia, O. Wenxian, China

953 Addressing the shortfalls of glucose management indicator (GMI) and glycated hemoglobin (HbA_{1c}): validation of updated GMI and personalised A_{1c}

R. Ajjan, Y. Xu, T. Dunn, P. Choudhary, R. Bergenstal, UK, USA

Short Oral Event F

Thursday, 14:00 - 15:00

SO 090 Prediction and treatment of diabetes-related kidney complications

Chair: Susanne Kaser, Austria

954 Regenerating protein Ia predicts diabetic kidney disease progression: a prospective cohort study

N. Huang, X. Huang, Q. Shen, L. Chen, L. Li, China

955 Key factors associated with rapid eGFR decline in two ethnically different cohorts of individuals with type 1 diabetes diabetes

R. Lithovius, M. Özdede, S. Ayis, E. Valo, S. Mutter, P.-H. Groop, L. M. Thorn, J. Karalliedde, N. Sandholm-Lafferre, Finland, UK, Türkiye

956 Temporal changes in kidney function in youth with type 1 diabetes during transition from paediatric to adult care

J. M. Forbes, U. Pham, A. Fotheringham, N. D'Silva, J. Nisbet, S. Teasdale, D. W. Johnson, H. Barrett, L. Phillips, Australia

957 Predictions of onset and progression of albuminuria and kidney failure in type 1 diabetes by proteomics

S. Mutter, E. Dahlström, X. Luo, E. Valo, V. Harjutsalo, P.-H. Groop, N. Sandholm, FinnDiane Study Group, Finland, Australia

958 GLP-1 receptor agonists and prevention of chronic kidney disease in type 2 diabetes: multicentre emulated target trials

C.-M. Hwu, F.-S. Ko, F.-S. Yen, J.-H. Yang, C.-C. Hsu, J.-Y. Huang, J.-C. Wei, Taiwan

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

959 Re-evaluating the albuminuria-eGFR relationship using genetics for precision monitoring: the READ-GEN study

T. S. Ahluwalia, C. H. Naaman, P. Rossing, T. W. Hansen, Denmark

960 Role of body mass index variability an index of ‘cardio-metabolic cycling’ on progression of kidney disease in people with type 1 diabetes

M. Ozdede, P. Pavlou, S. Ayis, J. Karalliedde, UK

961 Impact of oral semaglutide on renal outcomes in type 2 diabetes: insights from a multicentre real-world cohort: Renal_ENDO2S-RWD substudy

O. Moreno-Perez, R. Reyes, C. Guillén-Morote, V. Doulatram-Gamgaram, C. Casado Cases, N. Arias Mendoza, C. Tejera-Pérez, J. Cárdenas-Salas, S. Martínez-Fuster, B. Largiés-Sánchez, R. Márquez Pardo, P. Pinés, A. Tejera-Muñoz, J. Fernandez Garcia, I. Modrego-Pardo, Spain

962 Prediction of renal disease using cystatin C as a serum biomarker versus serum creatinine in hospitalised diabetic patients

J. Rodríguez Despradel, M. De León Céspedes, E. Cuevas Del Rosario, Dominican Republic

Short Oral Event A

Tuesday, 12:00 - 13:00

SO 091 Basic insights in diabetes-related kidney complications

Chair: Assaad A. Eid, Lebanon

963 Tubule-specific VHL gene ablation protects against diabetic kidney disease

X. Zheng, Y. Iwamura, J. Grünler, C. Xu, S. Eliasson Angelstig, S. Narayanan, T. Gardovic, B. Yan, A. Zhao, N. Suzuki, F. Palm, S.-B. Catrina, Sweden, Japan

964 Study on the mechanism of ELA regulating metabolic reprogramming in renal tubular epithelial cells via C/EBP β -mediated MRPL12 to improve diabetic kidney fibrosis

Z. Wang, China

965 Role of the NLRP3 inflammasome in peripheral immune cells and the therapeutic potential of ND-13 in diabetic nephropathy

C. Arias Sánchez, M. Caballero Herrero, E. Guillén, I. Quevedo, A. Núñez Sancho, D. Angosto, P. Pelegrín, S. Cuevas, Spain

966 Fecal microbiota transplantation improves diabetic kidney disease by regulating gut tryptophan metabolism

Y. Zeng, M. Guo, Q. Wu, F. Teng, B.-K. Law, Y. Long, Y. Xu, China

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

967 Blocking neuroblastoma suppressor of tumorigenicity 1 (NBL1) prevents diabetic kidney disease

A. Petrazzuolo, E. Assi, A. Maestroni, V. Usuelli, M. Zocchi, G. Rossi, I. Pastore, A. Monestiroli, M. Ben Nasr, F. D'addio, A. Krolewski, P. Fiorina, Italy, USA

968 Genetic deletion of NOX5 provides renoprotection in a rabbit model of diabetic kidney disease

F. Liu, K. Jandeleit-Dahm, M. Cooper, J. Jha, Z. Chai, J. Yang, E. Ran, X. Li, Q. Yang, China, Australia

969 Pericyte-specific MDM2 knockout alleviates renal injury and inflammation in diabetic nephropathy mice

Z. Xu, Y. Chen, C. Zhang, H.-P. Hammes, A. Linkermann, J. Lin, Germany, China

970 Finerenone alleviates diabetic nephropathy by improving lipid metabolism reprogramming of renal tubular epithelial cells

H. Guo, J. Wang, B. Sun, L. Chen, China

Short Oral Event B

Tuesday, 13:15 - 14:15

SO 092 Biomarkers in diabetes-related kidney complications

Chair: Stefan Mutter, Finland

971 TNF α , TNF receptors and their role in progression of diabetic kidney disease and incidence of cardiovascular events in type 2 diabetes

M. Giambalvo, D. Lucchesi, M. Capobianco, G. Mancini, G. Di Cianni, S. Del Prato, P. Marchetti, G. Penno, M. Garofolo, Italy

972 Unravelling diabetic kidney disease: the mitochondrial and immune cell connection

T. Zhang, USA

973 Proenkephalin as a predictor of renal function and major adverse renal events in patients with chronic kidney disease

M. Würfel, L. Pirlich, R. Schürfeld, A. Bachmann, J. Breifeld, R. Wendt, R. Baber, I. Bast, J. Beige, B. Isermann, P. Kovacs, M. Blüher, M. Stumvoll, A. Tönjes, T. Ebert, Germany

974 The effect of combined assessment of urinary L-FABP and urinary albumin in the evaluation of diabetic kidney disease in Japanese patients with type 2 diabetes

H. Satoh, N. Sasatsuki, S. Nakamura, A. Haba, N. Sekine, A. Mochida, T. Katahira, D. Sugimoto, Japan

975 The research on the impact of dysregulated gut microbiota on ferroptosis in renal fibrosis associated with diabetic kidney disease

H. Yuan, S. Tang, S. Zhang, China

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

976 Association of serum total bilirubin to cholesterol ratio with progression of chronic kidney disease in patients with type 2 diabetes: a retrospective cohort study

L. Chen, Y. Chen, S. Wang, H. Guo, F. Han, B. Sun, N. Li, H. Yang, China

977 Dynamics of oxidative stress markers in patients with type 2 diabetes at high risk of CI-AKI during endovascular radiographic contrast procedures

S. Muminova, L. Daminova, B. Nigmonov, Uzbekistan

978 Renotruue: a machine learning model to better estimate glomerular filtration rate for people with diabetes

R. Kwok, K. Kishore, T. Zafari, D. Koye, M. Hachem, I. H. De Boer, T.-D. Jeong, W.-K. Min, E. Porrini, P. Bjornstad, T. Chung, R. MacIsaac, L. Churilov, E. Ekinci, Australia, USA, Republic of Korea, Spain, Singapore

979 Prognostic significance of stress hyperglycaemia ratio for renal outcomes in patients with type 1 diabetic nephropathy

Y. Wang, China

Short Oral Event C

Wednesday, 11:45 - 12:45

SO 093 Animal and cell culture models of diabetes-related kidney complications

Chair: Jaroslawnna Meister, Germany

980 Pericyte MDM2-knockout inhibits renal fibrotic damage in diabetes

J. Lin, Y. Chen, Z. Xu, U. Wenzel, H.-P. Hammes, A. Linkermann, Germany, China

981 USP15 K39 crotonylation drives renal tubular inflammation via TAB2 stabilisation in diabetic kidney disease

C. Zhang, Y. Luo, M. Kou, China

982 Mechanistic study on the pathogenic role of cell division autoantigen 1 in diabetic kidney disease in Akita mice

M. Huang, J. Tang, T. Wu, M. Cooper, Z. Chai, Australia

983 Tau hyperphosphorylation causes functional and structural damage in diabetic kidney disease

E.-Y. Lee, E.-S. Lee, J.-S. Kang, S.-H. Jo, C.-H. Chung, Republic of Korea

984 RAGE antagonism restores immune homeostasis and improves kidney function in an outbred CD-1 mouse model of diabetic kidney disease

S. Zambre, R. O. Whiddett, D. A. McCarthy, C. Du, E. Tejo, J. D. Loaiza Naranjo, I. Buckle, J. Forbes, A. Fotheringham, Australia

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

985 Pharmacological benchmarking of a renin-angiotensin system inhibitor and a dual sodium-glucose transport protein inhibitor in a non-human primate model of diabetic nephropathy

F. P. De Villa, Z. Zhu, Y. Yong, L. Yang, R. M. Perez, China

986 Synergistic effect of Bisphenol A and high glucose on renal tubular oxidative stress and epithelial mesenchymal transition: an in vitro study

F. Raggi, C. Rossi, G. Pugliese, G. Gruden, A. Solini, Italy

Short Oral Event D

Wednesday, 13:00 - 14:00

SO 094 New in the treatment of diabetes-related kidney complications

Chair: Anna Solini, Italy

987 Short-term treatment with a novel complex I ROS modulator improves mitochondrial respiration in renal cortex of diabetic mice

A. Aboolian, A. Romero, M. Ouwens, M. M. Taboada, J. Jha, O. Dürschmidt, C. Granata, N. Trinks, A. Dai, M. Roden, S. Urner, K. Jandeleit-Dahm, J. Meister, Germany, Austria, Ireland, Australia

988 Association between polypharmacy and renal function decline in older adults with diabetes kidney disease: a cross-sectional study in Vietnam

T. X. Nguyen, L. H. Ha, H. T. Vu, T. N. Thuy, Viet Nam

989 SGLT2 inhibition modulates fate of cells of renin lineage in kidney disease

L. A. Van der Pluijm, J. A. De Klerk, A. Koudijs, J. I. Rotmans, K. W. Gross, R. Bijkerk, Netherlands, USA

990 Effect of ursodeoxycholic acid as a reno-protective agent in people with type 1 diabetes and residual albuminuria despite renin angiotensin system inhibition

P. Pavlou, N. Fountoulakis, S. Ayis, F. Ibrahim, A. Corcillo, D. Stathi, L. Gnudi, J. Karalliedde, UK

991 Enhanced renal protective effects of Tirzepatide in type 2 diabetes people

S. Kaneko, A. Nakasaki, T. Hirobata, Japan

992 Beyond albuminuria: effects of SGLT2 inhibitors in type 2 diabetes patients with non-albuminuric proteinuria: a retrospective cohort study

M. Choi, M. Yu, H. Kim, M. Lee, Y.-H. Lee, E. Kang, B.-S. Cha, B.-W. Lee, Republic of Korea

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

993 Strategic management of blood pressure and serum albumin levels in older adults with diabetes-related chronic kidney disease

M. Yamazaki, Y. Kawai, Y. Shibata, M. Komatsu, Japan

994 Can we de-escalate pharmaco-therapies for certain patients living with type 2 diabetes and chronic kidney disease?

Z. Gabr, L.-A. Leger, S. Kidwai, A. Krentz, A. Jaun, Switzerland

995 Sodium glucose co-transporter 2 inhibitors and cardiorenal events in non-albuminuric kidney disease

C.-M. Hwu, F.-S. Ko, F.-S. Yen, J.-H. Yang, K. Chong, J.-C. Wei, J.-S. Liu, Y.-L. Wu, C.-M. Chen, C.-C. Hsu, Taiwan

GENERAL
INFO

PROGRAMME

TUESDAY

Short Oral Event E

Thursday, 12:45 - 13:45

SO 095 Epidemiology of diabetes-related kidney complications

Chair: Lena Thorn, Finland

996 The prevalence of kidney disease decrease in people with type 2 diabetes: the Diamant study

G. Nijpels, J. A. Overbeek, P. J. Elders, R. M. Herings, Netherlands

997 Developing a machine learning model to predict renal function decline within three years using one year longitudinal data in patients with type 2 diabetes

S. Meguro, M. W. Kaneda, K. Kimura, Y. Harada, M. Enomoto, K. Hayashi, Japan

998 A body shape index and chronic kidney disease risk: the mediating role of weight-adjusted waist index

J. Wen, K. Mutailipu, J. Cheng, Y. Zhao, C. Tong, J. Guo, J. Yin, L. Bu, China

999 Association between insulin use, type of diabetes, and mortality in patients on haemodialysis: a nationwide cohort study

J. Kim, S. Kim, S. Park, S. Cho, R. Oh, M. Jang, H.-J. Cha, Y.-B. Lee, G. Kim, S.-M. Jin, K. Hur, J. Kim, Republic of Korea

1000 Prevalence and risk factors of chronic kidney disease in individuals with type 1 diabetes: a population-based study in Salford, Manchester

H. Habte-Asres, M. Stedman, A. Forbes, D. Wheeler, A. Heald, UK

1001 Serum REG Ia as a predictor of early renal function decline in type 2 diabetes: a prospective cohort study

N. Huang, X. Huang, Q. Shen, L. Chen, L. Li, China

1002 Glycaemic control in ambulatory patients aged 80 and above with type 2 diabetes: benefits and risks

J.-H. Yang, Y.-K. Yeh, H.-S. Chen, Taiwan

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

1003 A correlation study between different urinary albumin-to-creatinine ratio (UACR) levels and pancreatic cell function in patients with type 2 diabetes

H. Guo, China

Short Oral Event F

Thursday, 14:00 - 15:00

SO 096 Clinical aspects of diabetes during pregnancy

Chair: Ilze Konrade, Latvia

1004 Association of Cesarean section delivery and increased neonatal cord C-peptide levels: evidence from a large population-based pregnancy outcome study

G. Firneisz, A. Nemes, L. Németh, Á. Nádasdi, Z. Benyó, Hungary

1005 Mediation of in-utero glycaemic status in association between maternal prepregnant overweight/obesity and trajectory of offspring's cardiovascular health

H. Wu, H. Tam, W. Tam, C. Ma, C. Wang, Hong Kong

1006 Type 1 diabetes in pregnancy: a comparative study of hybrid closed-loop systems, continuous glucose monitoring, and home blood glucose monitoring

S. Cadogan, A. McCarthy, D. Fennell, A. O'Higgins, J. L. Hogan, B. Kinsley, Ireland

1007 Inpatient use of automated insulin delivery during type 1 diabetes pregnancy including intrapartum and delivery: a secondary analysis from the AiDAPT trial

T. T. Lee, C. Collett, S. Bergford, S. Hartnell, E. M. Scott, R. S. Lindsay, K. F. Hunt, D. R. McCance, R. M. Reynolds, M. E. Wilinska, J. Sibayan, C. Kollman, R. Hovorka, H. R. Murphy, UK, USA

1008 Ethnic disparities, obesity and diabetes as predictors of mode of delivery in first births: insights from a tertiary centre in United Kingdom

P. Eng, E. Mullins, S. Lee, P. Phan, R. Agha-Jaffar, Singapore, UK, USA

1009 Pregestational BMI, age, insulin dose increase and time above range during pregnancy are related to delivering large to gestational age babies in type 1 diabetes

A. Juza, M. Dąbrowski, Poland

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

1010 Who benefits most from advanced hybrid closed loop therapy in pregnancy based on baseline characteristics? A secondary analysis of the CRISTAL trial

K. Benhalima, I. Geerts, N. Van Wilder, D. Ballaux, G. Vanhaverbeke, Y. Taes, X.-P. Aers, F. Nobels, J. Marlier, D. Lee, J. Cuypers, V. Preumont, S. Siegelaar, P. Gillard, C. Mathieu, Belgium, Netherlands

1011 Low blood glucose index: When and how to use it for prediction of large-for-gestational-age newborns in pregnancy with type 1 diabetes?

G. Leksic, M. Baretic, M. Ivanisevic, Croatia

1012 Cardiovascular disease risk profile in women with type 1 diabetes under pre-conceptual care and obstetric and neonatal implications (preliminary data)

K. Castillo, F. Migliorelli, M. Giménez, D. Roca, C. Figueredo, N. Anton, A. Amor, I. Vinagre, Spain

Short Oral Event A

Tuesday, 12:00 - 13:00

SO 097 Clinical aspects of gestational diabetes

Chair: Elisabeth R. Mathiesen, Denmark

1013 Novel subtypes of gestational diabetes and their associations with maternal and fetal outcomes: a data-driven cluster analysis in two ethnically diverse birth cohorts

M. Pigeys, W. Q. Deng, S. Azab, N. Shen, D. Desai, G. Pare, R. J. De Souza, S. Anand, Canada

1014 Impact of gestational diabetes on birth outcomes and early neurocognitive and motor development: findings from the PREG study

L. Semeia, J. Hartkopf, J. Sbierski-Kind, D. Löffler, S. Hülskämper, A. Vosseler, K. O. Kagan, A. L. Birkenfeld, A. Fritsche, H. Preissl, Germany

1015 Gestational diabetes affects umbilical cord blood plasma markers of cardiovascular stress: implications for endothelial function

C. Tocantins, E. Weiss, A. Rieder, J. Strutz, P. J. Oliveira, S. P. Pereira, U. Hiden, Austria, Portugal

1016 Postpartum dietary interventions and maternal cardio-metabolic profiles after pregnancies complicated by gestational diabetes: a systematic review and meta-analysis

A. Phee, R. Foo, C. Guivarch, P. Liu, R. Gneezy, J. Q. Tee, S. Shanmugan, J. Shen, C. Zhang, L.-J. Li, Singapore, USA

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

1017 Subtypes of gestational diabetes according to screening oral glucose tolerance test are associated with different clinical-metabolic features and neonatal outcomes

F. Citro, C. Bianchi, M. Aragona, T. Belcari, F. Galleano, C. Venturi, L. Battini, G. Penno, P. Marchetti, A. Bertolotto, Italy

1018 Associations between cardiorespiratory fitness and muscle strength with metabolic health outcomes and inflammatory parameters at 1-year postpartum in women with after gestational diabetes

D. Quansah, A. Arhab, A. Horsch, J. Puder, Switzerland

1019 Diabetes distress and glycaemic management in women with gestational diabetes

A. Munda, D. Pongrac Barlovic, Slovenia

1020 Beyond glycaemia: intrinsic fetal growth and maternal factors in high-risk gestational diabetes pregnancies in south east Asia

P. Eng, L.-C. Law, A. Teo, D. Lim, L. Tan, T. Yew, C. Khoo, Singapore

Short Oral Event B

Tuesday, 13:15 - 14:15

SO 098 Gestational diabetes: exciting new data

Chair: Jennifer Wyckoff, USA

1021 Comparison of adverse pregnancy between assisted and spontaneous conception among women with gestational diabetes: a secondary analysis of retrospective cohort data

M. Duraiswamy, H. Sagili, P. Rajandran, India

1022 Spexin as a novel biomarker: insights into glucose-lipid metabolism and gestational diagnosis

J. Zhang, K. Yu, J. Zhu, Y. Lu, Y. Lu, L. Chen, China

1023 Impact of integrated care for pregnancies complicated by diabetes in South Carolina

D. Fu, M. Leyva, M. Schellinger, B. Campbell, C. Cart, H. White, J. Britt, U. Lilavivat, M. Smith, J. Kimsey, M. Finneran, M. Manson, K. Hunt, T. J. Lyons, MOMs Diabetes Program of SC, USA

1024 Gestational diabetes and maternal and offspring neurocognitive dysfunction

C. W. Por, J. Ma, R. Hong, N. Yeo, M. Chen, Q. Tee, J. Shen, R. Gneezy, L.-J. Li, Australia, Singapore, USA

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

1025 Investigating gestational diabetes phenotypes through traditional biomarkers and their associations with foetal growth and neonatal outcomes: a data-driven cluster analysis

L.-J. Li, Y. Wang, Q. Yang, X. Wang, H. Qi, Singapore, China

1026 The effect of the treatment of gestational diabetes on foetal parameters and on maternal weight changes in Tolna County between 2009 and 2019: a population-based cohort study

A. Kun, G. Á. Visolyi, M. Svebis, I. Panykó, A. G. Tabák, Hungary, UK

1027 Comparison of pregnancy outcomes between recurrent and new onset gestational diabetes in multiparous women: a prospective cohort study

S. Pillutla, H. Sagili, J. Sahoo, R. K G, India

1028 Maternal and neonatal outcomes in women with recurrent gestational diabetes (RGDM): secondary analysis of a retrospective cohort

H. Sagili, M. Duraiswamy, P. Rajandran, India

1029 Disparities in gestational diabetes mellitus risk linked to natural environment: a double jeopardy

W. W. Takele, L. L. Dalli, R. Beare, K. Adhinugraha, D. Taniar, L. L. Knibbs, S. Mavoia, S. Lim, J. A. Boyle, Australia

Short Oral Event C

Wednesday, 11:45 - 12:45

SO 099 Biomarkers and mechanisms in diabetes and pregnancy

Chair: Lilian Mendoza, Spain

1030 Pancreatic beta cell plasticity: trans-differentiation of delta to beta cells during pregnancy

B. F. Thirunavuakarsu, E. J. Arany, D. J. Hill, Canada

1031 Maternal metabolic dysfunction reshapes offspring brain neurometabolic and energy balance pathways in a sex-dependent manner

A. Amaro, B. Prazeres, F. I. Baptista, M. Castelo-Branco, P. Matafome, Portugal

1032 The roles of autophagy in maintaining pancreatic beta cell homeostasis during pregnancy

S. Masaoka, Y. Nishida, S. Aoyama, H. Uzawa, H. Tsuchiya, A. Kanai, K. Ueki, F. Ikeda, H. Iida, M. Komatsu, A. Itakura, H. Watada, Japan

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

1033 Adenosine receptor A_{2A}R triggers endothelial nitric oxide synthase activation in gestational diabetes-derived neonatal endothelial progenitor cells

M. S. Diniz, E. Weiß, P. J. Oliveira, U. Hiden, S. P. Pereira, Portugal, Austria

1034 Impact of SOCS2 deficiency on cytokine profile in gestational diabetes and macrosomia

L. Hernández-Baraza, A. M. Wägner, L. Fernández-Pérez, L. Rodrigo-González, C. Recio, M. M. Díaz-Sarmiento, B. Guerra, Y. Brito-Casillas, Spain

1035 Expression of long non-coding RNAs MALAT1, MEG3, and XIST in gestational diabetes: a cross-sectional study

R. Bhattacharjee, B. K. Dey, S. Banerjee, P. Adhikary, S. Goswami, S. Roy, S. B. Roy, S. Chowdhury, India

1036 Role of Apelin during pregnancy and one year postpartum: the possible mechanism to understand the transition from gestational diabetes to type 2 diabetes

B. K. Dey, S. Roy, S. Chowdhury, S. Basu Roy, P. Jati, D. Biswas, T. C. Das, P. K. Sahana, R. Bhattacharjee, India

1037 Intrauterine programming in pregestational diabetes: does placental microbiota play a role?

C. Valverde Tercedor, J. Guillen Salgado, B. Bega Guedes, J. Alvarez Cuenod, F. Jroundi, L. Hernandez Baraza, Y. Brito Casillas, R. Vilchez Vargas, A. Wagner, Spain, Germany

1038 The role of MAS receptor in the prevention and treatment of polycystic ovary syndrome

X. Cao, W. L. Yang, L. N. Song, China

Short Oral Event D

Wednesday, 13:00 - 14:00

SO 100 Treatment and monitoring of gestational diabetes

Chair: Helen Murphy, United Kingdom

1039 Association of gestational weight gain with adverse pregnancy outcomes in gestational diabetes pregnancies: a secondary analysis of data from a retrospective cohort

N. Patel, H. Sagili, P. Rajandran, India

1040 Nutritional status and glucose metabolism in pregnant women following bariatric surgery

W. Neibig, J. Nowak, A. Mayadali, M. Hildebrand, S. Wollersheim, P. Wagenlecher, A. T. Billeter, B. Müller-Stich, F. Billmann, U. Zech, J. Szendroedi, A. Sulaj, Germany, Switzerland

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

1041 Gestational weight gain disparities among ethnic and BMI groups: evaluating IOM guidelines in multicultural South Western Sydney

M. Manoharan, A. Hussian, V. Wong, Australia

1042 Metformin, insulin and metformin added to insulin for gestational diabetes

N. G. Asatiani, R. Kurashvili, E. Inashvili, E. Shelestova, S. Kublashvili, R. Kvanchakhadze, Georgia

GENERAL
INFO

1043 Early gestational diabetes (EGDM) vs late gestational diabetes (LGDM): maternal and neonatal outcomes in a retrospective cohort

H. Sagili, M. Duraiswamy, P. Rajandran, India

PROGRAMME

TUESDAY

1044 Comparison of pregnancy outcomes in women with diabetes diagnosed during pregnancy receiving combination of insulin and metformin vs insulin therapy alone: a prospective cohort study

S. Tiwari, H. Sagili, M. Duraiswamy, N. Plakkal, India

WEDNESDAY

THURSDAY

1045 Longitudinal NMR study of metabolites in gestational diabetes: pregnancy to 5-year follow-up

Y. Kober, L. Semeia, J. Hartkopf, D. Löffler, S. Hülskämper, A. Vosseler, A. Fritsche, N. Stefan, A. Birkenfeld, H. Preissl, C. Trautwein, J. Sbierski-Kind, Germany

FRIDAY

SHORT ORAL
DISCUSSIONS

1046 Dietary fiber modulates gut microbiota to improve maternal-offspring glucose metabolism in gestational diabetes

Y. Hu, H. Yuan, China

PRESENTER
INDEX

Short Oral Event E

Thursday, 12:45 - 13:45

SATELLITE
SYMPOSIA

SO 101 Diagnosis of diabetes-related neuropathy

Chair: Fabiana Picconi, Italy

INDUSTRY

1047 Perception threshold tracking: A measure of small fiber pathology?

M. Sjogaard, J. Lindgård Graversen, M. Madsen, P. Vestergaard, C. D. Mørch, J. Roeikjer, P. Karlsson, N. Ejskjaer, Denmark

PROGRAMME

EXHIBITION

1048 Association between the eGFRcys/eGFRcre ratio and diabetic polyneuropathy: a potential marker for sarcopenia in patients with diabetes

M. Motegi, T. Himeno, Y. Ishida, K. Tsuzuki, T. Hayami, K. Makoto, E. Miura-Yura, Y. Morishita, M. Kondo, T. Shin, Y. Kato, J. Nakamura, K. Maeda, H. Kamiya, Japan

THANKS

1049 Hearing, smell and taste function in people with and without diabetes

K. Wilk, M. Dąbrowski, K. Augustyn, Poland

1050 Serum phosphorylated neurofilament-heavy chain protein as a biomarker for peripheral neuropathy in type 2 diabetic patients: a case control study

F. Kyrillos, E. El-refaiy, R. Elzehery, H. A. Abd El-Hafez, Egypt

1051 Associations of nerve abnormalities and neuropathic pain with corneal nerve measures in prediabetes and type 2 diabetes

M. K. Borbjerg, S. Mokhtar, N. Sutedja, A. Koster, T. Berendschot, C. D. Mørch, N. Schaper, N. Ejskjaer, J. Roeikjer, Denmark, Netherlands

1052 Risk factors for corneal nerve fiber loss in Chinese patients with type 2 diabetes

L. Liu, L. Huang, X. Chen, China

1053 Altered expectation-driven modulation of pain perception in painful diabetic neuropathy: an fMRI study

S. Meftah, K. Teh, A. Anandhanarayanan, G. Sloan, M. S. Gonoo, I. D. Wilkinson, S. Tesfaye, D. Selvarajah, UK

1054 Neuropathy and chronic low-grade inflammation are associated with hearing loss in type 2 diabetes: sex-specific findings from the DD2 cohort

T. Olesen, J. Razay, J. Schmidt, M. Olsen, Denmark

Short Oral Event F

Thursday, 14:00 - 15:00

SO 102 Potential treatments of diabetes-related neuropathy

Chair: Abd Tahrani, UK

1055 The association between CGM-derived metrics and diabetic peripheral neuropathy in people with type 1 diabetes

M. Kulecki, A. Lemanska, D. Naskret, A. Uruska, S. Moska, I. Anderko, B. Lasowski, P. Haras, A. Grzelka-Wozniak, A. Araszkiwicz, D. Zozulinska-Ziolkiewicz, Poland

1056 Impairment of NK degranulation and angiogenic potential in patients with diabetic peripheral neuropathy

M. Palano, F. Riccio, L. Sambado, E. Tagliabue, M. Campanile, E. Durante, M. Fassan, P. Stefani, G. Chiorino, A. Grimaldi, A. Bruno, M. Sambataro, G. Spinetti, Italy

1057 Radio frequency resonant cavity therapy improves diabetic peripheral neuropathy

Z. Wu, Z. Sun, Z. Jing, H. Yin, H. Hu, China

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

1058 A formulation containing palmitoylethanolamide and phenolic compounds counteracts peripheral neuropathy in high-fat diet-induced obese and diabetic mice

S. Melini, C. De Caro, N. Navatti, N. Opallo, F. Comella, R. Russo, M. D'Angelo, G. Mattace Raso, C. Pirozzi, R. Meli, Italy

1059 Glucagon-like peptide-1 receptor agonist associated diabetic lumbosacral radiculoplexus and common peroneal neuropathies: a case-control evaluation

J. D. Triplett, M. V. Pinto, N. P. Young, N. P. Staff, C. S. Marathe, M. Horowitz, C. Pinto, R. S. Laughlin, K. Shouman, S. E. Berini, M. L. Mauremann, D. Dubey, J. N. Mandrekar, C. J. Klein, USA, Australia

1060 Dapagliflozin induces nerve fibre regeneration via the microRNA 146a5p, inflammasome pathway in subjects with type 2 diabetes

A. Mondal, P. Jati, B. K. Dey, S. Banerjee, C. Bose, P. K. Sahana, S. Naskar, R. A. Malik, S. Mukhopadhyay, India, Qatar

1061 Diabetic foot ulcer: value of bedside blind bone biopsy and bedside toe amputation practiced by a diabetologist on major inferior limb amputation incidence

F. Féron, J.-B. Julla, J.-L. Nguewa, J.-F. Gautier, J.-P. Kevorkian, France

Short Oral Event A

Tuesday, 12:00 - 13:00

SO 103 Pathophysiology of diabetes-related neuropathy

Chair: Christina Brock, Denmark

1062 The association between platelet morphological parameters and diabetic peripheral neuropathy in people with type 1 diabetes

M. Kulecki, S. Moska, D. Naskret, A. Uruska, A. Lemanska, I. Anderko, B. Lasowski, P. Haras, A. Grzelka-Wozniak, A. Araszkiwicz, D. Zozulinska-Ziolkiewicz, Poland

1063 PCSK9 dysregulation and corneal nerve damage in patients with type 1 diabetes

M. Ferdousi, A. Kamath, R. Pasha, A. Aspiyan, B. Bashir, S. Azmi, R. Malik, H. Soran, UK, Qatar

1064 Postural control in type 2 diabetes

M. D. Madsen, S. W. Pedersen, C. L. Svendsen, D. Arulanandam, J. L. Graversen, P. Vestergaard, J. Røikjer, N. H. Rasmussen, Denmark

1065 Diabetic peripheral neuropathy and associated microvascular complications in type 2 diabetes: insights from a Greater Manchester cohort

M. Ahmed, M. Mankumare, V. Malreddy, S. Azmi, J. Lim, UK

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

1066 Obesity and inflammation negatively impact small fiber neuropathy, assed by corneal confocal microscopy in autoimmune diabetes

L. D'Onofrio, P. Manni, A. Di Dario, F. Barbaro, F. De Vita, A. Carafa, V. Berna, R. Amendolara, R. Risi, A. Balena, E. Maddaloni, A. Lambiase, R. Buzzetti, Italy

1067 Evaluation of potential blood-based biomarkers of peripheral neuropathy in type 2 diabetes: a systematic review and meta-analysis

J. D. Triplett, S. El-Masri, C. S. Marathe, M. Horowitz, C. J. Klein, S. D. Bacchi, S. Vucic, Australia, USA

1068 Afro Diale: an investigation of diabetic foot ulcers in 10 different countries across African continent: a multi-centre observational study, PART 1 ulcer characteristics at baseline

R. Naemi, K. Dhatariya, Z. Abbas, UK, Tanzania, United Republic of

1069 Learning from the clinic and artificial intelligence: a possible predictive model for clinical suspicion of Charcot neuro-osteoarthropathy in the acute phase

F. Giangreco, R. Tintori, E. Iacopi, G. Aringhieri, S. Ortori, A. Piaggese, Italy

Short Oral Event B

Tuesday, 13:15 - 14:15

SO 104 Advancements in diabetes-related autonomic neuropathy

Chair: Rasa Verkauskiene, Lithuania

1070 Prevalence and associated factors of sexual dysfunction among female living with diabetes in Kenya: a multi-centre cross-sectional study

R. A. Mohamed, S. M. Sokwalla, O. A. Ale, M. V. Mukuni, J. G. Stower, T. E. Onsinini, N. M. Kisilu, F. N. Keli, A. W. Wairagu, N. A. Okech, N. N. Wakaba, E. Youm,, B. M. Ale, Kenya Diabetes Study Group, Kenya

1071 Nonlinear association between serum 25-hydroxyvitamin D and cardiac autonomic dysfunction in diabetic foot: a threshold effect on heart rate variability

M. Bai, D. Yan, X. Ran, Y. Gao, China

1072 Improvement of small fibre peripher nerve function after two years of treatment with antidiabetic drugs and/or lifestyle modification in prediabetes: the ePREDICE European trial

R. Gabriel, J. Tuomilehto, Spain, Finland

1073 Impact of vitamin B12 supplementation on electrochemical skin conductance in diabetic patients with peripheral neuropathy: a retrospective analysis

A. Hinduja, India

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

1074 Low-grade chronic inflammation and heart rate variability parameters in internally displaced individuals with type 2 diabetes and subclinical cardiac neuropathy

V. Serhiyenko, V. Segin, K. Moskva, A. Serhiyenko, Ukraine

1075 Cardiac autonomic neuropathy as an independent risk factor for diabetic sensorimotor polyneuropathy: insights from a cross-sectional and prospective cohort study

Z. Kender, D. Schmalzridt, L. Schimpfle, M. Roshan, L. Seebauer, H. Bartl, S. Herzig, T. Fleming, J. Szendroedi, S. Kopf, D. Tsilingiris, Germany, Greece

1076 Slow breathing and heart rate variability biofeedback in individuals living with diabetes: a systematic review

J. Mullen, M. Lehoux, E. Byrne, P. J. Dunne, T. Kyaw-Tun, J. Laiti, Ireland

Short Oral Event C

Wednesday, 11:45 - 12:45

SO 105 Treatment of diabetes-related retinopathy

Chair: Alicia Jenkins, Australia

1077 Automatic insulin delivery is associated with reduced retinopathy incidence compared with multiple insulin injections in type 1 diabetes: a prospective cohort study

L. Nattero Chávez, S. De Lope Quiñones, A. Quintero Tobar, E. De la Calle, H. Escobar-Morreale, A. Bayona, T. Ruiz Gracia, M. Luque-Ramirez, Spain

1078 Metformin eye drops improve early diabetic retinopathy in db/db mice through oxidative stress suppression and anti-inflammatory mechanisms

X. Geng, Y. Qiu, X. Zhang, Y. Zhao, Z. Xu, Y. Yang, China

1079 Efficacy of sodium-glucose cotransporter 2 inhibitor in mild diabetic macular edema: a sub-analysis from the COMET trial

R. Ishibashi, Y. Takatsuna, M. Koshizaka, T. Tatsumi, T. Baba, S. Yamamoto, K. Yokote, Japan

1080 Early vs late vitrectomy for vitreous haemorrhage associated with proliferative diabetic retinopathy: a single-centre comparison

Y. Li, China

1081 Prospective analysis of renal function changes in diabetic macular edema patients receiving intravitreal anti-VEGF therapy: findings from the COMET trial

T. Sakai, R. Ishibashi, M. Koshizaka, Y. Takatsuna, T. Tatsumi, T. Baba, S. Yamamoto, K. Yokote, Japan

GENERAL INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL DISCUSSIONS

PRESENTER INDEX

SATELLITE SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

1082 Re-examining the retinal neuroprotective effects of sitagliptin eye drops: lessons from glaucoma

P. Bogdanov, A. Duarri, M. Canz, D. Sabater, H. Isla-Magrané, A. Deàs-Just, C. Hernández, R. Simó, Spain

Short Oral Event D

Wednesday, 13:00 - 14:00

SO 106 Pathophysiology of diabetes-related retinopathy

Chair: David J. Preiss, UK

1083 Postload-fasting gap and its association with vascular complications: a population-based study

Z. Sun, X. Xu, D. Wang, S. Jaffar, U. Alam, S. Qiu, A. Garrib, China, UK

1084 Diaph1-rage binding as a potential therapeutic target in diabetes-triggered changes in retina and optic nerve: preliminary studies

J. K. Juranek, K. Zglejc-Waszak, P. Mizia, B. Kordas, K. Mukherjee, Poland, USA

1085 The impact of retinal screening with artificial intelligence and visualisation on patient motivation and metabolic outcomes in diabetes care

L. Ilavska, A. Ilavska, Slovakia

1086 Lipoprotein(a) in diabetic retinopathy progression and severity

S. Lampsas, A. Kountouri, E. Korakas, L. Pliouta, I. Chatziralli, V. Lambadiari, Greece

1087 Association of protein-derived toxic molecules and soluble vascular cell adhesion molecule with central macular thickness in diabetic retinopathy

S. Pramanik, C. Bose, A. Mondal, L. Mondal, India

1088 Metabolic memory in type 1 diabetes: long-term complications in patients with rapidly progressive diabetic retinopathy despite improved glycaemic control

J. Jefroykin, A. Benchimol, B. Dupas, P. Massin, J.-P. Riveline, J.-B. Julla, France

1089 Adaptive diabetes subtype assignment improves prediction of insulin secretion failure and diabetic retinopathy

M. Schön, O. Zaharia, C. Binsch, G. Bönhof, A. Strom, K. Prystupa, K. Bodis, I. Yurchenko, D. Mendez, Y. Karusheva, R. Guthoff, D. Ziegler, O. Kuss, M. Roden, R. Wagner, Germany

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

SO 107 Arterial hypertension: more than a risk factor in diabetes

Chair: Jelizaveta Sokolovska, Latvia

1090 Effectiveness and safety of telmisartan-amlodipine fixed-dose combination in Indian hypertensive patients with type 2 diabetes: a subgroup analysis from the TACT India real-world study

A. Sugumaran, A. Das, M. Tiwaskar, J. Abdullakutty, A. Pande, V. Kumar, F. Francis, N. Zalte, R. Iyer, S. Sawant, S. Mohanasundaram, India

1091 Impact of insulin resistance, central obesity, and glycaemic status on systolic blood pressure among 120,266 Mongolian adults: a cross-sectional analysis

O. Byambasukh, K. Enkhtugs, B. Bayartsogt, B. Dangaa, A. Khasag, O. Enebish, Mongolia

1092 Vascular mechanoreceptors magnetic activation, haemodynamic evidence, and potential applications in diabetic macro- and microvascular dysfunction

J. Gmitrov, Slovakia, Japan

1093 Silent hypertension in newly diagnosed type 2 diabetes: age-dependent prevalence and cardiovascular risk implications

S. Patil, S. Singla, A. Maheshwari, A. Saxena, D. Bagri, D. Sanghavi, D. Shah, D. Patil, D. Gajare, D. Ansari, S. Khot, N. Kumawat, D. Rathi, D. Gangurde, B. Saboo, India

1094 Association between grip strength and risk of metabolic multimorbidity in Chinese adults: a prospective cohort study

T. Gao, China

1095 Associations between dynamic change of Chinese visceral adiposity index and hypertensive co-morbidities in the middle-aged and elderly population: a Chinese prospective cohort study

J. Xu, Y. Chen, H. Li, X. Wu, China

1096 Hyperdynamic circulation in people with type 2 diabetes and obesity

S. Haugaard, R. Hadad, E. Malm, A. Hviid, P. Bonde, A. Sarac, A. Asmar, M. H. Domínguez, A. Sajadieh, Denmark

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONSPRESENTER
INDEXSATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

SO 108 Pathogenetic mechanisms in diabetes-related foot*Chair:* Joanna Gastol, Poland**1097 Ajuba-mediated activation of mitophagy regulates macrophage efferocytosis and promotes diabetic wound healing**

W. Deng, A. David G, L. Dai, S. Rui, F. Xiao, Y. Wang, China, UK, USA

1098 Platelet-derived exosomes promote angiogenesis in diabetic wounds via the Gdf15/Akt signalling pathway

S. Rui, W. Deng, F. Xiao, X. Li, B. Deng, J. Lu, D. Armstrong, China, UK, USA

1099 Upregulation of THSB1 and COL12A1 by miR-146a-5p inhibition in human dermal fibroblasts: implications for diabetic wound healing

N. Stanojevic, M. Petkovic, L. T. Dalgaard, Denmark

1100 PPARs mediated diabetic wound healing regulates endothelial cells mitochondrial function via sonic hedgehog signalling

F. Xiao, W. Deng, S. Rui, G. Huang, D. G. Armstrong, China, USA

1101 Deciphering bone microarchitecture in diabetic charcot neuroarthropathy of foot: a case control study

A. Rastogi, R. Dangwal, R. Kesavan, S. Seshabhattaru, U. N. Saikia, India

1102 AZGP1-mediated mitophagy regulates epithelialisation to enhance diabetic wound healing via PINK1 interaction

S. Rui, W. Deng, Q. Li, F. Xiao, W. Mou, A. David G, China, UK, USA

1103 Challenging inactivity in diabetes-related foot ulcers: the DFU-Ex study evaluates exercise for cardiovascular health in a high-risk diabetes population

C. J. Baker, D. Min, V. Chuter, S. Twigg, N. Johnson, Australia

1104 Multimodal approach to post-revascularisation monitoring among diabetes patients with peripheral artery disease in a tertiary high-risk foot clinic: outcomes at 6 months

S. Promislow, C. Speter, L. Borovoi, O. Tamir, Israel

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONSPRESENTER
INDEXSATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

SO 109 Diagnosis and treatment of diabetes-related foot*Chair:* Roberto Anichini, Italy**1105 Development and evaluation of fish-derived dECM-based 3D bioprinted patches for diabetic wound healing**

J. Moon, H. Lee, H.-S. Yi, Republic of Korea

GENERAL
INFO**1106 Lower limb amputations in patients with diabetes: survival, comorbidities and sex differences**

B. Radlinger, J. Blasinger, N. Köllenberger, V. Streitberger, L. Kopp, E. Bifano, F. Aziz, H. Sourij, G. Göbel, J. Klocker, S. Kaser, Austria

PROGRAMME

TUESDAY

1107 Combined point-of-care devices, DPN-check and SUDOSCAN, diagnose early DPN and predict diabetic foot ulceration and all-cause mortality: the Sheffield prospective study

M. Goonoo, D. Selvarajah, O. Binns-Hall, J. Vollert, G. Sloan, S. Caunt, D. Rao, S. Tesfaye, UK

WEDNESDAY

THURSDAY

FRIDAY

1108 Impact of changing diabetes management on cardiovascular mortality after diabetic foot amputation in the Northern Barcelona area

Á. Ortiz Zúñiga, O. Simo-Servat, J. Samaniego, R. Busquets, J. Royo, P. Gil, J. Amigo, A. Barrios, R. Simo, C. Hernandez, Spain

SHORT ORAL
DISCUSSIONS**1109 The impact of limb offloading on the skeleton condition in men with type 2 and type 1 diabetes during diabetic foot syndrome therapy**

B. Katra, S. Borys, B. Matejko, M. T. Matecki, Poland

PRESENTER
INDEX**1110 3D printed nano-hydrogel containing PRP for the treatment of diabetic wound healing**

A. Guan, H. He, China

SATELLITE
SYMPOSIA

INDUSTRY

1111 Prediction model of lower extremity deep vein thrombosis in patients with diabetic lower extremity ulcer

Y. Qiu, X. Geng, Q. Gao, Y. Zhao, Z. Xu, Y. Yang, China

PROGRAMME

EXHIBITION

1112 Diagnostic accuracy and inter-rater reliability of a simplified diabetes foot screening tool for use by minimally trained laypersons

K. Venkataraman, T. A. Kalhan, S. D. Avinashi, D. Natarajan, S. Chew, M. Manasi, W. Tan, C. Khoo, Singapore

THANKS

SO 110 Epidemiology and treatment of diabetes-related foot

Chair: Brij Mohan Makkar, India

1113 Bedside amputation surgery for isolated toe necrosis in diabetes units as an alternative to conventional amputation in surgery units

F. Féron, J.-P. Kevorkian, J.-B. Julla, N. Ghozlane, S. Ah Glele, C. Fourmont, J.-M. Petit, J.-F. Gautier, M. Didier, B. Bouillet, France

1114 Hand pathology in patients with type 1 diabetes: a case-control study

C. Sager La Ganga, F. Sebastián Valles, E. Carrillo Lopez, M. Tapia Sanchiz, V. Navas Moreno, M. Sampedro Núñez, M. Marazuela Azpiroz, J. Arranz Martín, Spain

1115 Metabolic decompensation parameters as predictors of mortality in diabetic foot patients

A. Piaggese, E. Iacopi, C. Goretti, L. Pieruzzi, F. Giangreco, Italy

1116 Diabetic foot patients aging and survival over 20 years of activity of a third-level specialized unit

A. Piaggese, E. Iacopi, C. Goretti, L. Pieruzzi, F. Giangreco, Italy

1117 Incidence and hospitalisation costs for amputations in the lower extremities during 2015-2020 in patients with diabetes: an observational, retrospective study from Sweden

M. I. Hellgren, L. Sundberg, U. Tang, Sweden

1118 The association of macro- and microcirculation with the efficacy of ATB therapy in patients with infected diabetic foot ulcers: DFIATIM study

V. Fejfarová, R. Jarošíková, P. Tůma, J. Polak, J. Mrázek, V. Wosková, S. Antalová, P. Beca, M. Dubský, D. Sojáková, A. Němcová, M. Petrлік, J. Mareš, K. Bebjaková, Czechia

1119 ¹⁸F-sodium fluoride positron emission tomography/computed tomography: a novel modality for diagnosis and monitoring of active charcot neuro-osteoarthropathy of foot in patients with diabetes

A. Rastogi, J. Ghosh, A. Subrhamanian, D. Arjunan, H. Singh, A. Sinha, S. K. Bhadada, India

1120 Impact of malnutrition on survival and amputation risk in patients hospitalised for diabetic foot ulcer: a retrospective single-center cohort study

N. Van Poppel, P. Lauwers, C. De Block, K. Wouters, E. Dirinck, Belgium

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

SO 111 Lipid and non-lipid drugs impacts on lipids, vascular tissues and outcomes*Chair:* Paul Welsh, UK**1121 Alirocumab is associated with fewer ischemic events in patients with or without diabetes and atherosclerotic cardiovascular disease and no prior events**

M. Castro Cabezas, D. L. Bhatt, L. Tokgozoglu, N. Marx, I. Khan, J. F. Tuñón, M. Vrablik, P. Perrone-Filardi, S. Gruber, M. J. Van Der Laan, K. E. Andrade, Z. Lou, K. Pol, K. Lee, K. Ray, Netherlands, USA, Türkiye, Germany, Spain, Czechia, Italy, Poland, UK

1122 Fenofibrate response in statin-treated subjects with well-controlled lipid profile is influenced by PPARA genetic variability: a precision medicine trial

M. Morieri, C. Boscaro, C. Fagarazzi, M. Marassi, A. Rodella, L. Migliozi, F. Amendolagine, E. Iori, M. Giordano, C. Pipino, C. Zambon, A. Doria, P. Fioretto, M. Albiero, G. Fadini, Italy, USA

1123 The Association between lipid-lowering drugs and the prevalence of sarcopenia: Korea National Health and Nutrition Examination Survey (KNHANES) 2008-2011

S. Kim, E. Park, S. Kwon, J.-H. Lee, Republic of Korea

1124 Dapagliflozin does not reduce LDL catabolism but modifies VLDL₁ catabolism in a more physiological way, in patients with type 2 diabetes

B. Vergès, L. Duvillard, A. Rouland, I. Simoneau, I. Regazzoni, L. Houbachi, J.-M. Petit, B. Bouillet, France

1125 Dose-dependent impact of cumulative low-density lipoprotein cholesterol exposure on cardiovascular risk in patients with type 2 diabetes: a nationwide cohort study in Korea

W.-Y. Lee, D.-J. Koo, E.-J. Rhee, Republic of Korea

1126 Impact of bempedoic acid on LDL-cholesterol management in patients with and without diabetes: insights from the MILOS study

K. G. Parhofer, I. Gouni-Berthold, J. W. Jukema, J. E. Van Lennepe, K. K. Ray, K. Koskinas, M. Averna, T. Stulnig, T. Vanassche, M. Lamparter, K. Wenz-Pöschl, R. Chhabra, M. D. Climente, X. Pinto, Germany, Netherlands, UK, Switzerland, Italy, Austria, Belgium, Spain

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONSPRESENTER
INDEXSATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

1127 Tirzepatide prevents palmitate-induced apoptosis, autophagy, and senescence in human cardiac progenitor cells

C. Colabufo, I. Calderoni, R. D’Oria, C. Caccioppoli, G. Palma, C. Tedesco, G. Santarpino, T. Bottio, A. D. Milano, A. Leonardini, A. Natalicchio, S. Perrini, A. Cignarelli, F. Giorgino, L. Laviola, Italy

1128 Blocking of mineralocorticoid signalling reduces atherosclerosis in hyperglycaemia-induced ApoE knockout mice without altering glycolipid metabolism

H. Iwamoto, J. Sanada, T. Kimura, K. Dan, T. Sugisaki, Y. Iwamoto, M. Shimoda, S. Nakanishi, T. Mune, K. Kaku, H. Kaneto, Japan

Short Oral Event D

Wednesday, 13:00 - 14:00

SO 112 Novel lipid and lipoprotein insights

Chair: Sophia Zoungas, Australia

1129 Impact of Friedewald vs Martin-Hopkins equations on LDL-C estimates and target achievement in a diabetic population of inpatients

U. Capece, C. Iacomini, S. Patarnello, C. Masciocchi, A. Cesario, S. Gugliandolo, C. Morciano, G. Di Giuseppe, G. Ciccarelli, M. Brunetti, L. Soldovieri, T. Mezza, F. Cinti, A. Giaccari, N. Di Giorgi, Italy

1130 Cholesterol-efflux capacity is associated with indirect markers of insulin resistance: exploratory data from the InLipoDiab1 study

M. Mietkiewska-Dolecka, A. Zawiejska, A. Rohatgi, A. Grzelka-Wozniak, J. Flotyńska, M. Kulecki, D. Zozulinska-Ziolkiewicz, A. Uruska, Poland, USA

1131 Lipoprotein(a) levels and long-term risk in diabetics

I. Kamel, A. Mahmoud, S. Esteghamati, A. Esteghamati, USA, Iran, Islamic Republic of

1132 Post 1 mg dexamethasone suppression test cortisol elevations predict significant impairment in postbariatric surgery glucose metabolism: a retrospective longitudinal cohort study

F. De Domenico, O. Lanza, V. Zanghi Buffi, S. Manfrini, D. Tuccinardi, Italy

1133 Obesity and higher HbA_{1c} levels are independently associated with impaired cholesterol uptake capacity of HDL in patients with type 2 diabetes

T. Otsuka, K. Kato, H. Jinnouchi, M. Nagao, Japan

1134 Glycation of apolipoprotein A-I by methylglyoxal does not affect acute inflammation but can promote oxLDL-induced innate immune memory

X. Zhang, D. Mikolajetz, J. Hermann, J. Jankowski, K. Wouters, C. Schalkwijk, E. P. Van der Vorst, Germany, Netherlands

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

1135 Associations of the hs-CRP/HDL-C ratio with incidence of cardiovascular events among adults with type 2 diabetes

M. Garofolo, M. Giambalvo, D. Lucchesi, M. Capobianco, G. Mancini, G. Di Cianni, S. Del Prato, P. Marchetti, G. Penno, Italy

1136 The correlation analysis between trajectory patterns of triglyceride-glucose index and its combination with obesity index and ASCVD in patients with type 2 diabetes

L. Men, L. Qiao, N. Wang, J. Du, China

GENERAL
INFO

Short Oral Event E

Thursday, 12:45 - 13:45

PROGRAMME

SO 113 Endothelial interaction in diabetes

TUESDAY

Chair: Sindre Lee-Ødegård, Norway

WEDNESDAY

1137 Effects of semaglutide and empagliflozin on markers of endothelial function in persons with type 2 diabetes: a post-hoc analysis of a randomised trial

S. Gullaksen, L. Vernstrøm, S. Sørensen, K. Funck, P. Poulsen, E. Laugesen, Denmark

THURSDAY

FRIDAY

1138 Defining the vascular niche of human adipose tissue across metabolic conditions

I. AlZaim, M. N. Hassan, L.-C. Conradi, A. Luttun, C. Hagberg, J. Heeren, A. Etzerodt, E. D. Rosen, L. Massier, M. Rydén, M. Blüher, B. Sheikh, N. Jessen, L. P.M.H. de Rooij, J. Kalucka, Denmark, Germany, Belgium, Sweden, USA, Austria

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

1139 Heterogeneity of human endothelial cells from subcutaneous adipose and skeletal muscle tissue in type 2 diabetes

A.-F. Bruns, C. W. Cheng, A. Skromna, C. Luk, N. Makava, O. I. Brown, K. I. Bridge, K. K. Witte, M. T. Kearney, UK

SATELLITE
SYMPOSIA

INDUSTRY

1140 microRNA-210 in red blood cells differentially regulates vascular endothelial function between type 1 and type 2 diabetes

T. Jiao, J. Tengbom, E. Kontidou, R. Humoud, M. Alvarsson, K. Manickam, J. Yang, A. Mahdi, A. Collado, J. Pernow, Z. Zhou, Sweden

PROGRAMME

EXHIBITION

1141 Therapeutic role of genetically modified BM-MSC derived exosomes in rescuing endothelial cells damaged in hyperglycaemia

S. Sen, S. Nandula, USA

THANKS

1142 Heterogeneity of endothelial dysfunction in multiple organs at single-cell level during diabetes: a MIDY pig model study

A. S. Nadukkandy, S. Kalaiselvan, A. N. Schou, S. Renner, L. Dokshokova, I. Alzaim, J. Kalucka, E. Wolf, Y. Luo, L. Lin, Denmark, Germany

1143 Blocking EndMT in diabetes: insights from diabetic patient serum and AP-1 inhibition

A. Waheed-Khan, M. Aziz, K. Sourris, J. Pinzoncortes, K. Jandeleit-Dahm, Australia, Germany

1144 METTL3/YTHDC1 axis-mediated m6a modification of foxo1 mRNA promote endothelial autophagic apoptosis in diabetic atherosclerosis

X. Wu, Y. Zhao, L. Tang, H. Zhang, X. Liu, H. Zhang, X. Chen, China

Short Oral Event F

Thursday, 14:00 - 15:00

SO 114 All things immune

Chair: Eva M. Bru-Tari, Switzerland

1145 Low-grade inflammation does not mediate the associations between the n-3 polyunsaturated fatty acids and CVD in participants with and without type 2 diabetes: The Maastricht Study

E. C. Tore, A. M. Briones, R. M. Bruno, J. Dalli, S. J. Eussen, C. G. Schalkwijk, M. M. Van Greevenbroek, Netherlands, Spain, France, UK

1146 Effect of colchicine on vascular inflammation in patients with type 2 diabetes: results from a randomised placebo-controlled FDG-PET/CT study

J. M. Baier, K. Funck, A. Dons-Jensen, O. Munk, A. H. Dias, L. C. Gormsen, E. Laugesen, P. L. Poulsen, Denmark

1147 Profiling gene expression and immune cell abundance of atherosclerotic plaques in patients with impaired glucose metabolism and type 2 diabetes

A. Antonucci, L. Antonetti, M. Cardellini, F. Davato, T. Mazza, A. Napoli, V. Casagrande, R. Menghini, E. Martelli, C. Menzaghi, R. Di Paola, V. Trischitta, M. Federici, Italy

1148 A novel immuno-metabolic therapy for type 2 diabetic cardiomyopathy

P. Yavari, J. Choi, M. Pervin, J. De Haan, Australia

1149 Prognostic value of IL-6, NT-proBNP, and TNF- α biomarkers in predicting mortality and assessing platelet functionality in type 2 diabetes patients with cardiovascular complications

A. Nowak-Szwed, C. Eyileten, Z. Wicik, G. Kafali, Y. Yuceyurt, H. Evirgen, A. Kaplon-Cieslicka, M. Postula, Poland

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

1150 Expression of lymphocyte subpopulations and CD68 positive cells correlates with fecal inflammatory markers, endotoxaemia and gastrointestinal symptoms in type 1 diabetes

J. Sokolovska, P. Zalizko, R. Isaks, A. Fedulovs, J. Nazarovs, S. Dubencovs, H. Salmenkari, M. Lehto, P.-H. Groop, S. Ivanova, L. Pahirko, Latvia, Finland

1151 Efficacy of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine in adults ≥ 60 years of age with diabetes and/or obesity across 3 RSV seasons

V. Hulstrom, A. Papi, R. A. Incalzi, R. G. Feldman, M. G. Ison, T. F. Schwarz, D.-G. Lee, L. Fissette, M.-P. David, S. Xavier, C. Maréchal, M. Van der Wielen, on behalf of the ARESVi-006 Study Group, Belgium, Italy, USA, Germany, Republic of Korea, India

1152 Stearic acid induces a pro-inflammatory M1-like shift in primary human M2 macrophages through glycolysis activation: protective role of empaglifozin

A. D'Antuono, G. Cinquegrani, F. Bagnaresi, E. Giordano, V. Spigoni, F. Fantuzzi, A. Taggio, R. Aldigeri, R. C. Bonadonna, A. Dei Cas, Italy

Short Oral Event A

Tuesday, 12:00 - 13:00

SO 115 Type 1 diabetes and novel CV insights

Chair: John Petrie, UK

1153 Pre-eclampsia is an independent predictor of atherosclerosis progression in women with type 1 diabetes: a 5 year prospective study

A. Mesa, C. Puig-Jové, A. Pané, I. Vinagre, E. López-Quesada, E. Meler, N. Alonso-Carril, C. Quirós, A. Amor, V. Perea, Spain

1154 Higher daily insulin requirements as an indicator of cardiovascular risk in adults with type 1 diabetes: results from the DPV initiative

J. Seufert, M. Heni, J. Rosenbauer, W. Karges, L. Bozkurt, P. Jehle, S. Meyhöfer, S. Zimny, C. Bächle, S. Merger, S. Gözl, S. Lanzinger, R. Jung, M. Plaumann, R. Holl, Germany, Austria

1155 Integrated risk score prediction of cardiovascular, kidney and lower-limb outcomes in people with type 1 diabetes: a composite score approach

M. Camoin, L. Potier, G. Velho, M. Marre, K. Mohammadi, France

1156 Impact of cardiovascular risk factors control on atherosclerosis progression in individuals with type 1 diabetes

C. Viñals, I. Conget, M. Granados, C. Solà, A. Mesa, T. Serés-Noriega, V. Perea, J. Blanco, I. Vinagre, M. Giménez, A. Amor, Spain

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

1157 Detection of diffuse myocardial fibrosis in young patients with type 1 diabetes using cardiac MRI

V. Oksana, B. Irina, S. Olga, I. Ksenia, K. Victor, M. Natalia, Russian Federation

1158 Global prevalence of heart failure in 19 million individuals with type 1 and type 2 diabetes: a systematic review and meta-analysis by continent

H. J. Rennison, J. Osmanska, A. Sardar, U. B. Razzaq, N. Sattar, M. C. Petrie, P. S. Jhund, J. J. McMurray, M. M. Lee, UK

1159 Recurrent hypoglycaemia in a rodent model of type 1 diabetes promotes cardiac vulnerability and cardiomyopathy after 20 but not 6 weeks

H. J. Merchant, C. D. Forteach, C. X. Kocherry, C. E. Murdoch, J. G. Kerr, J. G. Gallagher, R. J. McCrimmon, A. D. McNeilly, UK

1160 Evaluating the long-term risk of major adverse cardiovascular events in type 1 diabetes: the role of albuminuria and diastolic impairment

E. K. Frimodt-Møller, H. S. Bahrami, A. K. Azar, T. W. Hansen, P. Rossing, M. T. Jensen, Denmark

Short Oral Event B

Tuesday, 13:15 - 14:15

SO 116 Known and novel biomarkers in cardiometabolic health

Chair: Janaka Karalliedde, UK

1161 Analysis of the diabetic arterial transcriptome reveals novel biomarkers of macrovascular disease

A. Shouma, M. Giannoudi, M. C. Rowland, M. Drozd, O. I. Brown, C. Cheng, P. Sukumar, K. I. Bridge, E. Levelt, M. A. Bailey, K. J. Griffin, M. T. Kearney, R. M. Cubbon, UK, Egypt

1162 Role of 3-hydroxisobutyrate in cardiometabolic disease

V. Casagrande, L. Antonetti, L. Panarello, A. Quatrana, A. Lepri, C. Internò, M. Federici, R. Menghini, Italy

1163 Protein and mRNA comparison in complications of type 2 diabetes: integrating proteomics with transcriptomics

H. Francis, A. S. Januszewski, A. Mangani, M. O'Rourke, M. L. Huang, F. K. Ema, A. A. Hardikar, M. V. Joglekar, D. R. Sullivan, R. Scott, A. J. Jenkins, M. P. Molloy, A. C. Keech, Australia, New Zealand

1164 Dapagliflozin activates the RAP1B/NRF2/GPX4 signalling to alleviate vascular endothelial ferroptosis

Y. Zhu, F.-F. Wang, China

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

1165 The association of change in endogenous sex hormones with incident cardiovascular disease in people with type 2 diabetes: the LookAHEAD ancillary study

T. Gisinger, J. He, C. Oyeka, J. Ma, N. Srialluri, M. Woodward, E. Michos, R. Kalyani, A. Kautzky-Willer, D. Vaidya, W. Bennett, Austria, USA, UK

1166 Refining socio-economic analyses of cardiovascular disease in type 2 diabetes: why postcodes are too large for meaningful insights

A. S. Januszewski, L. Li, R. L. O'Connell, J. D. Best, D. R. Sullivan, T. M. Davis, A. C. Keech, Australia

GENERAL
INFO

1167 Derivation and validation of the incremental prognostic value of increased triglyceride glucose index

S. Athanasopoulos, G. Mavraganis, G. Georgiopoulos, C. Chrysochoou, D. Delialis, G. Zervas, L. Kokkinidou, C. Konstantaki, N. Rachiotis, M. Dimopoulou, P. Kostakou, E. Lympelopoulos, K. Stellos, D. Panagiotakos, K. Stamatelopoulos, Greece, Germany

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

1168 Independent association of estimated pulse-wave velocity with incidence of cardiovascular events in type 2 diabetes

M. Capobianco, M. Giambalvo, D. Lucchesi, G. Mancini, G. Di Cianni, S. Del Prato, P. Marchetti, G. Penno, M. Garofolo, Italy

SHORT ORAL
DISCUSSIONS

Short Oral Event C

Wednesday, 11:45 - 12:45

SO 117 Heart failure and other CV insights in people with diabetes

Chair: Darren McGuire, USA

PRESENTER
INDEX

1169 Risk profile of heart failure in people with type 2 diabetes: clinical parameters and patient perspectives

J.-F. Raposo, R. Ribeiro, R. Andrade, I. Almeida, S. Nobre, D. Nascimento do Ó, M. Silva, S. Santo, S. Ferreira, M. Barros, J. M. Boavida, P. Matos, Portugal

SATELLITE
SYMPOSIA

INDUSTRY

1170 Trends in the prevalence of heart failure among 6.2 million individuals with diabetes: a meta-analysis of temporal changes from 1990 to 2020

A. Sardar, J. Osmanska, U. Razzaq, H. Rennison, N. Sattar, M. C. Petrie, P. Jhund, J. McMurray, M. M. Lee, UK

PROGRAMME

EXHIBITION

THANKS

1171 Natriuretic peptide screening predicts survival outcomes in individuals with diabetes without known heart failure

R. Pop-Busui, E. Repetto, J. Baron, D. Schumacher, M. Vaduganathan, A. Pandey, USA

1172 Differentiation between atherosclerotic cardiovascular disease and heart failure risk in type 2 diabetes: a new multi-outcome risk score

J. W. Sacre, A. Salim, K. Mohammedi, D. J. Magliano, H. C. Gerstein, J. E. Shaw, Australia, France, Canada

1173 Incidence and associates of aortic valve replacement in people with or without type 2 diabetes: the Fremantle Diabetes Study Phase II

T. M. Davis, W. A. Davis, Australia

1174 Increased endotrophin levels are associated with the risk of MACE in individuals with type 2 diabetes: the Thousand&2 study

C. F. Laursen, H. S. Bahrami, E. Martin, P. Frederiksen, F. Genovese, M. Karsdal, T. W. Hansen, P. Rossing, M. T. Jensen, P. G. Jørgensen, Denmark

1175 Timing of coronary angiography in patients with diabetes after out-of-hospital cardiac arrest without ST-segment elevation: a prespecified analysis from the TOMAHAWK trial

T. Zelniker, T. Thevathasan, A. Freund, H. Thiele, S. Desch, M. R. Preusch, TOMAHAWK Investigators, Austria, Germany

1176 Ten-year trends in diabetic patients hospitalised for acute myocardial infarction

P.-S. Song, Republic of Korea

Short Oral Event D

Wednesday, 13:00 - 14:00

SO 118 Prediction and management of complications and adverse therapy outcomes

Chair: Katarzyna Cyganek, Poland

1177 Relationship between different definitions of glucose time in range and 28-day mortality in surgical critically ill patients

S. Liu, Y. Ma, Q. Zhou, C. Wang, China

1178 Diabetic ketoacidosis: a 10-year retrospective single-site review

S. B. Soleim, K. Løvås, E. Søfteland, G. Å. Ueland, Norway

1179 Precipitating factors and clinical outcomes of hyperosmolar hyperglycaemic state: systematic review and meta summary

J. French, L. Bompfrey, K. Malhotra, P. Kempegowda, UK

1180 Factors predicting adverse pregnancy outcomes in gestational diabetes: a retrospective cohort study

P. R. H. Sagili, A. Keepanaserril, N. Plakkal, S. Nair, India

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

1181 Effects of hormone replacement therapy in midlife women with type 2 diabetes: a retrospective cohort study

M. Anson, A. Paisley, R. Kochhar, U. Alam, A. Mukherjee, UK

1182 A novel tool to identify the individual susceptibility to develop complications in type 2 diabetes patients

S. Gallo, L. Sacchetta, S. Di Molfetta, T. Piticchio, D. Tumino, E. Rempelou, I. Anastasiou, T. Scozzaro, G. Sebastiani, N. Tentolouris, L. Frittitta, A. Solini, L. Laviola, A. Natali, Italy, Greece

1183 Quantifying the multisectoral burden of obesity

A. Zafar, M. Fatima, M. Syed, C. Scarlata, UK

1184 Association of arterial stiffness with whole-body and tissue-specific insulin resistance and with incident diabetes: The Maastricht Study

J. Shen, K. Reesink, S. J. Eussen, A. Koster, C. J. Van der Kallen, B. E. De Galan, C. G. Schalkwijk, M. M. Van Greevenbroek, Netherlands

Short Oral Event E

Thursday, 12:45 - 13:45

SO 119 Type 2 diabetes: muscles, fat, bones

Chair: Srikanth Bellary, UK

1185 Glycaemic overtreatment and sarcopenia among older diabetic patients having multi-comorbid: a cross-sectional study

T. N. Nguyen, T. M. Ngo, H. T. Vu, Viet Nam

1186 Predicting bone strength in diabetes: a DXA-based model for estimating HR-pQCT failure load

A. U. Eriksen, A. A. Xylander, E. Biver, S. Ferrari, T. Kronborg, Denmark, Switzerland

1187 Dysregulated NEAT1/miR-146a axis may exacerbate inflammatory responses in periodontitis with type 2 diabetes

S. Banerjee, A. Mondal, P. Jati, C. Bose, J. G. Ray, S. Mukhopadhyay, India

1188 Adipose-tissue insulin resistance is an independent predictor of mortality in individuals at cardiovascular risk

K. B. Bódis, S. Goh, C. Binsch, K. Prystupa, O.-P. Zaharia, M. Schön, P. Wischmann, L. Busch, M. Heni, M. Kelm, A. Niessner, M. Roden, W. Maerz, R. Wagner, Germany, Austria

1189 Joint association of skeletal muscle mass and grip strength with the progression of carotid plaque score in patients with type 2 diabetes

J. Shin, Republic of Korea

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

1190 EZH2-driven epigenetic regulation in foam cell formation: implications for diabetes-induced atherosclerosis

M. Aziz, K. Sourris, K. Jandeleit-Dahm, A. Khan, Australia, Germany

1191 Chrebp deletion in Akita mice exacerbates skeletal muscle atrophy and weakness

T. Imaizumi, K. Iizuka, D. Yabe, Japan

1192 Glucose deprivation impairs lipid tolerance related to mitophagy disorder in cardiomyocytes

L. Huang, L. Liu, China

Short Oral Event F

Thursday, 14:00 - 15:00

SO 120 Non-obvious (?) complications of type 2 diabetes

Chair: Irina Kowalska, Poland

1193 Incident sepsis in people with or without type 2 diabetes: the Fremantle Diabetes Study Phase II

W. A. Davis, E. J. Hamilton, T. M. Davis, Australia

1194 Insulin resistance links glycaemic dysregulation with restrictive pulmonary impairment

M. Di Marco, K. B. Bodis, Z. Li, D. M. Mendez Cardenas, K. Prystupa, I. Yurchenko, K. Fricke, A. Gastaldelli, S. Trenkamp, O. Zaharia, M. Heni, M. Kelm, A. Di Pino, M. Roden, R. Wagner, Germany, Italy

1195 Muscle wasting and type 2 diabetes: normative data for muscle composition changes with ageing

J. Linge, M. Petersson, O. Dahlqvist Leinhard, Sweden

1196 Malnutrition and sarcopenia are associated with risk of mortality in older patients with type 2 diabetes

Y. Hashimoto, S. Yamamoto, F. Takahashi, T. Okamura, H. Okada, M. Hamaguchi, M. Fukui, Japan

1197 Vascular stiffness is an independent risk factor for bone microarchitectural deterioration in type 2 diabetes patients: a cross-sectional study

X. Chen, Y. Wang, Q. Ying, X. Wu, China

1198 The effect of type 2 diabetes on bone quality: a systematic review and meta-analysis of cohort studies

O. Ojo, Y. Onilude, J. Brooke, V. Apau, I. Kazangarare, O. Ojo, UK

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

1199 The association of haptoglobin levels and phenotype with cardiovascular disease in adults with type 2 diabetes: a FIELD trial sub-study

K. L. Ong, A. S. Januszewski, H. Francis, R. L. O'Connell, A. Mangani, L. Li, P. G. Colman, D. R. Sullivan, J. D. Best, R. S. Scott, A. J. Jenkins, A. C. Keech, on behalf of the FIELD Study Investigators, Australia, Singapore, New Zealand

1200 Arterial stiffness is associated with worse beta cell function: The Maastricht Study

J. Shen, K. Reesink, M. T. Schram, B. E. De Galan, C. G. Schalkwijk, M. M. Van Greevenbroek, Netherlands

GENERAL
INFO

PROGRAMME

TUESDAY

Short Oral Event A

Tuesday, 12:00 - 13:00

SO 121 Type 1 diabetes: late and acute complications

Chair: Tomasz Klupa, Poland

1201 Bone mineral density and trabecular bone score in Indian children and adolescents with type 1 diabetes

A. N. Maldar, A. Prasanth, M. Chadha, J. M. Modhe, K. Meshram, A. Parab, M. Almeida, P. Chauhan, India

1202 Prevalence and characteristics of functional hyperandrogenism and polycystic ovary syndrome in premenopausal women with type 1 diabetes

A. Bayona, L. Nattero-Chávez, E. De la Calle de la Villa, A. Quintero Tobar, S. De Lope Quiñones, B. Dorado Avendaño, M. Luque-Ramírez, H. Escobar-Morreale, Spain

1203 Risk of complications in an adolescent and young adult population with type 1 diabetes: a regional perspective

S. Barton, A. Briggs, H.-Y. Chien, R. Sheldon, R. Dias, L. Quinn, UK

1204 Beyond the marginal pool: hypoglycaemia stimulates erythropoiesis, in part mediated through adrenaline, in people with and without type 1 diabetes

I. F. Mustafajev, M. S. Hendriksz, J. I. Van Heck, C. E. Verhulst, B. E. De Galan, R. Stienstra, C. J. Tack, R. I. Meijer, Netherlands

1205 Highs, lows and inflammatory flows: the link between glycaemic variability and inflammation in diabetes

E. Schupp, R. Stienstra, C. J. Tack, B. E. De Galan, R. I. Meijer, Hypo-RESOLVE consortium, Netherlands

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

1206 Adrenaline at concentrations seen during hypoglycaemia elicits an inflammatory response in people with and without type 1 diabetes

I. F. Mustafajev, M. S. Hendriksz, B. E. De Galan, R. Stienstra, C. J. Tack, R. I. Meijer, Netherlands

1207 Machine learning of bird's eye images produced by continuous wavelet transform may predict a signal of glucose change in adverse coronary events

Y. Nakamura, N. Takahashi, Japan

Short Oral Event B

Tuesday, 13:15 - 14:15

SO 122 Cognitive dysfunction on the target

Chair: Katarzyna Cyranka, Poland

1208 Papez circuit and glymphatic system involvement in type 2 diabetes patients: abnormal effective connectivity patterns and enlarged choroid plexus volume

Y. Zhang, X. Yin, W. Xia, X. Yin, China

1209 Association of physical frailty with the risk of vascular dementia in patients with type 2 diabetes: a population-based cohort study

Z. Dai, X. Yue, R. Lu, S. Qiu, China

1210 Olfactory training improves cognitive function in type 2 diabetes patients with mild cognitive impairment: a 16-week randomised controlled trial

Y. Bi, Y. Chao, Z. Zhang, China

1211 Lung function and risk of incident dementia in type 2 diabetes: a population-based cohort study

Y. Sun, L. Cai, B. Yu, Y. Yu, K. Zhang, Y. Lu, N. Wang, China

1212 Immune markers and cognitive function in persons with type 1 diabetes: analysis of the REVADIAB study

F. Alzaid, L. Al-Abdullah, D. Altarrah, M. Al-Onaizi, C. Potier, N. Venteclef, J.-B. Julla, J.-P. Riveline, France, Kuwait

1213 Risk factors of cognitive impairment caused by type 2 diabetes and brain resting-state fMRI study

H. Liu, Y. Wang, P. Xu, X. Xia, T. Sun, China

1214 Comparative analysis of hearing loss between diabetic and non-diabetic populations

W. Tan, J. Li, China

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Short Oral Event C

Wednesday, 11:45 - 12:45

SO 123 Neurological, emotional, cognitive status of people with diabetes

Chair: Katharine Barnard-Kelly, UK

1215 Impact of genetic predisposition to glycaemic dysregulation on psychiatric endophenotypes

E. T. Gebretsadik, P. Speckert, A. Aman, D. M. Lyall, R. J. Strawbridge, UK

1216 High levels of HbA_{1c} were associated with cerebral microbleeds and white matter hyperintensities in lacunar stroke patients

H. Park, Republic of Korea

1217 Global and cohort-based analysis of dementia burden and modifiable risk factors in type 2 diabetes

C. Sun, Y. Bi, China

1218 GLP-1 receptor agonist and metformin alleviate diabetes-associated cognitive impairment via the ANGPTL8-pirb signalling pathway

X. Zhou, China

1219 Diabetic peripheral neuropathy is independently associated with increased risk of dementia and cerebrovascular disease

A. Wiggers, V. Kosjerina, M. Nilsson, B. Brock, S. Andersen, E. Reynolds, B. Callaghan, E. Feldman, J. Rungby, C. Hansen, Denmark, USA

1220 Early detection of choroid plexus volume and reduced cortical thickness in diabetic cognitive impairment

S. Fan, X. Yin, S. Ge, W. Xia, China

1221 Diabetes complications and their association with patient-reported outcome measures: a longitudinal study of the SwissDiab cohort

G. Hofer, F. Renström, M. Braendle, C. Cavelti-Weder, Switzerland

Short Oral Event D

Wednesday, 13:00 - 14:00

SO 124 Neurodegeneration and depression in people with diabetes

Chair: Dominic Ehrmann, Germany

1222 Type 2 diabetes and risk of clinically relevant depressive symptoms: role of microvascular dysfunction, neurodegeneration, inflammation, AGEs and arterial stiffness: the Maastricht Study

I. Steens, M. Schram, B. Houben, T. Berendschot, A. Koster, H. Bosma, S. Eussen, B. De Galan, T. Van Sloten, Netherlands

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

1223 Lower sleep quality is associated with nocturnal hypoglycaemia and hyperglycaemia and is a predictor of impaired short- and long-term mental health

N. Hermanns, B. Kulzer, A. Schmitt, L. Klinker, D. Ehrmann, Germany

1224 Impact of eating disorders on mortality and cardiovascular outcomes in type 2 diabetes: a nationwide study

S. Cho, S. Kim, R. Oh, J. Kim, M. Jang, Y.-B. Lee, S.-M. Jin, K. Hur, G. Kim, J. Kim, Republic of Korea

1225 Impact of a multidisciplinary lifestyle-based diabetes management programme on physical and mental health outcomes in Indian type 2 diabetes individuals living with obesity

B. Sharma, P. Tripathi, N. Kadam, A. Vyawahare, T. Kathrikolly, D. Tiwari, M. Ganla, B. Saboo, India

1226 A dynamic network approach to health-risk behaviours and depressive symptoms in people with or without diabetes: longitudinal findings from the survey of health and retirement in Europe

A. McInerney, S. Deschênes, Germany, Ireland

1227 Effects of GLP-1R genetic variants on type 2 diabetes and depressive symptoms

Z. Balkhiyarova, G. Deganutti, Y. Sharhorodska, C. A. Reynolds, B. Jones, I. Prokopenko, UK

1228 Cardiovascular autonomic neuropathy and subclinical heart failure in type 2 diabetes: the CANCAN study

J. Schaarup, L. Bjerg, C. Hansen, D. Witte, H. H. Thomsen, J. Fleischer, R. Pop-Busui, A. Sandbæk, S. T. Andersen, Denmark, USA

Short Oral Event E

Thursday, 12:45 - 13:45

SO 125 Type 2 diabetes: financial, social considerations, prevention of complications

Chair: Mariusz Dabrowski, Poland

1229 Systemic glucocorticoid use increases fracture risk equally in those with and those without type 2 diabetes: a Danish nationwide cohort study

Z. K. Al-Mashhadi, R. Viggers, J. Starup-Linde, B. L. Langdahl, V. Van Hulten, J. Van den Bergh, J. H. Driessen, P. Vestergaard, S. Gregersen, Denmark, Netherlands

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

1230 Characteristics and impact of diabetes and prediabetes in pre- and post-liver transplantation: results of a large single-centre study

M. Scopelliti, R. Del Testa, P. Carrai, G. Gezici, C. Van Strijdonck, F. Indovina, F. R. Femia, R. Pellungrini, F. Giannotti, D. Pedreschi, G. Catalano, P. De Simone, D. Ghinolfi, P. Marchetti, L. Marselli, Italy, Belgium

1231 Trends in pharmacotherapy costs and cardiovascular risk factor management in type 2 diabetes: a 26-year study from tertiary diabetes centres in Greece

G. Karamanakos, A. Papazafiropoulou, A. Koutsovasilis, I. Frestis, A. Vakka, S. Bakogianni, K. Magganas, P. Michou, K. Salapatas, A. Garbi, V. Chatzivasiloglou, N. Tentolouris, S. Liatis, Greece

GENERAL
INFO

PROGRAMME

TUESDAY

1232 Social deprivation and rate of decline in renal function in people living with diabetes

C. Casey, P. M. Kearney, C. M. Buckley, S. F. Dinneen, M. D. Griffin, T. P. Griffin, Ireland

WEDNESDAY

THURSDAY

1233 Urine dipstick test as a predictive tool for future development of urinary tract infection and SGLT2 inhibitor-related risks: findings from CANVAS and CREDENCE trials

Y. Doi, T. Hamano, M. Fukuda-Doi, Y. Isaka, Japan

FRIDAY

SHORT ORAL
DISCUSSIONS

1234 Prevalence of foot pathology among the patients of outpatient diabetes clinic between 1996 and 2024

V. Urbancic-Rovan, M. Garbas, M. Lunder, M. Janić, M. Slak, Slovenia

PRESENTER
INDEX

1235 Predicting 10-year cardiovascular disease events using risk calculators in insulin-treated pilots within the European diabetes protocol

G. L. Garden, F. Shojaee-Moradie, I. Parsons, G. Koehler, E. J. Hutchison, B. M. Frier, K. M. Shaw, S. R. Heller, G. A. Roberts, J. Mader, D. L. Russell-Jones, EASA Diabetes Consortium, UK, Austria, Ireland

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

1236 Insufficient guideline adherence in the treatment of patients with type 2 diabetes with established cardiovascular disease: real-world evidence from the DPV Registry

J. Altrogge, J. Seufert, S. Schmid, S. Meyhöfer, S. Lanzinger, Germany

EXHIBITION

THANKS

Short Oral Event F

Thursday, 14:00 - 15:00

SO 126 Type 1 diabetes: it is not just about insulin management

Chair: Dorota Zozulinska, Poland

1237 Muscular fitness components in a cohort of individuals with type 1 diabetes: a cross-sectional study

F. Greco, G. Guarascio, M. G. Tarsitano, A. Cutruzzolà, A. Gnasso, C. Irace, G. P. Emerenziani, Italy

1238 Preclinical pathways and predictors of diabetic ketoacidosis upon onset of type 1 diabetes in children and adolescents

O. Kordonouri, M. Niemeyer, S. Landsberg, T. Von dem Berge, J. Weiskorn, F. Reschke, K. Kapitzke, T. Biester, K. Lange, Germany

1239 The association of selected fat tissue indices with periodontal inflammation in adults with type 1 diabetes: a cross-sectional study

A. Duda-Sobczak, M. L. Wyganowska, D. Zozulinska-Ziolkiewicz, Poland

1240 Exploring the role of FIB4 in type 1 diabetes control

P. Pérez Reyes, J. Silva Fernández, Á. Rebollo Román, D. L. Marginean, V. Torres Herrera, R. Palomares Ortega, Spain

1241 Fracture susceptibility in type 1 diabetes: exploring potential biomarkers

E. Paulsson, H. J. Arnqvist, S. I. Chisalita, Sweden

1242 Impact of diet and nutritional status on gingival crevicular fluid metabolome and microbiome in people with type 1 diabetes

M. Kania, Z. Drab, M. Dabrowska, E. Samborowska, N. Zeber-Lubecka, M. Kulecka, T. Klupa, I. Gregorczyk-Maga, Poland

1243 Pedal acceleration time is a suitable test to detect peripheral circulatory disorders in diabetic patients

P. Pithová, I. Kecman, M. Kvapil, Czechia

Short Oral Event A

Tuesday, 12:00 - 13:00

SO 127 Cancer, liver and diabetes

Chair: Anca Pantea-Stoian, Romania

1244 Intensive weight loss intervention and cancer mortality in adults with type 2 diabetes: analysis of the Look AHEAD randomised trial

H.-C. Yeh, D. Han, USA

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

1245 Glucose metabolism in pancreatic tumors: distinct patterns in pancreatic cancer, neuroendocrine tumors and ampullary carcinoma

M. Brunetti, G. Gliozzo, G. Di Giuseppe, L. Soldovieri, G. Ciccarelli, L. Carciaro, F. Cinti, C. Morciano, S. Gugliandolo, A. Avolio, A. Splendore, A. Giaccari, T. Mezza, Italy

1246 Association of adiposity, metabolic syndrome, diabetes and skin autofluorescence with incident cancer

B. H. Wolffenbuttel, H. E. Boersma, G. A. Sidorenkov, B. Van der Vegt, A. D. Paterson, A. J. Smit, G. H. De Bock, M. M. Van der Klauw, Netherlands, Canada

1247 Diabetes is associated with increased cancer risk after accounting for dietary and lifestyle factors: insights from the Diabetes and Cancer Outcomes in a Real-world SETTING (DISCOURSE) study

P. Kaul, M. Ye, D. C. Dover, L. Chu, S. Butalia, R. Yeung, D. Lau, P. Senior, J. Johnson, G. Tu, J. Vena, D. T. Eurich, Canada

1248 Assessing thyroid cancer risk: GLP-1 RA shows short to intermediate-term safety

V. Aroda, T. Vilsbøll, S. Dandanell, J.-P. David, C. Kristiansen, F. Roberts, M. Stellfeld, L. Hegedus, USA, Denmark

1249 Novel genetic and metabolic findings from a study of UK South Asian population with chronically elevated alanine aminotransferase

R. Mallik, X. Dai, C. Chaplin, . Genes and Health Research Team, J. Makaronidis, G. A. Hitman, E. Bochukova, W. Alazawi, UK

1250 Transcriptional activation of endogenous paraoxonase 2 by CRISPR/dCas9 technology to improve the function of hepatocytes under pro-diabetic conditions: an in vitro and in vivo strategy

L. Toma, T. Barbalata, J. I. Ciobanu, G. M. Sanda, E. V. Fuior, M. I. Fenyo, L. S. Niculescu, A. V. Sima, C. S. Stancu, Romania

1251 Incorporating the existence of MASLD into the original cardiovascular-kidney-metabolic syndrome health stage improves the predictive ability for coronary artery disease

T. Sato, M. Tanaka, Y. Akiyama, W. Kawaharata, H. Aida, R. Matsumori, I. Hosaka, T. Ogawa, K. Nakata, H. Kouzu, N. Hanawa, M. Furuhashi, Japan

Short Oral Event B

Tuesday, 13:15 - 14:15

SO 128 Biochemical face of cognitive impairment and dementia

Chair: Aleksandra Araszkiwicz, Poland

1252 Plasma proteomic profiling identifies biomarkers for prediction of cognitive impairments in type 2 diabetes

Y. Bi, S. Yang, T. Wu, Z. Zhang, China

GENERAL INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL DISCUSSIONS

PRESENTER INDEX

SATELLITE SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

1253 Identification of CYP27A1 and 27-hydroxycholesterol as indicated targets for mild cognitive impairment in type 2 diabetes

T. Niu, K. Liu, D. Niu, R. Sun, S. Wang, China

1254 Atorvastatin modulates lipid profile, glucose transporters, and neuronal markers in the brain of diabetic mice: insights into potential neuroprotective role

R. Junges Moreira, M. Estimo Michalani Toledo, M. Mitiko Okamoto, U. Fabres Machado, L. Giorgetti de Britto, Brazil

1255 Sterol regulatory element binding protein cleavage activating protein promotes diabetic neuroinflammation and cognitive impairment via upregulation of lipocalin-2

K. Liu, T. Niu, S. Wang, China

1256 J-curve thresholds of Galectin-3 predict mild cognitive impairment in type 2 diabetes: a population-based stratification study

X. Zhou, China

1257 Development and validation of a clinical prediction model based on plasma sTREM2 for mild cognitive impairment in type 2 diabetes

F. Liu, S. Wang, China

1258 Age-related adaptations in methylglyoxal detoxification: insights from normoglycaemia and prediabetes

M. Campos Campos, E. Kliemank, J. Morgenstern, J. Szendroedi, T. Fleming, Germany

LBA Short Oral Event A

Tuesday, 12:00 - 13:00

LBA SO 01 Beyond GLP-1 horizon: oral drugs, dual agonists

Chair: Fawaz Alzaid, France

LBA 39 Efficacy and safety of a novel oral small molecule GLP-1RA (HRS-7535) in Chinese patients with type 2 diabetes inadequately controlled by metformin and SGLT2 inhibitor

L. Yan, M. Xu, W. Song, F. Lv, Y. Fu, L. Yang, X. Bin, X. Zhang, Z. Ye, D. Zhang, W. Dai, C. Shu, China

LBA 40 Orforglipron is associated with improvements in markers of beta cell function and insulin sensitivity when used as monotherapy in people with type 2 diabetes

L. Ludwig, M. Thomas, S. Eyde, J. Li, R. Liu, M. Denning, Y. Chen, USA

LBA 41 Dorzagliatin enhances GLP-1 secretion by restoring the function of intestinal L-cells

Q. Shao, L. Gao, Y. Xu, Y. Zhang, China

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

LBA 42 Decoupling glycaemic control from weight loss in advanced type 2 diabetes using a bispecific GLP-1/GLP-2 agonist with enhanced human tolerability

S. Kim, S.-I. Yang, K.-H. Son, S.-A. Lee, J.-G. Kim, Y. Sung, Korea, Republic of

LBA 43 Efficacy and safety of cagrilintide 2.4 mg in adults with overweight/obesity: data from REDEFINE 1

W. T. Garvey, A. B. Kuhlman, J. Rømer, K. H. Pietiläinen, K. B. Tvermosegaard, D. C. Lau, USA, Denmark, Finland, Canada

LBA 44 Sex differences in the weight response to GLP-1RA in people with type 2 diabetes: a long-term longitudinal real-world study

M. Marassi, A. Cignarella, G. Russo, L. Nollino, M. Strazzabosco, G. Aimaretti, F. Leonetti, A. Avogaro, A. Consoli, G. Fadini, Italy

LBA 45 Impact on food noise after initiating semaglutide treatment: results from a US survey (INFORM)

T. Arnaut, B. Ó Hartaigh, K. Byrne, S. Duncan, K. Kvist, Denmark, USA, Switzerland

LBA 46 Orforglipron, an oral non-peptide GLP-1 receptor agonist for early type 2 diabetes

L. Ludwig, S. Hsia, L. Ruiz, S. Eyde, D. Cox, W.-S. Wu, R. Liu, J. Li, L. Lando, M. Denning, Y. Chen, J. Rosenstock, USA, Mexico

LBA Short Oral Event B

Tuesday, 13:15 - 14:15

LBA SO 02 Thinking big about treating obesity

Chair: Ilke Sen, France

LBA 47 HM101460, a potent and G protein-biased oral GLP-1R agonist with enhanced bioavailability, exhibits robust efficacy in animal models of type 2 diabetes and obesity

S. Kim, D. Hong, S. Park, S. Kim, S. Han, S. Kim, D. Lee, B. Ye, S. Lee, S. Bae, I. Choi, Korea, Republic of

LBA 48 Leveraging primary mitochondrial disorders to uncover mechanisms underlying constitutional leanness and obesity resistance in humans

M. Fiorenza, T. Nielsen, M. Andersen, S. Larsen, S. Torekov, J. Vissing, Denmark

LBA 49 Outcomes of a group-based meal replacement programme for adults living with obesity who were declined bariatric surgery

R. Murphy, J. A. Shand, N. Brosnahan, Y. Jiang, New Zealand, UK

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

LBA 50 Improving safety vs efficacy of duodenal jejunal bypass liner treatment for type 2 diabetes and obesity

R. E. Ryder, R. Drummond, B. McGowan, S. Amiel, R. Lopez-Gonzalez, J. Pujol, H. Frydenberg, J. Stein, T. Battelino, S. Fishman, C. De Jonge, J. Greve, R. Cohen, M. Yadagiri, P. Sen Gupta, UK, Spain, Australia, Germany, Slovenia, Israel, Netherlands, Brazil

LBA 51 Adipose tissue and liver mitochondrial adaptations after bariatric surgery parallel hepatic lipid reduction in obesity-associated insulin resistance

K. Pafili, K. Bodis, J. Pützer, C. Binsch, C. Granata, B. Dewidar, G. Heilmann, I. Esposito, M. Schlensak, F. A. Ganderath, S. Kahl, M. Roden, Germany

LBA 52 GenSci156, a potent bi-specific antibody targeting ActRIIA/B and GIPR for obesity treatment without causing muscle loss

G. Sun, S. Hu, T. Yang, L. Wang, Y. Lv, J. Zeng, X. Liao, R. Tian, M. Chu, S. Sun, R. Hu, S. Liang, L. Kang, G. Xia, L. Jin, China

LBA 53 Left atrial dysfunction in class III obesity: a pilot study using two-dimensional speckle tracking echocardiography

M. Pec, J. Jurica, P. Tudik, B. Focko, Z. Miertova, I. Sagova, T. Bolek, M. Samos, M. Mokan, Slovakia

LBA Short Oral Event C

Wednesday, 11:45 - 12:45

LBA SO 03 Incredible incretins

Chair: Jonathan E. Campbell, USA

LBA 54 Frequency, clinical characteristics, and outcomes associated with various definitions of remission after initiation of GLP-1RA for type 2 diabetes management

G. Fadini, A. Giaccari, F. Broglio, A. Avogaro, A. Consoli, Italy

LBA 55 Effects of a six-week continuous s.c. infusion of GIP alone or in combination with once-weekly s.c. semaglutide on bone turnover markers

C. Fonnesbeck-Wulff, M. M. Helsted, N. L. Schartz, I. W. Lund, J. Forman, C. K. Nielsen, A. Englund, B. Hartmann, T. Vilsbøll, J. J. Holst, A. B. Lund, M. B. Christensen, F. K. Knop, L. S. Gasbjerg, Denmark

LBA 56 A phase 1, double blind, multiple ascending dose study of eloralintide in Japanese participants with overweight or obesity

K. Ohwaki, T. Eto, R. Nasu, K. J. Mather, S. Bhattachar, E. Pratt, Japan, USA

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

LBA 57 Once-monthly zovaglutide (ZT002) for the treatment of overweight or obesity in adults: a phase 2 study

L. Ji, L. Gao, J. Zhang, H. Jiang, Z. Cheng, D. Liu, J. Tian, K. Wang, H. Shu, X. Dong, L. Liu, X. Song, R. Zhao, X. Zhang, Y. Zhang, China

LBA 58 Metabolic and cardiovascular effects of 13-week utreglutide treatment in individuals with obesity and MASLD

R. Thennati, V. Burade, M. Natarajan, P. Shahi, R. Nagaraja, B. Thorens, T. Vilsbøll, R. Pratley, J. Olynyk, R. Loomba, India, Switzerland, Denmark, USA, Australia

GENERAL
INFO

LBA 59 Mazdutide inhibits ASK1 phosphorylation and SLC7A11-GPX4 ferroptosis axis to improve rat uric acid nephropathy

Y. Zhang, Y. Ren, Z. Chen, C. Liu, X. Chen, H. Jiang, China

PROGRAMME

TUESDAY

LBA Short Oral Event D

Wednesday, 13:00 - 14:00

LBA SO 04 Putting obesity under microscope

Chair: Dominik Pesta, Germany

LBA 60 Multi-organ magnetic resonance-based imaging can predict health benefit from anti-obesity pharmacotherapy

H. Thomaides Brears, E. Jackson, T. Kailayanathan, M. Pansini, A. Dennis, M. O. Harhay, N. Samala, R. Banerjee, L. M. Kaplan, A. Banerjee, UK, Switzerland, USA

SHORT ORAL
DISCUSSIONS

LBA 61 Lac-Phe enhances hepatic energy homeostasis via ppara-mediated fatty acid oxidation

W. Zou, L. Zhang, Y. Gao, J. Zhang, J. Zheng, China

LBA 62 Exercise-induced rewiring of hepatic tryptophan metabolism promotes energy homeostasis via MFN1-dependent mitochondrial fusion

W. Zou, J. Zheng, Y. Gao, China

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

LBA 63 Diet induced obesity and insulin resistance is due to PTEN increase and is reversed by inhibiting PTEN

R. Mukherjee, P. Pancholi, M. Sharma, H. Solomon, S. Carrasco, E. De Stanchina, K. Vanaja, N. Rosen, USA

PROGRAMME

EXHIBITION

LBA 64 CDK4/6 inhibition promotes Brown Adipose Tissue (BAT) thermogenesis via mitochondrial metabolic remodelling

J. Qiao, S. Ling, Y. Jiang, D. Lu, H.-D. Song, China

THANKS

LBA 65 Sox4 drives a cancer associated fibroblast-like transition in adipose stromal cells to promote metabolic disease

K. Drareni, R. P. Calhoun, L. Cheng, S. E. Traynor, A. H. Weller, D. M. Merrick, P. Seale, USA

LBA Short Oral Event E

Thursday, 12:45 - 13:45

LBA SO 05 Beta cell reserve and resilience: new insights

Chair: Diego Balboa, Finland

LBA 66 WITHDRAWN

LBA 67 Post-weaning protein restriction impairs glucagon-like peptide 1 action and leads to pancreatic islet atrophy in mice

K. M. Oliveira, J. A. Silva Junior, G. M. Soares, K. C. Bem, E. M. Carneiro, Brazil

LBA 68 Novel MIDY-mouse models show no decrease in beta cell mass despite overt diabetes from a young age

M. R. Schmidtke, M. Hrabec de Angelis, A. Harten, G. Przemeczek, Germany

LBA 69 “It’s not just the numbers”: the human factor motivating pursuit of stem-cell therapies in type 1 diabetes on closed-loop systems

A. Anandhakrishnan, J. Jordan, J. Speight, S. Hussain, UK, Australia

LBA 70 Rapid entry of newly synthesized insulin and C-peptide in plasma reveals beta cell insulin reserve relative to secretory demand, precedes diet-induced hyperglycemia in ZDF rats and differs by strain

V. Pirro, O. Cabrera, E. Zanley, K. Li, J. Willency, J. Ficorilli, K. Duffin, J. Perfield, M. Hellerstein, USA

LBA 71 A stable isotope-based method to quantify beta cell insulin and C-peptide kinetics in humans: a window into insulin secretory reserve

L. Bally, D. Herzig, A. Brunasso, A. Tripyla, A. Thomas, O. Cabrera, V. Pirro, J. Willency, K. Li, E. Zanley, M. Hellerstein, Switzerland, Italy, Germany, USA

LBA 72 Interplay between cGMP and cAMP signalling in the primary cilium of islet cells

C. Incedal Nilsson, O. Idevall Hagren, Sweden

LBA Short Oral Event F

Thursday, 14:00 - 15:00

LBA SO 06 Diabetes-related nephropathy: contemporary approaches to prevention and treatment

Chair: Samy Hadjadj, France

LBA 73 Protective effect of dapagliflozin on podocytopathy and renal ultrastructure in early diabetic kidney disease

H. Kim, R.-H. Kim, H. XuanYuan, H. Park, H. Lee, E. Kang, Korea, Republic of

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

LBA 74 CONFIDENCE Asia: effect of simultaneous initiation of finerenone and empagliflozin on urinary albumin-to-creatinine ratio in Asian participants from the CONFIDENCE trial

R. Agarwal, J. B. Green, H. J. Heerspink, J. F. Mann, J. B. McGill, A. Mottl, T. Osonoi, A. Pal, P. Rossing, J. Rosenstock, M. Vaduganathan, C. Scott, P. Manjrekar, S. Yamashita, M. Nangaku, USA, Netherlands, Germany, Japan, India, Denmark

GENERAL
INFO

LBA 75 Prospective evaluation of anthropometric indices for predicting mortality, MACE and MARE in patients with chronic kidney disease

R. Schürfeld, M. Haussmann, E. Baratashvili, A. Bachmann, I. Bast, J. Beige, R. Wendt, M. Blüher, M. Stumvoll, A. Tönjes, T. Ebert, Germany

PROGRAMME

TUESDAY

LBA 76 Diagnostic glycaemic thresholds for diabetes based on biopsy confirmed diabetic kidney disease: comparative analysis with retinopathy derived criteria

J.-K. Yang, F.-Y. Yang, X.-C. Han, China

WEDNESDAY

THURSDAY

LBA 77 High sensitivity CRP and future rise in urine ACR / fall in eGFR over 24 years in people with type 2 diabetes

A. Heald, S. Veluchamy Rathakrishnan, A. Matheou, O. Zavlis, S. White, T. McDonnell, L. Shalamanova, E. Jude, B. Mankovsky, H. Habte-Asres, A. Lay, M. Whyte, M. Gibson, P. A. Kalra, UK, Ukraine

FRIDAY

SHORT ORAL
DISCUSSIONS

LBA 78 The metabolism-related transcriptomic signature in PBMCs of patients with type 2 diabetes and diabetic kidney disease is associated with systemic inflammation

C. Luna-Marco, J. F. Català-Senent, J. Cacace, A. Hermo-Argibay, O. Hernández-López, J. Pantoja, A. Sancho, C. Morillas, C. Bañuls, M. Rocha, V. Víctor, S. Rovira-Llopis, Spain

PRESENTER
INDEX

SATELLITE
SYMPOSIA

LBA 79 Empagliflozin, semaglutide and their combination reduce renal sinus fat in patients with type 2 diabetes

L. Vernstrøm, S. Gullaksen, K. L. Funck, E. Laugesen, P. Poulsen, Denmark

INDUSTRY

PROGRAMME

LBA 80 The mechanism of MMP-7 mediating RAAS activation associated with diabetic kidney injury through syndecan-1 pathway

L. Yang, Y. Wang, R. Li, J. Yang, China

EXHIBITION

THANKS

LBA Short Oral Event C

Wednesday, 11:45 - 12:45

LBA SO 07 **The Diabetes-Brain Axis: from pathophysiology to protection**

Chair: Thomas van Sloten, Netherlands

LBA 81 Distinct effects of exercise training and high-fat diet in cortex, hippocampus and hypothalamus

M. Vamvini, E. Tieu, S. Fass, Z. Liu, J. Park, P. Nigro, J. Yang, K. Galani, L.-L. Ho, M. Hirshman, M. Kellis, L. J. Goodyear, USA

LBA 82 Neurodegeneration onset with glucagon-like peptide-1 receptor agonists in a global real-world cohort of people living with type 2 diabetes

M. Schechter, A. Fishkin, O. Mosenzon, T. Cukierman-Yaffe, G. Leibowitz, G. Aharon-Hananel, Israel, USA

LBA 83 Determinants of extremely declined parasympathetic activity (Q1 quartile) in prediabetes

R. Dimova, N. Chakarova, T. Tankova, Bulgaria

LBA 84 Zovaglutide (ZT002), a novel ultra long-acting GLP-1 receptor agonist improves memory function and prevents degenerative processes in Alzheimer's disease animal models

Y. Zhang, C. Zhao, S. Lin, X. Zhang, Y. Zhang, China

LBA 85 ZT006, a novel oral GLP-1 receptor agonist improves memory function, reduces brain insulin resistance and neuroinflammation in Alzheimer's disease animal models

Y. Zhang, C. Zhao, S. Lin, X. Zhang, Y. Zhang, China

LBA 86 Uncovering the hepatic signature in the comorbidity of diabetes and Alzheimer's disease: a novel peripheral target for neurodegeneration

C. Pirozzi, S. Melini, F. Comella, N. Navatti, G. Mattace Raso, C. Sgheddu, M. Morgese, R. Meli, Italy

LBA Short Oral Event D

Wednesday, 13:00 - 14:00

LBA SO 08 **If type 1 diabetes has any secrets, they can be found here**

Chair: Esther Latres, USA

LBA 87 Tirzepatide accelerates diabetes onset in NOD mouse model of type 1 diabetes

A. R. Purcell, N. Rodrigo, S. Saad, M. S. Longfield, C. Pollock, S. J. Glastras, Australia

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

LBA 88 F.prausnitzii-derived butyrate induces remission of type 1 diabetes through CPT1A-mediated TIGIT+ Treg metabolic reprogramming

T. Zhong, X. Li, R. Tang, K. Lei, X. Li, B. Zhao, China

LBA 89 Acute i.v. infusion of the amylin analogue pramlintide does not affect glucagon levels in individuals with type 1 diabetes or in healthy controls

M. K. Preskou, D. S. Mathiesen, B. Hartmann, A. H. Lange, L. K. Winther, J. J. Holst, F. K. Knop, A. B. Lund, J. I. Bagger, Denmark

LBA 90 Beyond the average: heterogeneity in glycaemic patterns across the menstrual cycle

M. Rothenbühler, A. Lizoain, V. Braunack-Mayer, L. Burlando, M. Friedman, S. Khan-Gallo, S. Hossmann, Switzerland, USA

LBA 91 Sustained glycaemic improvements with extended use of the Omnipod 5 Automated Insulin Delivery (AID) system: results of the RADIANT 13-week Extension study

P. Gillard, E. Wilmot, M. Nicolino, T. Ly, for the RADIANT Study Group, Belgium, UK, France, USA

LBA Short Oral Event E

Thursday, 12:45 - 13:45

LBA SO 09 From mastering the scoring to fine-tuning the treatment

Chair: Robert Wagner, Germany

LBA 92 Negative impact of HLA haplotype DR4DQ8 is stronger than DR3DQ2 in LADA patients: results from a Norwegian and Swedish population

V. Grill, I. Hals, S. Carlsson, J. Edstorp, E. Ahlqvist, E. Sørgjerd, Sweden, Norway

LBA 93 A simple clinical risk score identifies Chinese patients with severe insulin deficiency diabetes subtypes and adverse outcomes: a prospective cluster analysis

M. Shi, B. Fan, C. O, E. Lau, A. Yang, J. Lui, H. Wu, E. Chow, A. Kong, A. Luk, R. Ma, J. Chan, China

LBA 94 Employing Bayesian models to explore and rank different approaches to type 2 diabetes remission: a systematic review and network meta-analysis

Y. Song, S. Katsarova, C. Lawson, E. Brady, UK

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

LBA 95 Cardiovascular risk associated with pre-existing and post-transplant diabetes in kidney transplant recipients

H. Kim, S. Lee, H. Lee, J. Lee, J. Lee, M. Kim, E. Kang, Korea, Republic of

LBA 96 Once-weekly insulin efsitora alfa showed consistent time in range and rates of hypoglycaemia throughout the week relative to day of administration in insulin naive adults with type 2 diabetes

T. Martens, S. Heller, A. Bhargava, L. Ji, S. Murthy, V. Patel, L. Goncalves, J. Mitra, A. Murro, K. Syring, T. Battelino, USA, UK, China, India, Slovenia

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

PRESENTING AUTHORS OF ORALS AND SHORT ORAL DISCUSSIONS

Last Name, Initials, Presentation Number

GENERAL INFO	Abdelalim, E. 231	Andersen, C. F. LBA 32
	Åberg, S. 335	Andersen, O. E. 212
	Aboolian, A. 987	Andersson Hall, U. 336
	Abouelnasr, S. 904	Anson, M. 332, 1181
	Abu Aqel, Y. 426	Antonetti, L. 750
	Acosta, F. M. 650	Antonucci, A. 1147
PROGRAMME	Acosta-Manzano, P. 89	Ares, J. 378
TUESDAY	Adeshara, K. 274	Arias Sánchez, C. 965
	Aggarwal, R. 4, LBA 33, LBA 74	Armirola-Ricaurte, C. 102
	Agholme, J. 366	Arnaut, T. LBA 45
WEDNESDAY	Aguayo, G. A. 118	Aroda, V. 1248
	Ahluwalia, T. S. 959	Arora, P. S. 222
THURSDAY	Ahmed, M. 1065	Arrojo e Drigo, R. 633, 783
	Aiello, E. 302	Arshad, M. 933
FRIDAY	Ajjan, R. 953	Asatiani, N. G. 1042
	Akinrimisi, O. I. 590	Assi, E. 434
SHORT ORAL DISCUSSIONS	Akpınar, Ç. 942	Asteljoki, J. V. 35
	Al-Ansari, D. E. 674	Åsvold, B. O. LBA 02
	Al-Mashhadi, Z. K. 1229	Atawneh, F. 417
	Al-Mrabeh, A. H. 383	Athanasopoulos, S. 1167
PRESENTER INDEX	Albiero, M. 398	Auddino, S. 460
	Alieva, A. 883	Avgousti-Varela, I. 558
SATELLITE SYMPOSIA	Alkady, H. 835	Avolio, A. 454
	Almdal, T. 368	Aziz, F. 331
	Alqarni, A. 665	Aziz, M. 1190
INDUSTRY	Alshannaq, H. 936	Baek, J. 376
	Altaie, N. 796	Baek, J.-H. 84
PROGRAMME	Altrogge, J. 1236	Bai, M. 1071
	Álvarez Hernández, E. 578	Baier, J. M. 1146
EXHIBITION	Alzaid, F. 1212	Baker, C. J. 1103
	AlZaim, I. 1138	Balazova, L. 575
	Alzebdeh, L. 944	Balkhiyarova, Z. 286, 1227
THANKS	Amaro, A. 1031	Bally, L. LBA 71
	Ammi, M. 324	Banerjee, S. 1187
	Amouyal, C. 258, 794	Bannon, C. 506
	Amuedo, S. 566	Baranowski, B. J. 227
	Anagnostakis, F. 246	Barchetta, I. 564
	Anandhakrishnan, A. 862, LBA 69	Barigou, M. 584
	Anastasiou, I. A. 144	Bartolomé, A. 424

Last Name, Initials, Presentation Number

Barton, S.	1203	Byambasukh, O.	1091
Basco, D.	635	Cadogan, S.	1006
Bassas Letissier, N.	791, 831	Cai, Z.	588
Basu, L.	711	Calderon, E.	377
Bayona, A.	1202	Calders, P.	603
Beato Vibora, P.	905	Callebaut, A.	164
Behan, T. D.	842	Camoin, M.	1155
Ben-Zvi, D.	396, 534	Campos Campos, M.	1258
Benhalima, K.	845, 1010	Cañeque-Rufo, H.	636
Bergdal, R.	LBA 30	Canha, D.	206
Berk, K. A. C.	LBA 35	Cao, B.	463
Berrada, L.	914	Cao, X.	320, 1038
Berry, S. A.	825	Cao, Y.	565
Bhagat, V.	418	Capece, U.	1129
Bhattacharjee, R.	1035	Capobianco, M.	1168
Bi, Y.	1210, 1252	Caramelo, B.	671
Billings, L. K.	276	Cardoso, P.	131
Binsch, C.	296	Carey, E.	884
Birkenfeld, A. L.	153	Carrieri, F.	353
Blok, L. C. H.	393	Carvalho, M. S.	252
Bódis, K. B.	1188	Casagrande, V.	1162
Bogdanov, P.	1082	Casey, C.	1232
Bogun, M. M.	17	Castillo, K.	1012
Bolek, T.	682	Castro Cabezas, M.	1121
Bonfield, G.	270	Cezard, G.	204
Borbjerg, M. K.	1051	Chai, S. M. H.	341
Borg, M. J.	815	Chan, W.	860
Bouzid, R.	326	Chapeau, D.	110
Braffett, B.	55	Chen, C.	659
Brahma, M. K.	685	Chen, H.	892
Briand, F.	767	Chen, L.	976
Briere, D. A.	738	Chen, Q.	912
Brors, K.	649	Chen, S.-Y.	453
Bru-Tari, E.	112	Chen, S.-P.	527
Brunasso, A.	530	Chen, W.	186
Brunetti, M.	1245	Chen, X.	1197
Bruns, A.-F.	1139	Chen, Y.-W.	713
Buch, A.	605	Chen, Y. Y. F.	749
Buckle, I.	438	Cheng, A. Y. Y.	181, 895
Busch, R. S.	83	Cherkaoui, I.	422
Buse, J. B.	127	Ching, M. E. A.	693
Butaye, F.	255	Chiriaco, M.	5, 529

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Last Name, Initials, Presentation Number

	Cho, S.	1224	de Wit, D. F.	315
	Choi, M.	992	DeFronzo, R. A.	61
	Choi, W.-I.	552	Del Zoppo, A.	197
	Chon, H.	226, 730	Delgadillo Silva, L.	109
	Choong, L. L. Y.	757	DeLong, T.	419
	Chow, E. Wing. Kar.	LBA 05	Demirkan, A.	285
GENERAL INFO	Christie, H. E.	507	Demizieux, L.	192
	Ciccarelli, G.	446	Deng, W.	1097
	Cimbalo, N.	159	Deng, Y.	533
PROGRAMME	Cimini, F. A.	583	Deng, Y.	88
TUESDAY	Citro, F.	1017	Desiderio, A.	698
	Claessen, H.	343	Desouter, A. K.	92
WEDNESDAY	Clemente-Postigo, M.	737	DeVries, J.	921
	Cline, D. L.	641	Dewhurst-Trigg, R. E.	433
THURSDAY	Colabufo, C.	1127	Dey, B. Kumar.	1036
	Colbert, P. L.	163	Di Gioia, L.	896
FRIDAY	Connery, L.	183	Di Giuseppe, G.	528
	Corcoy, R.	87	Di Marco, M.	1194
	Crawford, M.	937	Di Molfetta, S.	867
SHORT ORAL DISCUSSIONS	Croos, J. S.	863	Dickerson, M.	111
	Csanalosi Artigas, M.	621	Diederich, W.	709
	Csermely, A.	402, 854	Dietvorst, C. A. W.	775
PRESENTER INDEX	D'Antuono, A.	1152	Dimova, R.	LBA 83
	D'Onofrio, L.	1066	Diniz, M. S.	1033
	Da Porto, A.	312	Dinsdale, M. M.	194
SATELLITE SYMPOSIA	Dahl, D.	894	Đlasková, A.	496
	Dahl, K.	63	Doi, Y.	1233
	Dai, Z.	1209	Domazet, S. L.	549
INDUSTRY	Darmon, P.	875	Dominguez-Villar, M.	397
PROGRAMME	Darsalia, V.	40	dos Santos, R.	489
	Das, N.	477	Dou, Y.	339, 340
EXHIBITION	Das Sharma, A.	455	Doucette, C. A.	448
	Davies, M. J.	73	Dovc, K.	49
	Davis, T. M. E.	141, 1173	Drareni, K.	LBA 65
	Davis, W. A.	1193	Dry, S. EC. RA.	840
THANKS	De Block, C.	871	Du, C.	435
	De Domenico, F.	1132	Duda-Sobczak, A.	233, 1239
	De Franco, E.	265	Duraiswamy, M.	780, 1021
	de Koning, E. J.	166	Ebert, T.	123
	De Lorenzi, V.	499	Eckert, A. J.	18
	De Meulemeester, J.	54	Efthymiou, V.	812
	de Villa, F. P.	985	Egeberg, F.	LBA 28

Last Name, Initials, Presentation Number

Ehrmann, D.	116, 390	Francis, H.	1163
Eichenlaub, M.	851	Francis, J.	223
Ekim, B.	485	Freitas, B.	229
Ekinci, E.	616	French, J.	1179
Elbarbary, N.	918	Frimodt-Møller, E. K.	1160
Elding Larsson, H.	407	Fu, D.	1023
Eldor, R.	890	Fu, S.	758
Elhenawy, Y.	891	Fujiki, T.	722
Elksnis, A.	777	Fürnsinn, C.	525
Elliott, J.	908	Gabr, Z.	994
Eng, P.	1008, 1020	Gabriel, R.	1072
Englund, A.	714	Gaich, G.	LBA 14
Eriksen, A. Ulrich.	1186	Gallo, S.	1182
Eriksen, L. B.	6	Gao, T.	1094
Escalada, J.	898	Garcia Serrano, S.	291
Fadini, G.	LBA 54	Garden, G. L.951, 1235
Fan, K.	625	Garg, S.	130
Fan, S.	1220	Garofolo, M.	1135
Fan, Y.	913	Garvey, W. T.	190, LBA 43
Fanni, G.	717	Gasser, M.	428
Farnsworth, N. L.	491	Gebretsadik, E. T.	1215
Fedulovs, A.	305	Geng, X.	1078
Fejfarová, V.	1118	Gerst, F.	470
Fenaux, M.	135	Geurts, K. A. M.	785
Feng, Q.	80	Ghanem, S. S.	430
Feng, R.	58	Ghosh, A.	672
Ferdousi, M.	1063	Giagourta, E.	394
Fernandes, J.	148	Giambalvo, M.	971
Féron, F.	1061, 1113	Giangreco, F.	1069
Ferrara, A.	338	Giannakogeorgou, A.	180
Fiorenza, M.	LBA 48	Gibb, F.	887
Fiorina, P.	873	Gillard, P.	LBA 91
Firneisz, G.	1004	Gillespie, K. M.	408
Flabouris, K.	375	Girguis, M. S.	800
Flegka, V.	568	Gisinger, T.	1165
Fleming, T.	628	Glynn, L.	202
Folli, F.	25	Gmitrov, J.	1092
Fonnesbech-Wulff, C.	LBA 55	Gohlke, S.251, 724
Forbes, J. M.	956	Goldney, J.	388
Ford, B.	690	González-Casimiro, C. M.	497
Foti, F.	742	Goodman, I.	888
Fowles, D. J.	950	Goonoo, M.	1107

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Last Name, Initials, Presentation Number

	Gosmanov, A.	195	Hao, Y.	728
	Gottfried, J.	382	Hardikar, A.	279
	Gotthardt, M.	716	Hardikar, H.	501
	Gottlieb, R.	879	Hashimoto, Y.	1196
	Grace, S. L.	93	Hassanein, M.	799
	Grandl, G.	526	Hatlen, K.	314
	Greco, F.	1237	Haueise, T.	9
	Gribble, F. M.	510	Haugaard, S.	1096, LBA 15
	Gribsholt, S.	327	Hayashi, T.	306
	Grieco, G. E.	493	He, M.	562
	Grill, V.	LBA 92	Heald, A.	734, LBA 77
	Grilo, L. F.	632	Heimbürger, S.	707
	Groegler, J.	437	Heinonen, S. M.	676, 753
	Guan, A.	1110	Hellgren, M. I.	1117
	Guerci, B.	52, 205	Helsted, M. M.	77
	Gugliandolo, S.	198	Hendriksz, M. S.	599, 857
	Gui, W.	727	Henke, L.	577
	Gullaksen, S.	1137	Henriksen, K.	809
	Gulseth, H. L.	380	Herbers, E.	746
	Gundersen, T. W.	347	Hermanns, N.	1223
	Gunnarsson, S.	41	Hernandez-Baraza, L.	1034
	Guo, H.	970, 1003	Hernansanz, J.	278
	Guo, L.	770	Hernanz, M.	425
	Gupta, K.	587	Hernar, I.	115
	Gurgul Convey, E.	490	Hesse, D.	687
	Gurieva, I.	593	Hinds, C.	768
	Habte-Asres, H.	1000	Hinduja, A.	1073
	Hadjadj, S.	779	Hjelmæsæth, J.	147
	Haedersdal, S.	LBA 11	Hofer, G.	1221
	Häfele, L. E.	468	Hogan-Lamarre, S.	701
	Hagberg, C.	747	Hollstein, T.	752
	Haim, Y.	721	Hong, J.	585
	Hall, L. G.	547	Hong, J.	789
	Halling, J. F.	686	Hong, S.-H.	282
	Haltia, H.	150	Hornigold, D. C.	771
	Haluzik, M.	639	Horvath, C.	741
	Haluzík, M.	928	Housby, H.	117, 120
	Hamza, M.	211, 268	Hu, M.	560
	Han, S.	604	Hu, Y.	1046
	Handley, D.	LBA 03	Hu, Y.	597
	Hansen, A.	11	Huan, Z.	404
	Hansen, C. A.	361	Huang, I.	1192

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Last Name, Initials, Presentation Number

Huang, M.	982	Johnson, R. K.	273
Huang, N.	954, 1001	Jollet, M.	648
Huang, W.	598	Jouannot, O.	165, 400
Hukema, F. W.	745	Jude, E.	371
Hulstrom, V.	1151	Junges Moreira, R.	1254
Humphrey, R.	LBA 29	Juraneck, J. K.	1084
Hwu, C.-M.	958, 995	Just Maarbjerg, S.	189
Iacobelli, M. R.	399	Juza, A.	1009
Ikeda, K.	692	Kabbani, N.	LBA 13
Ilavská, L.	1085	Kabeya, Y.	329
Imai, S.	781	Kabibulatova, A.	328
Imaizumi, T.	1191	Kabisch, S.	776
Incedal Nilsson, C.	LBA 72	Kabthymmer, R.	162, 348
Inzucchi, S. E.	2	Kadiyala, N.	51
Irace, C.	870	Kahn, S. E.	710
Ishibashi, R.	1079	Kaicker, A.	161
Itkonen, S.	98	Kaldis, P.	591
Ivanova, S.	782	Kalin, K.	802
Iwamoto, H.	1128	Kamel, I.	354, 1131
Iwamoto, Y.	482	Kaminskyi, O. V.	611
Iwasa, Y.	670	Kamruzzaman, M.	787
Izumi, R.	824	Kanai, A.	478
Jackson, G. D.	232	Kaneko, S.	991
Jacq, X.	65	Kania, M.	880, 1242
James, E.	546	Karamanakos, G.	1231
Jancev, M.	248	Karayiannides, S.	199
Jancovicova, A.	652	Kasher Meron, M.	943
Jang, H.	651	Katra, B.	1109
Jansz, T.	125	Kaul, P.	1247
Januszewski, A. S.	1166	Kawahara, R.	504
Januszewski, A. S.	243	Kawaharata, W.	352
Jawurek, S.	436	Keidai, Y.	718
Jefroykin, J.	1088	Keller, A. C.	729
Jendle, J.	868	Keller, M. Julian.	545
Jensen, J. S.	269	Kender, Z.	1075
Jeong, H.-J.	609	Kerkadi, A.	308
Ji, L.	62, 869, LBA 57	Keysendal, E.	349
Jiao, T.	1140	Kézdi, Á.	856
Jin, Y.	385	Khamis, A.	294
Jin Hwa, K.	592	Kim, H.	389
Johansen, R. F.	538, 543	Kim, H.	LBA 73, LBA 95
Johnson, M. B.	72	Kim, J.	81

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Last Name, Initials, Presentation Number

	Kim, J. 819	Kvist, A. A. S. 346
	Kim, J. 999	Kvist, A. V. 46
	Kim, M. 471	Kwok, R. 978
	Kim, M. 561	Kyi, M. 833
	Kim, S. 1123	Kyrillos, F. 1050
	Kim, S. 132	Laalaoua, Y. 440
GENERAL INFO	Kim, S. 174	Lago Sampedro, A. 277
	Kim, S. 381	Lahiri, A. 330
	Kim, S. LBA 42	Lai, F. 90
PROGRAMME	Kim, S. LBA 47	Laimon, W. N. 823
	Kim, Y. 284	Laitinen, A. 535
TUESDAY	Kim, Y. 765	Lambadiari, V. 945
	Kimura, T. 694	Lambert, F. 684
WEDNESDAY	Kjær, S. K. 517	Lampsas, S. 1086
	Klein, K. R. 76	Lapinska, L. 736
THURSDAY	Klein, T. 187	Larroumet, A. 865
	Knecht, L. 813	Larsen, U. 457
FRIDAY	Knoch, K.-P. 502	Lartigue, R. 429
	Knoph, R. 940	Laterveer, R. 723
SHORT ORAL DISCUSSIONS	Kober, Y. 1045	Latva-Rasku, A. 626
	Koning, M. 175	Lauand, F. 929
	Konings, L. A. M. 623	Launbo, N. P. 544
PRESENTER INDEX	Korakas, E. 677	Laurberg, T. 372
	Kordonouri, O. 1238	Laurenzi, A. 910
	Kosijer, P. 654	Laursen, C. F. G. 762, 1174
SATELLITE SYMPOSIA	Kotte, M. 216	Lavens, A. 44, 48
	Koudelkova, K. 524	Le, T. 264
	Koutroukas, V. 932	Le Roux, E. 697
INDUSTRY	Kovzun, O. 760	Leandersson, M. R. 103
PROGRAMME	Krako Jakovljevic, N. LBA 09	Lebertova, L. 756
	Krasniqi, V. 239	Lecube, A. 647
EXHIBITION	Kristiansson, E. 536	Lee, D.-H. 351
	Kristoffersen, S. F. 119	Lee, D. 570, 660
	Kronborg, T. 911	Lee, E.-Y. 983
	Kruf, A. 421	Lee, H. 644
THANKS	Kruit, J. K. 447	Lee, J. 853
	Kruse, R. 610	Lee, J. Yi. 12
	Kuhre, R. E. 188	Lee, K.-W. 225
	Kulecki, M. 1055, 1062	Lee, M.-S. 657
	Kulzer, B. 899	Lee, S. 669
	Kumar, A. 532	Lee, S.-A. LBA 16
	Kun, A. 1026	Lee, T. T. M. 1007

Last Name, Initials, Presentation Number

Lee, W.-Y.	1125	Liu, M.	828
Lee, Y.-H.	553	Liu, Q.	LBA 31
Lee-Ødegård, S.	643	Liu, S.	1177
Leihener, A.	938, 939	Liu, S.	617
Leksic, G.	1011	Liu, Y.	237
Lender, D.	128	Liu, Y.	322
Leveau, C.	531	Liu, Y.	805
Li, D.	179	Ljubic, S.	412
Li, G.	297	Ljungberg, C.	196, 790
Li, L.-J.	1025	Lobato, C. B.	858
Li, L.	200	Løhde, J.	358
Li, S.	518	Lopes, E.	740
Li, X.	572	Lopez-Pedrosa, J. M.	373
Li, X.	893	Lorenc, D.	480
Li, X.	930	Lu, J. C.	906
Li, Y.	1080	Lu, Y.	8, 32
Li, Y.	663	Lu, Y.	830, 874
Li, Y.	754	Lucove, J.	313
Li, Y.	78	Ludwig, L.	LBA 40, LBA 46
Li, Z.	703	Luganceva, A.	881
Li-Gao, R.	784	Luna-Marco, C.	LBA 78
Liang, G.	846, 847	Lundqvist, M. H.	600
Liarakos, A. L.	841	Luo, S.	LBA 01
Liggett, C. M. H.	481	Lytrivi, M.	53
Lin, D.	363	Lyu, Y.	620
Lin, H.	290, 357	Ma, S.	786
Lin, J.	980	Maagensen, H.	70, 272
Lin, X.	719	MacGregor, K. A.	293
Lindén, D.	569	Madsen, M. D.	1064
Linder, T.	LBA 08	Maedler, K.	420
Lindqvist, A.	814	Mailhac, A.	681
Linge, J.	1195	Majewska, M.	494
Lisakovska, O.	574	Malbert, C.	817
Liskiewicz, D.	766	Maldar, A. N.	1201
Lithovius, R.	955	Malinska, H.	520
Liu, C.	79	Mallik, R.	1249, LBA 23
Liu, F.	1257	Mamjoud, I.	666
Liu, F.	968	Mancilla Fuentes, R.	104
Liu, H.	1213	Manco, M.	735
Liu, J.	731	Mandal, S.	818
Liu, K.	1255	Mangani, A.	171
Liu, L.	1052	Manoharan, M.	1041

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Last Name, Initials, Presentation Number

	Marassi, M. LBA 44	Mueller, A. 542
	Marí, H. 550	Muk, T. 97
	Marlier, H. 744	Mukherjee, O. 658, LBA 63
	Martens, T. LBA 96	Mukhuty, A. 476
	Martin-Vazquez, E. 113	Mullen, J. 1076
	Martine-Edith, G. 207	Muminova, S. 977
	Masaoka, S. 1032	Munda, A. 1019
	Mason, A. C. 281	Munoz, F. 427
	Mateus Goncalves, L. 114	Murphy, R. LBA 49
	Matheou, A. 240	Murray Leech, J. 68
	McCarthy, O. M. 57	Mustafajev, I. F. 1204, 1206
	McInerney, A. 1226	Mutailipu, K. 300, 755
	McNally, E. 886	Mutter, S. 957
	McVean, J. 50	Nadukkandy, A. S. 1142
	Meftah, S. 1053	Naemi, R. 1068
	Meguro, S. 997	Nag, S. 456
	Mehta, K. 247	Nagy, J. E. 751
	Melini, S. 1058	Nakamura, T. 167
	Men, L. 1136	Nakamura, Y. 1207
	Merchant, H. J. 1159	Nanayakkara, N. 864
	Mertes, B. 613	Narendran, P. 20, 409
	Mesa, A. 1153	Nattero Chávez, L. 1077
	Mietkiewska-Dolecka, M. 1130	Nazir, S. 15
	Milad, C. 696	Neibig, W. 1040
	Min, T. 596	Nelson, C. 804
	Minnion, J. 224	Nesti, L. 105
	Mitani, F. 495	Ng, F. Chi. Kin. 582
	Mohamed, R. A. 1070	Ngan, J. 877
	Molefe-Baikai, O. J. 307	Nguyen, T. N. 1185
	Mondal, A. 1060	Nguyen, T. X. 988
	Monfort-Pires, M. 655	Nielsen, A. B. LBA 06
	Moon, J. 1105	Nielsen, S. W. 509
	Morciano, C. 788	Nielsen, T. L. 242
	Moreno-Perez, O. 797, 961	Nijpels, G. 996
	Morgenroth, Y. 451	Nikontovic, A. 839, 844
	Moriconi, D. 39	Nitsche, A. 176
	Morieri, M. 1122	Niu, J. 321
	Mosenzon, O. LBA 17	Niu, T. 1253
	Moser, O. 540, 803	Nocquet, L. 465
	Motegi, M. 1048	Noll, C. 702
	Moyama, S. 778	Nørlev, J. 925
	Muallem, H. 700	Nørlev, J. T. D. 924

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Last Name, Initials, Presentation Number

Novikoff, A.	764	Panzer, J. K.	467
Novodvorsky, P.	900	Pappa, S.	615
Nowak, J.	704	Parambath, M.	469
Nowak-Szwed, A.	1149	Parenti, M.	172
Nyiraty, S.	917	Parhofer, K. G.	1126
O, C.	629	Park, H.	1216
Ogawa, T.	606	Park, Y.	680
Oger, F.	462	Parr, E. B.	158
Oh, T.	444	Pastorino, M.	739
Ohwaki, K.	LBA 56	Paszek, M. W.	466
Ojo, O.	1198	Patel, N.	1039
Oksana, V.	1157	Patibandla, C.	414
Olesen, T.	142, 1054	Patil, S.	14, 1093
Oliveira, K. Moreno de	LBA 67	Patsoukaki, V.	47
Olsen, M. T.	832	Paulsson, E.	1241
Oluwagbemigun, K.	56	Pavis, G. F.	LBA 36
Omar Alsaleh, A.	442	Pavlou, P.	909, 990
Ong, K. L.	1199	Pec, M.	LBA 53
Oosterom, N.	619	Peer, N.	367
Orazumbekova, B.	280, 362	Peifer-Weiß, L.	551
Ortega, R.	461, 475	Pemberton, J.	257
Ortiz de Zevallos, J.	213	Peng, X.-R.	522
Ortiz Zúñiga, Á.	1108	Pereira, M. J.	646
Osmanovic, A.	567	Perez Manghi, F.	217
Ostinelli, G.	808	Pérez Reyes, P.	1240
Otani, D.	450	Perezalonso-Espinosa, J.	334
Oteri, V.	903	Peters, A. L.	866
Otsuka, T.	1133	Petkovic, M.	59
Otten, J.	156	Petrazzuolo, A.	967
Oualla Bachiri, W.	10	Petrelli, A.	395, 439
Ozdede, M.	122, 960	Petriskova, L.	656
Pafili, K.	LBA 51	Pezzica, S.	699
Paget, D.	661	Pfabe, J. U.	449
Pahk, K.	556	Pfeiffer, A. F. H.	642
Pahwa, H.	486	Phan, N.-Q.	350
Painter, R. C.	LBA 07	Phee, A.	1016
Palano, M.	1056	Philipson, L.	24
Paliaras, I. C.	201	Philis-Tsimikas, A.	182
Pallo, L. P.	432	Piaggese, A.	1115, 1116
Pan, L.	LBA 26	Picard, F.	608
Panagiotou, G.	548	Picard, S.	902
Pande, A.	379	Pieri, B. A.	882

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Last Name, Initials, Presentation Number

	Pigeyre, M. 1013	Rastogi, A. 1101, 1119
	Pillutla, S. 1027	Ratzki-Leewing, A. 208, 926
	Pimiä, E. K. 907	Rawal, S. 234
	Pintado Losa, C. 640	Rawshani, A. 798
	Pinto-Hernandez, P. 289	Rebelos, E. 513
	Pirozzi, C. LBA 86	Reimann, F. 668, 810
GENERAL INFO	Pithová, P. 1243	Reininger, L. 473
	Plante, D. K. 834	Reinisch, I. 678
	Plattner, T. 304	Rella, M. 483
PROGRAMME	Pless, C. 505	Renaud, C. 423
TUESDAY	Pliouta, L. 576	Renklint, R. 618
	Podesta, I. 859	Rennison, H. J. 1158
WEDNESDAY	Pollastri, A. 759	Retford, M. 792
	Polvé, D. 602	Rewers, M. 406
THURSDAY	Pop-Busui, R. 100, 1171	Riahi, Y. 254
	Popescu, A.-I. 763	Ribeiro, P. V. 715
FRIDAY	Popp, K. H. 154	Rimpeläinen, K. 85
	Por, C. W. S. 1024	Riveline, J.-P. 365, LBA 27
	Pramanik, S. 1087	Rózycka-Kosmalska, M. 579
SHORT ORAL DISCUSSIONS	Pratley, R. LBA 13	Roca-Rivada, A. 95
	Pratt, E. 129	Rodbard, D. 852
	Preskou, M. K. 622, LBA 89	Rodbard, H. 218
PRESENTER INDEX	Pricci, F. 411	Rodbard, H. W. LBA 24
	Prokopenko, I. 283	Roden, M. 555
	Promislow, S. 1104	Rodríguez de Vera Gómez, P. 45
SATELLITE SYMPOSIA	Pujeri, N. V. 292	Rodríguez Despradel, J. 962
	Purcell, A. R. LBA 87	Røikjer, J. 60
	Qiao, J. LBA 64	Rolandsson, O. 386
INDUSTRY	Qiao, L. 573	Rondinone, C. 769
PROGRAMME	Qiu, J. 498	Rong, J. 155
	Qiu, Y. 1111	Roointan, A. 922
EXHIBITION	Quadri, F. 878	Rosager, E. V. 333
	Quah, P. 337	Rosendo-Silva, D. 26
	Quansah, D. 1018	Rosenskjold, J. 843
	Quiros, C. 260	Rosenstock, J. 184
THANKS	R, P. 1180	Rossi, C. Alberto. 614
	Radlinger, B. 1106	Rotbain Curovic, V. 837
	Raggi, F. 986	Rothenbühler, M. LBA 90
	Raho, I. 580	Ruan, Y. 27, 695
	Raposo, J.-F. 262, 1169	Rubio, B. M. 708
	Rasmussen, N. 82	Rui, S. 1098, 1102
	Rasmussen, R. S. 508	Russ-Silby, J. 271

Last Name, Initials, Presentation Number

Russell-Jones, D.	876	Semeia, L.	1014
Russon, C.	236	Sen, S.	1141
Ryang, S.	920	Seo, B.	705
Ryder, R. E. J.	LBA 50	Serhiyenko, V.	1074
Sabaratnam, R.	516	Seufert, J.	1154
Sabatini, S.	31	Sevits, K. J.	107
Saber, L.	230	Shaat, N.	267
Sacre, J. W.	1172	Shaikh, A.	946
Sager La Ganga, C.	1114	Shao, Q.	LBA 41
Sagili, H.	1028, 1043	Sharabi, K.	571
Saidi, A. N.	557	Sharma, A.	345
Sakai, T.	1081	Sharma, B.	1225
Saluja, S.	124	Sharp, L. N.	67
Samos, M.	806	Shen, J.	1184, 1200
Sandforth, A.	319, 384	Shi, M.	LBA 93
Sandhurst, E. S.	392	Shibata, M.	355
Sandsdal, R. M.	138	Shin, J.	1189
Sane, R.	581	Shinde, S. N.	706
Sanfilippo, S.	235, 541	Shooshtarian, A. K.	885
Santoni, L.	108	Shouma, A.	1161
Sardar, A.	1170	Shu, Z.	452
Sarkar, S.	484	Sibiak, R.	86
Sarnobat, D.	675	Siklova, M.	519
Sato, T.	1251	Silva, P. N.	459
Satoh, H.	974	Silva, V.	139
Sawatani, T.	253	Simó-Servat, O.	836
Saxena, A.	855	Sims, E.	23
Schaarup, J.	1228	Singh, N.	374
Schechter, M.	193, LBA 82	Singh, S.	691
Schierbauer, J.	210	Singla, S.	13, 16
Schill, S. S.	21	Sinha, N.	500
Schmidt, K. R.	539	Siracusano, G.	405
Schmotz, C.	521	Sjogaard, M.	1047
Schön, M.	1089	Skop, V.	795
Schupp, E.	1205	Smink, A. M.	403
Schürfeld, R.	LBA 75	Snaith, J. R.	75
Scilletta, S.	725	Soeholm, U.	838
Scirè Calabrisotto, S.	259	Sokolovska, J.	1150
Scopelliti, M.	1230	Solà, C.	901
Sebastiani, G.	441	Soleim, S. B.	1178
Sebraoui, S.	43	Soliz-Rueda, J. R.	673
Selvarajah, D.	99	Somanath, P.	66

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Last Name, Initials, Presentation Number

	Song, K.-H.	387	Tan, H.	318
	Song, P.-S.	203, 1176	Tan, J. K.	356
	Song, S. H.	298	Tan, W.	1214
	Song, Y.	LBA 94	Tan, X.	LBA 19
	Sonne, N.	683	Tang, J.	266
	Sørnum, N. E.	91	Tang, S.	309
	Sun, G.	LBA 52	Tang, X.	133
	Sourij, C.	323	Tao, Y.	364
	Sourij, H.	821	Tappe, C.	464
	Sousa, D.	511	Tavajoh, S.	645
	Spencer, R. J.	458	Teh, M. M.	915
	Squintani, R.	96	Templeman, E.	22
	Sree, S.	523	Teng, Y.	537
	Sriram, A.	69	Tentolouris, A.	LBA 34
	Stanojevic, N.	1099	Teshima, A.	662
	Steens, I.	1222	Thabit, H.	889
	Stefanowicz, M.	748	Thennati, R.	LBA 58
	Steffan, D.	214	Thirunavuakarsu, B. F.	1030
	Stocks, B.	215	Thomaidis Brears, H.	LBA 60
	Stover, H.	168	Thomas, J. J. C.	916
	Stoyanov, S.	19	Thomas, T.	7
	Su Khin, K.	822	Thomsen, R. W.	360, 793
	Sugawara, L.	250	Tiwari, D.	772
	Sugiyama, T.	344	Tiwari, S.	1044
	Sugumaran, A.	1090	Tocantins, C.	1015
	Suleman, S. A.	726	Tokgöz, S.	688, 689
	Sun, B.	927	Tolmach, A.	941
	Sun, C.	1217	Toma, L.	1250
	Sun, K.	607	Tomas, A.	807
	Sun, Y.	1211	Tore, E. C.	1145
	Sun, Y.	160	Toussaint, B.	743
	Sun, Z.	1083	Tozzi, M.	149
	Svehlikova, E.	897	Tran, L. L.	134, 136
	Sygitowicz, G.	443	Tremblay, E.-J.	30
	Szablowski, M.	934	Trico, D.	177
	Szanto, I.	554	Trinh, X.	275
	Taguchi, R. S.	472	Triolo, T.	410
	Tajima, T.	816	Triolo, T. M.	401
	Takasawa, S.	170	Tripathi, P.	773
	Takeda, R.	712	Triplett, J. D.	1059, 1067
	Takele, W. W.	342, 1029	Tuomilehto, J.	152
	Tam, H. C. H.	288	Tynjälä, A.	238

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Last Name, Initials, Presentation Number

Tziannou, A.	209	Wang, X.	95
Ufer, G.	512	Wang, X.	503
Ukropec, J.	LBA 37	Wang, Y.	325
Ulz, M.	679	Wang, Y.	979
Urbancic-Rovan, V.	1234	Wang, Z.	964
Urbanova, J.	311	Wasehuus, V.	514
Usuelli, V.	431	Waterman, H.	631
Valdecantos, M.	811	Wei, Y.	3
Valdivia, L. F. G.	653	Weiskorn, J.	861
Valgaerts, L.	931	Wen, J.	998
Valverde Tercedor, C.	1037	Wen, Q.	64
Vamvini, M.	LBA 81	Werel- Oldziejewska, P.	595
van der Pluijm, L. A. K.	989	Westerbeke, F. H. M.	33
van der Velde, J. H. P.	244	Wharton, S.	145, 146
van Genugten, M.	949	Whitsett, N. H.	601
Van Poppel, N.	1120	Wiggers, A.	1219
Varughese, M. S.	140	Wilk, K.	1049
Velardi, V.	594	Wilkes, E.	LBA 04
Velasco-Andonegui, A.	624	Williams, C. L.	413
Venkataraman, K.	1112	Wilmot, E. G.	948
Vergès, B.	1124	With, C.	228
Verma, S.	LBA 21	Wolfenbuttel, B. H. R.	1246
Vernstrøm, L.	LBA 79	Wright, Jr., E. E.	935
Vessari, H.	923	Wu, H.	1005
Vianna, A.	872	Wu, H.	185
Vidal Trecan, T.	563	Wu, H.	391
Vilsbøll, T.	219, LBA 22	Wu, J. Jason.	827
Viñals, C.	1156	Wu, Q.	487
Virgilio, E.	71	Wu, S.	178, 664
Vivoli, A.	221	Wu, T.	245
Vuong, B. Tran.	28	Wu, X.	1144
Vuori, N.	143	Wu, Z.	1057
Waheed-Khan, A.	1143	Würfel, M.	973
Waibel, M.	220	Xia, M.-F.	36
Waki, H.	359	Xia, M.	850
Wang, F.	LBA 25	Xia, Y.	369
Wang, H.	474	Xiang, C.	634
Wang, J.	299	Xiao, F.	1100
Wang, N.	173	Xie, C.	801
Wang, Q.	370, 586	Xourafa, G.	241
Wang, S.	919	Xu, J.	34, 1095
Wang, W.	310	Xu, J.	37

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Last Name, Initials, Presentation Number

	Xu, S.	826	Zhang, T.	38, 972
	Xu, X.	126	Zhang, X.	1134
	Xu, X.	303	Zhang, Y.	1208
	Xu, Y. Y.	151	Zhang, Y.	LBA 59
	Xu, Z.	969	Zhang, Y.	LBA 84, LBA 85
	Yairi, I.	515	Zhao, G.	42, 612
	Yamazaki, M.	993	Zhao, L.	256
	Yang, J.-H.	1002	Zhao, Q.	720
	Yan, L.	LBA 39	Zhao, Y.	630
	Yang, J.	101	Zheng, J.	261
	Yang, J.-K.	LBA 76	Zheng, J.	952
	Yang, L.	LBA 80	Zheng, J.	LBA 38
	Yang, S.-I.	LBA 18	Zheng, X.	963
	Yavari, P.	1148	Zhichao, G.	249
	Yeh, H.-C.	1244	Zhong, T.	LBA 88
	Yesildag, B.	416, 479	Zhou, J.	191
	Yi, X.	488	Zhou, X.	1218, 1256
	Young, K.	316	Zhu, R.	559
	Yu, D.	157	Zhu, X.	589
	Yu, D.	LBA 10	Zhu, Y.	1164
	Yu, G.	263	Zimath, P. L.	492
	Yu, X.	121	Zindrili, R.	445
	Yuan, H.	415, 975	Zivkovic, J.	106
	Yung, J. H. M.	301	Zocchi, M.	627
	Zafar, A.	1183	Zorko, K.	848, 849
	Zaidi, S. E.	732	Zügner, E.	94
	Zalloua, P.	287	Zou, W.	LBA 61, LBA 62
	Zambre, S.	984		
	Zangen, S. W.	820		
	Zangerolamo, L.	637		
	Zarytovska, M.	829		
	Zatterale, F.	137		
	Zelniker, T.	1175		
	Zemer, A.	638		
	Zeng, Y.	966		
	Zhang, C.	981		
	Zhang, H.	774		
	Zhang, J.	1022		
	Zhang, J.	169		
	Zhang, J.	29		
	Zhang, J.	761		
	Zhang, S.	733		

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

INVITED SPEAKER

Last Name, First Name, Page

Adolfsson, Peter	54	Dey, Amit K.	38
Agarwal, Rajiv	64	Docherty, Kieran	94
Ahlgren, Ulf	68	Dotta, Francesco	92
Alfaris, Nasreen	63	Drucker, Daniel J.	29
Arai, Hidenori	90	Edison, Paul	92
Aroda, Vanita R	63	Ehrmann, Dominic	70
Atri, Alireza	43	Eizirik, Decio L.	108
Balbi, Carolina	65	Eriksson, Jan W.	40
Barbour, Linda A.	106	Evans-Molina, Carmella	29
Barroso, Inês	107	Farokhnia, Mehdi	92
Benhalima, Katrien	39, 69	Farrington, Jill	44
Bergental Richard M.	100	Ferrannini, Ele	71
Birkenfeld, Andreas L.	40	Finer, Sarah	41
Blondin, Denis P.	95	Fioretto, Paola	64
Bjornstad, Petter M.	31	Florez, Jose C.	40
Boëthius, Hanna	107	Foghsgaard, Signe	42
Bonnefond, Amelie	64	Forouhi, Nita G.	70
Boughton, Charlotte	39	Freckmann, Guido	107
Bozkurt, Latife	69	Frias, Juan P.	106
Bursac, Nenad	94	Gachon, Frédéric B.M.	68
Cadenas Sanchez, Cristina	67	Galindo, Rodolfo	79
Campbell, David J.T.	95	Gerhart-Hines, Zach	106
Campbell, Jonathan E.	68	Gerstein, Hertzal C.	66, 94
Carpentier, André C.	91	Göbl, Christian	69
Castera, Laurent	71	Gokalani, Rutul	38
Cavender, Matthew A.	42	Gregg, Edward W.	106
Chaturvedi, Nish	39	Gupta, Amit	52
Chimienti, Raniero	70	Haluzik, Martin	52
Choudhary, Pratik	50	Hannon, Tamara S.	90
Cicinelli, Maria V.	95	Hattersley, Andrew T.	20
Cnop, Miriam	80	Hebrok, Matthias	70
Colhoun, Helen M.	91	Heni, Martin	92
Conte, Caterina	54	Herder, Christian	69
Corcoy Pla, Rosa	106	Hermanns, Norbert	70
Dahl-Jørgensen, Knut	108	Hodges, Maria	65
D'Alessio, David	66	Hofer, Sabine	52, 80
De Block, Christophe	69	Holst, Jens J.	68
Del Prato, Stefano	44, 54, 80	Holt, Richard I.G.	63, 90
Deshmukh Atul S.	79	Hunt, Nicholas J.	66
DeVries, Hans J.	91	Hyoty, Heikki A.	108

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Last Name, First Name, Page

	Irace, Concetta	54	Mulder, Hindrik	65
	Jais, Alexander	79	Murphy, Helen R.	66
	Janez, Andrej	66	Newman, Daniel	40
	Jenkins, Alicia	95	Newsome, Philip N.	71
	Johnson, James D.	107	Nicholls, Stephen	66
	Jones, Angus	107	Nobels, Frank	82
	Jumpertz-vonSchwartzberg, Reiner	105	Nostro, Maria	70
GENERAL INFO	Kahn, C. Ronald	65	Olsen, Mikkel T.	61
	Kahn, Steven, E.	82	Oram, Richard	39
PROGRAMME	Kanc, Karin	63	Patel, Chirag J.	64
TUESDAY	Kar, Partha	107	Pearson, Ewan R.	64
	Karagiannis, Thomas	63	Pereira Marques, Inês	95
	Karalliedde, Janaka	40	Peters, Anne	90
WEDNESDAY	Kempfer, Péter	69	Petersmann, Astrid	107
	Lambers Heerspink, Hidido J.	64	Phillip, Moshe	39
THURSDAY	Larraufie, Pierre	65	Pieber, Thomas	29, 92
	Lauschke, Volker	94	Pivovarova-Ramich, Olga	68
FRIDAY	Lavens, Astrid	44	Pop-Busui, Rodica	42
	Law, Michelle	63	Raposo, Joao-Filipe	94
SHORT ORAL DISCUSSIONS	le Roux, Carel	54	Rawshani, Aidin	106
	Lean, Michael E.	70	Regazzi, Romano	65
	Lee-Ødegård, Sindre	67	Ren, Huixia	68
PRESENTER INDEX	Lingvay, Ildiko	42	Renard, Eric	80
	Liskiewicz, Daniela	106	Rewers, Marian	39
	Livingston, Gill	43	Riccardi, Gabriele	52
SATELLITE SYMPOSIA	Loskill, Peter	94	Richardson, Erica	50
	Lund, Jens	67	Ritchie, Scott C.	40
	MacDonald, Patrick E.	68	Rodriguez Manas, Leocadio	90
INDUSTRY	Maddaloni, Ernesto	105	Rossing, Peter	91
	Magliano, Dianna	39	Rutters, Femke	95
PROGRAMME	Malecki, Maciej T.	70	Rydén, Mikael	38, 54
	Mallone, Roberto	82	Sander, Maike	44
EXHIBITION	Marx, Nikolaus	42	Sandri, Marco	40
	Mathieu, Chantal	20, 39, 92	Scharfmann, Raphael	43
	McLaughlin, Tracey L.	69	Scherer, Philipp E.	91
THANKS	Meek, Claire	42	Schön, Martin	67
	Meems, Laura M.G.	91	Schürmann, Annette	65
	Mezza, Teresa	62	Sebastiani, Guido	100
	Misra, Shivani	79	Shaw, James A.M.	91
	Moffett, Charlotte	66	Sherr, Jennifer L.	100
	Mohan, Viswanathan	93	Sinclair, Alan J.	90
	Müller, Timo D.	68	Soleimanpour, Scott A.	44

Last Name, First Name, Page

Sourij, Harald	94
Spanakis, Elias K.	61
Speight, Jane	63, 91
Strachan, Mark	107
Sturt, Jacqueline	63
Suliman, Sara	42
Szadkowska, Agnieszka	90
Szendroedi, Julia	69
Taylor, Roy	82
Torekov, Signe S.	40
Tuomi, Tiinamaija	105
Valabhji, Jonathan	106
van der Velde Jeroen	68
van Sloten, Thomas T.	43
Vas, Prashanth	82
Veijola Riitta	31
Wabitsch, Martin	90
Webber, Matthew J.	66
Welsh, Paul	94
Wharton, Sean	63
Wolfrum, Christian	91
Wyckoff, Jennifer A.	106
Zangen, Sarah	44
Zhou, Zhichao	79
Ziegler, Anette-Gabriele	39
Zierath, Juleen R.	31
Zorzano, Antonio	52
Zoungas, Sophia	66

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

**SATELLITE SYMPOSIA
ON THE
OCCASION
OF THE
EASD ANNUAL MEETING**

DASG SYMPOSIUM

Mon, 15 Sept 2025

09:00 - 10:30

Cairo Hall

Chairs: Abdul Basit, Pakistan; Bishwajit Bhowmik, Bangladesh

Speaker: Banshi Saboo, India:

Welcome Address

V. Mohan, India:

Position statement on 1-Hour Plasma Glucose: Implications for Early Detection

Mohammed Hasnein, UAE:

Postprandial Hyperglycemia :A Distinct Metabolic Challenge of Asian population

Nadima Shegam, Jordan:

Why Asia is Ground Zero for the Global Epidemic of diabetes

Dai Yabe, Japan:

Leveraging Technology for Diabetes: Equity, Access, and Accuracy

Discussion

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Diabetes India SYMPOSIUM

Mon, 15 Sept 2025

11:00 - 12:30

Cairo Hall

Chairs: S. R. Aravind; Anuj Maheshwari; Rutul Gokalani

Speaker: S. R. Aravind:
Welcome Address

Shashank Joshi:
Pre-diabetes/intermediate hyperglycaemia: latest guidance and screening

B. M. Makkar:
Sarcopenia - Is that fuelling the Diabetes Epidemic

Sunil Gupta:
Addressing GDM Disparities: Preconception Care and Early Detection in High-Risk Communities

Manoj Chawla:
Elevating T2DM Care: Harnessing CGM for Smarter Treatment Decisions

Sanjay Agarwal
Indian T2DM and CKD - Learnings from the CITE study Discussion

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

DiabetPerio SYMPOSIUM

Periodontitis: The underestimated sixth complication of diabetes

Mon, 15 Sept 2025

13:00 - 15:00

Cairo Hall

Chairs: Luca Lione; Fancesco D’Aiuto

Speaker: Luca Lione; Fancesco D’Aiuto:

Introduction

Eduardo Montero Solis:

What are the periodontal and peri-implant diseases? Why are they associated with different systemic conditions?

Virginia Bellido; Fancesco D’Aiuto:

Periodontitis and diabetes: a bidirectional association

Edoardo Mannucci:

Periodontitis in Diabetes Clinics: what a Diabetologist can (should) do

David Gabriel; Eduardo Montero Solis:

Experiences from the real world

Discussion

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

DFSG SYMPOSIUM

What's going on in the world of the Diabetic Foot: guidelines, research, and outcomes

Mon, 15 Sept 2025

15:30 - 16:30

Cairo Hall

Chairs: Mateo López-Moral, Spain; Vladimíra Fejfarová, Czechia

Speaker: Mateo López-Moral, Spain:
Biomechanics and guidelines

Vladimíra Fejfarová, Czechia:
PAD and guidelines

Tarunveer S. Ahluwalia Denmark:
Genome-Wide Association Meta-Analyses Identifies Novel Loci for Diabetic Foot Ulcers

Patrick Lauwers, Belgium:
Independency after lower extremity amputation. Prescription of a functional prosthesis after major amputation, and degree of independent living after minor and major amputation in Belgium in the period 2009-2018

Dirk Hochlenert Germany:
18 years of shared care for 60,908 people with DFS improved outcomes, except for treatment duration

Michal Dubsy Czechia:
Long-term efficacy of autologous cell therapy, repeated PTA and conservative treatment in people with diabetes and chronic limb-threatening ischemia

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

NEUROdiab SYMPOSIUM

Treatment of diabetic neuropathy: realities and perspectives

Tue, 16 Sept 2025

08:30 - 10:00

Cairo Hall

Chairs: Triantafyllos Didangelos, Greece; Vincenza Spallone, Italy

Speaker: Harvey Davis, UK:

Unravelling the mechanism of reduced nerve blood flow in diabetic neuropathy

Pietro Guaraldi, Italy:

Symptomatic and pathogenetic treatment of autonomic neuropathy: updates from non-diabetic neuropathies

Shazli Azmi, UK:

Highlights from NEUROdiab Annual Meeting 2025: the Youth Committee perspectives

Solomon Tesfaye, UK:

Treatment of painful diabetic neuropathy: current status and future outlooks

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

D&CVD SG in cooperation with DCVD SG Diabetes India SYMPOSIUM
Focus on Early Reversion of Dysglycemia in Type-2 Diabetes
Benefits and Practicalities

Tue, 16 Sept 2025

11:00 - 13:00

Cairo Hall

Chairs: Katarina Lalic, Serbia; Jan Škrha, Czechia; Banshi Saboo, India

Speaker: Antonio Ceriello, Italy:

Welcome

Roy Taylor, UK :

Maximizing Cardiovascular-Kidney Benefit by a priori Aiming at Normoglycemia: the DIRECT Study Paradigm

Eberhard Standl, Germany:

Addressing the Cancer Connection upon Diagnosis of Dysglycemia: the Common Soil

Nebojsa Lalic, Serbia:

Central Role of CGM for Early Diagnosis and Reversion of Dysglycemia: Messages from a Recent Expert Consensus

Chairs: Dario Rahelic, Croatia; Oliver Schnell, Germany

Speaker: Paul Valensi, France:

Are GLP1-RA-Based Therapies Equally Effective as Metabolic Surgery in Attaining Normoglycemia?

Banshi Saboo, India:

Reversion of Dysglycemia in Type-2 Diabetes – the Asian (phenotype) challenge

Baruch Itzhak, Israel:

Practicalities including the use of AI for Early Reversion of Dysglycemia at the Primary Care Level

Doina Catrinou, Romania:

The Cardiovascular-Kidney-Metabolic Risk Cluster: Specific Approaches at a University Center

General Discussion and Close

GENERAL INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL DISCUSSIONS

PRESENTER INDEX

SATELLITE SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

DNSG SYMPOSIUM

Current evidence and research priorities for the role of nuts in cardiometabolic health: A focus on almonds

Tue, 16 Sept 2025

13:30 - 15:30

Cairo Hall

Chairs: Cyril Kendall, Canada; Hana Kalheova, Czechia/USA

Speaker: Maha Tahiri, USA:

Results of a roundtable process for defining the role of almonds in cardiometabolic health

John Sievenpiper, Canada:

Role of almonds in the prevention and management of diabetes

Anoop Misra, India:

Almonds and cardiometabolic health in at-risk South Asian populations

Laura Chiavaroli, Canada:

New research leveraging guidelines-based dietary patterns containing almonds for diabetes remission and cardiovascular disease prevention

Panel Discussion

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

ExPAS SYMPOSIUM

Ten Years in Motion: The Impact of Exercise and Physical Activity in Diabetes Prevention and Treatment

Tue, 16 Sept 2025

16:00 - 18:00

Cairo Hall

Chair: Jozef Ukropec, Slovakia

Speaker: Erik Richter, Denmark:
Interaction of exercise and insulin regulating glucose metabolism

Ruth Loos, Denmark:
Genes, Jeans and gyms: how lifestyle and genetics influence obesity risk

Richard Bracken, UK:
Significant Advances in Physical Activity and Diabetes Research: 10 years moving forward

Dominik Pesta, Germany:
Targeting Mitochondrial Dysfunction in Type 2 Diabetes: A Novel Role for Blood-Flow Restricted Resistance Exercise

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

HSRHE-SG SYMPOSIUM

The Double Burden: Obesity and Diabetes

Through the Lens of Health Services and Economics

Wed, 17 Sept 2025

09:00 - 11:00

Cairo Hall

Chairs: Andrea Icks, Germany; Ketan Dhatariya, UK

Speaker: Edward Gregg, Ireland:

The Epidemiological Weight of Obesity: Impacts on Diabetes and Health Systems

Francesco Rubino, UK:

Bridging the Gap: Insights from the Lancet Commission on Obesity for Diabetes Health Services

Michael Laxy, Germany:

Effectiveness and Budget Impact of GLP-1 receptor agonists for obesity management: Modelling Reimbursement Scenarios

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

PCDE SYMPOSIUM

Hot Topics in Primary Care Diabetes Management

Wed, 17 Sept 2025

12:00 - 13:30

Cairo Hall

Chair: Ana Cebrian Cuenca, Spain

Speaker: Ana Cebrian Cuenca, Spain:

Introduction

Samuel Seidu, UK:

Update On CKD/HF

Gabriel Cuatrecasas, Spain:

Obesity in Primary Care

F. Xavier Cos Claramunt, Spain:

Digital Health in Diabetes Primary Care Management

Pinar Topsever, Turkey:

Liver Disease in Primary Care Management

Q&A and Discussion

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

EUDF SYMPOSIUM

The new face of diabetes: EUDF recommendations for implementing disease modifying therapies and tackling diabesity

Wed, 17 Sept 2025

14:00 - 16:00

Cairo Hall

Chairs: Chantal Mathieu, Belgium; Stefano Del Prato, Italy

Speaker: Stefano Del Prato, Italy:

The European Diabetes Forum (EUDF): a forum for turning the tide on diabetes in Europe

Carmen Hurtado del Pozo:

Implementing disease modifying therapies in the clinic: recommendations from the EUDF Strategic Forum

Chantal Mathieu, Belgium; Sabine Hofer, Austria; Loredana Marcovecchio; Sufyan Hussain; Alessandro Sorrentino:

Round Table

Jean-François Gautier, France:

Tackling the interplay between obesity and diabetes: recommendations from the EUDF Strategic Forum

Stefano Del Prato, Italy;; Timo Müller, Germany; Gabriel Cuatrecasas, Eugenia Vlachou; Deniz Tutkunkardas; Georgios Dimitriadis:

Round Table

Q&A - Discussion

Chantal Mathieu, Belgium:

Wrap-up and Conclusion

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

MASLD SYMPOSIUM
MASLD and metabolic health:
expert perspectives and clinical insights

Wed, 17 Sept 2025

16:30 - 17:30

Cairo Hall

Chairs: Amalia Gastaldeli, Italy; Cyrielle Caussy, France

Speaker: Amalia Gastaldeli, Italy:

Introduction

Short talks and panel discussion with experts

Speaker: Laurent Castera, France

Onno Holleboom, Netherlands

Phil Newsome, UK

Michael Trauner, Austria

Michael Roden, Germany

Amalia Gastaldelli, Italy

Cyrielle Caussy, France

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

DESG SYMPOSIUM

TPE from concept to implementation

Thu, 18 Sept 2025

08:30 - 10:30

Cairo Hall

- Speaker:* Tatjana Milenkovic:
Introduction of the Symposium
- Jill Faringhton:
TPE from concept to implementation - from challenges to solutions
- Mohamed Hassanein:
TPE project in WHO-EMERO
- Joao Raposo:
TPE during consultations
- Questions and Answers**
- Moderators:* Dario Rahelic; Zelija Velija Ashimi
TPE in real life
- Speaker:* Tzvetalina Tankova
Bulgaria
- Cornelia Bala
Romania
- Mohamed Hassanein
UAE
- Florian Toti
Albania
- Banshi Saboo:
India
- Tatjana Milenkovic:
Next challenges to TPE

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

IDF EUROPE SYMPOSIUM

Advancing integrated diabetes care across Europe

Thu, 18 Sept 2025

11:00 - 12:30

Cairo Hall

Speaker: Tadej Battelino, Slovenia:

Welcome and opening remarks

Cajsa Lindberg:

What did we learn about personalisation of care at our last symposium?

Cajsa Lindberg; Ermal Nazifi:

The value of personalised and integrated care: a perspective from a person living with diabetes

Integrated care in action: country examples from Europe

Thomas Griffin, Ireland:

Integrated Care Programmes for Prevention and Management of Chronic Disease

Alexandre Lourenço, Portugal:

Integration of Population Based Care and Management through Local Health Units

Scott Cunningham, UK:

My Diabetes My Way – Personalisation and Integration

Cajsa Lindberg; Christine Haberland, Austria; Benedetta Armocida, Italy; Martin Clodi, Austria; Joao Raposo:

Panel discussion – Overcoming fragmentation: enablers, barriers and the path forward to integrated care

Audience Q&A

Tadej Battelino, Slovenia:

Closing remarks

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

PSAD SYMPOSIUM

Methods, impacts and implementation of the EASD Clinical Guidelines for assessing and managing Diabetes Distress

Thu, 18 Sept 2025

13:00 - 15:00

Cairo Hall

Chairs: Jane Speight, Australia; Richard Holt, UK

Speaker: Jane Speight, Australia; Richard Holt, UK:

Welcome

Francesco Zaccardi, UK:

Overview of the guideline development process

Jackie Sturt, UK:

Overview of the rapid realist review informing Good Practice Statements for assessing diabetes distress

Norbert Hermanns, Germany:

What are the Good Practice Statements for assessing Diabetes Distress?

Femke Rutters, Netherlands:

Overview of the meta-analysis informing Clinical Recommendations for managing diabetes distress

Karin Kanc, Slovenia:

What are the Clinical Recommendations for managing diabetes distress?

Moderator: Jane Speight, Australia:

Q&A with panel

Speaker: Michelle Law, UK; Walther Jensen, Denmark:

What this guideline means to us, as people living with diabetes

Richard Holt, UK:

Help! I'm not a psychologist: a medical professional's perspective on what this means in practice

Andrea Mocan, Romania:

Stay calm and carry on: a clinical psychologist's perspective on what this means in practice

Jane Speight, Australia:

Implementing the guideline: opportunities and challenges

Moderator: Richard Holt, UK

Q&A with panel

Speaker: Jane Speight, Australia; Richard Holt, UK:

Final remarks

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

#dedoc° SYMPOSIUM

Lived experience transforming diabetes care across professional and systemic levels: What we wish you know and why

Thu, 18 Sept 2025

15:30 - 17:00

Cairo Hall

Chair: Bastian Hauck; Renza Scibilia

Speaker: Bastian Hauck:

Opening Remarks

Chantal Mathieu, Belgium:

Words of Welcome

Sheila Lumsden, UK:

Improving Type 1 Diabetes Care Through Lived Experience and Good Governance

Myriam, Mikhael, Lebanon:

Wearing Two Coats: Living with Diabetes, Working in Science

Mark Tiller UK:

Improving my Type 2 Diabetes Management: Beyond Technology to Quality of Life

Gráinne Flynn, Ireland:

From the Clinic to the Community: The Role of Healthcare & Research Professionals in Peer-Led Diabetes Initiatives

Q&A

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

EGIR SYMPOSIUM

Unraveling the Paradox: Organ-Specific Insulin Resistance and Metabolic Cross-Talk in Metabolic Diseases

Thu, 18 Sept 2025

17:30 - 18:30

Cairo Hall

Chairs: Andrea Natali, Italy; Amalia Gastaldeli, Italy

Speaker: Antonio Zorzano, Spain:

Skeletal Muscle: Mitochondrial Dysfunction and Insulin Resistance

Maria Paula Macedo, Portugal:

Liver in the Spotlight: Emerging Pathways in Insulin Resistance

Domenico Tricò, Italy:

Cross-talk between adipose tissue and beta cell

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

IHSG SYMPOSIUM

Hypoglycaemia in the CGM era: Is what matters measured, and does what's measured matter?

Fri, 19 Sept 2025

08:30 - 10:00

Cairo Hall

Chair: Alexandria Ratzki-Leewing, USA

Speaker: Alexandria Ratzki-Leewing, USA:

Welcome & Introduction

David Moreno:

The lived experience of hypoglycaemia

Pratik Choudhary, UK:

Understanding non-severe hypoglycaemia

Ulrik Pedersen-Bjergaard, Denmark:

Revisiting severe hypoglycaemia

Julia Mader, Austria

Exercising without hypoglycaemia

Q&A and panel discussion

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

DIABIMAGE SYMPOSIUM

Insights from in vivo metabolic imaging by MRI/MRS and PET/SPECT

Fri, 19 Sept 2025

10:30 - 12:30

Cairo Hall

Chairs: Vera Schrauwen-Hinderling, Germany; Martin Krssak, Austria

Speaker: Louise Thomas, UK:

How the UK Biobank Imaging Study is MRI Redrawing the Landscape of Health

Lars Johansson, Sweden:

Imaging of diabetes/obesity and end organ protection

André Carpentier, Canada:

Adipose tissue metabolic dysfunction in prediabetes and type 2 diabetes: insights from molecular imaging

Discussion

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

SGGD SYMPOSIUM
Evolving landscapes in diabetes genetics

Fri, 19 Sept 2025

13:00 - 14:00

Cairo Hall

Chairs: Amna Khamis, France; Marcel den Hoed, Sweden

Speaker: Philippe Froguel, France:
Latest insights in the genetics of monogenic obesity

Elisa De Franco, UK:
Novel genetic discoveries in neonatal diabetes

Marcel den Hoed, Sweden:
Zebrafish larvae towards target identification, drug repurposing, and precision medicine in type 2 diabetes

Pål Njølstad, Norway:
Introducing the upcoming 2026 SGGD Meeting in Bergen

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

INDUSTRY SESSIONS

ON THE OCCASION
OF THE

61ST ANNUAL MEETING

EUROPEAN ASSOCIATION
FOR THE STUDY OF DIABETES

15 - 19
SEPTEMBER
2025
VIENNA
AUSTRIA

Organised by




INTERPLAN
media & service gmbh

#EASD2025
www.easd-industry.com

INDUSTRY SESSIONS

Monday, 15 September 2025

GENERAL INFO
PROGRAMME
TUESDAY
WEDNESDAY
THURSDAY
FRIDAY
SHORT ORAL DISCUSSIONS
PRESENTER INDEX
SATELLITE SYMPOSIA
INDUSTRY PROGRAMME
EXHIBITION
THANKS



INDUSTRY SESSIONS

Monday, 15 September 2025

Milan	Beijing	Chicago	Lima	Sydney	
					09:00
					09:30
					10:00
Abbott Diabetes Care					10:30
					11:00
					11:30
			Bayer AG	Amarin	12:00
					12:30
	SIBIONICS CGM & CKM	Boehringer Ingelheim International GmbH			13:00
					13:30
					14:00
					14:30
					15:00
			Daiichi Sankyo	Vertex Pharma- ceuticals, Inc.	15:30
					16:00
Sinocare Meditech Inc.	Medtronic International Trading Sàrl	Amgen			16:30
					17:00
					17:30
					18:00

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION


THANKS

INDUSTRY SESSIONS

Tuesday, 16 September 2025

- GENERAL INFO
- PROGRAMME
- TUESDAY
- WEDNESDAY
- THURSDAY
- FRIDAY
- SHORT ORAL DISCUSSIONS
- PRESENTER INDEX
- SATELLITE SYMPOSIA
- INDUSTRY PROGRAMME
- EXHIBITION
- THANKS

	Spotlight Stage	Arena	Beijing	Chicago	Lima	Sydney
11:30 12:00	SANOFI	Insulet				
14:15 14:45	Abbott	Sciarc				
16:15 16:45	Novo Nordisk A/S	SERVIER				
18:00						
18:30			Menarini Group	Merck Healthcare KGaA	Novo Nordisk A/S	Ypsomed Diabetes Care AG
19:00						
19:30						



INDUSTRY SESSIONS

Wednesday, 17 September 2025

	Spotlight Stage	Arena	Beijing	Chicago	Lima	Sydney
07:15						
07:45			Medscape Education Global	Medscape Education Global		
08:15						
11:15	Eli Lilly and Company	Bayer AG				
11:45						
14:00	Dexcom	Tandem Diabetes Care, Inc.				
14:30						
16:00	SANOFI	Medtronic International Trading Sàrl				
16:30						
17:45						
18:15			Boehringer Ingelheim & Eli Lilly and Company	AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC.	Novo Nordisk A/S	Pfizer Inc.
18:45						
19:15						

GENERAL INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL DISCUSSIONS

PRESENTER INDEX

SATELLITE SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

INDUSTRY SESSIONS

Thursday, 18 September 2025

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY
PROGRAMME

EXHIBITION

THANKS

Spotlight Stage

Arena

12:15
12:45

Novo Nordisk
A/S

SANOFI

15:00
15:30

Medtronic
International
Trading Sàrl

Metsera

17:00
17:30

Eli Lilly
and
Company

Novo Nordisk A/S
and
ECHOSENS



INDUSTRY SESSIONS

Friday, 19 September 2025

Spotlight Stage

09:30
10:00



Dexcom

11:00
11:30



Abbott

12:30
13:00



Roche



GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY
PROGRAMME
EXHIBITION

THANKS

MONDAY, 15 SEPTEMBER 2025

09:00 – 17:00
VIENNA HALL

REVOLUTIONISING CARDIOMETABOLIC HEALTH: INNOVATING, TRANSFORMING AND PROGRESSING CARE

Chairs: Alice Cheng (CAN)
Mikael Rydén (SWE)

Part 1: Exploring the background of person-centred care across the spectrum of related cardiometabolic diseases

09:00 – 09:15 The Prologue: welcome and introductions

Alice Cheng (CAN)
Mikael Rydén (SWE)

09:15 – 09:35 Chapter 1: Person-centred care – the evolving landscape and new horizons in obesity management

Carel le Roux (IRL)

09:35 – 09:55 Chapter 2: Person-centred care – the need for treatment of cardiometabolic diseases

John Buse (USA)

09:55 – 10:10 Chapter 3: Focus on PAD – synergistic strategies across ASCVD

Subodh Verma (CAN)

10:10 – 10:25 Chapter 4: Person-centred care – heart failure for people with cardiometabolic diseases

Michele Senni (ITA)

10:25 – 10:40 Chapter 5: Summarising the evidence for person-centered care across cardiometabolic diseases

All faculty

10:40 – 10:55 Coffee break

Part 2: Focusing in on an expanding spectrum of cardiometabolic diseases and patient phenotypes

10:55 – 11:00 Checking the contents page: welcome back

Alice Cheng (CAN)
Mikael Rydén (SWE)

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

MONDAY, 15 SEPTEMBER 2025

**09:00 – 17:00
VIENNA HALL**

- 11:00 – 11:15 Chapter 6: Focus on kidneys – synergistic strategies across cardiometabolic diseases**
Christoph Wanner (DEU)
- 11:15 – 11:35 Chapter 7: Focus on MASH – integrating emerging data into clinical pathways**
Laurent Castera (FRA)
- 11:35 – 11:50 Chapter 8: Focus on childhood – charting new paths in obesity management**
Antje Körner (DEU)
- 11:50 – 12:05 Chapter 9: Summarising the focus and translating it into clinical practice**
All faculty
- 12:05 – 12:45 Lunch**
- Part 3: Semaglutide and the path to holistic cardiometabolic disease care**
- 12:45 – 12:50 Checking the contents page: welcome back**
Alice Cheng (CAN)
Mikael Rydén (SWE)
- 12:50 – 13:15 Chapter 10: The prequel to semaglutide and the evidence that started the journey**
Anna Secher (DNK)
- 13:15 – 13:40 Chapter 11: The science of the cardiometabolic care – clinical evidence and perspectives**
Arya Sharma (DEU)
- 13:40 – 13:55 Chapter 12: The voice of the patient – hearing their call to action for personalised care**
A person living with CVD
- 13:55 – 14:10 Chapter 13: Summarising the journey and exploring the co-authors' views**
All faculty
- 14:10 – 14:25 Coffee break**

**GENERAL
INFO**

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

**SHORT ORAL
DISCUSSIONS**

**PRESENTER
INDEX**

**SATELLITE
SYMPOSIA**

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Part 4: The future chapters – advancing the management of cardiometabolic diseases

GENERAL
INFO

14:25 – 14:30 **Checking the contents page: welcome back**
Alice Cheng (CAN)
Mikael Rydén (SWE)

PROGRAMME

14:30 – 14:45 **Chapter 14: Advancements in nutrient-stimulated hormone therapies: the evolution of amylin**
Matthias Blüher (DEU)

TUESDAY

14:45 – 15:00 **Chapter 15: Advancements to clinical excellence in obesity through the potential of complementary biologics**
Timothy Garvey (USA)

WEDNESDAY

THURSDAY

15:00 – 15:15 **Chapter 16: Advancements across the metabolic disease continuum – expanding the evidence**
Melanie Davies (GBR)

FRIDAY

SHORT ORAL
DISCUSSIONS

15:15 – 15:30 **Chapter 17: Advancements in the treatment toolbox – integrating amycretin**
Ania Jastreboff (USA)

PRESENTER
INDEX

15:30 – 15:50 **Chapter 18: Summarising the advancements and looking to a future of clinical excellence**
All faculty

SATELLITE
SYMPOSIA

15:50 – 16:05 **Coffee break**

Part 5: Innovating our heritage – once-weekly basal insulin therapy

INDUSTRY
PROGRAMME

16:05 – 16:10 **Checking the contents page: welcome back**
Alice Cheng (CAN)
Mikael Rydén (SWE)

EXHIBITION

16:10 – 16:30 **Chapter 19: Innovation in basal insulins – individualised treatment in focus**
Athena Philis-Tsimikas (USA)
Harald Sourij (AUT)

THANKS

MONDAY, 15 SEPTEMBER 2025

**09:00 – 17:00
VIENNA HALL**

- 16:30 – 16:45** **Chapter 20: Innovation in combination insulin therapy – benefits beyond glycaemic control**
Linong Ji (CHN)
- 16:45 – 16:55** **Chapter 21: Summarising the innovation for people in need of insulin**
All faculty
- 16:55 – 17:00** **The Epilogue: summary and close**
Alice Cheng (CAN)
Mikael Rydén (SWE)

**GENERAL
INFO**

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

**SHORT ORAL
DISCUSSIONS**

**PRESENTER
INDEX**

**SATELLITE
SYMPOSIA**

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Organised by: Novo Nordisk A/S

MONDAY, 15 SEPTEMBER 2025

09:30 – 15:30
PARIS HALL

SANOFI SYMPOSIUM DAY

09:30 – 10:00 **Arrival & Welcome Coffee**

GENERAL
INFO

A New Dawn in T1D: How Early Screening and Intervention Could Light the Way to Improved Clinical Outcomes

Chair: Sabine Hofer (AUT)

10:00 – 10:10 **Welcome**
Sabine Hofer (AUT)

10:10 – 10:30 **The Reality of Early Identification: The New Imperative in T1D Management**
Anastasia Albanese-O'Neill (USA)

10:30 – 10:55 **Missed Signals – When T1D Goes Unrecognised**
Amir Tirosh (ISL)
Carmella Evans-Molina (USA)

10:55 – 11:15 **Beyond Diagnosis: Evolving Therapeutic Strategies in T1D**
Colin Dayan (GBR)

11:15 – 11:30 **Q&A and Summary**
Sabine Hofer (AUT)

11:30 – 12:00 **Lunch Break (compliments of Sanofi)**

Lunch & Learn with Beta - Scientific Insights Into Beta-Cell Function in Type 1 Diabetes

12:00 – 12:02 **Welcome and introductions**
Conan Tu (USA)

12:02 – 12:10 **Beta Cells: The foundation of glucose homeostasis**
Conan Tu (USA)

12:10 – 12:20 **T1D: A progressive autoimmune attack on beta cells**
Conan Tu (USA)

12:20 – 12:30 **The value of residual beta cell function to determine the course of a patient's journey**
Teresa Quattrin (USA)

12:30 – 12:38 **The future of T1D through the lens of beta cells**
Teresa Quattrin (USA)

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

MONDAY, 15 SEPTEMBER 2025

**09:30 – 15:30
PARIS HALL**

12:38 – 12:43 Q&A
Conan Tu (USA)
Teresa Quattrin (USA)

12:43 – 12:45 Session close
Teresa Quattrin (USA)

12:45 – 13:00 Break

Holistic and Simplified Approaches to Type 2 Diabetes Management: Let's act timely.

Chairs: Tadej Battelino (SVN)
Raffaella Buzzetti (ITA)

13:00 – 13:05 Welcome and introduction
Tadej Battelino (SVN)

13:05 – 13:15 The holistic approach: Embracing timely intervention to help address key challenges
Raffaella Buzzetti (ITA)

13:15 – 13:45 Second-generation basal insulins in T2D: Reaching glycemic targets with a low hypoglycemia risk
Samy Hadjadj (FRA)
Alexandria Ratzki-Leewing (USA)

13:45 – 14:15 Simplify management: A potential path for BI and GLP-1 RA FRCs to support better glycemic control in T2D
Rory McCrimmon (GBR)

14:15 – 14:45 Optimal lipid management to Prevent The Event
Klaus Parhofer (DEU)
Manuel Castro Cabezas (NLD)

14:45 – 15:00 Panel discussion and closing remarks
All faculty

15:00 – 15:30 Networking

Organised by: SANOFI

**GENERAL
INFO**

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

**SHORT ORAL
DISCUSSIONS**

**PRESENTER
INDEX**

**SATELLITE
SYMPOSIA**

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

MONDAY, 15 SEPTEMBER 2025

10:30 – 12:00
MILAN HALL

TECHNOLOGICAL ADVANCES AND THE EVOLUTION OF CGM-BASED MANAGEMENT OF DIABETES

GENERAL
INFO

10:30 – 10:50 **The Profound Positive Impact of Dual CGM and Ketone Monitoring Across the Spectrum of Diabetes Care**
Richard Bergenstal (USA)

PROGRAMME

10:50 – 11:15 **CGM-Mediated Improvements in HA1c and Regimen Adherence with Noninsulin Agents in the Setting of T2D**
Monika Kellerer (DEU)

TUESDAY

11:15 – 11:35 **The Foundational Role of CGM for Personalized A1c Optimization**
Ramzi Ajjan (GBR)

WEDNESDAY

THURSDAY

11:35 – 12:00 **Translating Evolving CGM Technologies into Real World Case-Based Diabetes Management**
Thomas Wascher (AUT)

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Organised by: **Abbott Diabetes Care**

MONDAY, 15 SEPTEMBER 2025

12:00 – 12:30
SYDNEY HALL

TRIGLYCERIDES AND RESIDUAL CV RISK: RETHINKING CARDIOMETABOLIC PROTECTION IN DIABETES

- Chair:** Martin Clodi (AUT)
- 12:00 – 12:05** **Welcome & Introduction**
Martin Clodi (AUT)
- 12:05 – 12:10** **CV residual risk in patients with diabetes**
Martin Clodi (AUT)
- 12:10 – 12:25** **Role of triglycerides and therapeutic options**
Dirk Müller-Wieland (DEU)
- 12:25 – 12:30** **Q&A**
All faculty

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Organised by: **Amarin**

MONDAY, 15 SEPTEMBER 2025

12:00 – 13:00
LIMA HALL

TRANSFORMING CKD CARE IN DIABETES: BREAKTHROUGHS WITH FINERENONE TREATMENT

Chair:	Per-Henrik Groop (FIN)
12:00 – 12:10	Welcome and introduction: Finerenone - The Future is Now Per-Henrik Groop (FIN)
12:10 – 12:25	Act with CONFIDENCE for people living with T2D and CKD Peter Rossing (DNK)
12:25 – 12:35	...But what about me? Per-Henrik Groop (FIN) Uroš Bogdanović (SRB)
12:35 – 12:50	Closing the Gap for people living with T1D and CKD Hiddo Lambers Heerspink (NLD)
12:50 – 13:00	Q&A & Closing remarks Per-Henrik Groop (FIN)

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Organised by: **Bayer AG**

MONDAY, 15 SEPTEMBER 2025

12:00 – 13:00
SOFIA HALL

CAN THE EVOLUTION OF CVOTS REVOLUTIONIZE THE T2D CARE OF TOMORROW?

- Chair:** Oliver Schnell (DEU)
- 12:00 – 12:05** **Welcome and introduction**
Oliver Schnell (DEU)
- 12:05 – 12:20** **How are CVOT studies evolving to drive a new standard of care in T2D?**
Melanie Davies (GBR)
- 12:20 – 12:35** **What drives the lowering of CV risk with novel T2D therapeutics?**
Pam Taub (USA)
- 12:35 – 12:45** **Moderated panel discussion**
Oliver Schnell (DEU)
Melanie Davies (GBR)
Pam Taub (USA)
- 12:45 – 12:55** **Audience Q&A**
All faculty
- 12:55 – 13:00** **Wrap-up**
Oliver Schnell (DEU)

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Organised by: **Eli Lilly and Company**

MONDAY, 15 SEPTEMBER 2025

13:00 – 14:00
BEIJING HALL

USE OF CGM PLUS CKM FOR BETTER MANAGEMENT OF DIABETES

Chairs: Linong Ji (CHN)
Stefano Genovese (ITA)

13:00 – 13:20 The Insight of CGM Use in Type 2 Diabetes
Andrej Janež (SVK)

13:20 – 13:40 Continuous Ketone Monitoring (CKM) in Health and Diabetes
Nina Jendrike (DEU)

13:40 – 14:00 Introduction to Next-Generation SIBIONICS CGM System
Yifei Mo (CHN)

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY
PROGRAMME

EXHIBITION

THANKS

Organised by: **SIBIONICS CGM & CKM**

MONDAY, 15 SEPTEMBER 2025

13:00 – 14:30
MUMBAI HALL

WE'RE TALKING ABOUT REMISSION WHEN WE SHOULD BE TALKING ABOUT DURABILITY IN TYPE 2 DIABETES

- Chair:** Stefano Del Prato (ITA)
- 13:00 – 13:03** **Welcome and introduction**
Stefano Del Prato (ITA)
- 13:03 – 13:18** **Evolving the definition of diabetes remission**
Amy Rothberg (USA)
- 13:18 – 13:33** **Progressive decline in beta-cell function in type 2 diabetes is not irrevocable**
David Matthews (GBR)
- 13:33 – 13:48** **Durability of (near) normal glycemic control in people with type 2 diabetes. The holy grail?**
Stefano Del Prato (ITA)
- 13:48 – 14:18** **Moderated panel discussion**
Jonathan Rachman (GBR)
David Matthews (GBR)
Stefano Del Prato (ITA)
Amy Rothberg (USA)
- 14:18 – 14:28** **Audience Q&A**
All faculty
- 14:28 – 14:30** **Wrap-up**
Stefano Del Prato (ITA)

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Organised by: **Eli Lilly and Company**

MONDAY, 15 SEPTEMBER 2025

13:00 – 14:30
WARSAW HALL

UNLOCKING THE COMBINED POTENTIAL OF SGLT2I AND GLP-1 RA MECHANISMS FOR ORGAN PROTECTION

GENERAL
INFO

Chair: Hiddo L. Heerspink (NLD)

13:00 – 13:10 Welcome and introductions
Hiddo L. Heerspink (NLD)

13:10 – 13:25 SGLT2is and GLP-1 RAs: Defined mechanisms, combined impact on cellular health
Michael Roden (DEU)

13:25 – 13:40 Turning the cogs: Clinical evidence of SGLT2is and GLP-1 RAs for kidney protection
Hiddo L. Heerspink (NLD)

13:40 – 13:55 Unlocking the potential of SGLT2is and GLP-1 RAs for CV protection
Biykem Bozkurt (USA)

13:55 – 14:25 Looking to the future: The combined potential for SGLT2is and GLP-1 RAs to improve CV, renal, and metabolic health
All faculty

14:25 – 14:30 Summary and close
Hiddo L. Heerspink (NLD)

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Organised by: [AstraZeneca](#)

MONDAY, 15 SEPTEMBER 2025

13:00 – 14:30
CHICAGO HALL

**INTERWOVEN PATHWAYS, UNIFIED EFFORTS:
INTERPLAY BETWEEN OBESITY AND MASH DRIVES THE SHIFT
TOWARDS MULTIDISCIPLINARY CARE**

- Chair:** Sarah Jarvis (GBR)
- 13:00 – 13:05 Pathways to progress**
Sarah Jarvis (GBR)
- 13:05 – 13:15 More than a single disease: Approaching obesity holistically**
Ania Jastreboff (USA)
- 13:15 – 13:30 The role of non-invasive tests to enable early diagnosis and timely intervention in MASLD/MASH**
Quentin Anstee (GBR)
- 13:30 – 13:55 Advancing early diagnosis of MASLD/MASH: The role of non-invasive tests**
All faculty
- 13:55 – 14:05 Moving towards holistic management through multidisciplinary collaboration**
Sean Wharton (CAN)
- 14:05 – 14:25 Navigating challenges in adopting multidisciplinary care**
All faculty
- 14:25 – 14:30 Future directions**
Sarah Jarvis (GBR)

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Organised by: **Boehringer Ingelheim International GmbH**

MONDAY, 15 SEPTEMBER 2025

14:30 – 16:00
LONDON HALL

**TIRZEPATIDE: BREAKING BARRIERS IN WEIGHT MANAGEMENT,
TYPE 2 DIABETES, AND OSA**

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

- Chair:** Barbara McGowan (GBR)
- 14:30 – 14:40 Welcome and Introduction**
Barbara McGowan (GBR)
- 14:40 – 14:50 The Science Behind Tirzepatide**
Timo Müller (DEU)
- 14:50 – 15:10 Breaking Barriers in Weight Management + Discussion**
Carel le Roux (IRL)
- 15:10 – 15:30 Breaking Barriers in Type 2 Diabetes + Discussion**
Bernhard Ludvik (AUT)
- 15:30 – 15:55 Tirzepatide’s Emerging Role in the Management of Obstructive Sleep Apnea + Discussion**
Ron Grunstein (AUS)
- 15:55 – 16:00 Closing Remarks**
Barbara McGowan (GBR)

Organised by: **Eli Lilly and Company**

MONDAY, 15 SEPTEMBER 2025

15:00 – 16:00
LIMA HALL

RETHINKING LIPID MANAGEMENT – THE POTENTIAL OF COMBINATION THERAPY IN PATIENTS WITH DIABETES

- Chair:** Heinz Drexel (AUT)
- 15:00 – 15:05** **Welcome and introduction**
Heinz Drexel (AUT)
- 15:05 – 15:17** **Beyond Monotherapy – a guideline update**
Dirk Müller-Wieland (DEU)
- 15:17 – 15:29** **Oral therapy options for Patients with Diabetes and Dyslipidemia**
Maeve Durkan (IRL)
- 15:29 – 15:41** **Case study: Implementing Combination Therapy in Diabetology**
Marc Evans (GBR)
- 15:41 – 16:00** **Panel discussion and Q&A**
All faculty

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Organised by: **Daiichi Sankyo**

MONDAY, 15 SEPTEMBER 2025

15:00 – 16:30
SOFIA HALL

**BEYOND AVERAGE: UNLOCKING THE POWER OF PREDICTION IN
PERSONALIZED DIABETES CARE**

GENERAL
INFO

Chairs: Samuel Seidu (GBR)
Ralph Ziegler (DEU)

PROGRAMME

15:00 – 15:25 Empowered by Data, Driven by Need: The Patient Call for Predictive Diabetes Technology
Michelle Schmidt (DEU)

TUESDAY

15:25 – 15:50 Clinical Perspectives on Predictive Glucose Monitoring: Enhancing Proactive Diabetes Care
Julia Mader (AUT)

WEDNESDAY

THURSDAY

15:50 – 16:10 Real-World Data on the Accu-Chek SmartGuide’s Night Low Predict Feature
Timothy Bailey (USA)

FRIDAY

16:10 – 16:25 Q&A
All faculty

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Organised by: **Roche**

MONDAY, 15 SEPTEMBER 2025

15:00 – 16:30
SYDNEY HALL

THE NEXT CHAPTER IN T1D CARE WITH ISLET CELL THERAPY

Chair:	Stephanie Amiel (GBR)
15:00 – 15:05	Welcome and introduction Stephanie Amiel (GBR)
15:05 – 15:25	Setting the scene: progression of treatments and technology and the remaining T1D burden Pratik Choudhary (GBR)
15:25 – 15:45	The story so far: the current landscape of islet cell therapy Lorenzo Piemonti (ITA)
15:45 – 16:05	Turning the page: unlocking the potential of stem cell-derived islet cell therapy in T1D Trevor Reichman (CAN)
16:05 – 16:15	Summary and conclusions Stephanie Amiel (GBR)
16:15 – 16:30	Panel Q&A All faculty

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Organised by: **Vertex Pharmaceuticals, Inc.**

MONDAY, 15 SEPTEMBER 2025

15:30 – 16:30
WARSAW HALL

DRIVING REDUCED DIABETES-RELATED COMPLICATIONS AND ENHANCED THERAPY OPTIMISATION SOLUTIONS

Chair:	Sufyan Hussain (GBR)
15:30 – 15:35	Introduction Sufyan Hussain (GBR)
15:35 – 15:55	CGM Usage and Reduction in Micro- and Macrovascular Complications Ann Peters (USA)
15:55 – 16:15	CGM in Action: Advancing Outcomes Along the Care Journey Halis Akturk (USA)
16:15 – 16:25	Driving Innovation in Diabetes Management Jake Leach (USA)
16:25 – 16:30	Q&A All faculty

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Organised by: **Dexcom**

MONDAY, 15 SEPTEMBER 2025

16:00 – 17:00
BEIJING HALL

**EXPANDING HORIZONS OF THE MINIMED 780G SYSTEM FOR ALL
PEOPLE LIVING WITH DIABETES.**

- Chair:** Ohad Cohen (CHE)
Gerlies Treiber (AUT)
- 16:00 - 16:05** **Expanding access to the MiniMed™ 780G system**
Ohad Cohen (CHE)
- 16:05 - 16:17** **The use of the MiniMed™ 780G system for all, aged 2+ with
reference to cognitive function**
Tadej Battelino (SVN)
- 16:17 - 16:29** **MiniMed™ 780G system for pregestational diabetes**
Tali Cukierman-Yaffe (ISR)
- 16:29 - 16:41** **MiniMed™ 780G system for type 2 diabetes**
Kirsten Nørgaard (DNK)
- 16:41 - 16:51** **The importance of screening: EDENT1FI**
Jurgen Vercauteren (BEL)
- 16:51 - 17:00** **Q&A**

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Organised by: **Medtronic International Trading Sàrl**

MONDAY, 15 SEPTEMBER 2025

16:00 – 17:30
MUMBAI HALL

BEYOND THE BREAKTHROUGH: CELEBRATING TEN YEARS OF SGLT2 INHIBITORS SINCE EMPA-REG OUTCOME

GENERAL
INFO

Chair: Silvio Inzucchi (USA)

PROGRAMME

16:00 – 16:03 Welcome and introduction
Silvio Inzucchi (USA)

TUESDAY

16:03 – 16:28 TENacity of purpose: EMPA-REG OUTCOME and the journey to improved patient care
Silvio Inzucchi (USA)
Christoph Wanner (DEU)
Bernard Zinman (CAN)

WEDNESDAY

THURSDAY

16:28 – 16:43 InTENSifying efforts since EMPA-REG OUTCOME: the revolutionary impact of SGLT2 inhibitors in CRM conditions
Paola Fioretto (ITA)
Javed Butler (USA)

FRIDAY

SHORT ORAL
DISCUSSIONS

16:43 – 17:08 PersISTENCE in progress: successful implementation of SGLT2 inhibitors in clinical practice
All faculty

PRESENTER
INDEX

17:08 – 17:20 Panel discussion and audience Q&A
All faculty

SATELLITE
SYMPOSIA

17:20 – 17:25 Defining a decade: reflecting on EMPA-REG OUTCOME
Silvio Inzucchi (USA)
Christoph Wanner (DEU)
Bernard Zinman (CAN)

INDUSTRY

17:25 – 17:30 Summary and close
Silvio Inzucchi (USA)

PROGRAMME

EXHIBITION

THANKS

Organised by: **Boehringer Ingelheim & Eli Lilly and Company**

MONDAY, 15 SEPTEMBER 2025

16:15 – 17:15
CHICAGO HALL

**A NOVEL APPROACH TO TREATING OBESITY AND TYPE 2 DIABETES:
EXPLORING AN ALTERNATIVE MECHANISM**

- Chair:** Abd Tahrani (DNK)
- 16:15 - 16:20 Introduction of Speakers and Agenda**
Abd Tahrani (DNK)
- 16:20 - 16:35 Decoding GIPR (Ant)agonism in Obesity and Diabetes**
Timo Müller (DEU)
- 16:35 - 16:55 Monoclonal Antibody Peptide Conjugate As An Emerging Therapy for Obesity and Type 2 Diabetes**
Murielle Veniant-Ellison (USA)
- 16:55 - 17:05 Clinical Development in Focus: Rationale and Future Directions for an Ongoing Phase 3 Program**
Donna Ryan (USA)
- 17:05 - 17:15 Q&A with audience**
Abd Tahrani (DNK)

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Organised by: **Amgen**

MONDAY, 15 SEPTEMBER 2025

16:30 – 17:30
MILAN HALL

**PERFORMANCE – PRACTICALITY – PEDIATRICS: NEW INSIGHTS ON
THE ICAN CGM SYSTEM FROM EUROPE AND THE USA**

Chair: Lori Laffel (USA)

16:30 - 16:35 **Welcome**
Lori Laffel (USA)

16:35 - 16:50 **iCan CGM System Performance: Insights from Germany**
Guido Freckmann (DEU)

16:50 - 17:05 **Practical Insights on CGM Use Inflight: Experience from Europe**
Julia Mader (AUT)

17:05 - 17:20 **Initiating CGM in Pediatrics: Learnings from the USA**
Lori Laffel (USA)

17:20 - 17:30 **Q&A**
Lori Laffel (USA)
Guido Freckmann (DEU)
Julia Mader (AUT)

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Organised by: **Sinocare Meditech Inc.**

TUESDAY, 16 SEPTEMBER 2025

11:30 – 12:00
SPOTLIGHT STAGE

BRIDGE TALKS: BEYOND A BLUEPRINT – PRACTICAL INSIGHTS INTO T1D SCREENING

- Chair:** Alice Cheng (CAN)
- 11:30 – 11:35** **Welcome**
Alice Cheng (CAN)
- 11:35 – 11:55** **Conversations on Setting-up General Population Screening in Different Healthcare Systems**
Ezio Bonifacio (DEU)
Francesco Giorgino (ITA)
- 11:55 – 12:00** **Call to Action: Advocate for T1D General Population Screening**
Alice Cheng (CAN)

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Organised by: **SANOFI**

TUESDAY, 16 SEPTEMBER 2025

11:30 – 12:00
ARENA

**DISRUPTING DIABETES CARE: REIMAGINE YOUR CLINICAL PRACTICE
TO SAVE TIME AND LIVES WITH OMNIPOD 5**

11:30 – 12:00 **Disrupting Diabetes Care: Reimagine Your Clinical Practice to Save Time and Lives with Omnipod 5**
Pratik Choudhary (GBR)
Sandra Schlüter (DEU)

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Organised by: Insulet

TUESDAY, 16 SEPTEMBER 2025

14:15 – 14:45
SPOTLIGHT STAGE

FROM RISK TO RESPONSE: UNLOCKING DKA PREVENTION WITH DUAL GLUCOSE KETONE SENSING

Chair: Mahmood Kazemi (USA)

14:15 – 14:45 **From Risk to Response: Unlocking DKA Prevention with Dual
Glucose Ketone Sensing**

Thomas Danne (PRT)
Pratik Choudhary (GBR)

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Organised by: **Abbott**

TUESDAY, 16 SEPTEMBER 2025

14:15 – 14:45
ARENA

EMPOWERING CHANGE: OVERCOMING BARRIERS IN OBESITY AND LIVER DISEASE CARE

Chair: Carel le Roux (IRL)

14:15 – 14:17 Welcome and Introduction

Carel le Roux (IRL)

14:17 – 14:25 Impulse lecture: Obesity, T2D & MASLD/MASH: Connecting the dots

Vlad Ratziu (FRA)

**14:25 – 14:33 Interview: Navigating Life with Obesity and Liver Disease –
Exploring needs of patients**

Marko Korenjak (BEL)

Ana Cebrián Cuenca (ESP)

**14:33 – 14:43 Panel Discussion: Closing the Hepato-Metabolic Gap – Current and
future perspectives**

All faculty

**14:43 – 14:45 Once weekly basal insulins across T2D populations:
what do we know so far?**

Carel le Roux (IRL)

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

**Organised by: Sciarç // supported by an Independent Medical Grant from
Boehringer Ingelheim International GmbH**

TUESDAY, 16 SEPTEMBER 2025

16:15 – 16:45
SPOTLIGHT STAGE

**PROACTIVE CARE: EARLY DETECTION AND INTERDISCIPLINARY
APPROACHES FOR MANAGING CHRONIC KIDNEY DISEASE AND
PERIPHERAL ARTERY DISEASE IN PEOPLE WITH T2D**

- Chair:** Ildiko Lingvay (USA)
- 16:15 – 16:19** **Setting the scene: the importance of early screening in people with T2D**
Ildiko Lingvay (USA)
- 16:19 – 16:28** **Enhancing early detection: a nephrologist’s insights on chronic kidney disease screening in people with T2D**
David Cherney (CAN)
- 16:28 – 16:37** **Navigating peripheral artery disease and T2D: a vascular medicine specialist’s insights on screening in people with T2D**
Marc P. Bonaca (USA)
- 16:37 – 16:45** **Collaborative care: strategies for interdisciplinary management of people with diabetes**
All faculty

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Organised by: Novo Nordisk A/S

TUESDAY, 16 SEPTEMBER 2025

16:15 – 16:45
ARENA

**ATTAINING GLYCEMIC CONTROL & CARDIORENAL PROTECTION
TOGETHER WITH SYNERGISTIC THERAPIES – HOW TO ACHIEVE &
WHAT IS THE EVIDENCE?**

GENERAL
INFO

Chair: Siew Pheng Chan (MYS)

16:15 – 16:17 Introduction
Siew Pheng Chan (MYS)

16:17 – 16:27 Glycemic control vs Cardiorenal Protection: Can we achieve both together?
Mohamed Hassanein (UAE)

16:27 – 16:37 Leveraging Synergistic Therapies to achieve therapeutic sweet spot with Real world evidence
Rodrigo de Oliveira Moreira (BRA)

16:37 – 16:42 Discussion
All faculty

16:42 – 16:45 Conclusion
Siew Pheng Chan (MYS)

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Organised by: **SERVIER**

TUESDAY, 16 SEPTEMBER 2025

18:00 – 19:00
BEIJING HALL

**EARLY ACTION, LONG-LASTING IMPACT:
ACT2DAY WITH SGLT2IS**

- Chairs:** Hiddo L. Heerspink (NLD)
Ana Cebrian (ESP)
- 18:00 – 18:05 Introduction**
Hiddo L. Heerspink (NLD)
- 18:05 – 18:13 Early Glycaemic Control: pursuing long-term protection in T2D patients**
Samuel Seidu (GBR)
- 18:13 – 18:21 SGLT2 inhibition: Kidney protection and beyond**
Hiddo L. Heerspink (NLD)
- 18:21 – 18:29 Protecting the Heart with SGLT2is**
Gianluigi Savarese (SWE)
- 18:29 – 18:34 Roundtable Introduction**
Ana Cebrian (ESP)
- 18:34 – 18:57 Roundtable Discussion: Acting together towards patients' future**
All faculty
- 18:57 – 19:00 Wrap-up & take-home messages**
Ana Cebrian (ESP)

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Organised by: **Menarini Group**

TUESDAY, 16 SEPTEMBER 2025

18:00 – 19:00
CHICAGO HALL

THE FUTURE OF DIABETES WITH METFORMIN

Chair:	Jeffrey Mechanick (USA)
18:00 – 18:04	Introduction Jeffrey Mechanick (USA)
18:04 – 18:21	Transcultural Diabetes Care Algorithms & the role of metformin Jeffrey Mechanick (USA)
18:21 – 18:38	Dementia, aging & the effects of metformin Jose Luchsinger (USA)
18:38 – 18:55	Weight maintenance after GLP1-RA & the potential of metformin Mohamed Hassanein (UAE)
18:55 – 19:00	Questions & Answers All faculty

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Organised by: **Merck Healthcare KGaA**

TUESDAY, 16 SEPTEMBER 2025

18:00 – 19:00
SYDNEY HALL

MOVING WITH MYLIFE CAMAPS FX IN T1D: REAL-TIME EXERCISE, REAL-LIFE INSIGHTS

Chair: Othmar Moser (GER)

18:00 – 19:00 **Clinical strategies for safe and effective exercise with mylife CamAPS FX.**
Live workout showcase: Watch three individuals with T1D perform strength, endurance, and HIIT exercises, with real-time expert commentary.
Othmar Moser (GER)

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: Ypsomed Diabetes Care AG

THANKS

TUESDAY, 16 SEPTEMBER 2025

18:00 – 19:30
LIMA HALL

PERSON-CENTRED CARE IN OBESITY MANAGEMENT: CONNECTING WITH YOUR PATIENTS

GENERAL
INFO

Chair: Carel le Roux (IRL)

18:00 – 18:07 **Welcome and introduction**
Carel le Roux (IRL)

18:07 – 18:27 **Obesity care: then, now and beyond**
Paolo Sbraccia (ITA)

18:27 – 18:57 **Recent developments and findings: the most current data from obesity studies**
Steven Kahn (USA)
Ildiko Lingvay (USA)

18:57 – 19:22 **Connecting to your patient with obesity: integrating evidence and guidelines into clinical practice**
Domenica Rubino (USA)

19:22 – 19:30 **Key takeaways and closing remarks**
All faculty

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Organised by: **Novo Nordisk A/S**

WEDNESDAY, 17 SEPTEMBER 2025

07:15 – 08:15
BEIJING HALL

BREAKFAST WITH BREAKTHROUGHT1D: PERSONAL JOURNEYS AND EMERGING THERAPIES IN TYPE 1 DIABETES

- Chair:** Thomas Danne (PRT)
- 07:15 – 07:20** **Welcome and Introduction**
Thomas Danne (PRT)
- 07:20 – 07:55** **Patient Journey Videos**
Poster Walk and Interaction With Faculty
All faculty
- 07:55 – 08:15** **Faculty Debrief and Q&A Session**
All faculty

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Organised by: Medscape Education Global // Initiative supported by Breakthrough T1D and developed in collaboration with Medscape Education Global

WEDNESDAY, 17 SEPTEMBER 2025

07:15 – 08:15
CHICAGO HALL

TARGETING DIABESITY FROM MULTIPLE ANGLES: FUTURE PROSPECTS AND IMMINENT REALITIES

- Chair:** Carel Le Roux (IRL)
- 07:15 – 07:20** **The Challenge: Healthcare and Societal Hazards of the Global ‘Diabesity’ Pandemic**
Carel Le Roux (IRL)
- 07:20 – 07:40** **The Science: Understanding Weight and Glucose Regulation Mechanisms**
Matthias Blüher (DEU)
- 07:40 – 08:05** **The Promise: Novel Multi-Pronged Treatment Concepts**
Kirsi Pietiläinen (FIN)
- 08:05 – 08:10** **The Outlook: Conclusion and Call to Action**
Carel Le Roux (IRL)
- 08:10 – 08:15** **Audience Q&A and EBAC Evaluation**
All faculty

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Organised by: Medscape Education Global // supported by an independent educational grant from Novo Nordisk A/S

WEDNESDAY, 17 SEPTEMBER 2025

11:15 – 11:45
SPOTLIGHT STAGE

DISEASE MODIFICATION IN TYPE 2 DIABETES. WHAT HAVE WE LEARNED?

Chair: Jonathan Rachman (GBR)

11:15 – 11:45 **Disease modification in type 2 diabetes. What have we learnt?**

Stefano Del Prato (ITA)

Jonathan Rachman (GBR)

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Organised by: **Eli Lilly and Company**

WEDNESDAY, 17 SEPTEMBER 2025

11:15 – 11:45
ARENA

“HIT EARLY HIT HARD”: OPTIMIZE TREATMENT IN PEOPLE LIVING WITH T2D AND CKD

GENERAL
INFO

Chairs: Paola Fioretto (ITA)
Peter Rossing (DNK)

PROGRAMME

11:15 – 11:30 “Hit Early Hit Hard”: Optimize treatment in people living with T2D and CKD

TUESDAY

Paola Fioretto (ITA)
Peter Rossing (DNK)

WEDNESDAY

11:30 – 11:45

Q&A
Paola Fioretto (ITA)
Peter Rossing (DNK)

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Organised by: **Bayer AG**

WEDNESDAY, 17 SEPTEMBER 2025

14:00 – 14:30
SPOTLIGHT STAGE

CONTINUOUS GLUCOSE MONITORING AS THE CATALYST FOR BEHAVIORAL CHANGE ACROSS PEOPLE WITH DIABETES

- Chair:** Nick Oliver (GBR)
- 14:00 – 14:05 Introduction**
Nick Oliver (GBR)
- 14:05 – 14:25 Continuous Glucose Monitoring as the Catalyst for Behavioral Change across People with Diabetes**
Mohammed Al-Sofiani (SAU)
Giesje Nefs (NLD)
- 14:25 – 14:30 Q&A**
All faculty

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Organised by: **Dexcom**

WEDNESDAY, 17 SEPTEMBER 2025

14:00 – 14:30
ARENA

**EASY STEPS WITH CONTROL-IQ TECHNOLOGY:
FROM DAY 1 TO DAILY LIFE**

Chair: Laurel Messer (USA)

14:00 – 14:30 Easy steps with Control-IQ: From Day 1 to Daily Life
Laurel Messer (USA)

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY
PROGRAMME

EXHIBITION

THANKS

Organised by: Tandem Diabetes Care, Inc.

WEDNESDAY, 17 SEPTEMBER 2025

16:00 – 16:30
SPOTLIGHT STAGE

REWRITING THE SCRIPT - NOVEL PATIENT PATHWAYS AND QUALITY OF CARE IN AUTOIMMUNE T1D

- 16:00 – 16:05** **Why current pathways have become obsolete?**
Lucien Engelen (NLD)
- 16:05 – 16:15** **Co-creation of novel pathways via collaboration between primary and specialty care**
Naresh Kanumili (GBR)
Steve Edelman (USA)
- 16:15 – 16:25** **New standards of quality of care and experience**
Korey Hood (USA)
Shara Bialo (USA)
- 16:25 – 16:30** **Q&A**

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Organised by: **SANOFI**

WEDNESDAY, 17 SEPTEMBER 2025

16:00 – 16:30
ARENA

UNLOCKING POTENTIAL: THE MINIMED™ 780G SYSTEM IN TYPE 2 DIABETES

Chair: Ohad Cohen (CHE)

16:00 - 16:15 **Glycemic outcomes with MiniMed™ 780G system in people living with type 2 diabetes**

Ohad Cohen (CHE)

16:15 - 16:30 **Diabetes and renal failure: glycemic management with the MiniMed™ 780G system**

Kirsten Nørgaard (DNK)

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Organised by: **Medtronic International Trading Sàrl**

WEDNESDAY, 17 SEPTEMBER 2025

17:45 – 18:45
BEIJING HALL

THE MISSING LINK: OPTIMISING PARTNERSHIPS AND COMMUNICATION BETWEEN ENDOCRINOLOGISTS AND OTHER SPECIALTIES

- Chair:** Alice Cheng (CAN)
- 17:45 – 17:50** **Establishing a connection: addressing the relationship between cardio, renal and metabolic conditions**
Alice Cheng (CAN)
- 17:50 – 18:05** **Stepping into the clinic: Patient case study**
Pam Kushner (USA)
- 18:05 – 18:25** **Closing the loop: taking SGLT2 inhibitors from evidence into clinical practice**
All faculty
- 18:25 – 18:35** **Don't break the chain: the importance of maintaining treatment in people with cardio, renal and metabolic conditions**
Per-Henrik Groop (FIN)
Nikolaus Marx (DEU)
- 18:35 – 18:45** **Audience Q&A and closing remarks**
All faculty

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Organised by: **Boehringer Ingelheim & Eli Lilly and Company**

WEDNESDAY, 17 SEPTEMBER 2025

17:45 – 18:45
CHICAGO HALL

**A NEW ERA IN MASH: HOW DISEASE-SPECIFIC THERAPIES ARE
CHANGING THE GAME AND BEST PRACTICES FOR CLINICAL
INTEGRATION**

GENERAL
INFO

Chair: Michael Roden (DEU)

**17:45 – 17:55 The Growing Burden of MASLD/MASH:
A Call to Action, New Treatments Are Coming**
Michael Roden (DEU)

17:55 – 18:10 Need to Improve Screening and Diagnosis in Patients with Diabetes
Michael Trauner (AUT)

**18:10 – 18:25 Changing the MASH Paradigm with THR- β Agonists and Other
Disease-specific Therapies**
Amalia Gastaldelli (ITA)

**18:25 – 18:35 Integrating MASLD/MASH-Specific Therapy into Guideline-Aligned
Real-World Practice**
All faculty

18:35 – 18:45 Conclusions and Q&A
All faculty

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

**Organised by: AKH Inc., Advancing Knowledge in Healthcare and Catalyst
Medical Education, LLC. // supported by an educational grant from Madrigal
Pharmaceuticals**

WEDNESDAY, 17 SEPTEMBER 2025

17:45 – 18:45
SYDNEY HALL

THE IMPACT OF COVID-19 ON INDIVIDUALS WITH CARDIOMETABOLIC DISEASES: A CALL TO ACTION

Chair:	Robert Krause (AUT)
17:45 – 17:53	Welcome and introduction Robert Krause (AUT)
17:53 – 18:08	The interplay of COVID-19 and cardiometabolic diseases Gillian Booth (CAN)
18:08 – 18:23	The importance of staying up-to-date with vaccinations for individuals with cardiometabolic diseases Robert Krause (AUT)
18:23 – 18:38	Integrating COVID-19 vaccination into care pathways for cardiometabolic disorders Ber Oomen (NLD)
18:38 – 18:45	Questions and answers and closing remarks Robert Krause (AUT)

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Organised by: **Pfizer Inc.**

WEDNESDAY, 17 SEPTEMBER 2025

17:45 – 19:15
LIMA HALL

THE EVOLVING ROLE OF GLP-1RAS FOR HOLISTIC CARDIOVASCULAR, KIDNEY, LIVER AND METABOLIC CARE

GENERAL
INFO

Chair: Steven Kahn (USA)

17:45 – 17:50 Welcome and introduction
Steven Kahn (USA)

PROGRAMME

TUESDAY

17:50 – 18:05 Stepping up holistic care: incretin-based and novel combination therapies in obesity
John Wilding (GBR)

WEDNESDAY

18:05 – 18:20 Taking the next step: the role of GLP-1RAs in the CKD and T2D nexus
Paola Fioretto (ITA)

THURSDAY

18:20 – 18:35 At the end of the road: managing subclinical and clinical CVD with incretin-based and novel combination therapies
Subodh Verma (CAN)

FRIDAY

SHORT ORAL
DISCUSSIONS

18:35 – 18:50 Integrating MASH in the CKM syndrome: the potential role of GLP-1RAs for the missing link
Eric Lawitz (USA)

PRESENTER
INDEX

18:50 – 18:55 Looking into the future: advancing CKM management strategies
Steven Kahn (USA)

SATELLITE
SYMPOSIA

18:55 – 19:15 Q&A
All faculty

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Organised by: **Novo Nordisk A/S**

THURSDAY, 18 SEPTEMBER 2025

12:15 – 12:45
SPOTLIGHT STAGE

**A NEW ERA OF CARDIOMETABOLIC CARE: ADVANCING HOLISTIC
TREATMENT AMBITIONS WITH AMYLIN**

- Chairs:** Alice Cheng (CAN)
Arya Sharma (DEU)
- 12:15 – 12:17 Welcome and introduction**
Alice Cheng (CAN)
Arya Sharma (DEU)
- 12:17 – 12:21 Setting the scene: cardiometabolic management in people with obesity and T2D**
Alice Cheng (CAN)
- 12:21 – 12:25 A match made in heaven: how can amylin complement incretin?**
Arya Sharma (DEU)
- 12:25 – 12:37 Unleashing the power of two: amylin and incretins in clinical trials**
Alice Cheng (CAN)
Arya Sharma (DEU)
- 12:37 – 12:43 Q&A**
Alice Cheng (CAN)
Arya Sharma (DEU)
- 12:43 – 12:45 Summary and close**
Alice Cheng (CAN)
Arya Sharma (DEU)

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Organised by: **Novo Nordisk A/S**

THURSDAY, 18 SEPTEMBER 2025

12:15 – 12:45
ARENA

A BETA WAY OF LOOKING AT T1D - SCIENTIFIC INSIGHTS INTO BETA-CELL FUNCTION IN TYPE 1 DIABETES

GENERAL
INFO

12:15 - 12:17 **Welcome and introduction**

Conan Tu (USA)

12:17 - 12:22 **Beta Cells: The foundation of glucose homeostasis**

Conan Tu (USA)

12:22 - 12:27 **T1D: A progressive autoimmune attack on beta cells**

Conan Tu (USA)

12:27 - 12:32 **The value of residual beta cell function to determine the course of a patient's journey**

Conan Tu (USA)

12:32 - 12:37 **The future of T1D through the lens of beta cells**

Conan Tu (USA)

12:37 - 12:42 **Q&A**

Conan Tu (USA)

12:42 - 12:45 **Session close**

Conan Tu (USA)

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Organised by: **SANOFI**

THURSDAY, 18 SEPTEMBER 2025

15:00 – 15:30
SPOTLIGHT STAGE

REDEFINING MDI THERAPY: THE SMART MDI SYSTEM

- Chair:** Ohad Cohen (CHE)
- 15:00 - 15:10** **Why Smart MDI? Early Insights from real-world evidence**
Goran Petrovski (GRC)
- 15:10 - 15:30** **Why Smart MDI? Expert Experience**
Laurent Crenier (BEL)

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Organised by: **Medtronic International Trading Sàrl**

THURSDAY, 18 SEPTEMBER 2025

15:00 – 15:30
ARENA

**ENGINEERED TO LAST: HOW DURABLE NUSH ANALOGS
CAN TRANSFORM OBESITY CARE AT SCALE**

GENERAL
INFO

15:00 - 15:10 **How durable NuSH analogs can improve tolerability, reduce dosing frequency, and simplify titration**
Robert Stoekenbroek (USA)

PROGRAMME

15:10 - 15:20 **Clinical data for ultra-long acting NuSH analogs**
Steve Marso (USA)

TUESDAY

15:20 - 15:30 **Engineering ultra-long acting NuSH analogs**
Will Adams (USA)

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY
PROGRAMME

EXHIBITION

THANKS

Organised by: **Metsera**

THURSDAY, 18 SEPTEMBER 2025

17:00 – 17:30
SPOTLIGHT STAGE

REDEFINING SUCCESS IN OBESITY MANAGEMENT

Chair: Rachel Batterham (GBR)
17:00 – 17:30 **Redefining Success in Obesity Management**
Arya M. Sharma (DEU)
Rachel Batterham (GBR)

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Organised by: **Eli Lilly and Company**

THURSDAY, 18 SEPTEMBER 2025

17:00 – 17:30
ARENA

FROM AT-RISK TO RECOGNITION: IMPROVING DETECTION OF MASH

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

- Chairs:** Lise Lotte Gluud (DNK)
Harpreet Bajaj (CAN)
- 17:00 – 17:17** **Spotlight on MASH: navigating early detection in the clinic**
Lise Lotte Gluud (DNK)
Harpreet Bajaj (CAN)
- 17:17 – 17:27** **Enabling action in real-world care: audience Q&A**
Lise Lotte Gluud (DNK)
Harpreet Bajaj (CAN)
- 17:27 – 17:30** **Final reflections and key takeaways**
Lise Lotte Gluud (DNK)
Harpreet Bajaj (CAN)

Organised by: **Novo Nordisk A/S and ECHOSENS**

FRIDAY, 19 SEPTEMBER 2025

09:30 – 10:00
SPOTLIGHT STAGE

DEMONSTRATING THE VALUE OF DEXCOM CGM IN GESTATIONAL DIABETES MELLITUS

- 09:30 – 09:45** **How Dexcom CGM improves outcomes for mother and child in GDM**
Christian Göbl (AUT)
Tina Linder (AUT)
- 09:45 – 10:00** **Best practices and key considerations for CGM in GDM**
Helen Murphy (GBR)

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Organised by: **Dexcom**

FRIDAY, 19 SEPTEMBER 2025

11:00 – 11:30
SPOTLIGHT STAGE

BEYOND MDI: WHY CGM BELONGS IN EVERY TYPE 2 DIABETES CARE PLAN

Chair: Stefano Del Prato (ITA)

11:00 – 11:30 Beyond MDI: Why CGM Belongs in Every Type 2 Diabetes Care Plan

Emma Wilmot (GBR)

Virginia Bellido (ESP)

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY
PROGRAMME

EXHIBITION

THANKS

Organised by: **Abbott**

FRIDAY, 19 SEPTEMBER 2025

12:30 – 13:00
SPOTLIGHT STAGE

**THE VALUE OF REAL-WORLD DATA IN DIABETES TECHNOLOGY:
VIEWPOINTS FROM THE DIABETES COMMUNITY**

12:30 – 13:00 The Value of Real-World Data in Diabetes Technology: Viewpoints from the Diabetes Community

Jackie Elliott (GBR)
Rob Malcolm (GBR)
John Pemberton (GBR)
Andrei Stroila (ROU)

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Organised by: Roche

VISIT THE INDUSTRY EXHIBITION IN HALL B

Don't miss out on the opportunity to explore this dynamic space, filled with valuable resources and engaging experiences.



Seating areas and recharge lounge

Take a moment to relax and recharge in our comfortable seating areas. Whether you need a quick break between sessions or want to network with fellow attendees, these designated spaces provide the perfect opportunity to unwind and refuel.



Free fruits and coffee

We believe in keeping you refreshed and energised throughout the day. Enjoy complimentary fruits and freshly brewed coffee, available for your convenience.



Virtual Meeting stations

Our dedicated Virtual Meeting stations allow you to follow the live sessions virtually and access on-demand content, so you won't miss a beat as you explore the industry exhibition.



Opening hours


Tuesday, 16 September	09:00 – 16:30
Wednesday, 17 September	09:30 – 16:30
Thursday, 18 September	09:30 – 16:30

See you there!

Organised by



INTERPLAN
media & service gmbh



GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY
PROGRAMME
EXHIBITION

THANKS

EXHIBITOR DIRECTORY

	Company	Booth	Company	Booth
GENERAL INFO	A. Menarini Diagnostics	D2.03	KEYENCE	D2.09
	Abbott	C5.01	Kunming Biomed International	D4.05
	Amarin	B5.01	Madrigal Pharmaceuticals	B1.03
	Amgen	D1.05	MDE Technologies	C3.03
	Ascensia Diabetes Care	B5.02	MDPI	D4.02
	AstraZeneca	B2.01	Mediwhale Inc.	E2.03
	Bayer AG	B3.01, C3.05	Medscape Education Global	ONLINE company profile
	Beijing Ruicheng Medical Supplies Co.,Ltd	E2.02	Medtronic International Trading Sàrl	C2.01
	Biocytogen	E2.09	Medtrum Technologies Inc.	D2.04
	Bionime Corporation	D2.05	Menarini Group	D2.02
PROGRAMME TUESDAY WEDNESDAY THURSDAY FRIDAY	Boditech Med Inc.	D3.08	Merck Healthcare KGaA	ONLINE company profile
	Boehringer Ingelheim & Eli Lilly and Company	B2.03	MESI	C3.04
	Boehringer Ingelheim International GmbH	C1.02	Metsera	ONLINE company profile
	CAPTEUR PROTECT	C5.07	MicroTech Medical (Hangzhou) Co.,Ltd	C4.03
	Changsha Sinocare Inc.	C4.02	Morphic Medical Inc.	C6.06
	Daiichi Sankyo	C3.01	Nightingale Health	D3.03
	Dexcom	D1.01, D4.03	NINGBO MEDSUN MEDICAL CO.,LTD	E1.01
	Diamyd Medical	E2.05	Nova Biomedical	ONLINE company profile
	ECHOSENS	D3.02	Novo Nordisk A/S	B1.01
	Eli Lilly and Company	B1.02	Pfizer Inc.	ONLINE company profile
SHORT ORAL DISCUSSIONS	ELSEVIER	D2.08	Phoenix Europe GmbH	D4.01
	Enable Biosciences, Inc	D4.06	Premier Research	C6.06A
	E-Scopics	C5.09	Profil Institut für Stoffwechselforschung GmbH	D1.02
	EVA Pharma	B4.01	Radox Biosciences	D4.10
	Glooko AB	C6.07	Regeneron Pharmaceuticals, Inc.	C6.03
	GSK	C1.01	REMIDIO INNOVATIVE SOLUTIONS PVT LTD	D2.10
	Hisky Medical	C5.08	Roche	C2.02
	iCare	D2.07	SAB BIO	ONLINE company profile
	ICON	E1.02	SANOFI	C1.03, D4.14
	Impeto Medical	C5.06A	SERVIER	C5.10
PRESENTER INDEX	Inreda Diabetic BV	C5.06	Shenzhen CoinCell Battery Co., Ltd.	D4.09
	Insulet	D1.04	SIBIONICS CGM	D3.01
	i-SENS, Inc.	C4.01	Siemens Healthineers Point of Care Diagnostics	C3.02
	Kemtai Ltd.	C6.02		
SATELLITE SYMPOSIA				
INDUSTRY PROGRAMME EXHIBITION				
THANKS				

EXHIBITOR DIRECTORY

Company	Booth	Company	Booth
Sol-Millennium Europe Sp. z o.o.	E2.08	VoxelCloud	E2.10
SOOIL Development	D1.03	Wisepress Medical Bookshop	E2.06
Springer Medicine	D4.08	Worldwide Clinical Trials	ONLINE company profile
Syai Health Technology Pte. Ltd.	C6.08	Ypsomed Diabetes Care AG	C5.05
Tandem Diabetes Care, Inc.	D2.01	YUWELL MEDICAL	C4.04
Vertex Pharmaceuticals, Inc.	B2.02	YW MEMS(SUZHOU) CO.,LTD.	E2.01

Sponsored Areas

Free fruits - sponsored by Abbott	FRUITS1, FRUITS2
Meeting pods - sponsored by Boehringer Ingelheim International GmbH	MP1
Meeting pods - sponsored by Dexcom & Insulet	MP2
Recharge lounge - sponsored by Novo Nordisk A/S	RL
Seating areas - sponsored by Novo Nordisk A/S	SEATING1, SEATING3, SEATING5
Seating area - sponsored by Boehringer Ingelheim International GmbH	SEATING2
Seating area - sponsored by Eli Lilly and Company	SEATING4
Virtual Meeting stations - sponsored by Novo Nordisk A/S	VMS1, VMS2

Innovation Zone

DCB - Diabetes Center Berne with

Alva Innovations | Beep Insights | Diabetes Venture Fund | Diabetotech |
diateam | Digital Oxygen | Fada Medical | GlucoSet | Glucotrack | GLUCUBE |
GO-Pen | PercuSense | Phi Med Europe S.L. | Provigate | SNAQ |
Syntactiq | T1DScout | YW MEMS

To view the compliance/codex publication list and the full list of sponsors, please visit www.easd-industry.com/sponsors or scan the following QR code:



As of August 2025, details are subject to change.

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

EASD AND EFSD ACKNOWLEDGEMENTS

The European Association for the Study of Diabetes (EASD) is most grateful to the following companies and organisations for their ongoing support of activities on the occasion of the EASD Annual Meeting.

Lilly

GENERAL
INFO

The Albert Renold Prize is generously supported by Lilly.

The Minkowski Prize is generously supported by Lilly.

The EASD Diabetes Global Impact Prize is generously supported by Lilly.

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

Novo Nordisk

The Camillo Golgi Prize is generously supported by Novo Nordisk.

The Rising Star Symposium and Fellowship is generously supported by Novo Nordisk.

SHORT ORAL
DISCUSSIONS

Novo Nordisk Foundation

The EASD-NNF Diabetes Prize for Excellence is generously supported by the Novo Nordisk Foundation.

The *Diabetologia-Diabetes-Diabetes Care Expert Forum: Insulin resistance in the 21st century: new takes on an old problem* symposium is generously supported by the Novo Nordisk Foundation.

The *Clinical application of precision medicine in diabetes* symposium is generously supported by the Novo Nordisk Foundation.

The *EFSD-NNF Future Leaders Symposium* is generously supported by the Novo Nordisk Foundation.

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Sanofi

The Claude Bernard Prize is generously supported by Sanofi.

THANKS

The European Foundation for the Study of Diabetes (EFSD) is greatly indebted to the following companies and organisations for their most generous support of European diabetes research.

Japan Diabetes Society

EFSD/JDS Reciprocal Travel Research Fellowships

The objective of these Fellowships is to encourage collaborative research between Europe and Japan in the field of diabetes.

Lilly

EFSD and Lilly European Diabetes Research Programme

This Programme aims to promote increased European diabetes research and to raise public awareness and political understanding of the magnitude and burden of the disease. Grants are offered for any area of basic or clinical diabetes research.

EFSD and Lilly Young Investigator Research Award Programme

The objective of these Young Investigator Research Awards is to encourage innovative research in the field of diabetes and its complications, and to promote excellence in medical education.

Novo Nordisk

EFSD and Novo Nordisk Programme for Diabetes Research in Europe

This Programme aims to promote high-quality diabetes research in Europe and accepts applications from all fields of clinical and basic diabetes research.

EASD Rising Star Symposium & EFSD Research Fellowship Programme supported by Novo Nordisk

This combined EASD/EFSD initiative aims to identify promising and innovative young researchers in basic and clinical diabetes research.

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS

Novo Nordisk Foundation

EFSD/Novo Nordisk Foundation Future Leaders Award Programme

This Programme is intended to identify outstanding clinical and basic scientists in European diabetes research in the transition from postdoctoral/clinical fellow to a tenured academic appointment in diabetes research in Europe and support them through significant career development awards over 5 years and fostering their development into the leaders of tomorrow.

GENERAL
INFO

Sanofi

EFSD and Sanofi European Diabetes Research Programme on autoimmunity in type 1 diabetes

The Programme is intended to stimulate and accelerate European research aimed at understanding of any aspect of autoimmunity in type 1 diabetes, its pathogenesis, screening and monitoring, its clinical course and its interventions.

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THANKS



EASD

European Association
for the Study of Diabetes